<SEC-DOCUMENT>0001144204-12-029753.txt : 20120515
<SEC-HEADER>0001144204-12-029753.hdr.sgml : 20120515
<ACCEPTANCE-DATETIME>20120515171529
ACCESSION NUMBER:		0001144204-12-029753
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20120331
FILED AS OF DATE:		20120515
DATE AS OF CHANGE:		20120515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		12845989

	BUSINESS ADDRESS:	
		STREET 1:		3985 RESEARCH PARK DRIVE,
		STREET 2:		SUITE 200
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48108
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		3985 RESEARCH PARK DRIVE,
		STREET 2:		SUITE 200
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48108

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>v311052_10q.htm
<DESCRIPTION>10-Q
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 27pt"><B>UNITED STATES SECURITIES
AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 10-Q</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Mark One)</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%; padding-right: 0.8pt; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#120;</FONT></TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt; font-size: 10pt; font-weight: bold"><B>QUARTERLY REPORT PURSUANT TO SECTION 13
    OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For the quarterly period ended March 31, 2012</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>OR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%; padding-right: 0.8pt; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt; font-size: 10pt; font-weight: bold"><B>TRANSITION REPORT PURSUANT TO SECTION
    13 OR 15(d) OF THE SECURITIES ACT OF 1934</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For the transition period from &nbsp;____________ to&nbsp;____________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 1-12584</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SYNTHETIC BIOLOGICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Name of small business issuer in its
charter)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%; padding-right: 0.8pt; font-weight: bold; text-align: center"><B>Nevada</B></TD>
    <TD STYLE="width: 1%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 47%; padding-right: 0.8pt; font-weight: bold; text-align: center"><B>13-3808303</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; font-style: italic; text-align: center"><I>(State or other jurisdiction of incorporation
    or organization)</I></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; font-style: italic; text-align: center"><I>(IRS Employer Identification Number)</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; font-weight: bold; text-align: center"><B>3985 Research Park Drive, Suite 200</B></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; font-weight: bold; text-align: center"><B>Ann Arbor, MI</B></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; font-weight: bold; text-align: center"><B>48108</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; font-style: italic; text-align: center"><I>(Address of principal executive offices)</I></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; font-style: italic; text-align: center"><I>(Zip Code)</I></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registrant&rsquo;s telephone number,
including area code:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(734) 332-7800</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities registered pursuant to Section
12(b) of the Act:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock, $0.001 par value per share</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities registered pursuant to Section
12(g) of the Act:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>None.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Title of Class)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the issuer: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.&nbsp;Yes&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Wingdings">x
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp; </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such
shorter period that the registrant was required to submit and post such files).&nbsp;&nbsp;Yes&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Wingdings">x
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp; </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated file, a non-accelerated file, or a smaller reporting company.&nbsp;&nbsp;See the
definitions of &ldquo;large accelerated filer,&nbsp;&ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo;
in Rule 12b-2 of the Exchange Act.&nbsp;&nbsp;(Check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 42%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Large accelerated filer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 52%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accelerated filer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Non-Accelerated filer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Smaller reporting company&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT><FONT STYLE="font-family: Wingdings">x</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">(Do not check if a smaller reporting company)</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;&nbsp;Yes&nbsp;
</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;
</FONT><FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of May 14, 2012, the registrant had 33,016,175 shares of
common stock outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SYNTHETIC BIOLOGICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 10-Q</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 82%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 2%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 6%; border-bottom: black 1.5pt solid; padding-right: 0.8pt; text-align: center">Page</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">PART I.&mdash;FINANCIAL INFORMATION</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-right: 0.8pt">Item 1.</TD>
    <TD STYLE="padding-right: 0.8pt">Financial Statements</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">3</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">Consolidated Balance Sheets&nbsp;&nbsp;March 31, 2012 (Unaudited) and December 31, 2011</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">3</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">Consolidated Statements of Operations (Unaudited)</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">4</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">Consolidated Statements of Cash Flows (Unaudited)</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">5</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">Notes to Consolidated Financial Statements (Unaudited)</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">6</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt">Item 2.</TD>
    <TD STYLE="padding-right: 0.8pt">Management&rsquo;s Discussion and Analysis of Financial&nbsp;Information and Results of Operations</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">13</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-right: 0.8pt">Item 3.</TD>
    <TD STYLE="padding-right: 0.8pt">Quantitative and Qualitative Disclosures About Market Risks</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">23</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt">Item 4.</TD>
    <TD STYLE="padding-right: 0.8pt">Controls and Procedures</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">23</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">PART II&mdash;OTHER INFORMATION</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-right: 0.8pt">Item 1.</TD>
    <TD STYLE="padding-right: 0.8pt">Legal Proceedings</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">24</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt">Item 1A.</TD>
    <TD STYLE="padding-right: 0.8pt">Risk Factors</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">24</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-right: 0.8pt">Item 2.</TD>
    <TD STYLE="padding-right: 0.8pt">Unregistered Sales of Equity Securities and Use of Proceeds</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">35</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt">Item 3.</TD>
    <TD STYLE="padding-right: 0.8pt">Defaults Upon Senior Securities</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">35</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-right: 0.8pt">Item 4.</TD>
    <TD STYLE="padding-right: 0.8pt">Mine Safety Disclosures</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">35</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.8pt">Item 5.</TD>
    <TD STYLE="padding-right: 0.8pt">Other Information</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">35</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD STYLE="padding-right: 0.8pt">Item 6.</TD>
    <TD STYLE="padding-right: 0.8pt">Exhibits</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">36</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt">SIGNATURE</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">37</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,255,204)">
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt">GLOSSARY</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: right">38</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART I.&mdash;FINANCIAL INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><B>ITEM
1. FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 100%; font-size: 10pt; font-weight: bold; text-align: center">Synthetic Biologics, Inc. and Subsidiaries</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-decoration: underline; text-align: center">Consolidated Balance Sheets</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center">(In thousands, except share amounts)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; color: red; font-weight: bold">&nbsp;</TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt"><U>Assets</U></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2012</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,
    2011</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">(Unaudited)</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Current Assets:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 68%; font-size: 10pt; text-align: left; padding-left: 10pt">Cash</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">6,802</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">6,678</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Accounts receivable - net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">440</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">405</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Other</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">83</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">16</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Assets of discontinued operations</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">23</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 10pt">&nbsp;Total Current Assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7,325</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7,122</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Property and equipment, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">303</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">323</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Long-term note receivable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">700</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Deposits and other assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">31</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Assets</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">8,349</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">7,476</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-decoration: underline; text-align: center">Liabilities and Stockholders'
    Equity</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Current Liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Accounts payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">316</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">388</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Accrued liabilities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">127</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">29</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 10pt">&nbsp;Total Current
    Liabilities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">443</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">417</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total Liabilities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">443</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">417</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Stockholders' Equity:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Preferred stock,&nbsp; $0.001 par value; 10,000,000 shares
    authorized,</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">&nbsp;&nbsp;&nbsp;none issued and outstanding</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Common stock,&nbsp; $0.001 par value; 100,000,000 shares
    authorized,</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">&nbsp;&nbsp;32,857,609 issued and 32,776,127 outstanding
    and</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">&nbsp;&nbsp;31,374,002 issued and 31,292,520 outstanding</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">33</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">31</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">&nbsp;Additional paid-in capital</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">60,946</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">58,901</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">&nbsp;Accumulated deficit</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(53,073</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(51,873</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 10pt">&nbsp;Total Stockholders'
    Equity</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,906</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,059</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Liabilities and Stockholders'
    Equity</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">8,349</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">7,476</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 100%; font-size: 10pt; text-align: center">See accompanying notes to unaudited consolidated financial statements.</TD></TR>
</TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="1" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Synthetic Biologics, Inc. and Subsidiaries</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="1" STYLE="font-size: 10pt; font-weight: bold; text-decoration: underline; text-align: center">Consolidated Statements
    of Operations</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="1" STYLE="font-size: 10pt; font-weight: bold; text-align: center">(In thousands, except share and per share amounts)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="1" STYLE="font-size: 10pt; font-weight: bold; text-align: center">(Unaudited)</TD></TR>
</TABLE>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center">Three months ended March 31,</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0.75pt">Operating Costs and Expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; font-size: 10pt; text-align: left; padding-left: 10pt">General and administrative</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">1,468</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">1,233</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt; padding-bottom: 1pt">Research and development</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">386</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">231</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 20pt; padding-bottom: 1pt">Total Operating
    Costs and Expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">1,854</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">1,464</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.75pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0.75pt">Loss from Continuing Operations</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,854</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,464</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.75pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0.75pt">Other Income (Expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Warrant expense</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(716</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Change in fair value of warrant liability</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(94</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Loss on the sale of equipment</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(5</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt; padding-bottom: 1pt">Other income</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">5</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">56</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 20pt; padding-bottom: 1pt">Total Other Income
    (Expense), net</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">5</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">(759</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.75pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0.75pt">Net Loss from Continuing Operations</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,849</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2,223</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.75pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0.75pt; padding-bottom: 1pt">Net Income
    from Discontinued Operations</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">649</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt"></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">37</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.75pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0.75pt; padding-bottom: 2.5pt">Net Loss</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 2.5pt double">(1,200</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 2.5pt double">(2,186</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.75pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0.75pt">Net Income (Loss) Per Share&nbsp; -
    Basic and     Dilutive:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 10pt">Continuing operations</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(0.06</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(0.09</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 10pt; padding-bottom: 1pt">Discontinued operations</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">0.02</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">-</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.75pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-left: 10pt; padding-bottom: 2.5pt">Net Loss Per Share</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 2.5pt double">(0.04</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">)</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right; border-bottom: Black 2.5pt double">(0.09</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.75pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-left: 0.75pt">Weighted average number of shares outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0.12in">during the period - Basic and Dilutive</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 2.5pt double">32,003,164</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 2.5pt double">25,220,694</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>



<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 100%; font-size: 10pt; text-align: center; padding-left: 0.75pt">See accompanying notes to unaudited consolidated
    financial statements.</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 100%; font-size: 10pt; font-weight: bold; text-align: center; padding-left: 0.75pt">Synthetic Biologics,
    Inc. and Subsidiaries</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-decoration: underline; text-align: center; padding-left: 0.75pt">Consolidated
    Statements of Cash Flows</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; padding-left: 0.75pt">(In thousands)</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; padding-left: 0.75pt">(Unaudited)</TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three months
    ended March 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0.75pt">Cash Flows From Operating Activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; font-size: 10pt; text-align: left; padding-left: 0.75pt">Net loss</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">(1,849</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">(2,223</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.75pt">Net income  from discontinued operations</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">649</TD><TD STYLE="font-size: 10pt; text-align: left"></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">37</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.75pt">Adjustments to reconcile net loss to net cash used in
    operating activites:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Stock-based compensation</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">508</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">768</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Stock issued as employee compensation</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">76</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Stock issued for consulting fees</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">58</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Warrant expense</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">716</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Change in fair value of warrant liability</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">94</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 10pt">Depreciation</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">20</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">80</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Provision for uncollectible accounts receivable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">21</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Loss on sale of equipment</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Gain on the settlement of accounts payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(63</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.75pt">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Accounts receivable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(43</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(111</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Other current assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(67</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">268</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Note receivable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(700</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Deposits and other assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">10</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">68</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Assets of discontinued operations</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">23</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Accounts payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(72</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">154</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Accrued liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">98</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(192</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Liabilities of discontinued operations</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(40</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.75pt">Net Cash Used
    In Operating Activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,415</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(281</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.75pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0.75pt">Cash Flows From Investing Activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.75pt">Proceeds from the sale of equipment</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.75pt">Net Cash Provided
    By Investing Activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.75pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0.75pt">Cash Flows From Financing Activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.75pt">Proceeds from issuance of common stock for stock option
    exercises</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">68</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.75pt">Proceeds from issuance of common stock for warrant exercises</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,471</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.75pt">Proceeds from issuance of common stock</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.75pt">Cash paid as direct offering costs</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(296</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0.75pt">Net Cash Provided
    By&nbsp; Financing Activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,539</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,712</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.75pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 0.75pt">Net increase in cash</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">124</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,432</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.75pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 0.75pt">Cash at beginning of period</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,678</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,649</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 0.75pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt; padding-left: 0.75pt">Cash at end of period</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">6,802</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">6,080</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-left: 0.75pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-decoration: underline; text-align: left; padding-left: 0.75pt">Supplemental
    disclosures of cash flow information:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0.75pt">Cash paid for interest</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 0.75pt">Cash paid for taxes</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 100%; font-size: 10pt; text-align: center; padding-left: 0.75pt">See accompanying notes to unaudited consolidated
    financial statements.</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Synthetic Biologics,
Inc. and Subsidiaries</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Notes to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>(Unaudited)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>1.&nbsp;&nbsp;&nbsp;Organization</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (the &ldquo;Company&rdquo;
or &ldquo;Synthetic Biologics&rdquo;), formerly Adeona Pharmaceuticals, Inc., is a biotechnology company focused on the development
of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. In the area of synthetic
biology, the Company is initially developing a product candidate to treat pulmonary arterial hypertension (PAH). The Company also
intends to expand new and existing collaborations in the synthetic biology area. In addition, Synthetic Biologics has several
clinical-stage programs that are being funded, or partially funded, by grants, charitable organizations and corporate partners.
In this area we are developing, or have partnered the development of, product candidates to treat relapsing-remitting multiple
sclerosis (MS), cognitive dysfunction in MS, fibromyalgia and amyotrophic lateral sclerosis (ALS).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24%; border-bottom: black 1pt solid; padding-right: 0.8pt; font-weight: bold; text-align: center"><B>Medical
    Indication</B></TD>
    <TD STYLE="width: 2%; padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 24%; border-bottom: black 1pt solid; padding-right: 0.8pt; font-weight: bold; text-align: center"><B>Product
    Candidate</B></TD>
    <TD STYLE="width: 2%; padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 48%; border-bottom: black 1pt solid; padding-right: 0.8pt; font-weight: bold; text-align: center"><B>Status</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center">PAH</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">Synthetic DNA-based therapy</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">Preclinical</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center">Relapsing-remitting MS</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center">Trimesta</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center">(oral estriol)</P></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">All patients enrolled in Phase II clinical trial;<BR>
    dosing and monitoring underway</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center">Cognitive dysfunction in<BR>
    MS</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center">Trimesta</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: center">(oral estriol)</P></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">Patient enrollment underway in Phase II<BR>
    clinical trial</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center">Fibromyalgia</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">Effirma</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">Partnered with Meda AB</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">(oral flupirtine)</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center">ALS</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">AEN-100</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">Phase II/III clinical trial preparation underway</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">(gastroretentive zinc acetate)</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>2.&nbsp;&nbsp;&nbsp;Basis of Presentation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The accompanying
unaudited consolidated interim financial statements have been prepared in accordance with accounting principles generally accepted
in the United States of America and the rules and regulations of the United States Securities and Exchange Commission for interim
financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The financial
information as of December 31, 2011, is derived from the audited financial statements presented in the Company&rsquo;s Annual Report
on Form 10-K/A for the year ended December 31, 2011. The unaudited consolidated interim financial statements should be read in conjunction
with the Company&rsquo;s Annual Report on Form 10-K/A, which contains the audited financial statements and notes thereto, together
with the Management&rsquo;s Discussion and Analysis, for the year ended December 31, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Certain information
or footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted
in the United States of America have been consolidated or omitted, pursuant to the rules and regulations of the Securities and Exchange
Commission for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a
comprehensive presentation of financial position, results of operations, or cash flows. It is management's opinion, however, that
all material adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair financial statement
presentation. The interim results for the period ended March 31, 2012, are not necessarily indicative of results for the full year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has seven subsidiaries, Pipex
Therapeutics, Inc. (&ldquo;Pipex Therapeutics&rdquo;), Effective Pharmaceuticals, Inc. (&ldquo;EPI&rdquo;), Solovax, Inc. (&ldquo;Solovax&rdquo;),
CD4 Biosciences, Inc. (&ldquo;CD4&rdquo;), Epitope Pharmaceuticals, Inc. (&ldquo;Epitope&rdquo;), Healthmine, Inc. (&ldquo;Healthmine&rdquo;)
and Putney Drug Corp. (&ldquo;Putney&rdquo;). As of March 31, 2012, EPI, Healthmine and Putney are wholly owned and Pipex Therapeutics,
Solovax, CD4 and Epitope are majority-owned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>3.&nbsp;&nbsp;&nbsp;Summary of Significant Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Principles of Consolidation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All inter-company transactions and accounts
have been eliminated in consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Use of Estimates</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of consolidated financial
statements in conformity with accounting principles generally accepted in the U.S.A. requires management to make estimates and
assumptions that affect the reported amounts reported in the consolidated financial statements and accompanying notes. Such estimates
and assumptions impact, among others, the following: the amount allocated to goodwill, the estimated useful lives for property
and equipment, fair value of warrants and stock options granted for services or compensation, respectively, estimates of the probability
and potential magnitude of contingent liabilities, and the valuation allowance for deferred tax assets due to continuing and expected
future operating losses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Making estimates requires management to
exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or
set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating
its estimate could change in the near term due to one or more future confirming events. Accordingly, actual results could differ
from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Accounts Receivable and Allowance
for Doubtful Accounts</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable were reported at realizable
value, net of allowances for doubtful accounts, which were estimated and recorded in the period the related revenue was recorded.
The Company estimated and reviewed the collectability of its receivables based on a number of factors, including the period they
were outstanding. Historical collection and payer reimbursement experience was an integral part of the estimation process related
to allowances for doubtful accounts associated with Adeona Clinical Laboratory. In addition, the Company regularly assessed the
state of its billing operations in order to identify issues, which impacted the collectability of these receivables or reserve
estimates. Revisions to the allowances for doubtful accounts estimates were recorded as an adjustment to bad debt expense. Receivables
deemed uncollectible were charged against the allowance for doubtful accounts. Recoveries of receivables previously written-off
are recorded as credits to the allowance for doubtful accounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Revenue Recognition</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records revenue when
all of the following have occurred: (1) persuasive evidence of an arrangement exists, (2) the service is completed
without further obligation, (3) the sales price to the customer is fixed or determinable, and (4) collectability is
reasonably assured.&nbsp;&nbsp;The Company recognizes milestone payments or upfront payments that have no contingencies as
revenue when payment is received.&nbsp;&nbsp;For the three months ended March 31, 2012 and 2011, the Company&rsquo;s only
stream of revenue was laboratory revenue.&nbsp;Laboratory revenues are a component of discontinued operations for the three
months ended March 31, 2012 and 2011. <I>See Note 4 &ndash; Discontinued Operations of Adeona Clinical Laboratory and
Note Receivable.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>License Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s licensing agreements
may contain multiple elements, such as non-refundable up-front fees, payments related to the achievement of particular milestones
and royalties. Fees associated with substantive at risk performance-based milestones are recognized as revenue upon completion
of the scientific or regulatory event specified in the agreement. When the Company has substantive continuing performance obligations
under an arrangement, revenue is recognized over the performance period of the obligations using a time-based proportional performance
approach. Under the time-based method, revenue is recognized over the arrangement&rsquo;s estimated performance period based on
the elapsed time compared to the total estimated performance period. Revenue recognized at any point in time is limited to the
amount of non-contingent payments received or due. When the Company has no substantive continuing performance obligations under
an arrangement, it recognizes revenue as the related fees become due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues from royalties on third-party
sales of licensed technologies are generally recognized in accordance with the contract terms when the royalties can be reliably
determined and collectibility is reasonably assured. To date, the Company has not received any royalty revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 6, 2010, the Company entered into
the Meda Agreement for the development and commercialization of Effirma (oral flupirtine) for fibromyalgia.&nbsp; As consideration
for the sublicense, the Company received an up-front payment of $2.5 million upon execution of the Meda Agreement. This payment
was recorded as license revenue in 2010. Pursuant to the Company&rsquo;s license agreement with McLean Hospital, the Company paid
15% of the $2.5 million payment ($375,000), that was netted against the revenues received from Meda AB. The Company is also entitled
to additional milestone payments of $5 million upon filing of an NDA with the U.S. FDA for oral flupirtine for fibromyalgia and
$10 million upon marketing approval. The Meda Agreement also provides that the Company is entitled to receive net royalties of
7% of net sales of oral flupirtine approved for the treatment of fibromyalgia covered by issued patent claims in the U.S. and
Japan.&nbsp;The Meda Agreement provides that Meda AB will assume all future development costs for the commercialization of oral
flupirtine for fibromyalgia. Pursuant to the terms of the Company&rsquo;s agreement with McLean Hospital, the Company is obligated
to pay half of all future royalties the Company receives.&nbsp;&nbsp;Future milestone payments will be recorded as revenue when
payment is received as there are no future deliverables, and it is non-refundable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Laboratory Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company primarily recognized revenue
for services rendered upon completion of the testing process. Billing for services reimbursed by third-party payers, including
Medicare and Medicaid, were recorded as revenues, net of allowances for differences between amounts billed and the estimated receipts
from such payers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company maintained a sales allowance
to compensate for the difference in its billing practices and insurance company reimbursements. In determining this allowance,
the Company looked at several factors, the most significant of which is the average difference between the amount charged and
the amount reimbursed by insurance carriers over the prior 12 months, otherwise known as the yearly average adjustment amount.
The allowance taken was the averaged yearly average adjustment amount for these prior periods and multiplied by the period&rsquo;s
actual gross sales to determine the actual sales allowance for each period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company generated reimbursements from&nbsp;3 significant
insurance providers in March 31, 2012 and 2011, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Customer</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 30%; font-size: 10pt; text-align: center">A</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 30%; font-size: 10pt; text-align: center">68%</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"></TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 30%; font-size: 10pt; text-align: center">69%</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">B</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">5%</TD><TD STYLE="font-size: 10pt; text-align: left"></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">18%</TD><TD STYLE="font-size: 10pt; text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">C</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">9%</TD><TD STYLE="font-size: 10pt; text-align: left"></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">5%</TD><TD STYLE="font-size: 10pt; text-align: left"></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Risks and Uncertainties</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company's operations could be subject
to significant risks and uncertainties including financial, operational and regulatory risks and the potential risk of business
failure. The global economic crisis has caused a general tightening in the credit markets, lower levels of liquidity, increases
in the rates of default and bankruptcy, and extreme volatility in credit, equity and fixed income markets. These conditions may
not only limit our access to capital, but also make it difficult for our customers, our vendors and us to accurately forecast
and plan future business activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Cash and Cash Equivalents</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents include cash
and highly liquid short-term investments with original maturities of three months or less.&nbsp;&nbsp;At March 31, 2012 and 2011,
respectively, the Company had no cash equivalents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Goodwill</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Goodwill was not amortized, and was tested
for impairment at the reporting unit level annually and in interim periods if certain events occur indicating that the carrying
value of goodwill was impaired. A reporting unit was an operating segment for which discrete financial information was available
and was regularly reviewed by management. The Company had one reporting unit, Adeona Clinical Laboratory, to which goodwill was
assigned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASC No. 350 requires a two-step approach
to test goodwill for impairment for each reporting unit. The first step tests for impairment by applying fair value-based tests
to a reporting unit. The second step, if deemed necessary, measures the impairment by applying fair value-based tests to specific
assets and liabilities within the reporting unit. Application of the goodwill impairment tests require judgment, including identification
of reporting units, assignment of assets and liabilities to each reporting unit, assignment of goodwill to each reporting unit,
and determination of the fair value of each reporting unit. The determination of fair value for a reporting unit could be materially
affected by changes in these estimates and assumptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2011, in connection with
the Company classifying Adeona Clinical Laboratory as discontinued operations, previously recorded goodwill was considered impaired.
<I>See Note 4 &ndash; Discontinued Operations of Adeona Clinical Laboratory and Note Receivable</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Net Earnings (Loss) per Share</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net earnings (loss) per share
is computed by dividing net earnings (loss) less preferred dividends for the period by the weighted average number of
common shares outstanding. Diluted earnings (loss) per share is computed by dividing net income (loss) less preferred
dividends by the weighted average number of common shares outstanding including the effect of common share
equivalents.&nbsp;Since the Company reported a net loss for the three months ended March 31, 2012 and 2011, all common
equivalent shares would be anti-dilutive; as such there is no separate computation for diluted loss per share. The number of
options and warrants for the purchase of common stock, that were excluded from the computations of net loss per common share
for the three months ended March 31, 2012 were 3,843,465 and 2,414,922, respectively, and for the three months ended March
31, 2011 were 2,273,072 and 2,554,650, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Research and Development Costs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company expenses research and development
costs as incurred. Research and development expenses consist primarily of license fees, manufacturing costs, salaries, stock-based
compensation and related personnel costs, fees paid to consultants and outside service providers for laboratory development, legal
expenses resulting from intellectual property prosecution and other expenses relating to the design, development, testing and
enhancement of the Company&rsquo;s product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Stock-Based Payment Arrangements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Generally, all forms of stock-based payments,
including stock option grants, warrants, restricted stock grants and stock appreciation rights are measured at their fair value
on the awards&rsquo; grant date typically using a Black-Scholes pricing model, based on the estimated number of awards that are
ultimately expected to vest. Stock-based compensation awards issued to non-employees for services rendered are recorded at either
the fair value of the services rendered or the fair value of the stock-based payment, whichever is more readily determinable.
The expense resulting from stock-based payments are recorded in research and development expense or general and administrative
expense in the consolidated statement of operations, depending on the nature of the services provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Reclassifications</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To conform prior period amounts to current
year classifications, the Company has reclassified assets, liabilities, revenues and expenses associated with the sale of Adeona
Clinical Laboratory to discontinued operations. These reclassifications had no impact on the Company&rsquo;s previously reported
financial condition, results of operations or cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>4.</B></TD><TD STYLE="text-align: justify"><B>Discontinued
                                                                                      Operations of Adeona Clinical Laboratory
                                                                                      and Note Receivable</B></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 8, 2012, the Company sold all
of its interest in Adeona Clinical Laboratory, LLC (the &ldquo;Lab&rdquo;) to Hartlab, LLC, an entity controlled by the Lab&rsquo;s
former owner. In connection with the sale of the Lab, the consideration received was (i) the immediate assignment of the Lab&rsquo;s
outstanding accounts receivable up through the date of closing, plus (ii) $700,000 payable pursuant to the terms of a two-year
non-recourse promissory note bearing interest at 5.7% per annum secured by all of the assets of the Lab. The note and all unpaid
interest are due on March 1, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC Topic 205-20 &ldquo;<I>Presentation
of Financial Statements&mdash;Discontinued Operations</I> &rdquo; (ASC 205-20), the Company determined that all the criteria had
been met and classified the Lab as discontinued operations and its results of operations, financial position and cash flows are
separately reported for all periods presented. The assets of the discontinued operations are presented separately under the caption
&ldquo;Assets of discontinued operations&rdquo; in the accompanying Consolidated Balance Sheets at March 31, 2012, and December
31, 2011, and consist of the following <I>(in thousands</I> <I>):</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-style: italic">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2012</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,
    2011</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">Assets of discontinued operations:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 62%; font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Property and equipment,
    net</TD><TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 15%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 17%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">23</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 9pt">Total assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">23</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The summarized statement of operations data for Adeona Clinical
Laboratory for the three months ended March 31, 2012 and March 31, 2011 are as follows <I>(in thousands):</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-style: italic">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 62%; font-size: 10pt; text-align: left">Laboratory fees, net</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 16%; font-size: 10pt; text-align: right">115</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 16%; font-size: 10pt; text-align: right">323</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">Operating Costs and Expenses:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 9pt">General and administrative</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">27</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">35</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Cost of&nbsp; laboratory services</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">116</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">251</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 9pt">Total operating costs and expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">143</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">286</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">Income (loss) from discontinued operations</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(28</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">37</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">Other Income:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;Gain on the sale of Adeona Clinical Laboratory</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">677</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Net income from discontinued operations</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">649</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">37</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>5.</B></TD><TD STYLE="text-align: justify"><B>Selected Balance Sheet Information</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable consisted of the following
at March 31, 2012 and December 31, 2011 <I>(in thousands):</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2012</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2011</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 62%; font-size: 10pt; text-align: justify">Accounts receivable</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">736</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 17%; font-size: 10pt; text-align: right">692</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Bad debt allowance - customer</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(296</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(287</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">Accounts receivable, net</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">440</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">405</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and Equipment consisted of the
following at March 31, 2012, and December 31, 2011 <I>(in thousands)</I>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March&nbsp;31,&nbsp;2012</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid; text-align: center">December&nbsp;31, 2011</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 62%; font-size: 10pt; text-align: justify">Manufacturing equipment</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">400</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 17%; font-size: 10pt; text-align: right">400</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">Computer and office equipment</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">159</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">159</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Laboratory equipment</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">136</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">136</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">695</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">695</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Less accumulated depreciation</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(392</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(372</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">Property and equipment, net</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">303</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">323</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Depreciation expense for the three months ended March 31, 2012
and 2011 was $20,000 and $80,000, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>6.</B></TD><TD STYLE="text-align: justify"><B>Stock-Based
                                                                                      Compensation</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During 2001, Pipex Therapeutics&rsquo;
board of directors and stockholders adopted the 2001 Stock Incentive Plan (the &ldquo;2001 Stock Plan&rdquo;). This plan was assumed
by Pipex in the October 2006 merger with Sheffield. As of the date of the merger, there were 1,489,353 options issued and outstanding
under the 2001 plan. The total number of shares of stock with respect to which stock options and stock appreciation rights may
be granted to any one employee of the Company or a subsidiary during any one-year period under the 2001 plan shall not exceed
250,000. All awards pursuant to the 2001 Stock Plan shall terminate upon the termination of the grantee&rsquo;s employment for
any reason. Awards include options, restricted shares, stock appreciation rights, performance shares and cash-based awards (the
&ldquo;Awards&rdquo;). The 2001 Stock Plan contains certain anti-dilution provisions in the event of a stock split, stock dividend
or other capital adjustment, as defined in the plan. The 2001 Stock Plan provides for a Committee of the Board to grant awards
and to determine the exercise price, vesting term, expiration date and all other terms and conditions of the awards, including
acceleration of the vesting of an award at any time. As of March 31, 2012, there were 1,066,007 options issued and outstanding
under the 2001 Stock Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 20, 2007, the Company&rsquo;s
board of directors approved the Company&rsquo;s 2007 Stock Incentive Plan (the &ldquo;2007 Stock Plan&rdquo;) for the issuance
of up to 2,500,000 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation
rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees,
directors and consultants of the Company and its subsidiaries. This plan was approved by stockholders on November 2, 2007. The
exercise price of stock options under the 2007 Stock Plan is determined by the compensation committee of the Board of Directors,
and may be equal to or greater than the fair market value of the Company&rsquo;s common stock on the date the option is granted.
The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one
employee of the Company or a subsidiary during any one-year period under the 2001 plan shall not exceed 250,000. Options become
exercisable over various periods from the date of grant, and generally expire ten years after the grant date. As of March 31,
2012, there are 1,031,394 options issued and outstanding under the 2007 Stock Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 2, 2010, the board of
directors and stockholders adopted the 2010 Stock Incentive Plan (&ldquo;2010 Stock Plan&rdquo;) for the issuance of up to
3,000,000 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock
appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to
officers, other employees, directors and consultants of the Company and its subsidiaries. The exercise price of stock options
under the 2010 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or
greater than the fair market value of the Company&rsquo;s common stock on the date the option is granted. Options become
exercisable over various periods from the date of grant, and generally expire seven to ten years after the grant date. As of
March 31, 2012, there are 1,746,064 options issued and outstanding under the 2010 Stock Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event of an employee&rsquo;s termination,
the Company will cease to recognize compensation expense for that employee. There is no deferred compensation recorded upon initial
grant date, instead, the fair value of the stock-based payment is recognized ratably over the stated vesting period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has applied fair value accounting
for all stock-based payment awards since inception. The fair value of each option or warrant granted is estimated on the date
of grant using the Black-Scholes option-pricing model. The Black-Scholes assumptions used in the months ended March 31, 2012 and
2011 are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2012</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2011</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">Exercise price</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">$1.14 &ndash; $2.47</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">$1.21 &ndash; $2.22</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 62%; font-size: 10pt; text-align: justify">Expected dividends</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 18%; font-size: 10pt; text-align: center">0%</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 18%; font-size: 10pt; text-align: center">0%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">Expected volatility</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">108% &ndash; 174%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">185% &ndash; 188%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">Risk free interest rates</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">0.37% &ndash; 1.98%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">2.81% &ndash; 3.58%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">Expected life options</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">10 years</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">5 years &ndash; 7 years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">Expected forfeitures</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">0%</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">0%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records stock-based compensation
based upon the stated vested provisions in the related agreements, with recognition of expense recorded on the straight line basis
over the term of the related agreement. The vesting provisions for these agreements have various terms as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt; text-align: justify">immediate vesting,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">one-half vesting immediately and the remainder over three years</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">monthly over three years,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">quarterly over three years,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">annually over three years,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">one-third immediate vesting and remaining annually over two years,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&#9679;&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">one-eighth immediate vesting with remaining vesting over two years,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">one-half immediate vesting with remaining vesting over nine months;
    and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">one quarter immediate vesting with the remaining over three years.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended
March 31, 2012, the Company granted 1,300,000 options to employees and consultants having a fair value of approximately $3
million based upon the Black-Scholes option pricing model.&nbsp; During the same period of 2011, the Company granted 324,502
options to employees having a fair value of approximately $433,000 based upon the Black-Scholes option pricing model.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A summary of stock option activities as of March 31, 2012,
and for the year ended December 31, 2011, is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Weighted
    <BR>Average <BR>&nbsp;Exercise <BR>Price</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Weighted
    Average     Remaining <BR>Contractual <BR>Life</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Aggregate
    <BR>Intrinsic <BR>Value</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 48%; font-size: 10pt; text-align: justify">Balance &ndash; December 31, 2010</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">2,539,091</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">1.32</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">Granted</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">557,002</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1.26</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">Exercised</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(23,333</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.57</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Forfeited or expired</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(93,750</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">0.59</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">Balance &ndash; December 31, 2011</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,979,010</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1.34</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">Granted</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,300,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2.35</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">Exercised</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(289,343</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.23</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Forfeited or expired</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(146,202</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">0.80</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">Balance &ndash; March 31, 2012 &ndash; outstanding</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">3,843,465</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1.79</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">7.18
                                                                                                years</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,230,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">Balance &ndash; March 31, 2012 &ndash; exercisable</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,323,320</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1.62</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5.73
                                                                                                years</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,814,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The options outstanding and exercisable as of March 31, 2012,
are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="13" STYLE="font-size: 10pt; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"><B>Options&nbsp;Outstanding&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="9" STYLE="font-size: 10pt; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid"><B>&nbsp;Options&nbsp;Exercisable</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Weighted</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Weighted&nbsp;Average</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Weighted</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Weighted&nbsp;Average</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Range&nbsp;of</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Average</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Remaining</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Average</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Remaining</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Exercise&nbsp;Price</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Options</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Exercise&nbsp;Price</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Contractual&nbsp;Life</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Options</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Exercise&nbsp;Price</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Contractual&nbsp;Life</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: center">$0.09
                                                                        - $4.57</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">3,753,466</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">1.69</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 13%; font-size: 10pt; text-align: center">7.29 years</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">2,233,321</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">1.44</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 13%; font-size: 10pt; text-align: center">5.86 years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center">$4.58
                                                                                  - $9.05</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">89,999</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5.93</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">2.51 years</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">89,999</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5.93</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">2.51 years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: center">$0.09
                                                                                    - $9.05</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">3,843,465</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1.79</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: center">7.18 years</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,323,320</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1.62</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: center">5.73 years</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The options outstanding and exercisable
as of March 31, 2011, are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="13" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>&nbsp;Options&nbsp;Outstanding</B></TD><TD STYLE="font-size: 10pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="9" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>&nbsp;Options&nbsp;Exercisable</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Weighted</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Weighted&nbsp;Average</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Weighted</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Weighted&nbsp;Average</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Range&nbsp;of</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Average</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Remaining</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Average</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">Remaining</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Exercise&nbsp;Price</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Options</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Exercise&nbsp;Price</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Contractual&nbsp;Life</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Options</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Exercise&nbsp;Price</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Contractual&nbsp;Life</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: center">$0.09
                                                                        - $4.57</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">2,721,921</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">1.22</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 13%; font-size: 10pt; text-align: center">6.75 years</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">2,183,073</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 11%; font-size: 10pt; text-align: right">1.32</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 13%; font-size: 10pt; text-align: center">6.27 years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: center">$4.58
                                                                                  - $9.05</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">89,999</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5.93</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">3.51 years</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">89,999</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5.93</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; padding-bottom: 1pt; border-bottom: Black 1pt solid">3.51 years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: center">$0.09
                                                                                    - $9.05</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,811,926</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1.37</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: center">6.65 years</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,273,072</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1.50</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: center">6.16 years</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Options of Subsidiary</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During 2004 and 2007, CD4 granted 30,000
options. On August 5, 2009, 10,000 of these options expired. As of March 31, 2012, a total of 20,000 options were outstanding
and exercisable with an exercise price of $0.20 and a remaining contractual life of 0.12 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2012, Epitope has 50,000
options outstanding and 20,000 options exercisable with an exercise price of $0.001 and a remaining contractual life of 6.25 years.&nbsp;&nbsp;These
options were granted during 2008, vest annually over 5 years, and have a fair value of $50, which was determined using the Black-Scholes
model with the following assumptions: expected dividend yield of 0%; expected volatility of 200%, risk free interest rate of 2.47%
and an expected life of 10 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>7.</B></TD><TD STYLE="text-align: justify"><B>Stock
                                                                                      Purchase Warrants</B></TD>
</TR>     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 15, 2012, the Company entered
into a consulting agreement for a financial communications program, for a period of twelve months that began on February 20, 2012.
As compensation for such program, the consultant is paid a monthly fee and will be issued a performance warrant exercisable for
250,000 shares of the Company&rsquo;s common stock based on achievement of certain milestones. Upon initiation of the program,
50,000 of the performance warrants vested. The performance warrant is exercisable for a period of two years from the date the agreement
was executed for an exercise price equal to the price of the Company&rsquo;s common stock on the date of execution. The fair value
of the warrant approximated $61,000 and was measured using the Black-Scholes valuation model. The assumptions used by the Company
are summarized in the following table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt">Exercise price</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">$ &nbsp;&nbsp;&nbsp;&nbsp;2.20</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; width: 81%">Expected dividends</TD><TD STYLE="font-size: 10pt; width: 2%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; width: 15%">0</TD><TD STYLE="font-size: 10pt; text-align: left; width: 1%">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">Expected volatility</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">108</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Risk free interest rate</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.37</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">Expected life of warrant</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2 years</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Expected forfeitures</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 20, 2011, the Company entered
into a consulting agreement for financial advisory services, for a period of twelve months. As compensation for such services,
the consultant is paid a monthly fee and on February 2, 2012, was issued a warrant exercisable for 100,000 shares of the Company&rsquo;s
common stock. The warrant is exercisable upon issuance for a period of five years from the date of issue at an exercise price equal
to the price of the Company&rsquo;s common stock on the date of issue. The fair value of the warrant approximated $200,000 and
was measured using the Black-Scholes valuation model. The assumptions used by the Company are summarized in the following table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt">Exercise price</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">$&nbsp;&nbsp;&nbsp;&nbsp; 1.14</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; width: 81%">Expected dividends</TD><TD STYLE="font-size: 10pt; width: 2%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; width: 1%">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; width: 15%">0</TD><TD STYLE="font-size: 10pt; text-align: left; width: 1%">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">Expected volatility</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">174</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Risk free interest rate</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.71</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">Expected life of warrant</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5 years</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Expected forfeitures</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0</TD><TD STYLE="font-size: 10pt; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 6, 2011, the Company entered into
a Common Stock Purchase Agreement with an institutional investor. As part of this agreement, the Company issued a warrant to purchase
844,391 shares of common stock. The warrants have an exercise price of $1.00 and a life of fifteen months. The warrants vested
immediately and expire August 10, 2012. As of March 31, 2012, 344,391 of these warrants remained outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 28, 2011, the Company entered
into a Common Stock Purchase Agreement with three institutional investors. As part of this agreement, the Company issued warrants
to purchase 1,428,572 shares of common stock. The warrants have an exercise price of $1.40 and a life of fifteen months. The warrants
vested immediately and expire May 1, 2012. As of March 31, 2012, 746,429 of these warrants remained outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 2, 2010, the Company entered into
a Common Stock Purchase Agreement with a single investor. As part of this agreement, the Company issued warrants to purchase 60,606
shares of common stock to the placement agent, or its permitted assigns. The warrants have an exercise price of $1.32 and a life
of 5 years. The warrants vested on January 1, 2011 and expire December 31, 2015. Since these warrants were granted as part of an
equity raise, the Company has treated them as a direct offering cost. The result of the transaction has no affect to equity. As
of March 31, 2012, 18,182 of these warrants remained outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;A summary of warrant activities as of March 31, 2012,
and for the year ended December 31, 2011, is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Warrants</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Weighted
    <BR>Average&nbsp;Exercise Price</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 64%; font-size: 10pt; text-align: justify">Balance &ndash; December 31, 2010</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">1,131,078</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 15%; font-size: 10pt; text-align: right">3.49</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">Granted</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,272,963</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1.25</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">Exercised</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(15,615</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1.03</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Expired</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(129,240</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2.08</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">Balance &ndash; December 31, 2011</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,259,186</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1.95</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">Granted</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">350,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1.90</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify">Exercised</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,194,264</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1.24</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1pt">Expired</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">Balance &ndash; March 31, 2012 - outstanding</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,414,922</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2.36</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 2.5pt">Balance &ndash; March 31, 2012 &ndash; exercisable</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,214,922</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2.37</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The warrants outstanding as of March 31,
2012, are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Exercise<BR> Price</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Warrants<BR> Outstanding</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Warrants<BR> Exercisable</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Weighted&nbsp;Average<BR>
Remaining<BR> Contractual&nbsp;Life</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Aggregate<BR>
Intrinsic Value</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 16%; font-size: 10pt; text-align: right">1.00</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; font-size: 10pt; text-align: right">369,391</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; font-size: 10pt; text-align: right">369,391</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; font-size: 10pt; text-align: right">0.36 years</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 16%; font-size: 10pt; text-align: right">443,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1.14</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">100,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">100,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4.84 years</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">106,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1.32</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">18,182</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">18,182</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3.75 years</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">16,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1.40</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">721,429</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">721,429</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">0.08 years</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">577,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">2.20</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">250,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">50,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1.96 years</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">2.22</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">517,257</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">517,257</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4.66 years</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">3.30</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">61,207</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">61,207</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3.30 years</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">3.75</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">50,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">50,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3.88 years</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">6.36</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">327,456</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">327,456</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">0.61 years</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,414,922</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,214,922</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1.81 years</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,142,000</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>8.</B></TD><TD STYLE="text-align: justify"><B>Stockholders&rsquo;
                                                                                      Equity</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended
March 31, 2012, the Company issued 289,343 shares of common stock, in connection with the exercise of stock options, for
proceeds of  approximately $68,000. The Company also issued 1,194,264 shares of common stock in connection with the exercise
of warrants, for proceeds of approximately $1.5 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>9.</B></TD><TD STYLE="text-align: justify"><B>Subsequent Event</B>s</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 1, 2012, the Company was informed
by Berman &amp; Company, P.A. (&ldquo;Berman &amp; Company&rdquo;), the Company&rsquo;s independent registered accounting firm,
that during a regular Public Company Accounting Oversight Board (&ldquo;PCAOB&rdquo;) inspection of Berman &amp; Company, the PCAOB
issued a comment that the audit opinion included in the Company&rsquo;s Annual Report on Form 10-K for the year ended December
31, 2011 was issued by a partner at Berman &amp; Company who was not authorized under the PCAOB rules to issue the opinion or act
as our named engagement partner with respect to the Form 10-K audit (or prior 2011 Form 10-Q interim reviews) after the original
engagement partner rotated off the account under the Securities and Exchange Commission&rsquo;s independence rules as it pertains
to partner rotation (S-X Rule 2-01 - Qualifications of Accountants).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company received funds from the exercise
of warrants but will not issue any shares under any of its outstanding registration statements on Form S-3 until such time as it
receives guidance from the SEC whether the issue disclosed herein affects the Company&rsquo;s ability to continue to issue securities
thereunder. The Company intends to return all of the funds to the warrant holders. The Company has sought guidance from the SEC
staff regarding this matter and intends to file a waiver request to the extent it becomes necessary.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 10, 2012, Jeffrey J. Kraws was appointed
as the independent, non-executive Chairman of the Board. For his service as independent, non-executive Chairman of the Board, Mr.
Kraws will receive annual compensation of $150,000. Additionally, Mr. Kraws was granted options to purchase 100,000 shares of the
Company&rsquo;s common stock with an exercise price equal to our per share market price on the date of issue. These options will
vest pro rata, quarterly over a two year period with the first quarterly issuance of 12,500 options vesting immediately. The Company
measured the fair value of the stock options at approximately $166,000 using a Black-Scholes valuation model; these warrants were
indexed to the Company&rsquo;s own stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Black-Scholes assumptions used in calculating
the fair value of the stock options are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 40%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="width: 68%; font-size: 10pt">Exercise price</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 30%; font-size: 10pt; text-align: center">$1.70</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Expected dividends</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">0%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">Expected volatility</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">171%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Risk free interest rate</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">1.28%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,255,204)">
    <TD STYLE="font-size: 10pt; text-align: left">Expected life of options</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">7 years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Expected forfeitures</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">0%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 2. MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL
INFORMATION AND RESULTS OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The following discussion should be
read in conjunction with the attached unaudited consolidated financial statements and notes thereto, and with our audited consolidated
financial statements and notes thereto for the fiscal year ended December 31, 2011, found in our Annual Report on Form 10-K/A. In
addition to historical information, the following discussion contains forward-looking statements that involve risks, uncertainties
and assumptions. Where possible, we have tried to identify these forward looking statements by using words such as &ldquo;anticipate,&rdquo;
&ldquo;believe,&rdquo; &ldquo;intends,&rdquo; or similar expressions. Our actual results could differ materially from those anticipated
by the forward-looking statements due to important factors and risks including, but not limited to, those set forth under &ldquo;Risk
Factors&rdquo; in this 10-Q and as applicable in Part I, Item 1A of our Annual Report on Form 10-K/A. Unless the context requires
otherwise, references to &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; and &ldquo;Synthetic Biologics,&rdquo; refer to
Synthetic Biologics, Inc. (formerly Adeona Pharmaceuticals, Inc.) and its subsidiaries.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a biotechnology company focused
on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. Our initial
synthetic biologic product candidate is intended to treat PAH, a serious life-threatening lung disease, by locally delivering
therapeutic DNA to the lungs of PAH patients and controlling long-term expression of such DNA via an oral daily pill. We also
intend to expand new and existing collaborations in the area of DNA-based therapeutics. In addition, we have several small molecule
clinical-stage programs, the majority of which are being funded, or partially funded, by grants, charitable organizations and
corporate partners. In this area we are developing, or have partnered the development of, product candidates to treat relapsing-remitting
MS, cognitive dysfunction in MS, fibromyalgia and ALS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt"><I>Product Pipeline:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt"><I>Synthetic Biologics:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 4%; padding-right: 0.2pt; padding-left: 0.5in; text-indent: -0.48in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="width: 86%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 0; text-align: justify">Our initial synthetic
        biologic product candidate is intended to treat PAH, a serious life-threatening lung disease. This product is designed
        to deliver DNA that encodes a therapeutic protein called PGIS locally to the pulmonary arteries of PAH patients via a
        single procedure, and, via an oral daily pill, control the long-term local expression of such therapeutic protein. We
        are developing this initial product candidate pursuant a global exclusive channel collaboration that we entered into with
        the private synthetic biology company Intrexon in November 2011. As part of this collaboration, we have access to Intrexon's
        UltraVector<SUP>&reg;</SUP> platform and RheoSwitch Therapeutic System<SUP>&reg;</SUP> for this product application. We
        anticipate that by continuously producing and delivering prostacyclin directly where it is needed, in the pulmonary arteries
        of PAH patients, this product candidate may overcome the dose limiting side effects of systemic prostacyclin treatments
        for PAH, a mainstay of PAH treatment. According to GlobalData, the global market for PAH treatments is estimated to exceed
        $3.6 billion by 2015.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.4pt 0pt 0; text-align: justify">(UltraVector<SUP>&reg;
        </SUP>and RheoSwitch Therapeutic System<SUP>&reg;</SUP> are registered trademarks of Intrexon Corporation)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt">&nbsp;</P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt"><I>Funded / Small Molecule Clinical Programs:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 4%; padding-right: 0.8pt; padding-left: 0.5in; text-indent: -0.48in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="width: 86%; padding-right: 0.8pt; text-align: justify">Trimesta<SUP>TM</SUP> (oral estriol) is being developed
    as an oral once-daily treatment for relapsing-remitting MS in women. Patient enrollment of 164 patients is complete in this
    randomized, double-blind, placebo-controlled Phase II clinical trial being conducted at 15 centers in the U.S. Patients are
    being dosed and monitored for two years. This clinical trial is supported by grants exceeding $8 million, which should be
    sufficient to fund the trial through completion. Current sales of injectable disease-modifying therapies for MS are estimated
    at $8.9 billion annually.&nbsp;According to various reports, sales of oral disease-modifying therapies for MS, of which Trimesta&trade;,
    if and when approved, would be in such class, are anticipated to grow from $500 million in 2010 to $5 billion annually by
    2017.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 4%; padding-right: 0.8pt; padding-left: 0.5in; text-indent: -0.48in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="width: 86%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.6pt 0pt 0; text-align: justify">Trimesta<SUP>TM</SUP>
        (oral estriol) is also being developed for the treatment of cognitive dysfunction in female MS patients. In January 2012,
        patient enrollment began in a randomized, double-blind, placebo-controlled Phase II clinical trial being conducted at
        University of California, Los Angeles (UCLA). The majority of the costs of this trial are being funded by grants from
        foundations and charitable organizations and we have pledged approximately $500,000 to UCLA to partially fund this trial
        payable over three years. An estimated 50-65% of MS patients are expected to develop disabilities due to cognitive dysfunction
        and there is currently no approved treatment.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.6pt 0pt 0; text-align: justify">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; padding-left: 0.5in; text-indent: -0.48in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">Effirma<SUP>TM</SUP> (flupirtine) is being developed for the treatment
    of fibromyalgia. On May 6, 2010, we entered into a sublicense agreement with Meda AB, a multi-billion dollar international
    pharmaceutical company, covering all of our patents&rsquo; rights on the use of flupirtine for fibromyalgia in the U.S., Canada
    and Japan. According to Meda&rsquo;s 2011 Annual Report, flupirtine for fibromyalgia is in Phase II development. The sublicense
    agreement provides that all ongoing and future development costs are to borne by Meda and we are entitled to receive certain
    payments if milestones are achieved and royalties on sales. Based on an estimated annual price of $1,200 per fibromyalgia
    patient, we estimate that the total market potential in the U.S. is $6 billion.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 4%; padding-right: 0.8pt; padding-left: 0.5in; text-indent: -0.48in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="width: 86%; padding-right: 0.8pt; text-align: justify">AEN-100 (gastroretentive zinc acetate) is being developed
    under an investigator-initiated IND application for the treatment of ALS, also known as Lou Gehrig&rsquo;s disease. We intend
    to sponsor a multi-center, double-blind, placebo-controlled, adaptively designed Phase II/III clinical trial in ALS patients.
    It is anticipated that the clinical trial will comprise two phases. The first phase of the trial is anticipated to enroll
    at least 65 patients randomized to receive either AEN-100 or placebo for a period of six months at which time the average
    change in functional rating between the groups will be compared via an interim analysis conducted on a blinded basis. Should
    the interim analysis meet the threshold criteria in favor of the treatment group, the second phase of the study will be initiated
    and will seek to enroll approximately 50 additional subjects to receive treatment for nine months. This study is intended
    to be conducted by PNA which previously sponsored and completed a successful pilot Phase I/II study of oral zinc therapy for
    ALS.&nbsp;Separately, PNA intends to conduct a Phase I study of AEN-100 in normal volunteers prior to initiating the Phase
    II/III clinical trial in ALS patients. We have committed to support approximately $400,000 to PNA for the first phase of the
    Phase II/III clinical trial study, payable based upon study enrollment and milestones. There is only one approved therapy
    for ALS, the efficacy of which is considered to be marginal. Based on an estimated annual price of $10,000 per ALS patient,
    we estimate that the total market potential in the U.S. is $300 million.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 18, 2011, we entered into
a Channel Agreement with Intrexon that governs an &ldquo;exclusive channel collaboration&rdquo; arrangement in which we intend
to use Intrexon&rsquo;s technology directed towards the production of PGIS, through the use of <I>in vivo</I> conditionally regulated
embedded controllable bioreactors for the treatment of PAH. The Channel Agreement establishes committees comprised of our and
Intrexon representatives that will govern activities related to the PAH program in the areas of project establishment, chemistry,
manufacturing and controls, clinical and regulatory matters, commercialization efforts and intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As partial consideration for execution
of the Channel Agreement, we entered into a Stock Purchase Agreement with Intrexon pursuant to which we issued to Intrexon a number
of shares of our common stock equal to 9.995% of the number of shares of our common stock issued and outstanding following and
giving effect to such issuance (the &ldquo;First Tranche&rdquo;) at a purchase price equal to the $0.001 par value of such shares,
which issuance was deemed paid in partial consideration for the execution and delivery of the Channel Agreement. We also agreed
to issue additional shares of our common stock to Intrexon upon dosing of the first patient in a Phase II clinical trial sponsored
by us in the U.S., or similar study as the parties may agree in a country other than the U.S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-align: justify">On December 21, 2011, we announced
that the Board of Directors had taken several actions to prioritize our focus on our entry into the emerging field of synthetic
biology. In connection with the change in business focus on March 8, 2012, we entered into a Membership Interest Purchase Agreement,
and certain related agreements, pursuant to which we sold all of our interest in the Lab to Hartlab, LLC, an entity controlled
by the Lab&rsquo;s former owner, in consideration for (i) the immediate assignment of the Lab&rsquo;s outstanding accounts receivable
up through the date of closing, plus (ii) Seven Hundred Thousand Dollars ($700,000) payable pursuant to the terms of a two-year
non-recourse promissory note secured by all of the assets of the Lab.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 15, 2012, upon stockholder
approval, we amended our Articles of Incorporation to change our name to Synthetic Biologics, Inc. Our common stock continues
trade on the NYSE Amex stock exchange, currently under the symbol &ldquo;SYN&rdquo;. Prior to this time and since October 16,
2008, our name was Adeona Pharmaceuticals, Inc. and we traded on the NYSE Amex stock exchange under the symbol &ldquo;AEN&rdquo;.
We are incorporated in the State of Nevada. We continue to maintain our principal executive offices in Ann Arbor, MI, and are
currently located at 3985 Research Park Drive, Suite 200, Ann Arbor, MI 48108.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective as of June 30, 2010, we emerged
from a &ldquo;Development-Stage Entity&rdquo; as defined by Financial Accounting Standards Board Accounting Standards Codification
(FASB ASC) 915-10. On May 6, 2010, we entered into a sublicense agreement with Meda&nbsp;AB of Sweden. This agreement provides
that Meda AB will assume all future development costs for the commercialization of oral flupirtine for fibromyalgia. As consideration
for such sublicense, we received an up-front payment of $2.5 million and are entitled to milestone payments of $5 million upon
filing of an NDA with the FDA of oral flupirtine for fibromyalgia and $10 million upon marketing approval, plus royalties. We
consider the agreement with Meda AB to be an indication that we have commenced our principal operations and therefore are not
required to report as a development-stage entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, we have financed our operations
primarily through public and private sales of our common stock, and we expect to continue to seek to obtain the required capital
in a similar manner. We have incurred an accumulated deficit of $53.1 million through March 31, 2012. We cannot provide any assurance
that we will be able to achieve profitability on a sustained basis, if at all, obtain the required funding, obtain the required
regulatory approvals, or complete additional corporate partnering or acquisition transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><B>Product
Candidates and Medical Indications</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Synthetic Biologic Products</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are engaged in the emerging field of
synthetic biology directed for the purpose of developing new human therapeutic products. Synthetic biology in an emerging field
that combines molecular biology and automation to design, optimize and construct new biological systems and functions. These technologies
utilize a combination of automated processes including, DNA sequencing, computer-aided design, DNA synthesis, fabrication of modular
transgenes and high throughput testing to create and optimize biologic products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our initial efforts in this area are being
conducted in collaboration with Intrexon, and are directed towards the design, optimization and development of synthetic DNA-based
therapeutic product candidates utilizing Intrexon&rsquo;s UltraVector<SUP>&reg;</SUP> platform for the treatment of PAH. Synthetic
DNA-based therapeutics comprise constructs of DNA that can be administered to patients via a single procedure. Once introduced,
they are intended to continuously produce therapeutic proteins <I>in vivo</I> in a controllable and localized fashion for up to
a period of years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An important feature of our product candidates
developed in collaboration with Intrexon may be the incorporation of Intrexon&rsquo;s RheoSwitch Therapeutic System<SUP>&reg;</SUP>.
Such system is intended to provide unprecedented control of therapeutic protein expression through the use of a highly specific
orally available activating ligand that can be taken by patients on a daily basis as one or more pills. In this way, the levels
of <I>in vivo</I> protein expression may be adjusted from time to time by treating physicians through simple dose adjustment of
the oral activating ligand. Such system also provides an important safety mechanism not previously available in gene therapy clinical
trials since in the absence of taking an oral pill, protein expression would not be expected to occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Pulmonary Arterial Hypertension
(PAH)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Synthetic DNA-Based Therapy</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Disease</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PAH is a progressive, disabling and life-threatening
disorder characterized by abnormally high blood pressure (hypertension) in the pulmonary artery, the blood vessel that carries
blood from the heart to the lungs. Hypertension occurs when most of the very small arteries throughout the lungs narrow in diameter,
therefore constricting blood flow through the lungs. The constriction of blood flow causes the pressure to increase in the pulmonary
artery and in the right ventricle (the heart chamber that pumps blood into the pulmonary artery). Signs and symptoms of PAH take
place when the increased pressure cannot overcome the constriction and there is insufficient blood flow to the body. Shortness
of breath during exertion and fainting spells are the most common early symptoms of PAH. Despite current treatments, PAH generally
has a very poor outcome and is associated with high rates of mortality within three to five years of diagnosis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Synthetic DNA-Based Therapeutic for
PAH</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.6pt 0pt 0; text-align: justify">Our initial synthetic DNA-based
therapeutic product candidate is intended for the treatment of PAH, a serious life-threatening lung disease. This product candidate
is designed to deliver DNA that encodes a therapeutic protein called prostacyclin synthase (PGIS) locally to the pulmonary arteries
of PAH patients via a single pulmonary catheter procedure and via an oral daily pill, control the long-term local expression of
such therapeutic protein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.6pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.6pt 0pt 0; text-align: justify">We are developing this initial
product candidate in collaboration with Intrexon. Under the collaboration, we intend to utilize Intrexon's advanced transgene
engineering platform for the controlled, precise and continuous <I>in vivo</I> cellular production of PGIS. PGIS is a specific
effector enzyme that regulates the production of prostacyclin, a potent mediator of arterial dilation that also prevents smooth
muscle proliferation and arterial wall thickening. PGIS expression is decreased in the lungs of PAH patients and deficiency in
prostacyclin production is strongly implicated in PAH. We anticipate that by continuously producing and delivering prostacyclin
directly where it is needed, in the pulmonary arteries of PAH patients via PGIS, this product candidate may overcome the dose
limiting side effects of systemic prostacyclin-based treatments for PAH. While systemic prostacyclin-based treatments for PAH
are currently a mainstay of PAH therapy, their considerable systemic side effects limit their dose and ultimate long-term utility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The global market potential for the treatment
of PAH is estimated to be up to $3.6 billion by 2015, according to GlobalData, Pulmonary Arterial Hypertension (PAH) &ndash; Drug
Pipeline Analysis and Market Forecasts for 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Relapsing-Remitting Multiple Sclerosis
(MS) in Women</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Trimesta (oral estriol)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Disease</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">MS is a progressive neurological disease
in which the body loses the ability to transmit messages along central nervous system nerve cells, leading to a loss of muscle
control, paralysis, cognitive impairment and in some cases death. According to the National Multiple Sclerosis Society (NMSS),
currently, more than 2.5 million people worldwide (approximately 400,000 patients in the U.S. of which 70% are estimated to be
women) have been diagnosed with MS. Young adults, ages 20 to 50, and two to three times as many women than men are predominantly
diagnosed with MS. According to the NMSS, approximately 85% of MS patients are initially diagnosed with the relapsing-remitting
form, compared to 10-15% with other progressive forms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are currently&nbsp;eight Food &amp;
Drug Administration (FDA) approved therapies for the treatment of relapsing-remitting MS: Betaseron<SUP>&reg;</SUP>, Rebif<SUP>&reg;</SUP>,
Avonex<SUP>&reg;</SUP>, Novantrone<SUP>&reg;</SUP>, Copaxone<SUP>&reg;</SUP>, Tysabri<SUP>&reg;</SUP>, Gilenya<SUP>&reg;</SUP>
and Extavia<SUP>&reg;</SUP>. These therapies provide only a modest benefit for patients with relapsing-remitting MS and therefore
serve to only delay progression of the disease. All of these drugs except Gilenya<SUP>&reg;</SUP> require frequent (daily, weekly
&amp; monthly) injections (or infusions) on an ongoing basis and can be associated with unpleasant side effects (such as flu-like
symptoms), high rates of non-compliance among users, and eventual loss of efficacy due to the appearance of resistance in approximately
30% of patients. Despite the availability of multiple FDA-approved therapies for the treatment of relapsing-remitting MS, the
disease is highly underserved and exacts a heavy economic toll.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Current sales of injectable disease-modifying
therapies for MS are estimated at $8.9 billion annually.&nbsp; According to various reports, sales of oral disease-modifying therapies
for MS, of which Trimesta, if and when approved, would be in such class, are anticipated to grow from $500 million in 2010 to
in excess of $5 billion annually by 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Background</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It has been scientifically documented
that pregnant women with certain autoimmune diseases experience a spontaneous reduction of disease symptoms during pregnancy,
particularly in the third trimester. The PRIMS (Pregnancy In MS) study, a landmark clinical study published in the <I>New England
Journal of Medicine</I> followed 254 women with MS during 269 pregnancies and for up to one year after delivery. The PRIMS study
demonstrated that relapse rates were significantly reduced by 71 percent (p &lt; 0.001) through the third trimester of pregnancy
compared to pre-pregnancy-rates, and that relapse rates increased by 120 percent (p &lt; 0.001) during the first three months
after birth (post-partum) before returning to pre-pregnancy rates. It has been hypothesized that the female hormone, estriol,
produced by the placenta during pregnancy, plays a role in&nbsp;&ldquo;fetal immune privilege&rdquo;, a process that prevents&nbsp;a
mother&rsquo;s immune system from attacking and rejecting&nbsp;her fetus.&nbsp;Maternal levels of estriol increase in a linear
fashion through the third trimester of pregnancy until birth, whereupon they abruptly return to low circulating levels. The anti-autoimmune
effects of estriol are thought to be responsible for the therapeutic effects of pregnancy on MS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Rhonda Voskuhl, M.D., Director, UCLA MS
program, UCLA Department of Neurology, has found that pregnancy levels of estriol have potent immunomodulatory effects. She further
postulated and tested in pilot clinical studies that oral doses of estriol may have a therapeutic benefit when administered to
non-pregnant female MS patients by, in essence, mimicking the spontaneous reduction&nbsp;in relapse rates seen in MS patients
during pregnancy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Estriol has been approved and marketed
for over 40 years throughout Europe and Asia for the oral treatment of post-menopausal symptoms. It has never been approved by
the U.S. FDA for any indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Clinical Development</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Trimesta (oral estriol) drug candidate
is for the treatment of relapsing-remitting MS in women. An investigator-initiated, 10-patient, 22-month, single-agent, crossover
clinical trial to study the therapeutic effects of 8 mg of oral Trimesta taken daily in non-pregnant female relapsing-remitting
MS patients was completed in the U.S. The total volume and number of gadolinium-enhancing lesions were measured by brain magnetic
resonance imaging (an established neuroimaging measurement of disease activity in MS). Over the next three months of treatment
with Trimesta, the median total enhancing lesion volumes decreased by 79% (p = 0.02) and the number of lesions decreased by 82%
(p = 0.09). They remained decreased during the next 3 months of treatment, with lesion volumes decreased by 82% (p = 0.01), and
numbers decreased by 82% (p =0.02). Following a six-month drug holiday during which the patients were not on any drug therapies,
median lesion volumes and numbers returned to near baseline pretreatment levels. Trimesta therapy was reinitiated during a four-month
retreatment phase of this clinical trial. The relapsing-remitting MS patients again demonstrated a decrease in enhancing lesion
volumes of 88% (p = 0.008) and a decrease in the number of lesions by 48% (p = 0.04) compared with original baseline scores.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A Phase II randomized, double-blind, placebo-controlled
clinical trial is currently underway at 15 centers in the U.S. The purpose of this clinical trial is to study whether 8 mg of
oral Trimesta taken daily over a two year period will reduce the rate of relapses in a large population of female patients with
relapsing-remitting MS. Investigators are administering either Trimesta or matching placebo, in addition to a standard of care,
glatiramer acetate (Copaxone<SUP>&reg;</SUP>) injections, an FDA-approved therapy for MS, to women between the ages of 18 to 50
who have been recently diagnosed with relapsing-remitting MS. The primary endpoint in this clinical trial being run under an investigator-initiated
IND application, is relapse rates at two years. As of January 23, 2012, 164 patients have been enrolled in the clinical trial
and the trial enrollment has been closed. The patients will be dosed and monitored for two years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With over $8 million in grant funding
to date, the ongoing Trimesta clinical trial should be funded to its completion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Cognitive Dysfunction in Multiple Sclerosis</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Trimesta (oral estriol)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Disease</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to the NMSS and the Multiple
Sclerosis Society of Canada publication, <I>Hold that Thought! Cognition and MS</I> , it is fairly common for people with MS to
complain of problems remembering things, finding the right words, concentrating on a task or something they are reading, or following
a conversation. These are all cognitive symptoms of MS. Of those affected by MS, 50-65% have cognitive dysfunction issues. Despite
the fact that most symptoms are mild to moderate, they can have a significant impact on a person&rsquo;s ability to normally function.
The overall cognitive dysfunction can be described as a reduction in mental &ldquo;sharpness.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The major areas of cognition that can
be dysfunctional include what are termed complex attention and executive functions<I>.</I> Complex attention involves multitasking,
the speed with which information can be processed, learning and memory, and perceptual skills; executive functions include problem
solving, organizational skills, the ability to plan, and word finding. Just as the nature, frequency, and severity of MS-related
physical problems can widely vary, not all people with MS will display these cognitive issues, and no two people will experience
exactly the same types or severity of problems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Background</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the investigator-initiated, 10-patient,
22-month, single-agent, crossover clinical trial conducted by Dr. Rhonda Voskuhl, a statistically significant 14% improvement
from baseline in Paced Auditory Serial Addition Test (PASAT) cognitive testing scores (p = 0.04) was observed in relapsing-remitting
MS patients after six months of Trimesta therapy. PASAT is a routine cognitive test performed in patients with a wide variety
of neuropsychological disorders such as MS. The PASAT scores are expressed as a mean percent change from baseline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><I>Clinical
Development</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Trimesta (oral estriol) drug candidate
is also being developed for the treatment of cognitive dysfunction in female MS patients. This randomized, double-blind, placebo-controlled
Phase II clinical trial to evaluate Trimesta&rsquo;s potential neuroprotective and therapeutic effect on cognitive dysfunction
in female MS patients is currently enrolling relapsing-remitting or secondary-progressive female MS patients at UCLA. Up to 64
patients between the ages of 18 and 50 will be randomized 1:1 into the treatment and placebo groups. Dr. Voskuhl will administer
either oral Trimesta or a matching placebo, in addition to any FDA-approved MS treatment. Each patient will be dosed and monitored
for one year after being enrolled. The primary endpoint in this clinical trial being run under an investigator-initiated IND application
is expected to be improvement in PASAT cognitive testing scores versus matching placebo. We and a private foundation have pledged
to equally support this new clinical trial, and we will also provide Trimesta drug supply. The trial also received contributions
from several other supporters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Fibromyalgia</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Effirma (flupirtine)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Disease</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fibromyalgia is a chronic and debilitating
condition characterized by widespread pain and stiffness throughout the body, often accompanied by severe fatigue, insomnia and
mood symptoms. Fibromyalgia affects an estimated 3-6% of the population worldwide, including an estimated 10 million people in
the U.S. There are presently three FDA products approved for this indication in the U.S. &ndash; Lyrica<SUP>&reg;</SUP>, Cymbalta<SUP>&reg;
</SUP>and Savella<SUP>&reg;</SUP>. Flupirtine is differentiated from these products in that it employs a unique mode of action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on an estimated annual price of $1,200 per fibromyalgia
patient, we estimate that the total market potential in the U.S. is $6 billion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Clinical Development</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Effirma (flupirtine) product candidate
is for the treatment of fibromyalgia. Effirma is a selective neuronal potassium channel opener that also has NMDA receptor antagonist
properties. Effirma is a non-opioid, non-NSAID, non-steroidal, analgesic. Preclinical data and clinical experience suggest that
Effirma should also be effective for neuropathic pain since it acts in the central nervous system via a mechanism of action distinguishable
from most marketed analgesics. Effirma is especially attractive because it operates through non-opiate pain pathways, exhibits
no known abuse potential, and lacks withdrawal effects. In addition, no tolerance to its antinocioceptive effects has been observed.
One common link between neuroprotection, nocioception and Effirma may be the N-methyl-D-aspartic acid glutamate system, a major
receptor subtype for the excitotoxic neurotransmitter, glutamate. Effirma has strong inhibitory actions on N-methyl-D-aspartic
acid-mediated neurotransmission. Flupirtine was originally developed by Asta Medica (subsequently acquired by Meda AB) and has
been approved and is marketed by Meda AB in Europe since 1984, as well as other countries, for the treatment of pain. It has never
been approved by the FDA for any indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Meda Corporate Partnership</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 6, 2010, we entered into a sublicense
agreement with Meda AB, a multi-billion dollar international pharmaceutical company, pursuant to which Meda AB assumed all future
development costs and may commercialize flupirtine for fibromyalgia in the U.S. As consideration for such sublicense, we received
an up-front payment of $2.5 million and are entitled to milestone payments of $5 million upon the FDA&rsquo;s acceptance of the
New Drug Application (NDA) for flupirtine for fibromyalgia and $10 million upon FDA approval of such NDA. Pursuant to the sublicense
agreement, we will also receive a 7% royalty on net sales of flupirtine for fibromyalgia in the U.S., Canada and Japan, with such
royalties being shared equally with our licensor, McLean Hospital, a Harvard teaching hospital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Flupirtine is approved and marketed by
Meda AB and its distributors in Europe and other countries for indications other than fibromyalgia and has been prescribed to
millions of patients worldwide. We believe that such substantial human experience with flupirtine should greatly assist the FDA
in its evaluation of the safety of flupirtine upon review of an NDA of flupirtine for fibromyalgia. According to Meda&rsquo;s
2011 Annual Report, flupirtine for fibromyalgia is in Phase II development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Amyotrophic Lateral Sclerosis (ALS)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>AEN-100 (gastroretentive zinc acetate)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Disease</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ALS, also known as Lou Gehrig&rsquo;s
disease, is a devastating progressive neurodegenerative disease that affects the motor nerve cells in the brain and the spinal
cords. It is estimated that as many as 30,000 Americans may have the disease at any given time. The progressive degeneration of
the motor neurons in ALS eventually leads to the death of the patient. Motor neurons reach from the brain to the spinal cord and
from the spinal cord to the muscles throughout the body. When motor neurons die, the ability of the brain to initiate and control
muscle movement is lost. With voluntary muscle action progressively affected, patients in the later stages of the disease may
become totally paralyzed. While non-invasive ventilation and gastrostomy tubes prolong life by 6-12 months, the average lifespan
from time of symptom onset is 2-5 years. Currently, RILUTEK<SUP>&reg;</SUP> is the only FDA-approved drug for ALS. RILUTEK is
an N-methyl d-aspartate (NMDA) receptor antagonist and has been shown to prolong life in patients with ALS by 3 months. Presently,
there is no cure for ALS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on an estimated annual price of $10,000 per ALS patient,
we estimate that the total market potential in the U.S. is $300 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Background</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical investigators at the PNA cite
multiple lines of scientific research that suggest a potential benefit of zinc therapy for ALS patients, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 4%; padding-right: 0.2pt">&#9679;</TD>
    <TD STYLE="width: 92%; padding-right: 0.2pt; text-align: justify">The use of zinc therapy for ALS patients is supported in
    animal models of ALS. Approximately 2% of ALS diagnoses are associated with a mutation in the copper/zinc superoxide dismutase
    (SOD1) gene. In ALS mutant SOD1 animal models, zinc supplementation has been shown to delay death.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 4%; padding-right: 0.2pt">&#9679;</TD>
    <TD STYLE="width: 92%; padding-right: 0.2pt; text-align: justify">Genetic mutations affecting the ability of a protein known
    as copper/zinc SOD1 to properly bind zinc are associated with the familial form of ALS, which shares many of the same features
    as the more prevalent sporadic form of ALS.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 4%; padding-right: 0.2pt">&#9679;</TD>
    <TD STYLE="width: 92%; padding-right: 0.2pt; text-align: justify">Zinc is an important modifier of glutamate toxicity, a neurotransmitter
    linked to cell death in ALS patients.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Clinical Development</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Preparations are underway to evaluate
the safety and efficacy of our proprietary drug candidate, AEN-100, a gastroretentive, sustained-release zinc-based tablet, in
a multi-center, double-blind, placebo-controlled clinical trial in ALS patients intended to be conducted under an investigator-initiated
IND application. Manufacturing of AEN-100 study material has been completed and stability studies are ongoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to provide the study material
and support a multi-center, double-blind, placebo-controlled, adaptively designed Phase II/III clinical trial in ALS patients
to be conducted by PNA. It is anticipated that the Phase II/III clinical trial will comprise two phases. The first phase of the
trial is anticipated to enroll at least 65 patients randomized to receive either AEN-100 or placebo for a period of six months
at which time the average change in functional rating between the groups will be compared via an interim analysis conducted on
a blinded basis. Should the interim analysis meet the threshold criteria in favor of the treatment group the second phase of the
study will be initiated and seek to enroll up to a total of 114 patients, inclusive of the 65 subjects from the first phase who
continue to meet eligibility criteria at such time, to receive treatment for nine months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2011, PNA reported top-line
results from its pilot Phase I/II open label, three month safety study of oral high dose zinc therapy in ALS. The clinical study
met its primary outcome as no safety issues related to zinc therapy were observed. In addition, an average decrease in the monthly
rate of disease progression was observed in the ALS patients on zinc therapy, compared to published historical controls, as well
as compared to the average monthly rate of disease progression of the subjects prior to enrollment in the study. AEN-100 is not
the same zinc formulation utilized by PNA in its previously completed Phase I/II safety study of zinc for ALS, and PNA intends
to conduct a Phase I study of AEN-100 in normal volunteers prior to initiating the Phase II/III clinical trial in ALS patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have committed to support approximately
$400,000 to PNA for the first phase of the Phase II/III clinical trial, payable based upon study enrollment and completion milestones.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Critical Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December of 2001, the SEC requested
that all registrants discuss their most &ldquo;critical accounting policies&rdquo; in management&rsquo;s discussion and analysis
of financial condition and results of operations. The SEC indicated that a &ldquo;critical accounting policy&rdquo; is one which
is both important to the portrayal of the company&rsquo;s financial condition and results and requires management&rsquo;s most
difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are
inherently uncertain. We believe that the following discussion regarding research and development expenses, general and administrative
expenses and non-cash compensation expense involve our most critical accounting policies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Accounts Receivable and Allowance for Doubtful Accounts</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable were reported at
realizable value, net of allowances for doubtful accounts, which were estimated and recorded in the period the related
revenue was recorded. We estimated and reviewed the collectability of our receivables based on a number of factors, including
the period they were outstanding. Historical collection and payer reimbursement experience was an integral part of the
estimation process related to allowances for doubtful accounts associated with Adeona Clinical Laboratory. In addition, we
regularly assessed the state of our  billing operations in order to identify issues, which impacted the collectability of
these receivables or reserve estimates. Revisions to the allowances for doubtful accounts estimates were recorded as an
adjustment to bad debt expense. Receivables deemed uncollectible were charged against the allowance for doubtful accounts.
Recoveries of receivables previously written-off are recorded as credits to the allowance for doubtful accounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Revenue Recognition</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We record revenue when all of
the following have occurred: (1) persuasive evidence of an arrangement exists, (2) the service is completed without
further obligation, (3) the sales price to the customer is fixed or determinable, and (4) collectability is
reasonably assured.&nbsp;&nbsp; We recognize milestone payments or upfront payments that have no contingencies as
revenue when payment is received.&nbsp;&nbsp;For the three months ended March 31, 2012 and 2011, our only stream of revenue
was laboratory revenue.&nbsp;Laboratory revenues are a component of discontinued operations for the three months ended March
31, 2012 and 2011. <I>See Note 4 to the Notes to the Consolidated Financial Statements &ndash; Discontinued Operations of
Adeona Clinical Laboratory and Note Receivable.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>License Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our licensing agreements may contain multiple
elements, such as non-refundable up-front fees, payments related to the achievement of particular milestones and royalties. Fees
associated with substantive at risk performance-based milestones are recognized as revenue upon completion of the scientific or
regulatory event specified in the agreement. When we have substantive continuing performance obligations under an arrangement,
revenue is recognized over the performance period of the obligations using a time-based proportional performance approach. Under
the time-based method, revenue is recognized over the arrangement&rsquo;s estimated performance period based on the elapsed time
compared to the total estimated performance period. Revenue recognized at any point in time is limited to the amount of non-contingent
payments received or due. When we have no substantive continuing performance obligations under an arrangement, it recognizes revenue
as the related fees become due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues from royalties on third-party
sales of licensed technologies are generally recognized in accordance with the contract terms when the royalties can be reliably
determined and collectibility is reasonably assured. To date, we have not received any royalty revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<I>Laboratory Revenues</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We primarily recognized revenue for services
rendered upon completion of the testing process. Billing for services reimbursed by third-party payers, including Medicare and
Medicaid, were recorded as revenues, net of allowances for differences between amounts billed and the estimated receipts from
such payers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We maintained a sales allowance to compensate
for the difference in our billing practices and insurance company reimbursements. In determining this allowance, we looked at
several factors, the most significant of which is the average difference between the amount charged and the amount reimbursed
by insurance carriers over the prior 12 months, otherwise known as the yearly average adjustment amount. The allowance taken was
the averaged yearly average adjustment amount for these prior periods and multiplied by the period&rsquo;s actual gross sales
to determine the actual sales allowance for each period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Research and Development Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expense research and development costs
as incurred. Research and development expenses consist primarily of license fees, manufacturing costs, salaries, stock-based compensation
and related personnel costs, fees paid to consultants and outside service providers for laboratory development, legal expenses
resulting from intellectual property prosecution and other expenses relating to the design, development, testing and enhancement
of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Share-Based Payment Arrangements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Generally, all forms of share-based payments,
including stock option grants, warrants, restricted stock grants and stock appreciation rights are measured at their fair value
on the awards&rsquo; grant date, based on the estimated number of awards that are ultimately expected to vest. Share-based compensation
awards issued to non-employees for services rendered are recorded at either the fair value of the services rendered or the fair
value of the share-based payment, whichever is more readily determinable. The expense resulting from share-based payments are
recorded in cost of goods sold, research and development or general and administrative expenses in the consolidated statement
of operations, depending on the nature of the services provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Three Months Ended March 31, 2012
and 2011</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>General and Administrative Expenses
</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses
increased to $1.5 million for the three months ended March 31, 2012, from $1.2&nbsp;million for the three months ended March
31, 2011. This increase of approximately 19% is primarily the result of the increased salary expense and consulting fees. The
non-cash charge relating to stock-based compensation expense was $499,000 for the three months ended March 31, 2012, compared
to $759,000 for the three months ended March 31, 2011. The stock-based compensation expense for the three months ended March
31, 2011 includes a one-time charge of $398,000 relating to the modification of certain stock options, prior to
expiration,&nbsp;held by a member of the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Research and Development Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses increased
to $386,000 for the three months ended March 31, 2012, from $231,000 for the three months ended March 31, 2011. This increase
of approximately 67% is primarily the result of the expansion of our pipeline, including the initiation of preclinical and clinical
programs. Research and development expenses also include a non-cash charge relating to stock-based compensation expense of $9,000
for the three months ended March 31, 2012 and 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Other Income (Expense), net</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other income was $5,000 for the three
months ended March 31, 2012. Other expense was $759,000 for the three months ended March 31, 2011.&nbsp;Other
expense for the three months ended March 31, 2011, included $810,000 relating to the estimated fair value of the warrants associated
with the January 2011 financing, adjusted for the change in their fair value at March 31, 2011. Other&nbsp;income for the three
months ended March 31, 2011&nbsp;included $63,000 relating to the settlement of accounts payable previously&nbsp;accrued in prior
periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Net Loss from Continuing Operations</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our net loss from
continuing operations was $1.8 million, or $0.06 per common share for the three months ended March 31, 2012, compared to a
net loss of $2.2 million, or $0.09 per common share for the three months ended March 31, 2011.&nbsp;&nbsp;The decrease in net
loss from continuing operations resulted from no warrant liability offset by increases in general and administrative expenses
and research and development expenses for the three months ended March 31, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Net Income from Discontinued Operations</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our net  income from discontinued
operations was $649,000, or $0.02 per common share for the three months ended March 31, 2012, compared to net income of
$37,000, or $0.00 per common share for the three months ended March 31, 2011.&nbsp;&nbsp;On March 8, 2012, we entered into a
Membership Interest Purchase Agreement, and certain related agreements, pursuant to which we sold all of our interest in the
Adeona Clinical Laboratory, LLC (the &ldquo;Lab&rdquo;) to Hartlab, LLC for a gain of $677,000. This resulted in
the classification of the Lab as discontinued operations. <I>See Note 4 &ndash; Discontinued Operations of Adeona
Clinical Laboratory and Note Receivable</I> for summarized statement of operations data for the three months ended March 31,
2012 and 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have financed our operations since
inception primarily through proceeds from equity financings and various private financings, primarily involving private sales
of our common stock and other equity securities, corporate partnering license fees and to a lesser extent from the&nbsp;proceeds
from the sale of our common stock under our registration statement on Form S-3, laboratory  revenues and miscellaneous
equipment sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our cash totaled $6.8 million as of March
31, 2012, an increase of approximately $100,000 from December 31, 2011.&nbsp;&nbsp;&nbsp;During the three months ended March 31,
2012, the primary sources of cash were proceeds from the stock option exercises of $68,000 and warrant exercises of $1.5 million.&nbsp;&nbsp;The
primary use of cash during the three months ended March 31, 2012 was for working capital requirements. Our cash at April 30, 2012
was approximately $6.5 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our continued operations will primarily
depend on our ability to raise additional capital from various sources including equity and debt financings, as well as, license
fees from potential corporate partners and joint ventures. Such additional funds may not become available on acceptable terms
and there can be no assurance that any additional funding that we do obtain will be sufficient to meet our needs in the long term.
We will continue to fund operations from cash on hand and through the similar sources of capital previously described. We can
give no assurances that any additional capital that we are able to obtain will be sufficient to meet our needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Current and Future Financing Needs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have incurred an accumulated deficit
of approximately $53.1 million&nbsp;as of&nbsp;March 31, 2012. With the exception of the quarter ended June 30, 2010, we have
incurred negative cash flow from operations since we started our business. We have spent, and expect to continue to spend, substantial
amounts in connection with implementing our business strategy, including our planned product development efforts, our clinical
trials, and our research and discovery efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Based on our current plans, we believe
that our cash will be sufficient to enable us to meet our planned operating needs for at least the next 12 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">However, the actual amount of funds we
will need to operate is subject to many factors, some of which are beyond our control. These factors include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt; text-align: justify">the progress of our research activities;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">the number and scope of our research programs;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">the progress of our preclinical and clinical development activities;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">the progress of the development efforts of parties with whom we have
    entered into research and development agreements;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">our ability to maintain current research and development&nbsp;licensing
    arrangements&nbsp;and to establish new research and development and licensing &nbsp;&nbsp;arrangements;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">our ability to achieve our milestones under licensing arrangements;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">the costs involved in prosecuting and enforcing patent claims and other
    intellectual property rights;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">the costs and timing of regulatory approvals; and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">profitability of our clinical laboratory diagnostic and microbiology
    services business.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have based our estimate on assumptions
that may prove to be wrong. We may need to obtain additional funds sooner or in greater amounts than we currently anticipate.
Potential sources of financing include strategic relationships, public or private sales of our shares or debt and other sources.
We may seek to access the public or private equity markets when conditions are favorable due to our long-term capital requirements.
We do not have any committed sources of financing at this time, and it is uncertain whether additional funding will be available
when we need it on terms that will be acceptable to us, or at all. If we raise funds by selling additional shares of common stock
or other securities convertible into common stock, the ownership interest of our existing stockholders will be diluted. If we
are not able to obtain financing when needed, we may be unable to carry out our business plan. As a result, we may have to significantly
limit our operations and our business, financial condition and results of operations would be materially harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>ITEM 3.&nbsp;&nbsp;QUANTITATIVE AND
QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 4. CONTROLS AND PROCEDURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in"><B>(a)&nbsp;&nbsp;&nbsp;</B>
<B>Evaluation of disclosure controls and procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Pursuant to Rule 13a-15(b)
under the Securities Exchange Act of 1934 (&ldquo;Exchange Act&rdquo;), the Company carried out an evaluation, with the participation
of the Company&rsquo;s management, including the Company&rsquo;s Chief Executive Officer (&ldquo;CEO&rdquo;) and Chief Financial
Officer (&ldquo;CFO&rdquo;), of the effectiveness of the Company&rsquo;s disclosure controls and procedures (as defined under
Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this report. Based upon that evaluation, the Company&rsquo;s
CEO and CFO concluded that the Company&rsquo;s disclosure controls and procedures are effective as of March 31, 2012 to ensure
that information required to be disclosed by the Company in the reports that the Company files or submits under the Exchange Act,
is recorded, processed, summarized and reported, within the time periods specified in the SEC&rsquo;s rules and forms, and that
such information is accumulated and communicated to the Company&rsquo;s management, including the Company&rsquo;s CEO and CFO,
as appropriate, to allow timely decisions regarding required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in"><B>(b) &nbsp;&nbsp;</B> <B>Changes
in Internal Control over Financial Reporting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">There has been no change in
our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred
during our fiscal quarter ended March 31, 2012, that has materially affected, or is reasonably likely to materially affect, our
internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART II&mdash;OTHER INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>ITEM 1.&nbsp;&nbsp;LEGAL PROCEEDINGS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>ITEM 1A. RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An investment in our securities is highly
speculative and involves a high degree of risk. Therefore, in evaluating us and our business you should carefully consider the
risks set forth below, which are only a few of the risks associated with our business and our common stock. You should be in a
position to risk the loss of your entire investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>RISKS RELATING TO OUR BUSINESS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will need to raise additional
capital to operate our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With the exception of the quarter ended
June 30, 2010, we have experienced significant losses since inception and have a significant accumulated deficit. We expect to
incur additional operating losses in the future and therefore our cumulative losses to increase. To date, other than the licensing
fee we received from Meda AB for the development and commercialization of Effirma (flupirtine) for fibromyalgia in the U.S., Canada
and Japan and limited laboratory revenues from Adeona Clinical Laboratory, which we have recently sold, we have generated very
minimal revenues. Inasmuch as our sole source of revenue (with the exception of the Meda licensing fee) has been our laboratory
revenue and our laboratory was sold recently, we do not expect to derive revenue from any source in the near future until we or
our partners successfully commercialize our products. As of March 31, 2012, our accumulated deficit totaled approximately $53.1
million on a consolidated basis. Until such time as we receive approval from the FDA and other regulatory authorities for our
product candidates, we will not be permitted to sell our products and therefore will not have product revenues from the sale of
products. For the foreseeable future we will have to fund all of our operations and capital expenditures from equity and debt
offerings, cash on hand, licensing fees and grants. If our current cash, cash equivalents and short-term investments are not sufficient
to sustain our operations, we will need to seek additional sources of financing and such additional financing may not be available
on favorable terms, if at all. If we do not succeed in raising additional funds on acceptable terms, we may be unable to complete
planned preclinical and clinical trials or obtain approval of our product candidates from the FDA and other regulatory authorities.
In addition, we could be forced to discontinue product development, forego sales and marketing efforts, and forego licensing in
attractive business opportunities. Any additional sources of financing will likely involve the issuance of our equity or debt
securities, which will have a dilutive effect on our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have not been able to sustain
profitability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other than with respect to the quarter
ended June 30, 2010, we have a history of losses and we have incurred&nbsp;and continue to incur substantial losses and negative
operating cash flow. Even if we succeed in developing and commercializing one or more of our product candidates, we may still
incur substantial losses for the foreseeable future and may not sustain profitability. We also expect to continue to incur significant
operating and capital expenditures and anticipate that our expenses will substantially increase in the foreseeable future as we
do the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="width: 90%; padding-right: 0.8pt">continue to undertake preclinical development and clinical trials for our product
    candidates;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="width: 90%; padding-right: 0.8pt">seek regulatory approvals for our product candidates;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="width: 90%; padding-right: 0.8pt">develop our product candidates for commercialization;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="width: 90%; padding-right: 0.8pt">implement additional internal systems and infrastructure;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="width: 90%; padding-right: 0.8pt">lease additional or alternative office facilities; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="width: 90%; padding-right: 0.8pt">hire additional personnel, including members of our management team.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may experience negative cash flow for
the foreseeable future as we fund our technology development with capital expenditures. As a result, we will need to generate
significant revenues in order to achieve and maintain profitability. We may not be able to generate these revenues or achieve
profitability in the future. Our failure to achieve or maintain profitability could negatively impact the value of our common
stock and underlying securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our research and development efforts
may not succeed in developing commercially successful products and technologies, which may limit our ability to achieve profitability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We must continue to explore opportunities
that may lead to new products and technologies. To accomplish this, we must commit substantial efforts, funds, and other resources
to research and development. A high rate of failure is inherent in the research and development of new products and technologies.
Any such expenditures that we make will be made without any assurance that our efforts will be successful. Failure can occur at
any point in the process, including after significant funds have been invested.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regardless of whether our clinical trials
are deemed to be successful, promising new product candidates may fail to reach the market or may only have limited commercial
success because of efficacy or safety concerns, failure to achieve positive clinical outcomes, inability to obtain necessary regulatory
approvals or satisfy regulatory criteria, limited scope of approved uses, excessive costs to manufacture, the failure to establish
or maintain intellectual property rights, or infringement of the intellectual property rights of others. Even if we successfully
develop new products or enhancements, they may be quickly rendered obsolete by changing customer preferences, changing industry
standards, or competitors' innovations. Innovations may not be quickly accepted in the marketplace because of, among other things,
entrenched patterns of clinical practice or uncertainty over third-party reimbursement. We cannot state with certainty when or
whether any of our products under development will be launched, whether we will be able to develop, license, or otherwise acquire
drug candidates or products, or whether any products will be commercially successful. Failure to launch successful new products
or new indications for existing products may cause our products to become obsolete, which may limit our ability to achieve profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>The recent issue raised by the PCAOB with our auditor
may have a negative impact on our ability to raise additional capital.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 1, 2012, we were informed by Berman
&amp; Company that during a regular PCAOB inspection of Berman &amp; Company, the PCAOB issued a comment that the audit opinion
included in our Annual Report on Form 10-K for the year ended December 31, 2011 was issued by a partner at Berman &amp; Company
who was not authorized under the PCAOB rules to issue the opinion or act as our named engagement partner with respect to the Form
10-K audit or subsequent interim reviews after the original engagement partner rotated off of the account under the Securities
and Exchange Commission&rsquo;s independence rules as it pertains to partner rotation (S-X Rule 2-01 -- Qualifications of Accountants).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> We included in our Annual Report on
Form 10-K/A, filed on May 11, 2012, an updated audit opinion for the year ended December 31, 2011, from a licensed CPA at
Berman &amp; Company who: (i) was the manager of our December 31, 2011 audit, (ii) was recently made a partner of the firm,
(iii) had performed most of the audit work on the December 31, 2011 audit after the original audit partner rotated off of the
account and (iv) will serve as our engagement partner on a going forward basis. We have sought guidance from the SEC staff
regarding this matter and intend to file a waiver request to allow it to use Form S-3 to the extent it becomes necessary,
however, no assurance can be given as to the outcome of any such waiver request. If we are unsuccessful in our attempt to
obtain a waiver from the SEC, for a period of time of up to one year we may be ineligible to utilize our Registration
Statement on Form S-3 to issue securities which may negatively impact our ability to raise necessary funds on terms
acceptable to us, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have a limited operating history
on which investors can base an investment decision.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not yet demonstrated our ability
to perform the functions necessary for the successful commercialization of any of our product candidates. We have only recently
entered into the emerging field of synthetic biology, and there can be no assurance that we will be successful in commercializing
any products in such field. The successful commercialization of our product candidates will require us to perform a variety of
functions, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="width: 90%; padding-right: 0.8pt; text-align: justify">continuing to undertake preclinical development and clinical
    trials;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">participating in regulatory approval processes;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">formulating and manufacturing products; and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">conducting sales and marketing activities.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our operations have been limited to organizing
and staffing our company, acquiring, developing, and securing our proprietary technology, and undertaking preclinical and clinical
trials of our principal product candidates. These operations provide a limited basis for you to assess our ability to commercialize
our product candidates and the advisability of investing in our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The technology on which our channel
partnering arrangement with Intrexon is based on early stage technology in the field of synthetic DNA-based therapy.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our exclusive channel collaboration arrangement
with Intrexon contemplates the use of Intrexon&rsquo;s transgene engineering platform technology and regulatory control technology
for the <I>in vivo</I> cellular production of PGIS, a specific effector enzyme that regulates the production of prostacyclin.
Such technologies have a limited history of use in the design and development of human therapeutic product candidates and may
therefore involve unanticipated risks or delays.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>DNA-based therapy has not yet been
proven to be successful.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA has not yet approved any human
DNA-based therapy product for sale. The field of DNA-based therapy, also referred to as gene therapy or gene transfer, is experimental
and has not yet proven successful in many clinical trials. Clinical trials with DNA-based therapy have encountered a multitude
of significant technical problems in the past, including, unintended integration with host DNA, poor levels of protein expression,
transient protein expression, viral overload, immune reactions to either viral capsids utilized to deliver DNA, DNA itself, proteins
expressed or cells transfected with DNA. There can be no assurance that our preclinical animals studies or human clinical trials
will be successful or that we will receive the regulatory approvals necessary to initiate such studies. To the extent that we
utilize viral constructs or other systems to deliver our DNA-based therapies and same or similar delivery systems demonstrate
unanticipated and/or unacceptable side effects in preclinical or clinical trials conducted by ourselves or others we may be forced
to, or elect to, discontinue development of such product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not generate additional revenue
from our relationships with our corporate&nbsp;collaborators.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 6, 2010, we entered into a sublicense
agreement with Meda AB whereby we may receive milestone payments totaling $17.5 million (including an upfront payment of $2.5
million that has already been received), plus royalties on our flupirtine program. There can be no assurance that Meda AB will
successfully develop flupirtine for fibromyalgia in the U.S., Canada or Japan that would allow us to receive such additional $15
million in milestone payments and royalties on sales in connection with such agreement. The successful achievement of the various
milestones set forth in the sublicense agreement is not within our control and we will be dependent upon Meda AB for achievement
of such milestones. According to Meda&rsquo;s 2011 Annual Report, flupirtine for fibromyalgia is in Phase II development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp; <B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have experienced several management
changes.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have had significant changes in management
in the past few years. Jeffrey Riley was appointed Chief Executive Officer and President on February 3, 2012. Effective February 6, 2012, C. Evan Ballantyne was appointed Chief Financial Officer. James S. Kuo, M.D.,
served as Chief Executive Officer and President from February 6, 2010 until February 3, 2012. Max Lyon served as Chief Executive
Officer, President and director from June 26, 2009 until February 6, 2010. Changes in our key positions, as well as additions
of new personnel and departures of existing personnel, can be disruptive, might lead to additional departures of existing personnel
and could have a material adverse effect on our business, operating results, financial results and internal controls over financial
reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not be able to retain rights
licensed to us by others to commercialize key products and may not be able to establish or maintain the relationships we need
to develop, manufacture, and market our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to our own patent applications,
we also currently rely on licensing agreements with third party patent holders/licensors for our products. We have an exclusive
license agreement with the McLean Hospital relating to the use of flupirtine to treat fibromyalgia which was sublicensed to Meda
AB and an exclusive license agreement with the Regents of the University of California relating to our Trimesta technology. Each
of these agreements requires us or our sublicensee to use our best efforts to commercialize each of the technologies as well as
meet certain diligence requirements and timelines in order to keep the license agreement in effect. In the event we or our sublicensee
are not able to meet our diligence requirements, we may not be able to retain the rights granted under our agreements or renegotiate
our arrangement with these institutions on reasonable terms, or at all. Furthermore, we currently have very limited product development
capabilities, and limited marketing or sales capabilities. For us to research, develop, and test our product candidates, we would
need to contract with outside researchers, in most cases those parties that did the original research and from whom we have licensed
the technologies. Our exclusive channel collaboration agreement with Intrexon provides that Intrexon may terminate such agreement
if we do not perform certain specified requirements, including developing therapies considered superior.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We can give no assurances that any of
our issued patents licensed to us or any of our other patent applications will provide us with significant proprietary protection
or be of commercial benefit to us. Furthermore, the issuance of a patent is not conclusive as to its validity or enforceability,
nor does the issuance of a patent provide the patent holder with freedom to operate without infringing the patent rights of others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will incur additional expenses
in connection with our exclusive channel collaboration arrangement with Intrexon.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to our exclusive channel collaboration
with Intrexon, we are responsible for future research and development expenses of product candidates developed under such collaboration,
the effect of which we expect will increase the level of our overall research and development expenses going forward. Although
all manufacturing, preclinical studies and human clinical trials are expensive and difficult to design and implement, costs associated
with the manufacturing, research and development of biologic product candidates are generally greater in comparison to small molecule
product candidates. We have added additional personnel and expect to add additional personnel to support our exclusive channel
collaboration with Intrexon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because our collaboration with Intrexon
is relatively new, we have only recently assumed development responsibility and costs associated with such program. In addition,
because development activities are determined pursuant to a joint steering committee comprised of Intrexon and ourselves and we
have limited experience, future development costs associated this program may be difficult to anticipate and exceed our expectations.
Our actual cash requirements may vary materially from our current expectations for a number of other factors that may include,
but are not limited to, unanticipated technical challenges, changes in the focus and direction of our development activities or
adjustments necessitated by changes in the competitive landscape in which we operate. If we are unable to continue to financially
support such collaboration due to our own working capital constraints, we may be forced to delay our activities. If we are unable
to obtain additional financing on terms acceptable to us or at all, we may be forced to seek licensing partners or discontinue
development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Developments by competitors may
render our products or technologies obsolete or non-competitive.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Companies that currently sell or are developing
both generic and proprietary products to treat serious diseases include: Actelion Pharmaceuticals, Bayer Health Care, Biogen Idec,
Eli Lilly &amp; Co., Genzyme, GlaxoSmithKline Pharmaceuticals, Merck &amp; Co., Pfizer, Novartis, Teva Pharmaceuticals and United
Therapeutics. Many of our competitors have significant financial and human resources. The pulmonary arterial hypertension market
is highly competitive and several different product classes currently compete in this space, including prostacyclin-based therapies,
endothelin receptor antagonists and phosphodiesterase type 5 inhibitors. Prostacyclin-based therapies for PAH are available in
a number of delivery formats, including intravenous, subcutaneous and inhaled routes and an oral prostacyclin-based product candidate
is currently under NDA review in the U.S. In addition, academic research centers may develop technologies that compete with our
Trimesta, sustained-release zinc preparation - AEN-100, and flupirtine technologies. Should clinicians or regulatory authorities
view these therapeutic regiments as more effective than our products, this might delay or prevent us from obtaining regulatory
approval for our products, or it might prevent us from obtaining favorable reimbursement rates from payers, such as Medicare,
Medicaid and private insurers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We operate in a highly competitive
environment</I>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The pharmaceutical and biotechnology industries
are characterized by rapidly evolving technology and intense competition. Our competitors include major multi-national pharmaceutical
companies and biotechnology companies developing both generic and proprietary therapies to treat serious diseases. Many of these
companies are well-established and possess technical, human, research and development, financial, and sales and marketing resources
significantly greater than ours. In addition, many of our potential competitors have formed strategic collaborations, partnerships
and other types of joint ventures with larger, well established industry competitors that afford these companies potential research
and development and commercialization advantages in the therapeutic areas we are currently pursuing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Academic research centers, governmental
agencies and other public and private research organizations are also conducting and financing research activities which may produce
products directly competitive to those being developed by us. In addition, many of these competitors may be able to obtain patent
protection, obtain FDA and other regulatory approvals and begin commercial sales of their products before us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Competitors could develop and/or
gain FDA approval of our products for a different indication.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since we do not have composition of matter
patent claims for flupirtine, estriol or zinc acetate, others may obtain approvals for other uses of these products that are not
covered by our issued or pending patents. For example, the active ingredients in both Effirma (flurpirtine) and Trimesta (oral
estriol) have been approved for marketing in overseas countries for different uses and an oral immediate release form of zinc
is approved in the U.S. and Europe for the treatment of Wilson&rsquo;s disease. Other companies, including the original developers
or licensees or affiliates may seek to develop Effirma or Trimesta or their respective active ingredient(s) for other uses in
the U.S. or any country we are seeking approval for. We cannot provide any assurances that any other company may obtain FDA approval
for products that contain flupirtine, estriol or zinc in various formulations or delivery systems that might adversely affect
our ability or the ability of Meda to develop and market these products in the U.S. We are aware that other companies have intellectual
property protection using the active ingredients and have conducted clinical trials of flupirtine, estriol and zinc for different
applications than what we are developing. Many of these companies may have more resources than us. We cannot provide any assurances
that our products will be FDA-approved prior to our competitors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a product containing our active ingredients
is already marketed or if the FDA approves other products containing our active ingredients in the future to treat indications,
physicians may elect to prescribe and substitute a competitor&rsquo;s products to treat the diseases for which we are intending
to commercialize; this is commonly referred to as &ldquo;off-label&rdquo; use. While under FDA regulations a competitor is not
allowed to promote off-label uses of its product, the FDA does not regulate the practice of medicine and, as a result, cannot
direct physicians to select certain products for their patients. Consequently, we might be limited in our ability to prevent off-label
use of a competitor&rsquo;s product to treat the diseases we are intending to commercialize, even if we have issued method of
use patents for that indication. If we are not able to obtain and enforce our patents, if any, or otherwise receive orphan drug
protection in the case of ALS, a competitor could develop and commercialize similar products for the same indications that we
are pursuing. We cannot provide any assurances that a competitor will not obtain FDA approval for a product that contains the
same active ingredients as our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We rely on method patents and patent
applications and various regulatory exclusivities to protect some of our product candidates and our ability to compete may be
limited or eliminated if we are not able to protect our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our competitiveness may be adversely affected
if we are unable to protect our proprietary technologies. We do not have composition of matter patents for Trimesta or Effirma,
or their respective active ingredients estriol and flupirtine. We rely on issued patent and pending patent applications for use
of Trimesta to treat MS (issued U.S. Patent No. 6,936,599) and various other therapeutic indications, which have been exclusively
licensed to us. We have exclusively licensed an issued patent for the treatment of fibromyalgia with flupirtine, which we have
sublicensed to Meda AB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our AEN-100 drug candidate (gastroretentive
zinc acetate) is the subject of U.S. and international pending patent applications, such as published U.S. patent application
Ser. No. 11/621,962 and corresponding international applications that claim priority to January 10, 2006 as well as additional
patent applications. On October 26, 2011, we received a final rejection letter with regard to U.S. patent application Ser. No.
11/621,962. On February 15, 2012, we filed a Request for Continued Examination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The patent positions of pharmaceutical
companies are uncertain and may involve complex legal and factual questions. We may incur significant expense in protecting our
intellectual property and defending or assessing claims with respect to intellectual property owned by others. Any patent or other
infringement litigation by or against us could cause us to incur significant expense and divert the attention of our management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Others may file patent applications or
obtain patents on similar technologies or compounds that compete with our products. We cannot predict how broad the claims in
any such patents or applications will be, and whether they will be allowed. Once claims have been issued, we cannot predict how
they will be construed or enforced. We may infringe intellectual property rights of others without being aware of it. If another
party claims we are infringing their technology, we could have to defend an expensive and time consuming lawsuit, pay a large
sum if we are found to be infringing, or be prohibited from selling or licensing our products unless we obtain a license or redesign
our product, which may not be possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also rely on trade secrets and proprietary
know-how to develop and maintain our competitive position. Some of our current or former employees, consultants, scientific advisors,
current or prospective corporate collaborators, may unintentionally or willfully disclose our confidential information to competitors
or use our proprietary technology for their own benefit. Furthermore, enforcing a claim alleging the infringement of our trade
secrets would be expensive and difficult to prove, making the outcome uncertain. Our competitors may also independently develop
similar knowledge, methods, and know-how or gain access to our proprietary information through some other means.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may fail to retain or recruit
necessary personnel, and we may be unable to secure the services of consultants.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of April 30, 2012, we had eight employees.
We have also engaged regulatory consultants to advise us on our dealings with the FDA and other foreign regulatory authorities
and have been and will be required to retain additional consultants and employees in order to fulfill our obligations under our
exclusive channel collaboration with Intrexon. Our future performance will depend in part on our ability to successfully integrate
newly hired officers into our management team and our ability to develop an effective working relationship among senior management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain of our directors,&nbsp;scientific advisors, and consultants serve as officers,
directors, scientific advisors, or consultants of other biopharmaceutical or biotechnology companies that might be developing
competitive products to ours. Other than corporate opportunities, none of our directors are obligated under any agreement or understanding
with us to make any additional products or technologies available to us. Similarly, we can give no assurances, and we do not expect
and stockholders should not expect, that any biomedical or pharmaceutical product or technology identified by any of our directors
or affiliates in the future would be made available to us other than corporate opportunities. We can give no assurances that any
such other companies will not have interests that are in conflict with our interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Losing key personnel or failing to recruit
necessary additional personnel would impede our ability to attain our development objectives. There is intense competition for
qualified personnel in the drug-development field, and we may not be able to attract and retain the qualified personnel we would
need to develop our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We rely on independent organizations,
advisors, and consultants to perform certain services for us, including handling substantially all aspects of regulatory approval,
clinical management, manufacturing, marketing, and sales. We expect that this will continue to be the case. Such services may
not always be available to us on a timely basis when we need them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If the parties we depend on for
supplying our drug substance raw materials and certain manufacturing-related services do not timely supply these products and
services, it may delay or impair our ability to develop, manufacture and market our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We rely on suppliers for our drug substance
raw materials and third parties for certain manufacturing-related services to produce material that meets appropriate content,
quality and stability standards and use in clinical trials of our products and, after approval, for commercial distribution. Our
AEN-100 product candidate has limited stability data to date and is the subject of ongoing stability studies. To succeed, clinical
trials require adequate supplies of drug substance and drug product, which may be difficult or uneconomical to procure or manufacture.
We and our suppliers and vendors may not be able to (i) produce our drug substance or drug product to appropriate standards for
use in clinical studies, (ii) perform under any definitive manufacturing, supply or service agreements with us or (iii) remain
in business for a sufficient time to successfully produce and market our product candidates. If we do not maintain important manufacturing
and service relationships, we may fail to find a replacement supplier or required vendor or develop our own manufacturing capabilities
which could delay or impair our ability to obtain regulatory approval for our products and substantially increase our costs or
deplete profit margins, if any. If we do find replacement manufacturers and vendors, we may not be able to enter into agreements
with them on terms and conditions favorable to us and, there could be a substantial delay before a new facility could be qualified
and registered with the FDA and foreign regulatory authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp; <B><I>&nbsp;&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If successful large-scale manufacturing
of DNA-based products is not possible, we or our collaborators may be unable to manufacture enough of our product candidates to
achieve regulatory approval or market our DNA-based products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Few companies to date have demonstrated
successful large-scale manufacturing of DNA-based products, including those that have had significantly more resources than us
and it is anticipated that significant challenges will be faced in the scale-up of our manufacturing process for commercial production.
There are a limited number of contract manufacturers qualified to perform large-scale manufacturing of DNA-based products. We
or our collaborators may be unable to manufacture commercial-scale quantities of DNA-based products or receive appropriate government
approvals on a timely basis or at all. Failure to successfully manufacture or obtain appropriate government approvals on a timely
basis or at all would prevent us from achieving our business objectives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Clinical trials are very expensive,
time-consuming, and difficult to design and implement.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Human clinical trials are very expensive
and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. The clinical trial
process is also time-consuming. We estimate that clinical trials of our product candidates would take at least several years to
complete. Furthermore, failure can occur at any stage of the trials, and we could encounter problems that cause us to abandon
or repeat clinical trials. Commencement and completion of clinical trials may be delayed by several factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 4%; padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="width: 92%; padding-right: 0.8pt">obtaining an IND application with the FDA to commence clinical trials;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="padding-right: 0.8pt">identification of, and acceptable arrangements with, one or more clinical sites;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="padding-right: 0.8pt">obtaining IRB approval to commence clinical trials;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">unforeseen safety issues;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">determination of dosing;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">lack of effectiveness during clinical trials;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">slower than expected rates of patient recruitment;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">inability to monitor patients adequately during or after treatment;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify">inability or unwillingness of medical investigators to follow our clinical
    protocols; and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="padding-right: 0.8pt">unwillingness of the FDA or IRBs to permit the clinical trials to be initiated.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we, IRBs or the FDA may suspend
our clinical trials at any time if it appears that we are exposing participants to unacceptable health risks or if IRBs or the
FDA finds deficiencies in our submissions or conduct of our trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The results of our clinical trials
may not support our product candidate claims and the results of preclinical studies and completed clinical trials are not necessarily
predictive of future results.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To date, long-term safety and efficacy
have not yet been demonstrated in clinical trials for any of our diagnostic product candidates. Favorable results in our early
studies or trials may not be repeated in later studies or trials. Even if our clinical trials are initiated and completed as planned,
we cannot be certain that the results will support our product candidate claims. Success in preclinical testing and Phase II clinical
trials does not ensure that later Phase II or Phase III clinical trials will be successful. We cannot be sure that the results
of later clinical trials would replicate the results of prior clinical trials and preclinical testing. In particular, the limited
results that we have obtained for our diagnostic tests may not predict results from studies in larger numbers of subjects drawn
from more diverse populations over a longer period of time. Clinical trials may fail to demonstrate that our product candidates
are safe for humans and effective for indicated uses. Any such failure could cause us or our sublicensee to abandon a product
candidate and might delay development of other product candidates. Preclinical and clinical results are frequently susceptible
to varying interpretations that may delay, limit or prevent regulatory approvals or commercialization. Any delay in, or termination
of, our clinical trials would delay our obtaining FDA approval for the affected product candidate and, ultimately, our ability
to commercialize that product candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We depend on third parties, including
researchers and sublicensees, who are not under our control.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since we have in-licensed some of our
product candidates, have sublicensed a product candidate and have a collaboration agreement for the development of another product
candidate, we depend upon our sublicensee and independent investigators and scientific collaborators, such as universities and
medical institutions or private physician scientists, to conduct our preclinical and clinical trials under agreements with us.
These collaborators are not our employees and we cannot control the amount or timing of resources that they devote to our programs
or the timing of their procurement of clinical-trial data or their compliance with applicable regulatory guidelines. Should any
of these scientific inventors/advisors or those of our sublicensee become disabled or die unexpectedly, or should they fail to
comply with applicable regulatory guidelines, we or our sublicensee may be forced to scale back or terminate development of that
program. They may not assign as great a priority to our programs or pursue them as diligently as we would if we were undertaking
those programs ourselves. Failing to devote sufficient time and resources to our drug-development programs, or substandard performance
and failure to comply with regulatory guidelines, could result in delay of any FDA applications and our commercialization of the
drug candidate involved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These collaborators may also have relationships
with other commercial entities, some of which may compete with us. Our collaborators assisting our competitors at our expense
could harm our competitive position. For example, we are highly dependent on scientific collaborators for our Trimesta development
program. Specifically, all of the clinical trials have been conducted under physician-sponsored IND applications, not corporate-sponsored
INDs. Generally, we have experienced difficulty in collecting data generated from these physician-sponsored clinical trials for
our programs. We cannot provide any assurances that we will not experience any additional delays in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are also highly dependent on government
and private grants to fund certain of our clinical trials for our product candidates. For example, Trimesta (oral estriol) has
received grants totaling over $8 million,&nbsp;predominantly from the Southern California Chapter of the NMSS and the National
Institutes of Health which funds a majority of the ongoing clinical trial in relapsing-remitting MS for women. Although we believe
that the grant funding received to date is sufficient to complete the current clinical trial based upon current cost estimates,
if we experience any additional unanticipated costs or require further clinical trials, and our scientific collaborator is unable
to maintain or receive additional grants, we might be forced to scale back or terminate the development of this product candidate.
We will also need to cross reference our IND with the inventor/IND holder for this program should we elect to file our own corporate
IND for our Trimesta (oral estriol) program. The on-going and future development and commercialization of Effirma (flupirtine)
for fibromyalgia is the responsibility of Meda AB and no assurance can be given that Meda will gain the FDA&rsquo;s acceptance
of the NDA or obtain NDA approval from the FDA of flupirtine for fibromyalgia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our AEN-100 program for ALS is reliant
on the investigator-initiated IND of PNA as well as their clinical trial capabilities. Although the planned Phase II/III clinical
trial that we intend to conduct with PNA has received regulatory approval to proceed, such clinical trial is still the subject
of further protocol development and IRB approval, either of which may alter the anticipated timing and budget of such clinical
trial. In addition, because AEN-100 is not the same zinc formulation utilized by PNA in its previously completed Phase I/II safety
study of zinc for ALS, PNA intends to conduct a Phase I study of AEN-100 in normal volunteers prior to initiating the Phase II/III
clinical trial in ALS patients. The IRB approval process is ongoing for the planned Phase I study of AEN-100 and the planned Phase
II/III clinical trial in ALS patients. Such Phase I study of AEN-100 may produce unanticipated and unacceptable safety, tolerability
or bioavailability results that may substantially delay initiation of the planned Phase II/III clinical trial in ALS patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With respect to our synthetic biologic
product candidates, we are dependent upon Intrexon&rsquo;s synthetic biology facilities and capabilities as we have no such facilities
and capabilities of our own. We are also reliant on their vector engineering platform, gene expression switch technology and know-how.
If any of the foregoing were to become inaccessible or terminated, it would be difficult for us to develop and commercialize our
synthetic biologic product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may incur substantial costs as
a result of litigation or other proceedings relating to patent and other intellectual property rights, as well as costs associated
with lawsuits.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any other person files patent applications,
or is issued patents, claiming technology also claimed by us in pending applications, we may be required to participate in interference
proceedings in the U.S. Patent and Trademark Office to determine priority of invention. We, or our licensors, may also need to
participate in interference proceedings involving our issued patents and pending applications of another entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The intellectual property environment
in the area of DNA-based therapeutics is particularly complex, constantly evolving and highly fragmented. Other companies and
institutions have issued patents and have filed or will file patent applications that may issue into patents that cover or attempt
to cover genes, vectors, cell lines, and methods of making and using DNA and DNA-based therapy products used in, or similar to
our product candidate, and technologies. We have not conducted freedom-to-use patent searches on all aspects of our product candidates
or potential product candidates, and we may be unaware of relevant patents and patent applications of third parties. In addition,
the freedom-to-use patent searches that have been conducted may not have identified all relevant issued patents or pending patents.
We cannot provide assurance that our proposed products in this area will not ultimately be held to infringe one or more valid
claims owned by third parties which may exist or come to exist in the future or that in such case we will be able to obtain a
license from such parties on acceptable terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot guarantee that the practice
of our technologies will not conflict with the rights of others. In some foreign jurisdictions, we could become involved in opposition
proceedings, either by opposing the validity of another&rsquo;s foreign patent or by persons opposing the validity of our foreign
patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may also face frivolous litigation
or lawsuits from various competitors or from litigious securities attorneys. The cost to us of any litigation or other proceeding
relating to these areas, even if deemed frivolous or resolved in our favor, could be substantial and could distract management
from our business. Uncertainties resulting from initiation and continuation of any litigation could have a material adverse effect
on our ability to continue our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we infringe the rights of others
we could be prevented from selling products or forced to pay damages.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If our products, methods, processes, and
other technologies are found to infringe the proprietary rights of other parties, we could be required to pay damages, or we may
be required to cease using the technology or to license rights from the prevailing party. Any prevailing party may be unwilling
to offer us a license on commercially acceptable terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><B>RISKS
RELATING TO OUR STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will seek to raise additional
funds in the future, which may be dilutive to stockholders or impose operational restrictions.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect to seek to raise additional
capital in the future to help fund development of our proposed products. If we raise additional capital through the issuance of
equity or of debt securities, the percentage ownership of our current stockholders will be reduced. We may also enter into strategic
transactions, issue equity as part of license issue fees to our licensors, compensate consultants or settle outstanding payables
using equity that may be dilutive. Our stockholders may experience additional dilution in net book value per share and any additional
equity securities may have rights, preferences and privileges senior to those of the holders of our common stock. If we cannot
raise additional funds, we will have to delay development activities of our products candidates.<BR>
&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are substantially controlled
by our current officers, directors, and principal stockholders.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Currently, our directors, executive officers,
and principal stockholders beneficially own a substantial number of shares of our common stock. As a result, they will be able
to exert substantial influence over the election of our Board of Directors and the vote on issues submitted to our stockholders.
Our executive officers and directors beneficially owned approximately 8.8 million shares of our common stock, including stock
options and warrants exercisable within 60 days of April 30, 2012. Our executive officers, directors and principal stockholders
together beneficially owned approximately 11.9 million shares of our common stock, including the stock options and warrants exercisable
within 60 days of April 30, 2012. Because our common stock has from time to time been &ldquo;thinly traded&rdquo;, the sale of
a substantial number of shares by our executive officers, directors and principal stockholders would have an adverse effect on
the market for our stock and our share price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our shares of common stock are from
time to time thinly traded, so stockholders may be unable to sell at or near ask prices or at all if they need to sell shares
to raise money or otherwise desire to liquidate their shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock has from time to time
been &ldquo;thinly-traded,&rdquo; meaning that the number of persons interested in purchasing our common stock at or near ask
prices at any given time may be relatively small or non-existent. This situation is attributable to a number of factors, including
the fact that we are a small company that is relatively unknown to stock analysts, stock brokers, institutional investors and
others in the investment community that generate or influence sales volume, and that even if we came to the attention of such
persons, they tend to be risk-averse and would be reluctant to follow an unproven company such as ours or purchase or recommend
the purchase of our shares until such time as we became more seasoned and viable. As a consequence, there may be periods of several
days or more when trading activity in our shares is minimal or non-existent, as compared to a seasoned issuer which has a large
and steady volume of trading activity that will generally support continuous sales without an adverse effect on share price. We
cannot give stockholders any assurance that a broader or more active public trading market for our common shares will develop
or be sustained, or that current trading levels will be sustained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We cannot assure you that the common stock will be liquid
or that it will remain listed on the NYSE Amex.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot assure you that we will be able
to maintain the continued listing standards of the NYSE Amex (formerly the American Stock Exchange). The NYSE Amex requires companies
to meet certain continued listing criteria including certain minimum stockholders' equity&nbsp;and equity prices per share&nbsp;as
outlined in the NYSE Amex Exchange Company Guide. We may not be able to maintain such minimum stockholders' equity or prices per
share or may be required to effect a reverse stock split to maintain such minimum prices and/or issue additional equity securities
in exchange for cash or other assets, if available, to maintain certain minimum stockholders' equity required by the NYSE Amex.&nbsp;If
we are delisted from the NYSE Amex then our common stock will trade, if at all, only on the over-the-counter market, such as the
OTC Bulletin Board securities market, and then only if one or more registered broker-dealer market makers comply with quotation
requirements. In addition, delisting of our common stock could depress our stock price, substantially limit liquidity of our common
stock and materially adversely affect our ability to raise capital on terms acceptable to us, or at all. Delisting from the NYSE
Amex could also have other negative results, including the potential loss of confidence by suppliers and employees, the loss of
institutional investor interest and fewer business development opportunities. In order to remain listed on NYSE Amex, we are required
to maintain a minimum stockholders&rsquo; equity of $6 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>There may be issuances of shares
of preferred stock in the future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although we currently do not have preferred
shares outstanding, the Board of Directors could authorize the issuance of a series of preferred stock that would grant holders
preferred rights to our assets upon liquidation, the right to receive dividends before dividends would be declared to common stockholders,
and the right to the redemption of such shares, possibly together with a premium, prior to the redemption of the common stock.
To the extent that we do issue preferred stock, the rights of holders of common stock could be impaired thereby, including without
limitation, with respect to liquidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>RISKS RELATED TO OUR INDUSTRY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are subject to government regulation,
compliance with which can be costly and difficult.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the U.S., the formulation, manufacturing,
packaging, storing, labeling, promotion, advertising, distribution and sale of our products are subject to regulation by various
governmental agencies, including (1) the FDA, (2) the Federal Trade Commission, or FTC, (3) the Consumer Product Safety Commission,
or CPSC, (4) the U.S. Department of Agriculture, or USDA. Our proposed activities may also be regulated by various agencies of
the states, localities and foreign countries in which our proposed products may be manufactured, distributed and sold. The FDA,
in particular, regulates the formulation, manufacture and labeling of over-the-counter, or OTC drugs, prescription drugs, medical
foods, conventional foods, homeopathic OTC drugs, dietary supplements, and cosmetics such as those that we intend to distribute.
FDA regulations require us and our suppliers to meet relevant cGMP regulations for the preparation, packing, labeling, and storage
of all drugs and foods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any products manufactured or distributed
by us pursuant to FDA approvals are subject to pervasive and continuing FDA regulation, including record-keeping requirements,
reporting of adverse experiences, submitting periodic reports, drug sampling and distribution requirements, manufacturing or labeling
changes, record-keeping requirements, and compliance with FDA promotion and advertising requirements. Drug manufacturers and their
subcontractors are required to register their facilities with the FDA and state agencies, and are subject to periodic unannounced
inspections for GMP compliance, imposing procedural and documentation requirements upon us and third-party manufacturers. Failure
to comply with these regulations could result, among other things, in suspension of regulatory approval, recalls, suspension of
production or injunctions, seizures, or civil or criminal sanctions. We cannot be certain that we or our present or future subcontractors
will be able to comply with these regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA regulates prescription drug labeling
and promotion activities. The FDA actively enforces regulations prohibiting the marketing of products for unapproved uses. The
FDA permits the promotion of drugs for unapproved uses in certain circumstances, subject to stringent requirements. We and our
product candidates are subject to a variety of state laws and regulations which may hinder our ability to market our products.
Whether or not FDA approval has been obtained, approval by foreign regulatory authorities must be obtained prior to commencing
clinical trials, and sales and marketing efforts in those countries. These approval procedures vary in complexity from country
to country, and the processes may be longer or shorter than that required for FDA approval. We may incur significant costs to
comply with these laws and regulations now or in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to develop our zinc candidate,
AEN-100, as a drug and intend to file an IND with the FDA in order to conduct necessary clinical trials to support new medical
claims and ultimately file one or more NDA with respect to such products which would subject us to time, expense and uncertainty
associated with achieving approval of such NDA by the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA, comparable foreign regulators
and state and local pharmacy regulators impose substantial requirements upon clinical development, manufacture and marketing of
pharmaceutical products. These and other entities regulate research and development and the testing, manufacture, quality control,
safety, effectiveness, labeling, storage, record keeping, approval, advertising, and promotion of our products. The drug approval
process required by the FDA under the Food, Drug, and Cosmetic Act generally involves:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt">preclinical laboratory and animal tests;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt">submission of an IND, prior to commencing human clinical trials;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt">adequate and well-controlled human clinical trials to establish safety and efficacy
    for intended use;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt">submission to the FDA of an NDA or Biologics License Application (BLA); and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt">&#9679;</TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt">FDA review and approval of an NDA or BLA.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The testing and approval process requires
substantial time, effort, and financial resources, and we cannot be certain that any approval will be granted on a timely basis,
if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Preclinical tests include laboratory evaluation
of the product candidate, its chemistry, formulation and stability, and animal studies to assess potential safety and efficacy.
Certain preclinical tests must be conducted in compliance with good laboratory practice regulations. Violations of these regulations
can, in some cases, lead to invalidation of the studies, requiring them to be replicated. In some cases, long-term preclinical
studies are conducted concurrently with clinical studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will submit the preclinical test results,
together with manufacturing information and analytical data, to the FDA as part of an IND, which must become effective before
we begin human clinical trials. The IND automatically becomes effective 30 days after filing, unless the FDA raises questions
about conduct of the trials outlined in the IND and imposes a clinical hold, in which case, the IND sponsor and FDA must resolve
the matters before clinical trials can begin. It is possible that our submission may not result in FDA authorization to commence
clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical trials must be supervised by
a qualified investigator in accordance with good clinical practice (GCP) regulations, which include informed consent requirements.
An independent IRB at each medical center reviews and approves and monitors the study, and is periodically informed of the study&rsquo;s
progress, adverse events and changes in research. Progress reports are submitted annually to the FDA and more frequently if adverse
events occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Human clinical trials of drug candidates
typically have three sequential phases that may overlap:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Phase I:&nbsp;The drug is initially tested
in healthy human subjects or patients for safety, dosage tolerance, absorption, metabolism, distribution, and excretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Phase II:&nbsp;The drug is studied in
a limited patient population to identify possible adverse effects and safety risks, determine efficacy for specific diseases and
establish dosage tolerance and optimal dosage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Phase III:&nbsp;When phase II evaluations
demonstrate that a dosage range is effective with an acceptable safety profile, Phase III&nbsp;&nbsp;trials to further evaluate
dosage, clinical efficacy and safety, are undertaken in an expanded patient population, often at geographically dispersed sites.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot be certain that we will successfully
complete Phase I, Phase II, or Phase III testing of our product candidates within any specific time period, if at all. Furthermore,
the FDA, an IRB or the IND sponsor may suspend clinical trials at any time on various grounds, including a finding that subjects
or patients are exposed to unacceptable health risk. Concurrent with these trials and studies, we also develop chemistry and physical
characteristics data and finalize a manufacturing process in accordance with good manufacturing practice (GMP) requirements. The
manufacturing process must conform to consistency and quality standards, and we must develop methods for testing the quality,
purity, and potency of the final products. Appropriate packaging is selected and tested, and chemistry stability studies are conducted
to demonstrate that the product does not undergo unacceptable deterioration over its shelf-life. Results of the foregoing are
submitted to the FDA as part of a NDA (or BLA in case of biologic products) for marketing and commercial shipment approval. The
FDA reviews each NDA or BLA submitted and may request additional information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Once the FDA accepts the NDA or BLA for
filing, it begins its in-depth review. The FDA has substantial discretion in the approval process and may disagree with our interpretation
of the data submitted. The process may be significantly extended by requests for additional information or clarification regarding
information already provided. As part of this review, the FDA may refer the application to an appropriate advisory committee,
typically a panel of clinicians. Manufacturing establishments often are inspected prior to NDA or BLA approval to assure compliance
with GMPs and with manufacturing commitments made in the application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Submission of an NDA or BLA with clinical
data requires payment of a fee. In return, the FDA assigns a goal of ten months for issuing its &ldquo;complete response,&rdquo;
in which the FDA may approve or deny the NDA or BLA, or require additional clinical data. Even if these data are submitted, the
FDA may ultimately decide the NDA or BLA does not satisfy approval criteria. If the FDA approves the NDA or BLA, the product becomes
available for physicians prescription. Product approval may be withdrawn if regulatory compliance is not maintained or safety
problems occur. The FDA may require post-marketing studies, also known as phase IV studies, as a condition of approval, and requires
surveillance programs to monitor approved products that have been commercialized. The agency has the power to require changes
in labeling or prohibit further marketing based on the results of post-marketing surveillance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Satisfaction of these and other regulatory
requirements typically takes several years, and the actual time required may vary substantially based upon the type, complexity
and novelty of the product. Government regulation may delay or prevent marketing of potential products for a considerable period
of time and impose costly procedures on our activities. We cannot be certain that the FDA or other regulatory agencies will approve
any of our products on a timely basis, if at all. Success in preclinical or early-stage clinical trials does not assure success
in later-stage clinical trials. Data obtained from preclinical and clinical activities are not always conclusive and may be susceptible
to varying interpretations that could delay, limit or prevent regulatory approval. Even if a product receives regulatory approval,
the approval may be significantly limited to specific indications or uses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even after regulatory approval is obtained,
later discovery of previously unknown problems with a product may result in restrictions on the product or even complete withdrawal
of the product from the market. Delays in obtaining, or failures to obtain regulatory approvals would have a material adverse
effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The FDA&rsquo;s policies may change, and additional government
regulations may be enacted which could prevent or delay regulatory approval of our potential products. Increased attention to
the containment of health care costs worldwide could result in new government regulations materially adverse to our business.
We cannot predict the likelihood, nature or extent of adverse governmental regulation that might arise from future legislative
or administrative action, either in the U.S. or abroad.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We do not have a guarantee of patent restoration and
marketing exclusivity of the ingredients for our drugs even if we are granted FDA approval of our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The U.S. Drug Price Competition and Patent
Term Restoration Act of 1984 (Hatch-Waxman) permits the FDA to approve Abbreviated New Drug Applications (ANDAs) for generic versions
of innovator drugs, as well as NDAs with less original clinical data, and provides patent restoration and exclusivity protections
to innovator drug manufacturers. The ANDA process permits competitor companies to obtain marketing approval for drugs with the
same active ingredient and for the same uses as innovator drugs, but does not require the conduct and submission of clinical studies
demonstrating safety and efficacy. As a result, a competitor could copy any of our drugs and only need to submit data demonstrating
that the copy is bioequivalent to gain marketing approval from the FDA. Hatch-Waxman requires a competitor that submits an ANDA,
or otherwise relies on safety and efficacy data for one of our drugs, to notify us and/or our business partners of potential infringement
of our patent rights. We and/or our business partners may sue the company for patent infringement, which would result in a 30-month
stay of approval of the competitor&rsquo;s application. The discovery, trial and appeals process in such suits can take several
years. If the litigation is resolved in favor of the generic applicant or the challenged patent expires during the 30-month period,
the stay is lifted and the FDA may approve the application. Hatch-Waxman also allows competitors to market copies of innovator
products by submitting significantly less clinical data outside the ANDA context. Such applications, known as &ldquo;505(b)(2)
NDAs&rdquo; or &ldquo;paper NDAs,&rdquo; may rely on clinical investigations not conducted by or for the applicant and for which
the applicant has not obtained a right of reference or use and are subject to the ANDA notification procedures described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The law also permits restoration of a
portion of a product&rsquo;s patent term that is lost during clinical development and NDA review, and provides statutory protection,
known as exclusivity, against FDA approval or acceptance of certain competitor applications. Restoration can return up to five
years of patent term for a patent covering a new product or its use to compensate for time lost during product development and
regulatory review. The restoration period is generally one-half the time between the effective date of an IND and submission of
an NDA, plus the time between NDA submission and its approval (subject to the five-year limit), and no extension can extend total
patent life beyond 14 years after the drug approval date. Applications for patent term extension are subject to U.S. Patent and
Trademark Office (USPTO) approval, in conjunction with FDA. Approval of these applications takes at least nine months, and there
can be no guarantee that it will be given at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hatch-Waxman also provides for differing
periods of statutory protection for new drugs approved under an NDA. Among the types of exclusivity are those for a &ldquo;new
molecular entity&rdquo; and those for a new formulation or indication for a previously-approved drug. If granted, marketing exclusivity
for the types of products that we are developing, which include only drugs with innovative changes to previously-approved products
using the same active ingredient, would prohibit the FDA from approving an ANDA or 505(b)(2) NDA relying on our safety and efficacy
data for three years. This three-year exclusivity, however, covers only the innovation associated with the original NDA. It does
not prohibit the FDA from approving applications for drugs with the same active ingredient but without our new innovative change.
These marketing exclusivity protections do not prohibit the FDA from approving a full NDA, even if it contains the innovative
change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>ITEM 2. UNREGISTERED SALES OF EQUITY
SECURITIES AND USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>ITEM 3.&nbsp;&nbsp;DEFAULTS UPON SENIOR
SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 4.&nbsp;&nbsp;<FONT STYLE="text-transform: uppercase">Mine
Safety Disclosures</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 5.&nbsp;&nbsp;OTHER INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ITEM 6. EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">31.1</TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt">Certification of Principal Executive Officer pursuant to Rule 13a-14(a)/15d-14(a)
    *</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">31.2</TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt">Certification of Principal Financial Officer pursuant to Rule 13a-14(a)/15d-14(a)
    *</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">32.1</TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt">Certification of Principal Executive Officer pursuant to Section 1350 of the
    Sarbanes-Oxley Act of 2002 *</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">32.2</TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt">Certification of Principal Financial Officer pursuant to Section 1350 of the
    Sarbanes-Oxley Act of 2002 *</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">*Filed herewith</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt">SYNTHETIC BIOLOGICS, INC.</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 34%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 10%; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 0.8pt">/s/&nbsp;Jeffrey Riley</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">Jeffrey Riley</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">Chief Executive Officer</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">(Principal Executive Officer)</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">Date: May 15, 2012</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 0.8pt">By:</TD>
    <TD STYLE="width: 34%; border-bottom: black 1pt solid; padding-right: 0.8pt">/s/ C. Evan Ballantyne</TD>
    <TD STYLE="width: 10%; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 2.8pt">C. Evan Ballantyne</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 2.8pt">Chief Financial Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 2.8pt">(Principal Financial and Principal Accounting Officer)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 2.8pt">Date: May 15, 2012</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>GLOSSARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="width: 30%; border-bottom: black 1pt solid; padding-right: 0.8pt; font-weight: bold"><B>Term</B></TD>
    <TD STYLE="width: 1%; vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 69%; vertical-align: top; border-bottom: black 1pt solid; padding-right: 0.8pt; font-weight: bold"><B>Definition</B></TD></TR>
<TR>
    <TD STYLE="padding-right: 0.7pt">Adverse Event</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Any adverse change in health or &ldquo;side-effect&rdquo; that occurs
    in a person participating in a clinical trial, from the time they consent to joining the trial until a pre-specified period
    of time after their treatment has been completed.</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.7pt">AEN-100 (zinc)</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Synthetic Biologics&rsquo; proprietary, once-daily, gastroretentive,
    sustained-release oral tablet formulation of zinc acetate.</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.7pt">Bioavailability</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">The quantity or fraction of the ingested dose that is absorbed by the
    body.</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.7pt">BLA - Biologics License Application</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">An application in the U.S. through which biologic sponsors formally
    propose that the FDA approve a new biologic for sale and marketing.</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.7pt">Clinical Study/Trial</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">A research study that is conducted to find out if a treatment or procedure
    is safe and/or effective in humans.</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.7pt">Controlled Clinical Trial</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">A clinical study that compares patients receiving a specific treatment
    to patients receiving an alternate treatment for the condition of interest. The alternate treatment may be another active
    treatment, standard of care for the condition and/or a placebo (inactive)&nbsp;treatment.</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.7pt">Double-blinded Study/Trial</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Both the participant and the researcher are unaware of who is receiving
    the active treatment or the placebo.</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.7pt">Effirma (flupirtine)</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Proposed tradename of Synthetic Biologics&rsquo; centrally-acting investigational
    oral drug for the treatment of fibromyalgia syndrome</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.7pt">FDA - Food &amp; Drug Administration</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">The U.S. government agency that ensures that medicines, medical devices,
    prescription medical foods and radiation-emitting consumer products are safe and effective. Authorized by Congress to enforce
    the Federal Food, Drug, and Cosmetic Act and several other public health laws, the agency monitors the manufacture, import,
    transport, storage, and sale of $1 trillion worth of goods annually.</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.7pt">Gastroretentive</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Medications designed to be retained in the upper gastrointestinal system.</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.7pt">GMP - Good Manufacturing Practice</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Regulations that require that manufacturers, processors, and packagers
    of drugs, medical devices, some food, and blood take proactive steps to ensure that their products are consistently produced,
    pure, and stable. GMP regulations require a quality approach to manufacturing, enabling companies to minimize or eliminate
    instances of contamination, mix-ups, and errors.</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.7pt">IND&nbsp;&nbsp;- Investigational New Drug</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">An application in the U.S. submitted to the FDA for a new drug or biologic
    that, if allowed, will be used in a clinical trial.</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.7pt">IRB&nbsp;- Institutional Review Board</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">A committee designated to formally approve, monitor, and review biomedical
    research at an institution involving human studies. Institutional Review Boards aim to protect the rights and welfare of the
    research subjects.</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.7pt">NDA - New Drug Application</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">An application in the U.S. through which drug sponsors formally propose
    that the FDA approve a new pharmaceutical for sale and marketing.</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.7pt">Open-label Clinical Study/Trial</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">A trial in which both the treating physician and the patient know they
    are receiving the experimental treatment.</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.7pt">Phase I Clinical Trial</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">A Phase I trial represents an initial study in a small group of patients
    to primarily test for safety.</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.7pt">Phase II Clinical Trial</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">A Phase II trial represents a study in a larger number of patients to
    assess the safety and efficacy of a product.</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.7pt">Phase III Clinical Trial</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Phase III trials are initiated to establish safety and efficacy in an
    expanded patient population and at multiple clinical trial sites and are generally larger than trials in earlier phases of
    development.</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.7pt">Placebo</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">An inactive pill or liquid. Many studies compare an active drug to a
    placebo to determine whether any changes seen during the study can be attributed to the active drug.</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.7pt">Principal Investigator</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">This is the study director who is ultimately responsible for the conduct
    of the study.</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.7pt">Prospective Clinical Study/Trial</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">A clinical study/trial in which participants are identified and then
    followed throughout the study going forward in time.</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.7pt">Protocol</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">A clinical study/trial&rsquo;s plan &mdash; includes the schedule of
    tests, requirements for participation, procedures, and medications.</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.7pt">Randomized Study/Trial</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Participants in a study are assigned by chance to either one or more
    of the active treatment group(s) or the placebo group.</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.7pt">Single-blinded Study/Trial</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">One party, either the participant or the researcher, does not know if
    the participant is taking the active treatment or the placebo.</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.7pt">Study/Trial Coordinator</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Staff member who is often the primary contact for research participants
    and coordinates their care and evaluations throughout the study.</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.7pt">Synthetic Biology</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Synthetic biology is an emerging field that combines molecular biology
    and automation to design, optimize and construct new biological systems and functions. These technologies utilize a combination
    of automated processes including, DNA sequencing, computer-aided design, DNA synthesis, fabrication of modular transgenes
    and high throughput testing to create and optimize biologic products.</TD></TR>
<TR>
    <TD STYLE="padding-right: 0.7pt">Trimesta (oral estriol)</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0.8pt">Proposed tradename of Synthetic Biologics&rsquo; investigational oral
    drug for the treatment of relapsing- remitting MS.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 38; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>v311052_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EXHIBIT 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE
OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-14&nbsp;OR RULE
15d-14 OF THE SECURITIES EXCHANGE ACT OF 1934,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;I, Jeffrey Riley, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">1.</TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt">I have reviewed this quarterly report on Form 10-Q of Synthetic Biologics, Inc.;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">2.</TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">3.</TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">4.</TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt">The registrant's other certifying officer(s) and I are&nbsp;responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))&nbsp;and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))&nbsp;for the registrant and have:</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt">a)</TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that&nbsp; material&nbsp;information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt">b)</TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt">c)</TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt">&nbsp;Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt">d)</TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">5.</TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt">The registrant's other certifying officer(s) and I&nbsp;have&nbsp;disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt">a)</TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt">b)</TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt">&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 57%; padding-right: 0.8pt">Date: May 15, 2012</TD>
    <TD STYLE="width: 5%; padding-right: 0.8pt">By:</TD>
    <TD STYLE="width: 38%; border-bottom: Black 1pt solid; padding-right: 0.8pt">/s/&nbsp;Jeffrey Riley</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">Name: Jeffrey Riley</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">Title: Chief Executive Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;(Principal Executive Officer)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>v311052_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>EXHIBIT 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL FINANCIAL
OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-14&nbsp;OR RULE
15d-14 OF THE SECURITIES EXCHANGE ACT OF 1934,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;I, C. Evan Ballantyne, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">1.</TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt">I have reviewed this quarterly report on Form 10-Q of Synthetic Biologics, Inc.;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">2.</TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">3.</TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">4.</TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt">The registrant's other certifying officer(s) and I are&nbsp;responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))&nbsp;and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))&nbsp;for the registrant and have:</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt">a)</TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that&nbsp; material&nbsp;information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt">b)</TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt">&nbsp;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt">c)</TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt">d)</TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">5.</TD>
    <TD STYLE="width: 94%; padding-right: 0.8pt">The registrant's other certifying officer(s) and I have disclosed, based on&nbsp;our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt">a)</TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt">b)</TD>
    <TD STYLE="width: 91%; padding-right: 0.8pt">&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 57%; padding-right: 0.8pt">Date: May 15, 2012</TD>
    <TD STYLE="width: 5%; padding-right: 0.8pt">By:</TD>
    <TD STYLE="width: 38%; border-bottom: Black 1pt solid; padding-right: 0.8pt">/s/&nbsp;C. Evan Ballantyne</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">Name: C. Evan Ballantyne</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">Title: Chief Financial Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">(Principal Financial Officer)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>v311052_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>EXHIBIT 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION&nbsp;PRINCIPAL EXECUTIVE
OFFICER </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO 18 U.S.C. SECTION 1350, AS
ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pursuant to 18 U.S.C. &sect;
1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Synthetic Biologics, Inc. (the &ldquo;Registrant&rdquo;)
hereby certifies, to such officer&rsquo;s knowledge, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 0.8pt">(1)</TD>
    <TD STYLE="width: 96%; padding-right: 0.8pt">the accompanying Quarterly Report on Form 10-Q of the&nbsp;Registrant for the quarter ended March 31, 2012 (the &ldquo;Report&rdquo;) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 0.8pt">(2)</TD>
    <TD STYLE="width: 96%; padding-right: 0.8pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">Date: May 15, 2012</TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 57%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 38%; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 0.8pt">/s/&nbsp;Jeffrey Riley</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">Name: Jeffrey Riley</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">Title: Chief Executive Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">(Principal Executive Officer)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>v311052_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>EXHIBIT 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION&nbsp;PRINCIPAL FINANCIAL
OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO 18 U.S.C. SECTION 1350, AS
ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pursuant to 18 U.S.C. &sect;
1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Synthetic Biologics, Inc. (the &ldquo;Registrant&rdquo;)
hereby certifies, to such officer&rsquo;s knowledge, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 0.8pt">(1)</TD>
    <TD STYLE="width: 96%; padding-right: 0.8pt">the accompanying Quarterly Report on Form 10-Q of the&nbsp;Registrant for the quarter ended March 31, 2012 (the &ldquo;Report&rdquo;) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 0.8pt">(2)</TD>
    <TD STYLE="width: 96%; padding-right: 0.8pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">Date: May 15, 2012</TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 57%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 38%; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 0.8pt">/s/&nbsp;C. Evan Ballantyne</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">Name: C. Evan Ballantyne</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">Title: Chief Financial Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">(Principal Financial Officer)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`$?`K\#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#T[QAX]MO!
MUU:07%C-<&X1G#1LHQ@CKGZUSG_"[M-_Z`]Y_P!]K_C65\;O^0KI'_7%_P"8
MKS[1_#^I:Z9C8Q(8X0#++)($1,]`6/>N^E0INFI2.2I5FI\J/5O^%W:;_P!`
M>\_[[7_&C_A=VF_]`>\_[[7_`!KQV]M)["^FL[E`LT+;'`.1GV(ZU!GVYK18
M6D]49^WJ'M/_``N[3?\`H#WG_?:_XT?\+NTW_H#WG_?:_P"->/"PNCIQU$6[
MFS$HA,P'R[SSBIM7TNYT7438W;(TP1)#Y9R,,,CGUI?5J-[![:H>M_\`"[M-
M_P"@/>?]]K_C1_PN[3?^@/>?]]K_`(UXMN^4MU4=:U8?#FHRZC_9\R1VD_D?
M:,7+A`R8R,'U--X:B@5:HSU3_A=VF_\`0'O/^^U_QH_X7=IO_0'O/^^T_P`:
M\5!!YY'OZ5T-GX*UZ_TR&_M;2-X9D,D2><H=P.#A>IZ4GAZ$=05:HSTG_A=V
MF_\`0'O/^^T_QH_X7=IO_0'O/^^T_P`:\BN]-FLK"TO97@,=T6VHKY="IP0P
M[4ND:7<:UJL6FVI03R[MOF'`X&3G\J?U>C:X>WJ'KG_"[M-_Z`]Y_P!]K_C1
M_P`+NTW_`*`]Y_WVO^->+ME693U5BI^HI,_4_2CZK1#V]0]H_P"%W:;_`-`>
M\_[[3_&E_P"%W:;_`-`>\_[[3_&O(K[39M/@LYI98'6[B\U!&^XJ,XPP[&J?
M'3'2A8:BT+V]1'M/_"[M-_Z`]Y_WVO\`C1_PN[3?^@/>?]]K_C7BU%/ZI2#Z
MQ,]I_P"%W:;_`-`>\_[[7_&C_A=VF_\`0'O/^^U_QKQ:BCZI2#ZQ4/:?^%W:
M;_T![S_OM/\`&C_A=VF_]`>\_P"^U_QKQ:BCZI2#ZQ4/:?\`A=VF_P#0'O/^
M^U_QH_X7=IO_`$![S_OM?\:\6HH^J4@^L5#VG_A=VF_]`>\_[[7_`!H_X7=I
MO_0'O/\`OM/\:\6HH^J4@^L5#VG_`(7=IO\`T![S_OM?\:/^%W:;_P!`>\_[
M[7_&O%J*/JE(/K%0]I_X7=IO_0'O/^^U_P`:/^%W:;_T![S_`+[7_&O%J*/J
ME(/K%0]I_P"%W:;_`-`>\_[[7_&C_A=VF_\`0'O/^^U_QKQ:BCZI2#ZQ4/:?
M^%W:;_T![S_OM?\`&C_A=VF_]`>\_P"^U_QKQ:BCZI2#ZQ4/:?\`A=VF_P#0
M'O/^^T_QH_X7=IO_`$![S_OM?\:\6HH^J4@^L5#VG_A=VF_]`>\_[[7_`!H_
MX7=IO_0'O/\`OM?\:\6HH^J4@^L5#VG_`(7=IO\`T![S_OM?\:/^%W:;_P!`
M>\_[[3_&O%J*/JE(/K%0]I_X7=IO_0'O/^^U_P`:/^%W:;_T![S_`+[7_&O%
MJ*/JE(/K%0]I_P"%W:;_`-`>\_[[7_&C_A=VF_\`0'O/^^U_QKQ:BCZI2#ZQ
M4/:?^%W:;_T![S_OM?\`&C_A=VF_]`>\_P"^U_QKQ:BCZI2#ZQ4/:?\`A=VF
M_P#0'O/^^U_QH_X7=IO_`$![S_OM?\:\6HH^J4@^L5#VG_A=VF_]`>\_[[3_
M`!H_X7=IO_0'O/\`OM?\:\6HH^J4@^L5#VG_`(7=IO\`T![S_OM?\:/^%W:;
M_P!`>\_[[7_&O%J*/JE(/K%0]I_X7=IO_0'O/^^U_P`:/^%W:;_T![S_`+[7
M_&O%J*/JE(/K%0]I_P"%W:;_`-`>\_[[7_&C_A=VF_\`0'O/^^U_QKQ:BCZI
M2#ZQ4/:?^%W:;_T![S_OM?\`&C_A=VF_]`>\_P"^U_QKQ:BCZI2#ZQ4/:?\`
MA=VF_P#0'O/^^U_QH_X7=IO_`$![S_OM?\:\6HH^J4@^L5#VG_A=VF_]`>\_
M[[7_`!H_X7=IO_0'O/\`OM?\:\6HH^J4@^L5#VG_`(7=IO\`T![S_OM?\:/^
M%W:;_P!`>\_[[7_&O%J*/JE(/K%0]I_X7=IO_0'O/^^U_P`:/^%W:;_T![S_
M`+[7_&O%J*/JE(/K%0]I_P"%W:;_`-`>\_[[7_&C_A=VF_\`0'O/^^U_QKQ:
MBCZI2#ZQ4/:?^%W:;_T![S_OM?\`&C_A=VF_]`>\_P"^U_QKQ:BCZI2#ZQ4/
M:?\`A=VF_P#0'O/^^U_QH_X7=IO_`$![S_OM?\:\6HH^J4@^L5#VG_A=VF_]
M`>\_[[3_`!H_X7=IO_0'O/\`OM?\:\6HH^J4@^L5#VG_`(7=IO\`T![S_OM?
M\:/^%W:;_P!`>\_[[7_&O%J*/JE(/K%0]I_X7=IO_0'O/^^U_P`:/^%W:;_T
M![S_`+[3_&O%J*/JE(/K%0]I_P"%W:;_`-`>\_[[7_&C_A=VF_\`0'O/^^U_
MQKQ:BCZI2#ZQ4/:?^%W:;_T![S_OM?\`&C_A=VF_]`>\_P"^U_QKQ:BCZI2#
MZQ4/:?\`A=VF_P#0'O/^^U_QH_X7=IO_`$![S_OM?\:\6HH^J4@^L5#VG_A=
MVF_]`>\_[[7_`!H_X7=IO_0'O/\`OM?\:\6HH^J4@^L5#VG_`(7=IO\`T![S
M_OM?\:Z_PAXNA\86-Q=06LMND,OE8D())P#V^M?,]>W?!3_D7-1_Z^__`&45
MAB,/3A"Z-:-6<I69B_&[_D*:1_UQD_F*Y_P%_:$B7UK#:6-_IUPR+>VEU,(S
MC^^N?2M_XWL/[5TCG_EC)_,5Y7E>O?UQ6U&*E12,ZC:J-GK6B6/AZ_U+5-#A
MF22PTF\34;:0_-E`/WB;NI`/%5=+\3,NG:??0&SC?4->D$P>-"5@8CCGH,5Y
MW8:O=Z9!=PVDBQK=Q>1-\O)3T![53!7VR1CD=J%0UU8>TTV/4KV^N'\%>)=.
MTN>UV6NJ2`Q93BU/)VYZ]>HY]*FUW64OE\1Z7-+:O8PZ3!+;@*NXRX&2&ZDX
M[5Y/E!QVZ=*/D]!Z]._K3^KKN)57V/7O$5Y;6_AFXDT^T6?31:1-:RB:$1Q.
M,'*K]_=GJ*FU&^EO/%VFW=U<VLFFR:3*8&RG,WE?-GN.>F:\:^7/]31E<8P,
M>F*7L$NH_:OL>B:J;L>`=/&C2V`T46`%ZIV>89MW/7YMWI^-;WAB:!-"\*3M
M!8,EM!,MQ>2W022S#,?NKGDD>U>._+G)'-(0A.2`3ZXIN@K6N)56I/0]3T9M
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M!?\`/<^]-T?,7M-=B24!9Y`KAU#D!U&`PSU`]#3:3(HR*Z;HQLQ:*3<*-PIW
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MT4FX4;A1=!9BU[=\%/\`D7-1_P"OO_V45XAN%>W?!,@^'=1'?[7_`.RBN;%-
M.F;X=/G.DUF**7Q;`)8HY,6+<.H/\8]:/L=K_P`^MO\`]^A_A3M6_P"1NA_Z
M\&_]#%25YSD[))G<HJ]VB$VEH,9MK89Z`QKS2?9+3C_1K;)Z#RUYKE?&5K+>
MZSID<#$7,=M<7$`!(^=-K#I]*SDU$:UXCTCQ"BN8GG:WMH\XR%B+-Q[MD?A6
ML:;>O,9N26ECO/LEJ?\`ET@Q_P!<A_A3'AL(V*O#:(P4N0R*,*._TKDM,\1:
MU/92:DZ)/`;.69D)3Y'7[H4`[L=CFJGVV:2XN+J;4K?4)?[`DFR(QB/)R5('
M4=J/9S[BYUV.Z%M9E0PMK8J1D$1K@BAK:S12[VULJCDDQJ`*YO3=5N;G45MV
MU*&PAM;:W86_EC_2-ZY;&><=ABLFXU^ZO8K^W^TO/976F7,J&6-4QMX!4`Y`
MQZ\TO9R[CYH]CNA;V;*K"WMBK8VD1K@_3UI?LEK_`,^MO_W[7_"N9UDC_A%/
M#_.`;FS`P>*8-9U5KY[@WL0MH]9^P?9_*'*'N6ZY':CED^H^:/8Z=[>RC*AX
M+92Q"KE%&2>F*$M[*1=R06K#."513SW%<9)J5SJ.I6$MQ?P@+K1A33]@#1!<
M@'/7D<G/KQ3K/6+D_9;**\@TV.XN[PO="-<?NVX`!XR>IIN$K7N)2C?8[/['
M:_\`/K;_`/?M?\*:]O91*&D@M44D#+(H&3TKE;_Q%=0:Q"EI?&:);N&VF7RD
M6++]<<[B>^>E4XY[B"SO_/ODNRNNI#Y<Z`^6-X^8>F>WI1R2[ASQ['<?9+4=
M;2W_`._:_P"%'V.U_P"?6#_OT/\`"N377]1DO8[L7T?[S5#9-IFP;@F<;B?O
M9[^E.L=8U62ZLKB2]C>VFU*:Q-N(0/E7=AMW][BER2[CYX]CJOL=K_SZV_\`
MWZ'^%9FOVMLNBS,MM`IWIR(P/XQ6S69XA_Y`<W^_'_Z&*S4I7W&TK;%YK2UW
M'%I;_P#?L?X4TVMFN,V]L,],QJ*L-RS#U-<7XNB^T>)-+BV64@:SG.V]D*1C
MISD=Q5QO*5K@[);'5_9K+S!'Y%KO(W;=BYQZX]*'MK*)"\EO;(BC+,R*`/J:
MX2QUN2SL;.XMXO.EM]&E=6F0-(Q63&<]=@ZX]*EU74+M](UBQFU*+48)-)6Z
M\Y$"B)B<;>.H/49YJ^25]R5-=CMQ:6A&1:VY!&<^6O\`A2_8[7C_`$6WYZ?N
MA_A7'7^OZA`NH3P7\5O_`&:84BLFC!^TAE7))//.2!CTJVFKZG>>*I-/@N?*
M2.["21E%QY6T$C).2V>*3IS?4.>/8Z1+>RE7='!:NO3*HI%.-I:`9-K;@=23
M&O'Z5Q>G:O<R)96,5Y;Z9'<27;O.(UVDHY`4`\9[FM/Q5)&R:''>2_\`$NFN
MP+R0':CC;\N3V4FERM/5AS*VQT"VMHR[EMK8J>XC4BE^R6I_Y=8/^_0_PKEM
M6U"TTJV%KH-TL+%)9]ELJ.F5`R2S'`'L.>:K3:]K%U!/-;WL-O\`9]*BOB!$
M&W.<Y'/0&CV<GJF/F78[![:RCC:22WMD11EF:-0`/>A;>R9F58+4LH!90BY&
M>F:XKQ%J]U>6NK0/?P6<$-E#(+=T!-QY@R3D\^PQ4]]J]Q87FJ"W:"%RUC`;
MDH"8PZ\LQ[X[9IJ$NXN==CKEM[)V94@MF9#A@(URI]_2G?8[;_GT@_[]#_"N
M.M;\V7]MDZGYTTNI1P)<P1J3*2@XP3M!]\XJO%JFHZC_`&!-/JGV9AJ<UL[[
M5P=O0MS@GMCI1R2[BYUV.Y^QVN,_9(/^_0_PH^QVO_/K;_\`?L?X5RVGZUK%
M]K1*JHMTO7MY86,:A(QD9'._=T/I77U$U*.GZEQ:ET,BVM;8^(M14VL!40PX
M'EC`X.:T?L=K_P`^MO\`]^Q_A5.U_P"1CU/_`*X0_P!:TJ4I2ON$4K;$/V.U
M_P"?6W_[]#_"C[':_P#/K;_]^A_A4U%+FEW*Y5V(?L=K_P`^MO\`]^A_A1]D
MM!UM;<#WC6IJP/&QQX,U+UVJ.N,_,.,TTY-VN)I)7L;(M;1@"MM;$'N(UH^Q
MVO\`SZV__?L?X5QDD.IZ%!->VL<&FI?7%M!%;;A*J9X9SVR>./:K%WJNN1:S
M<Z?;2B22R$0R_EQK/N^\6R<\\@8K3DE_,0IKJCJC:V:J6:VMU51DDQJ`!^5,
M2+3Y"`D5HY*AP%522IZ'Z&N=?4KF_EUQ9=2BMX[4RVZZ>4&YP$SN)SG.>XK(
M@U:XTW37EM?)66'1K1T<H"V6?!!/4C':CDE;<.==CNWM[*)-TEO:HO'+(H'/
M2G&TM0<&TMP?3RQ_A7(ZIJ%];V>L6=Y<07AMIK5D=X`%'F-R-O3`[&K<.MSR
M7.K75QJL5I#9RRQBR,0+!4&0^,Y)[^F*7))+<?,GT.@D@L8D+R06J*.I9%`%
M/^QVO_/K;_\`?H?X5Y_?ZO>7VEZK:7,[S0Q?9)HFF5`_S2=]IQC@>]>CM]\T
MIJ4>H1:?0@^QVO\`SZV__?H?X4?8[7_GUM_^_0_PJ:BHYI=R^5=B'[':_P#/
MK;_]^A_A1]CM?^?6W_[]#_"IJ*.:7<++L8]C:VS:SJP-M`0&BP/+''R"M+[)
M:_\`/K;_`/?L?X53L/\`D-:Q_OQ?^@"M*G*3N3%*VQ#]CM?^?6W_`._8_P`*
M/L=K_P`^MO\`]^A_A4U%+F97*NQ#]CM?^?6W_P"_0_PI#:VBC)MK8#U,:BIZ
MYKQQSHUF#$)MVH0#RB<"0$_=/UIQ;;LV*225[&ZT%BI0-#:@R'"`HOS?3UIW
MV.U(R+6W(_ZYK_A7$2:1?65_I$6^.P>YU65[>)#YJVJF/!`SP3U.*LG7[UM&
MMD>^<7[2W$8>&),RB(D;CN.U1[=^U6X2Z,A278Z[[':_\^L'_?H?X4?8[7_G
MU@_[]C_"N3M_$-_+'HMW=W(BM+J&,2?9PK,)6;'S*>=I[$=*?INM:S?:QN"*
M+87<D$L+,BK&BY`*C.XMD9_&APDNH^:/8ZG[+:<@6UOGT\M<_P`JBC739I)H
MXH[5WA?RY`$7Y6ZXZ=:Q3=QV/C76KF5OW<&EQ2-SV!:LY;9[:R\,2SY6XO-5
M6YF)Z[G#'!^@P*%!]Q.2['8"TM#TMK8CU$:FC[':_P#/K;_]^A_A6)X..=*O
M><_\3&X[Y_CKH:B3:=KEI)J]B'[':_\`/K;_`/?H?X4?8[7_`)];?_OT/\*F
MHI<TNX^5=B'[':_\^MO_`-^A_A6;K5K;+'8XMH1F]B!Q&.>OM6Q67K?^JL?^
MOV+^M5&4K[DR2ML7S:6N3_HMO_WZ'^%)]CM?^?6W_P"_0_PJ<]325/,RN5=B
M'[':_P#/K;_]^A_A1]CM?^?6W_[]C_"IJ*.:7<5EV(?L=K_SZV__`'['^%(;
M:S`RUO;*/5D4"I^O%<KXN7S=2\/1_9%O-]S)_HSN%$OR="3Q50<F]Q2LEHCH
MC;V0D6,P6H=AN52BY(]0*=]CM?\`GTM_^_0_PKAH=*U+3]5TNS%\MK=+97<@
M9%\WRDW`A%SUQP*FU#Q1>C0K6YANV2]-A]KDCCB382#C+%CTS_".:IPE?1DJ
M4>J.S^Q6O_/I;_\`?H?X4"SM3TM;<_2,?X5SJZU>)K=NMU-_HUQ$OV>*`*RL
M_E[F5Q]Y6SR#TQ47AK6-8U2ZMIYRKVL\3M*A9!Y;`_*$`.['8YHY)K6XU*+Z
M'3&ULQG_`$>UXZ_(O%+]DM#D"VMB1U`C7C]*X36'P_B3Y^FKV?(/3I71>'R#
MK?B8%LXU''7./D%$E)*]P35[6-G[':_\^MO_`-^Q_A1]CM?^?6W_`._8_P`*
MF_K16?-+N79=B'[':_\`/K;_`/?H?X4?8[7_`)];?_OT/\*FHHYI=PY5V(?L
M=K_SZV__`'Z'^%3>&(UCU'6ECC5!Y\?"@`?ZL44_PU_R$]:_Z[Q_^BQ3YFT]
M16LRKK$L<?BV$R2(@-@V-[`9^<>M+]KM?^?J#_OZO^-6;JPM;[QE&MW;0SJM
M@Q`D0,!^\'K6C_8&C?\`0*L_^_"_X4GRZ`KF&T]DTJRF>U,B@A7\Q<KGJ![4
MR/\`LR,1!#8J(26B"LHV$]2.>#6Z="T91DZ59#ZPK_A0-"T8]-*LO^_"_P"%
M*Z"SN8$4>DP3/-"MA%*_WW0H"WU--B@T>%&2*/3T5@58(4`(/4'U%=#_`&'H
MH./[+LL]<>2O3UZ4O]@:/_T";/\`[\+_`(47069S[)I3S13.+%I80!&Y9-R8
M]#V'\J:D&CQERJ:>IDR'(*`MGKGZUT7]@:-_T"K+_ORO^%)_86C8S_95F/\`
MM@O^%%T%F8C26#HD;26;(A!52ZX4CH0,\8IO_$MP1NL\&3S2-Z_?_O=>OO6Z
M="T;_H%6?_?A?\*/["T;/_()L_\`OPO^%*\1V9@!-)%PUQBP^T,P8RY3<3ZD
M]<TDD6D30^3*FGO#O,GEL4*[CU./4FN@_L+1O^@59_\`?A?\*7^P=&_Z!5G_
M`-^%_P`*KF0K,YXQZ2TPF9;`R@`;R4S@=.?:E9-):5Y2+$R2,&=BR98CH2>Y
M%=!_86C?]`JS'_;!?\*/[!T;_H%6?_?A?\*5T%F8`&F"\-X/L(NCP9PR!S^-
M*ITU=H5K,!7,B@,G#GOUZ\UN#0]%)Q_95E_WY7_"@Z'H@8`Z79`GH/)7G]*+
MH+,R/M5K_P`_4'_?U?\`&LWQ!<VYT28"YA)WQ\"0'^,5UG_"/Z/_`-`JR_[\
M+_A6/XFT/2H="F>/3;16WQX*PJ#]\>U-.-P?,#7=KO)^U6_7_GJO^-5KE-*O
M"OVK[#/L^[YK(V,^F>E=#_PC^CY_Y!5E_P!^%_PH_P"$?T?_`*!5E_WX7_"E
M>-[CU,'?IXD#B2S#!/+4AUR$_N_3VJ..'2(8988DL(XI?]8BE`'^OK6Y=:3H
M%G;27-QIUC'#&I9W:%<`?E45E8:#?QEXM(@4#M+:!">,Y`(Z4[H5C)==*ENH
M[F3["\\?"2,4++Z8-9+:!ICZC]K?4E*&X^U>5YB9\S_?^]M]LXKM3H>BJ,G2
M[(#WA7_"H'T[P\DTD)T^Q,T<?FM&(5R%YYZ>QIJ0K&-+%I$T(AE73Y(E8N$8
MKMW'^+&>#G\ZEEEL)XC#-+:21,,-&[J5(^E:MMIF@W=M'/%I=F4D0.H\A<X(
MR,C%$^F^'K6'SI["PCCW!-QB7&XG`'UR:5QF']FT7R8X?*T[RXSE%^3"GN0*
ME']F`-@V0W((R`Z\H.B_3VK932=#>:2(:3:@H`=QME"G/H<<]*;<Z9H%I:2W
M4VF60AB0NS"!3P.O0476P&++%I$\BO,FGR,B[%+E"0OH/:G.-+D657-DPE`6
M0,RG>!TSZXJ[:KX8O)&C33+=)%C\W9+:;&9/[P!'(^E%M_PBMW9V=W!96;0W
MDGE0G[,.6YX(QQT/6C810\K1_(:`)8"%L;HP4VDCH<4&/2&@$#+8-"K!Q&2F
M`WK]:U%MO#;ZN^EKI]F;Q(A*R?9QPI..N,?A5W^P=&_Z!5G_`-^%_P`*+I`M
M3GO+TK[6+O\`T'[4/^6V4W_G^E6/M5K_`,_4'_?U?\:VO^$?T<_\PJR_[\+_
M`(4?\(_H_P#T"K+_`+\+_A2;6Y6O0Y2VN;<>(M28W$(4PPX/F#!ZUI?:[;_G
MY@_[^K_C19Z)I3>*-4C.FVA1882`85P,@]L5L_\`"/Z/_P!`JR_[\K_A3ERW
M%'FL8OVNU_Y^K?\`[^K_`(T?:[7_`)^H/^_J_P"-;7]@:/\`]`NR_P"_"_X4
M?V!H_P#T"[+_`+\+_A2]T?O&+]JMO^?F#_OZO^--EFL9XFBFEM9(VX97D4@_
MK6Y_8&C_`/0*LO\`OPO^%']@:/\`]`JR_P"_"_X4:![QAR2V$P42S6DBJP8!
MI%ZCH>O&*AFCTJYF2:X^PRRI]V1V0E?H:Z+_`(1_1O\`H%67_?A?\*3^P-&'
M_,*LO^_"_P"%%T%F<^R:7)<FY?["UP5*&0LI;'3&>M!32BI4BQV[`F-R8VCD
M#Z`UT']@Z-_T"K+_`+\K_A1_8&CG_F%6?_?A?\*+H5F8+G39=_F-9/OQORRG
M=CIGGM3672FN6N6%@;A@5:4E"Q'N:Z'_`(1_1_\`H%67_?A?\*/^$?T?_H%6
M7_?A?\*?,AZG.)!H\<;1I'IZHV,J"@!P<C]>:M?:[4_\O5O_`-_5_P`:V?\`
MA']'_P"@59?]^%_PH_X1_1_^@59?]^%_PH;3W!71B_:[;_GY@_[^K_C2_:K;
M_GY@_P"_J_XUL_\`"/Z/_P!`JR_[\+_A1_PC^C_]`JR_[\+_`(4O=#WC%^UV
MO_/U!_W]7_&C[7:_\_5O_P!_5_QK:_X1_1_^@59?]^%_PH_L#1_^@59?]^%_
MPH]T/>.4L;FW&LZN3<0@%HL'S!@_(*T?M=M_S\P?]_5_QIVG:'I3Z]K*-IMH
M51X@`85P/W8Z<5L?\(_H_P#T"K+_`+\K_A3ERW)CS6,7[7;?\_4'_?U?\:/M
M=K_S]6__`']7_&MK_A']'_Z!5E_WY7_"C_A']'_Z!5E_WX7_``I>Z5[QB_:[
M;_GZ@_[^K_C39)K&9566:UD"L&`:13@CH>M;G_"/Z/\`]`JR_P"_"_X4?\(_
MH_\`T"K+_OPO^%&@:F&\UE(Z.\UJTD9W(YD4E3TR,]*A>/298UCD6P:-7+A2
M4(#'J1[UT7_"/Z/_`-`JR_[\+_A1_P`(_H__`$"K+_OPO^%.Z%9G."'2!)%+
MLT_S(AB-LIE/8>E.\O2A>?;!]A^U_P#/<%-Y]\UT/_"/Z/\`]`JR_P"_"_X4
M?\(_H_\`T"K+_OPO^%',@LSF-0M=+U.WE@GG@42[1(\<JAF53D*3GIFK3S6,
MAC+RVC&,AH\NIV$=".:W?^$?T?\`Z!5E_P!^%_PH_P"$?T?_`*!5E_WX7_"A
MM#U,..:QA4K%+:QJ26(210"3U/6G?:[7_GZ@_P"_J_XUM?\`"/Z/_P!`JR_[
M\+_A1_PC^C_]`JR_[\+_`(4M`]XQ?M=M_P`_,'_?U?\`&E^U6W_/S!_W]7_&
MMG_A']'_`.@59?\`?A?\*/\`A']'_P"@59?]^%_PH]T/>,7[7;?\_,'_`']7
M_&LW6KFW,5CBXA/^FQ9Q(..M=9_PC^C_`/0*LO\`ORO^%8WB'0]*BCT\IIMH
MI:^B4XA49'/M33C<E\U@-W;9/^E0?]_5_P`:3[7;?\_4'_?U?\:VO^$?T?\`
MZ!5E_P!^%_PH_P"$?T?_`*!=E_WX7_"E[I7O&+]KMO\`GZ@_[^K_`(T?:[;_
M`)^8/^_J_P"-;7_"/Z/_`-`JR_[\K_A1_P`(_H__`$"K/_ORO^%'NB]XQ?M=
MK_S]0?\`?U?\::\UC(Z.\UJSQG*,9%RIZ9'/%;G_``C^C_\`0+L_^_"_X4?\
M(_H__0*LO^_"_P"%%T/4PFEL&D65I;0RA2H<R+E0>H!SWJ%X='E6)94T]UB&
M(PQ0[1Z#T%='_P`(_H__`$"K+_OPO^%'_"/Z/_T"K+_OPO\`A1=!9G/*NEI<
MBY3["MP`%\U64-@=L]:(DTJ"=[B$6,4S_>D1D#-^-=#_`,(_H_\`T"K+_OPO
M^%'_``C^C_\`0*LO^_"_X470K,P&_LQ]^YK)B[!WRR_,PZ$\\D4Y);*-G:.:
MU5G.YV6106/J>:W?^$?T?_H%67_?A?\`"C_A']'_`.@59?\`?A?\*+H+,Q?M
M=M_S\P?]_5_QH^UVW_/S!_W]7_&MK_A']'_Z!5E_WY7_``H_X1_1_P#H%67_
M`'Y7_"C0?O&+]KM?^?J#_OZO^-+]JMO^?F#_`+^K_C6S_P`(_H__`$"K+_OP
MO^%'_"/Z/_T"K+_OPO\`A1[H>\8OVJV_Y^8/^_J_XU/X9D1]1UID=67SX^5.
M1_JQ6G_PC^C_`/0*LO\`OPO^%4=!M+>TUG7(K:&.&,3182-0H_U8]*:M;06M
M]2;_`)G1?^P>W_HQ:V>U8W_,Z+_V#V_]&+6S4L:.8\9,?(TM1;O<!K]`84?;
MYG!XS3-(:^TFZL--N`BPW)N)=C.7,2C!1`QZX!-=+-:PW#1F6-7,;[T)'W6]
M1[U%=Z;:7R*MU!',$;>H<=#57T%8Y.VUBYN(AJI\O[0-,F=<?=R)!BIKK5-:
MM5OF-W;,+6U2[XA^]GJG7IQUZUL7B:;I26T36D*02DV_9512"Q!]N*L;-.N4
M<A8)%EAVN>"&C]#[=:`,*YUV_$5_?0S0I#8R(AMG3+2Y"D_-V^]Q4CZOJ<=T
M)FDA-L-2%GY(C^8J?XBWJ/2M*6WT1KV&XD2T-UA1$Q(W''3`[]>*F*Z:TXMB
M+<S"3S_*XSO_`+V/6BX&+%KEW]J8K.L\$L$TD9,.P`IC&.<E>>]*^M7VFV=E
M>:A+#)#=0LQ*)M"RE0R*/7/(^M6Y9?#NG3(S"T5YY3"&7!Y89(]@<5-J5GI^
MHK9Z?)/"BQRQS"#C+A#D`#L,XH`+B]N+;0X);F80W<@124BW9=NRKZ]N:S8=
M5U2X2W@2:))VOI+9Y7CYV*N[.T'`;M6Y*]A?A[*62"=B-S1;@3@'K@>]5X/[
M,B$`L8()%$^,PE?D8C!)]\?C0@9A+J.H::/$=TUS]H\BY2.&,K@*6"C/TYSB
MK)U+6U582HC>6YCBBGGB`)5@=WRJ2."./7-:XBTB:]N0%M7N94VW"@@LZCLP
M[TEG:Z0A\BR2VS&PEVH0Q4XX;\J+@9SWSV\U_$)1%,;F*(21Q;WE8IG[N<9X
M/M4>GWTU]J.DRW#*95>ZB)48#;3C./7BM^;3+.Y2036\;>8P=LCDD<`_4"G0
MZ=:6XC$-O&GEDE-JXVYZX^M*Z"S+/:L7Q7_R+\W_`%TB_P#0UK;K$\5_\B_-
M_P!=(O\`T-:2*Z&W1110!3U1(9--N$N+9[F%D(>%!DL/85QSS7]GI\]^ANY;
M/39%EM3<#;+(F-LB'/48/!/.17>'I6(VJ:==W=UIM^8%*3+$L4C?ZPX#+Q]?
MY4T2S)71))TA2\BDF/\`9\LC98X\YV#8QGJ,G'TJ+3K*6/4;6XN[.8W,VE+&
M)64DB1=V0Q['!%=0NIV$EVUHMU$UPH),>[D8Z_E2+J^GM;R3K=Q&)&VN^[@'
MTI\S[!9')G2;VTL[=-.@GBFETJ1)2&.3*-F,YZ-][%12:4)]$NW6*XF3=`QM
MC;&/!5P68`G);;G-=C+J^GPV\<SWD(BE)$;%^&/MZU5@U^!O#0UJ=3'#Y32%
M5;=P"1P>^<4<S[!9&3J4$[K>-#;7)M"+4^4F06B!.]0,]<=JNWD,4_@W48=.
MLYHT>"01PLI#$X/0'UJP_B*P2>W9YHDM9H#.D[-@'D#'Z_I5V;5+*VDB2:ZB
M1I0/+!<?,#T/TH=PT.>'GZM<6%S%9W,$=G:RAVFCV%F9`H4#K[_@*J?V7>V5
M]H?DVTC6LTL4URH'^HE2,@D^S<?B*ZJ35M/AE=)+R)9(URZEN4'O^8I%U?3O
MLJW'VR#R7)`DWC!(ZCZT<S"R.8BM-71[?6GMXPYO#,\0!,PB?Y-I'3A=I_"N
MMM(KN/S/M-RDV6^3;'MVCT]Z2'4+.X53!<QRAD\Q=K@Y7.,_2K$,L<\*2Q.K
MQN,JRG((]:3=QI6)!THHH/2D,PK(X\6ZM_UQA_D:V]PKQ7XF:/K>J^-2=)M+
MN=4M4$GD$@`G.,UR7_"(^,_^@5JG_?1_QKHC04DFY'/*JXNR1]+Y%&17S1_P
MB/C/_H%:I_WT?\:/^$1\9_\`0*U3_OH_XU?U6/\`,@]N_P"4^E\BC(KYH_X1
M'QG_`-`K5/\`OH_XT?\`")>,_P#H%:I_WT?\:/JL/YD'MW_*?2^X4A/'6OFG
M_A$?&?\`T"M4_P"^C_C0?"/C/_H%ZH/^!'_&CZM'^9![=_RG<:7\7I;+5+FR
MURU\V".=T6X@&&4!CC<O?CTKT_2==TW6[47.FWD5S&1_`>1]1U%?*\B/'*\<
MJE71BK@]CGD'\:VO"VD^(M0U%9?#T=PLRG!N$;8B_5OZ5K4PL.6Z=C*G7E>U
MCZ?!S2UE>'X-6M]*CCUJ[@NKT?>DACVC'I[_`%XK5KS[69V(****!A1110`4
ME+24`8VF?\C#KG^_#_Z+%;58NF?\C%KG^_#_`.BQ6U52W%'8****D84444`%
M%%%`!1110`4444`%%%%`!1110`5A^)?]5IO_`&$(OZUN5A^)?]5IW_80B_K0
MMQ/8W****!A1110`4444`%%%%`!1110`4444`%%%%`!1110`5BZ3_P`A_7?^
MNT7_`*+%;58ND_\`(>UW_KM%_P"BQ30GN'_,Z+_V#V_]&+6S7`>,O&$7@_Q-
M9W,UG)<BXLVC"HX4C#@]ZR/^%WV7_0#N?^_R_P"%6J,Y)-(AU(Q=FSU?-(3Q
M7E/_``O"R_Z`=S_W^7_"C_A=]E_T`[K_`+_+_A5?5ZO8/:P[GH6KV)OIM.S"
MDD45SYD@;D`;2,X^I%<G=:7>V/DQ1QK')?7DUGM##_42'=N'T`;CWK)_X7?8
M_P#0#NO^_P`O^%-;XV:>S*QT&Y++T)F7C]*:HU5]DEU*;ZG0W5@\]]JME:Z8
MDFZ6!([DL!Y(5%Y]1C'&.]3VFBW,>KO]IBN7Q>-<QS1LFSGIGC=[$5R__"[+
M`$D:%<`GJ1*O/Z4H^-UCD_\`$DN>>WG+_A3]C5_E%SP[G4/HDMOH6DI%81O-
M:W2331#;EA\V<$\9Y!_"D&BW!UR9KB*[:.6[6YCFA=`J``8!R-W&#Q[US'_"
M[K'_`*`ES_W^7_"C_A=UC_T`[G_O\O\`A2]E5[![2GW.IAT&:'^S&6S0-%<S
M/<;2`Q1U;'/N2*33]+U"-+>$P,EI;W4;0B7:)%0`YW$<''&#UZUR_P#PN^Q_
MZ`=S_P!_E_PH_P"%W6/_`$`[G_O\O^%'L:O\H_:T^YTMGI-ZIT^W>Q$,EG,\
MLEX"#YJD-P._S;AGZ5:TW19K*]T61+9(4AM)([DI@?,=I`..O(-<A_PNZQ_Z
M`=S_`-_E_P`*/^%W6.<_V'<_]_E_PH]C5?V0]K#N>K@\4N:\H_X7A9?]`.Y_
M[_+_`(4?\+PLO^@'=?\`?Y?\*7U>IV'[:'<]7S6)XK_Y%^;_`*Z1?^AK7!_\
M+PLO^@'=?]_E_P`*HZO\8;/4]->U71[B,LR-N,JD<,#Z>U'U>IV#VT.Y[)2Y
MKRC_`(7A9?\`0#NO^_R_X4?\+OLO^@'<_P#?Y?\`"CZO4[`JL.YZL>E<K>Z3
MJ$USJ$`M8&M[VXCD\\O\R*NW/'<_+Q]:Y/\`X7?9?]`.Y_[_`"_X4G_"[[$_
M\P.Y_P"_R_X4U0J=@=6'<Z]=-U27589;I5>&*69L^8-I1E(4!0,]QG-5#H6J
M&U2-5=+>VG22WMFG&\*`0P#XXZ\9KFO^%VV)_P"8'<_]_E_PI?\`A=UCC']A
MW/\`W^7_``I^QJ_RD^TAW.KCT:\M+BWN[:Q60E9EFAGG#,I<@[]W3^'!`]:L
MVNCW2^"#I#B)+EK5XL*<HK'..?3D5Q8^-UC_`-`.Y_[_`"_X4?\`"[K$_P#,
M#N?^_P`O^%+V-7^4?M:?<[=-/NIYH;B>WCC=;![<J6#%7.._I@5CQ^&[Y4C2
M>-YHY+*&WF6*Y";2HP0<CD=QCGBL#_A=UB?^8)<_]_E_PH_X7=8_]`2Y_P"_
MR_X4>RJ]@]I#N=F^EWUM!?M9JBS372R#:0&:,!1@$]&P#@FL^2RO;.6R9K6.
M6:34GG6-G!RI3KNQ@-P:YS_A=UB/^8'<_P#?Y?\`"C_A=UAG/]AW/_?Y?\*/
M8U>P>TI]S<U#2[ZWLK5XPD5_=WDD31QG(2.8_,`1_=`W9]1[UV\$26]O'#&N
MV.-0BCT`&!7EA^-M@3DZ%<\=/WR\?I2_\+OL1_S`[G_O\O\`A0Z-5_9!5::Z
MGJ^:0]*\I_X7?9?]`.Z_[_+_`(4?\+PLO^@'<_\`?Y?\*7U>IV'[:GW.ZL1_
MQ5NK?]<8/Y&MO%>-V_Q@LX=8O+XZ/<$7"1J$\U<KM!SV]ZO_`/"[[+_H!W/_
M`'^7_"AX>KV#VL.YZKBC%>5?\+PLO^@'<_\`?Y?\*/\`A>%E_P!`.Y_[_+_A
M4^PJ=A^UAW/5<48KRK_A>%E_T`[G_O\`+_A1_P`+PLO^@'<_]_E_PH]A4[![
M6'<]5Q2$9%>5_P#"\++_`*`=S_W^7_"C_A=]E_T`[G_O\O\`A1["IV#VL.Y=
MTGX2:;'J,]_K,QO9))GD6%?EC4%B1GN>M>A6]K!:0)!;0I#$@PJ1J`!^`KS#
M_A=]E_T`[G_O\O\`A1_PO"R_Z`=S_P!_E_PJY4ZTGJ2ITUL>K#BBO*?^%WV7
M_0#NO^_R_P"%'_"\++_H!W/_`'^7_"I]A4[%>UAW/5\T9KRC_A>%E_T`[G_O
M\O\`A1_PO"R_Z`=S_P!_E_PH]A4[![6'<]7S1FO*/^%X67_0#N?^_P`O^%'_
M``O"R_Z`=S_W^7_"CV%3L'M8=SU?-)7E/_"\++_H!W/_`'^7_"C_`(7?9?\`
M0#N?^_R_X4>PJ=@]M#N=[IA_XJ+7/]^'_P!%BMG->-VOQAL[;4K^Z.CW!%T4
M8*)5RNU0ISQ5[_A>%E_T`[G_`+_+_A52H5.PE5A;<]7S1FO*/^%X67_0#N?^
M_P`O^%'_``O"R_Z`=S_W^7_"I]A4[#]K#N>KYHS7E'_"\++_`*`=S_W^7_"C
M_A>%E_T`[G_O\O\`A1["IV#VL.YZOFC->4?\+PLO^@'<_P#?Y?\`"C_A>%E_
MT`[G_O\`+_A1["IV#VL.YZOFC->4?\+PLO\`H!W/_?Y?\*/^%X67_0#N?^_R
M_P"%'L*G8/:P[GJ^:,UY1_PO"R_Z`=S_`-_E_P`*/^%X67_0#N?^_P`O^%'L
M*G8/:P[GJ^:,UY1_PO"R_P"@'<_]_E_PH_X7A9?]`.Y_[_+_`(4>PJ=@]K#N
M>KYHS7E'_"\++_H!W/\`W^7_``H_X7A9?]`.Y_[_`"_X4>PJ=@]K#N>K5B>)
M/]5IO_80B_K7"?\`"\++_H!W/_?Y?\*H:I\8+/4$M0-(N$\FX2;)E4YQGCI[
MTU0J7V%[6%MSV;-&:\H_X7A9?]`.Y_[_`"_X4?\`"\++_H!W/_?Y?\*7L*G8
M?M8=SU?-&:\H_P"%X67_`$`[G_O\O^%'_"\++_H!W/\`W^7_``H]A4[![6'<
M]7S1FO*/^%X67_0#N?\`O\O^%'_"\++_`*`=S_W^7_"CV%3L'M8=SU?-&:\H
M_P"%X67_`$`[G_O\O^%'_"\++_H!W/\`W^7_``H]A4[![6'<]7S1FO*/^%X6
M7_0#N?\`O\O^%'_"\++_`*`=S_W^7_"CV%3L'M8=SU?-&:\H_P"%X67_`$`[
MG_O\O^%'_"\++_H!W/\`W^7_``H]A4[![6'<]7S1FO*/^%X67_0#N?\`O\O^
M%'_"\++_`*`=S_W^7_"CV%3L'M8=SU?-&:\H_P"%X67_`$`[G_O\O^%'_"\+
M+_H!W/\`W^7_``H]A4[![6'<]6S6-I7_`"'M=_Z[1?\`HM:X+_A>%E_T`[G_
M`+_+_A72>`O$">)SJ^J16[P))<(H1V!.0@'44G3E%7:!3C)V1Q'QN'_$TT?_
M`*XR?S%>?:/X?U37VF73+;SS"`9/F"[0>G7Z5Z%\;O\`D*:1_P!<9/YBL+P-
M<65OX=\5-?QO-;_9HMT*2^6[C<>%/4&NZG)QH)Q.6<4ZK3./O+2?3[V:SND"
M7,)VR(&!VGZ]ZKEE]>M>D:1IUMKGA6R.E6D,?D:V)9DGE#/%!C^)VY(JW+?Q
M:2NL7-G;V#RMXC2!3+$KA(F`#8].*KV[VMJ3[);W/+5&Z1$!&7("Y/4G@?2K
M>JZ=<:+J<^GWNQ;B`@.$.1R,\'\:]1AM%MY=>/AZSTZ2]75U699@A"6V`25W
M=!G/(JV$LY?$'B>ZMHS<ZD+R$!8%BDD,.P9"A^-I/7'-)XAWV'[%=SQ@?,RK
MG!8X&:MZKIESHNIW&GW@1;BW.)`K;AR,]?I7IUE%M369?#^EV,6HC5$6XM[O
M8WDV^T9]@,YZ5S^NZ<NO?&">R1@T,URA=E.0$506.?H*I5[RVT)=))6N<SJV
MASZ0+!9I$>:\MUN!"@):-6/`/J34FI^%]9T:T2ZU&S\B%R%R74E2>@(!R#4V
MOZK)K'C2:]M753]H6.UW'"H$("9]N*[C6+&*ZET[5]:T]-,UJ34X8WB2</'>
M)D9?;G@8[T.K.*C?J"A%MV/*-Z>HQW]J-RCJP&?0UZ_<ZW''9WMPEGI(EM-=
M6SMS]G0[86/S<=_K5W3-+M[7Q!J4EK]G.GMJ822"&")MJE`29&;[L?/1>]+Z
MPUT*]C?J>5V/AK4M1@T^:V2(IJ$[V]ON?!+J,G/H,56T_2+[5=4_LVQ@\Z[R
MP\L$#.WKS7IFGBUM;WP_!"T211:_>!5#C"I@X_"N6\#2^3X]N)`ZH1%=%6)Q
MSM;'-$:TFGH)TXIHP;7P_JM[K,FD6]D[ZA$2)(>`5QUS6?<1O:7$EO.NR6)R
MCH3]T@X(KV"UU.QB_LOQ);SHNHZZ]K:2KQF/:?WA/IG`J&PBFS)+H=KI]S-)
MK4XU1IE1RL._CKT7'<5*Q$KZHIT8K9GEW]F7/]B_VOA/L7G_`&?=NYWXST]*
MI[QDX/3J*]1C30G1;;="=(_X28C:6^39LX_X#NK0U*+3Y=9T>WU?3&B3^T6$
M=S<+%&C)M.V,!#\R9V\FJ^L>1/LO,\>W*>A'X<U>TW2[K5Y+F.S",UO`UQ(&
M;&$7KSW/->D0VNK7NJ:S9:U8Z<E_/ILR:?'"D:EP'XZ?A@GFB.UCTR2UMG-N
MEPGA69)O+=<&3.#DCJU'UAO1(/9*^YY0&!P`03Z5J:3H&J:[)+'IEHT_E#+L
M6"JOIECP*]*N8M.@\'(MKICW>FOI2DO&L019<9+ER=^\'M7.:!:SZW\-+S1M
M+D1M4%ZLTD/F!&FCQQ@GK]/:FZS<=$#I)/4PF\(:U'M$UO'"S78L]LDH!$A&
MX>VW'>L>ZB-G=RVLVT2Q.4?:<C(/8]Z]%TRSET_1]*L=2>)[A/$<7F*91(`-
M@ZGT'2I[+4(=,AC-O;V+M<>));=S-$K$0LW(&>@]ZE5I)VL/V43SLZ9<C1EU
M;$?V1IO(!#@MNQG[O7'O5'<N,AACUS7J2V6BJ[6]Q';+:#Q2R'D?ZO;P/]W-
M2)::]/XJF_M""PM7B@F:T6VMHGEECSP$4_+G&,%J?M[;HGV?9GF]EI=UJ-I?
M75LJ-%8Q"68LV"%SCBK>D>%]9UVWDGTRS^T11N$9MX7YNN.:]"\116<`\0M`
ML<;W&APM(!M!:3>0<A>-W'.*Y[PY=:9:?#Z]DU-+B:*/5876*VE\MRP7(R?3
MUH]M)Q;2&J<>9)G%W4$ME=26MU&T,\;%7208*FHMRYQD9]*]#_X2F2ZT#Q'X
MA6TLQ?37L*1+-&)#$A7:<9ZG%;IMH8[&2,VFG?\`")#1RZSA4WFXVY^]][=G
MM3==QW0*DGU/'BZ@XW`=NO>@LH."PKU[5[=].\"2BRL4F6338@(HX(SY!(R\
MI8G>>#W%#3R7?BEM+L5L+>&UTU+E/*M8I)II&4`A=W!;ZU*Q+:ND'LO,\BW`
M#DBC<#P""?:O7M8>STR_UC4+>VLC=+HL4P26-&'G!R,E1QNXYQ4FH3V=[-J6
MGR6NFK;RZ&MZQCC16:<\9W#IZ8JOK#[!['S/'0P)^\..:6O1/&MN[^$;"[:%
M-/57C06#1QY)V?ZR-UY*GOFO.ZUISYU=F<X\KL@HHHK2Y(44447`****+@%%
M%%%P"BBBBX!1111<`HHHHN`4444!H%%%%`:!1111<`HHHHN`44447`****+@
M%%%%%P"BBBBX!1111<`HHHH#0****+@%%%%%P"BBBBX!1111<`HHHHN`4444
M7`****+@%%%%%P"O;O@I_P`BYJ/_`%]_^RBO$:]N^"G_`"+NH_\`7W_[**Y<
M7_#-\/\`&8GQN_Y"ND#_`*8R?S%>6?B??W^M>Y?$/PPWBCQ#8P"\%L(;1WW%
M-V<L!7+?\*D?_H-+_P!^344*T(TTFRJE.4IMH\VY`(!(!Z@'K17I/_"HW_Z#
M2_\`?@T?\*CD_P"@TO\`WX-:_6*5]S/V,SS;L1D\\'GJ/>E#,K;E=@V,;@Q!
M_.O2/^%1O_T&E_[\&C_A4;_]!I?^_)H]O2'[&IV/-N0"`2`>H!ZU;T[5+S2)
MI9K&412R1-"S$`G:W4#/3ZUWW_"HW_Z#2_\`?DT?\*CD_P"@TG_?DTG7I6W#
MV-0\U``&*4DG&68X&!DDX%>D_P#"HW_Z#2_]^31_PJ-_^@TO_?DTWB*7<%1J
M'FW/J?SH!(!`9@#UP>M>D_\`"I'_`.@TO_?@T?\`"HW_`.@TO_?@T>WI=P]C
M4/-OQ/YT=.G%>D_\*D?_`*#2_P#?DT?\*C?_`*#2_P#?DT?6*71@Z-3L>;=_
M\\4#(S@D9X.#UKTG_A4<G_0:3_OR:/\`A4C_`/0:7_OP:/;TNX>QJ=CS8@$8
M/(]*5BS?>9FXQ\Q)X]*](_X5(_\`T&E_[\&JVH?"]["R>Y.KJ^TJ-HB(ZG']
M:/;TA>RFC@-S;MVYMW8Y.13<8&.?SKTH_".0$C^VD_[\FC_A4C_]!I?^_)H^
ML4D]Q^QJ'F^6V[=S;,Y*Y./RI`2K!@2".A!Q7I/_``J1_P#H-+_WY-'_``J2
M3_H-)_WY-'UBD+V,SS;'U_.C\3^=>D_\*D?_`*#2_P#?@T?\*D?_`*#2_P#?
M@T>WI=P]C4['FU+EMP;<VX=#N.17I'_"I'_Z#2_]^#1_PJ1_^@TO_?DTOK%'
MN'L:AYMCZ_G1^)_.O2?^%1O_`-!I/^_)H_X5&_\`T&E_[\FG]8I;#]C4WL>;
M8H/*["3MZ[<\`^N*])_X5&__`$&E_P"_!H_X5&__`$&E_P"_)H>(IO<%2J=C
MF+KQKK%W9RV\C6RO-"+>:YC@`EDC'\!;TKG@2I&UF7'3!KTC_A4;_P#0:3_O
MR:/^%1O_`-!I?^_)J56HK1#=*HSS;\_SH[8R<?6O2?\`A4;_`/0:7_OR:/\`
MA4;_`/0:7_OR:KV](GV,SS<DMC<S$#@`G./I25Z!%\+GEU&YM/[74>0B/O\`
M).&W=OTJS_PJ-_\`H-+_`-^33^L4UI<%1F];'FU%>D_\*CD_Z#2_]^31_P`*
MC?\`Z#2_]^32^L4^X>PGV/-J*])_X5(__0:7_OP:/^%1R?\`0:3_`+\FCZS2
M[A[&?8\VHKTG_A4;_P#0:7_OR:/^%1R?]!I/^_)I_6*?</83['FU%>D_\*C?
M_H-+_P!^#1_PJ1_^@TO_`'X-+ZS3[A["?8\VHKTG_A4;_P#0:7_OR:/^%1O_
M`-!I?^_)H^L4^X>PGV/-J*])_P"%1R?]!I?^_)JN_P`+G34H+/\`M=3YL3R;
M_*/R[<?XT_K%/N'L9]CSZBO2?^%1O_T&E_[\&C_A4;_]!I?^_)H^L4^X>PGV
M/-J*])_X5&__`$&E_P"_)H_X5')_T&D_[\FE]9I]P]A/L>;45Z3_`,*D?_H-
M+_WX-'_"HW_Z#2_]^#1]9I]P]A/L>;45Z3_PJ-_^@TO_`'X-'_"I'_Z#2_\`
M?DT?6:?</83['FU%>D_\*C?_`*#2_P#?DT?\*DD_Z#2?]^33^L4^X>PGV/-J
M*])_X5&__0:7_OR:/^%1O_T&E_[\FE]9I]P]A/L>;45Z#?\`PM>QL)[K^UP_
ME+NVB$Y/(']:L#X2.0#_`&TO(!_U)H^L4^X>QGV/-J*])_X5&_\`T&E_[\FC
M_A4;_P#0:7_OR:?UBGW#V,^QYM17I/\`PJ.3_H-)_P!^31_PJ-_^@TO_`'Y-
M+ZS3[A["?8\VHKTG_A4C_P#0:7_OP:/^%2/_`-!I?^_!H^LT^X_83['FU%>D
M_P#"HW_Z#2_]^31_PJ1_^@TO_?DT?6:?</83['FU%>D_\*CD_P"@TG_?DT?\
M*C?_`*#:_P#?DT?6*?<7L9]CS:BO2?\`A4;_`/0:7_OP:K77PO>VFM(SJZM]
MIF\K(B/R\$T_K%-NUP]A/L>?T5Z3_P`*D?\`Z#2_]^31_P`*D?\`Z#2_]^32
M^L4^X>PGV/-J*])_X5(__0:7_OR:/^%1R?\`0:7_`+\&CZQ3[C]A/L>;45Z3
M_P`*C?\`Z#2_]^#1_P`*D?\`Z#2_]^#1]9I=Q>PGV/-J*])_X5(__0:7_OR:
M/^%1O_T&D_[\FCZS2[A["?8\VHKTG_A4<G_0:3_OR:/^%1R?]!I/^_)H^LTN
MX>QGV/-J*])_X5(__0:7_OR:/^%1O_T&E_[\FCZS3[A["?8\VKV[X*?\BYJ/
M_7W_`.RBN:_X5')_T&E_[\FNY^&VBGP_;ZMIQN!<>7<JV_;MZH#TK'$58SA:
M+-:-.4979I:K_P`C?#_UX-_Z&*?FH]5_Y&Z'_KP;_P!#%25P.VAUKJ<]XE\0
MW.AWEFD-M'-!(KR7!8G*HI&2N/K^E)=^(Y8_%EII=O'$]E(0LT[$Y#%2X`[8
MVXS5^_T9+_4[:ZED_=Q030/%M^^)`!GVK+T_P@EE;:=$]Z9FMKB2:61EYFW)
ML`SVP,#\*UC[.VIF^=/0T+;Q-IMTY"/(B>6\T<DB866-?O,I]!6<?%1N;R;[
M+OAMX].>ZW7$!!!!^5L=UQS2V'@Z*TMIK.5[62!X'@25+?;,%;CELX..G'6G
M)X8O7CD6[U5)F_L]K"/9#M"J>C=>30O9@W4+T/B"V::VM?W\\[Q1O(\,)*1[
MQP6_NY]*@O?$L4=O?QPQ3PWD5K+<0B>(JKA.I'J,TMKH%UI]_P"?9:DL<4T4
M4=S&T62Q1=H*G^'(ZYK/B\%NC2N]^KR/:S6WF>6=["3^)R3R12M3"\C2OM9N
M;/1-+O`B/+=2V\<F>!\_4CTIY\3Z=_:`L@;@O]H-J9/).P2=E+=B>U+>:*;O
M2=/LA<;?L<L,F_9G?Y?;';-1?\(Z0CJ+L?-J@U$?)TZ?+_\`7HM3'[Y#=^*(
MSJ-K9V(D;=?"VDE:$F-N#N"MTR*DA\2P16JM.\EU/)<S111VL!W,$//R^W<U
M%%X9N(;B,)J0^P0WQO8[<Q98$DDJ6].>*1/"]Q:O;W%EJ217D,T[B1XMRE)3
MDJ1GJ/6G:FQ>^:$^OVMM=0PS172K,ZHDQA(3>W1<^M9B>*FNK6X=(WLVAOUM
M-TT1<."P''3#']*6[\*2W>J?;9M05\3Q3Y>(EU*?P`YP%)YX%22>&IW^UQ"_
M7R)M06_13'\R,&!*D]^G%%J87F7/^$ET\ZB+/,X#3_9UN/*/E>;_`'-WK3;?
MQ/IUS?Q6D?G[Y)7@5S$0GF+G*;O7BJD?AF1)EA-^#I<=]]N6W\O$@?.<%L_=
MR<U-;^'3#%:QFZW>1J#WWW,;MV?E_#-3:`TYF[FLSQ#_`,@.;_?C_P#0Q6GU
M/-9GB'_D!S?[\?\`Z&*SC:Y;3L:C??/UI,TK?>/UI*)6N-7,?6M2O;.\TNSL
M5MS+?3-&6G!(3"[L\55B\4I:K=0ZQ%Y-S;3K`PMPSK(6&4*]^0#^-6]:TFYU
M&XT^XM+Q+:XL9FD4R1>8K97'3BJH\+?-'-)?-+>&^2\GF*8\PJ,!0!T'-;)P
ML9^]?0N?\)%8K;W<TGGH+0QB96C(92^-HQZ\TLWB*R@O_L;)<._G"W+QQ902
M$9VY^G-4=1\,W%]>7\D.IB&VOVC>6+R=S;TQC!]..:S%T_5(O%D]Y'8L[/>[
M@98\Q+%C!</G`..G&:2A!@W,W-3U2]36+;2-,C@-S+$T[RW&=D<:G'0<DDFG
MW&N+I<42ZI#*'PHFF@C+1(2<#YC2:IHT]SJ<&IZ?>?9+V%&BW21^8CH3G!&?
M7O69J?A*ZU61FNM425I(T5C)"?D96SE`#@`T+EV#WC2D\3:='?M9GSS(LXMW
M<1'RTD/W0S=LY%5=2\4117<5I8B5I!?1VTLK1$Q9/WE#=-PJ:3PX9$O5%V,7
M5_'>_<^[MV_+^.VH'\,7'VAUCU)5L#?B^$!BRP?.2I;T)HM3N+WR:/Q'!!'(
M;F5[AS>R6T26]N=WR]1C/.!U-1Z=XC,FA1ZA<PSS%Y)0/L\).$1CR1VXIO\`
MPC,\-REY9Z@L=Y'>S7*.\6Y=LG!0CUJ)O",IL+6T_M%7$3S%Q+%E)#)SN*@C
MYAVIVIA[Y;B\46\^LVME!!,]O<VOVE+G:<`9[_[..I['BK-AX@L-2N5@@:4-
M)&98C(FT2H#@LI]*I6_AE[5]-*7@*6MFUE,IC_UL;>G/RFG:%X;&C2IEK258
MD,<<BP%9<?[39Y]./2DU3MH.//<WZ***QT-=3-M?^1DU/_KA!_(UI9K-M?\`
MD9-3_P"N$']:TJJ5KDQO8*.:**E6*U.2N_%-];:C?*$LV@M;V.U\G<?.DW8Y
M7G!QGIBM0>*=,(N6!N"EN_E.WDG!DW;=@/=L]JDL-"M[/6;_`%*5(IYKJ<2H
MS1C=$``"`:IR^%EFT.;3GN@6>\:\20IE48MN`([CL:WO3>AC:9JV&J6VHPRO
M"Y0Q2&*1)1M9''8U@7_B?4+>VU!K2SAEGM]3%E"C$C<I&<GWK3L_#]HEGY-[
M:64K>9YF(82BAOH3G-0?\(U^]FD%UC?J::@`$Z8&-E*/LTQRY[:%.Z\8-]EN
MKJSACDACTQ;Q-^<[]^TJWT.:O6FK:A#JUG8:G#;8O8C)!/;[@-P`)4AO8]:I
MS>"HFN-;>"\\J+4H?+6/9D0L6#$CV)'2K]CH=S'J%O?ZE?B\N+:(Q6ZQQ>6B
M`C!.,G)XQ3ER6T%%2ZFUFC-&,45A9&JN%9MQ_P`C-8?]>LW\Q6E6;/\`\C-8
M?]>TW\Q51M<4KFE1114Z#U"LKQ%JDVCZ-)>0)&\HDC11+G;\S8R<=JU:S==T
MD:WI+6!E$:O(CEBNX$*V<8]#TJHVOJ*7-;0PI?%EY!/Y$JV\AAU".WEEM076
M5&4M\HY^;V&:VHO$%K<:=]L@@O)!YK1&%83YBNO4$=J=>:-!.-/%JL5I%9W:
MW(2./`?`(Q@?SJA<>&9)8V"WP^:]>Z9'0F-PPQM8`Y..HK5NFS.TT6X_$MA<
M&T%L)YVNT,B)'$254':2PZCFGMXAT]-1^QEY,^?]G,NS]V)<9V%O6LH>$)%T
MRPL$O8@EHVX3"$B53NW?(P/&>F.E3P^%TM]:ENT-J\$EP;C9-!ND1CU"MGUY
MZ<4N6`[S+YU*8>*1I)1/*^Q_:2_.[=NQCTQ6G6>=,SXC&K^=TM?L_E;?]K.[
M-:%9RY;Z%Q3ZAFC-%%3H5J9VO_\`(OWW_7/_`-F%:"_<3_='\JS]?_Y%^^_Z
MY_\`LPK07[B?[H_E5.W*3K<7-&:**G0=F8^O:K=:=+IL%K]F62]N##YESG8F
M%)SP16/;^,IWN+#S[?,4GVE)5M8S)YK1D`,G?;U-;FKZ-%J\VGM,5,5G.9GB
M=-PE&TC;BG2:2K:O97L3I#%:020B)$P/GQR/3%;1E"UFC-J=]".;Q'91:=#J
M"QW4UK+%YWF11%@J>K>F/2I8=;M+F_%G;B:9MB2-(B91`PRNX]LBL6X\&R3Z
M?:V9U!#'#;/`RR1EE^8Y\Q1D?-SBK8\-N=1T^X:ZC$=FBIE(BLLBA=I5FS@J
M>O(I6IA>=RY9^(=/OKM+:%I<R[O)D=,)-M^]M/?%9FH^);JS;6@D,3?8)[>)
M,Y^828SGZ9J;1/"XT:Z5@UI+''N$;>1B8!CT+YQTXX%%]X8^V/JS"\\O[?-#
M+C9_J_+QQ^-.U.X>_8Z(\'%)F@G)S166AI9A69JG_'YH_P#U^#_T`UIUFZI_
MQ^:/_P!?@_\`0#3C:XG<TN]&:**6@:AVK&UW5;K3[G3+:U-LCWLK1M)<YV1@
M+G/!]JV169JNBQ:O>:;-/L:.SE:1H77<LF01@_3K51<4]1-.VA@VWC.9Y[!Y
M[8F*6*?S$MHS(7>-L!D[[3R>:V[CQ'96]A#?!+F:UEB\[S(HBP6/^\WI]*DE
MT=7U:UOHI%BCM[66V6%4P,/W'H!CI6+=>#'N=/MK,Z@K1Q6IMR'B+`$G.]1G
MANV36C]FV0N=&Y%K5I/J+6<'FRE%5GE5/DC##<NX]>14=EXAL-0NTMX&E#2J
MSPNZ8655.&*GOBJI\..^JVEV]S$([>/RSY49625=FTJS9P5[\\TW0_#(T:=2
M&M94B5DB<0;9L'IN;...G'6AJ'0:<R"^\375J^K!((C]BO8+9,YY63&2??GB
MM33-2EOM0U>VD5%6RN?)0KU9=H.3[\U1N_#'VLZF1=[?MMW#=#Y/N>7_``^^
M:T;#3/L-[J=P9?,%]<"?:!]S@#'OTI7A8:4KFAFBBBL=#34*?X;_`.0GK?\`
MUWC_`/18IE/\-_\`(3UK_KO'_P"BQ51V9+WU*NKP7]QXNA6P-L&%BV[S]W3>
M.F*?_9?B+^_I?Y2?XUH'_D=%_P"P>W_HQ:V>U-RV$D<M_9?B'^_I?Y2?XT?V
M7XB_OZ7^4G^-3:KXEDTV]NHDLTEBM(HYI29=K,K$C"C')&#6E_;%B+M;4S@3
M-@;2#P3R`3V/M1J&AC_V9XBZ[]+_`"D_QH_LSQ#_`'M*_*3_`!J_!X@METZ.
MYOF$.]W48!(PK$9..E3W.NZ99L$GNXT)4/CDX4]&..WO1J&AE?V9XB_OZ7^4
MG^-']F>(C_'I?Y2?XUK2ZO:B6:"*5'GC0L0<[1QGENW'-12:]I]LL8N;J))7
M1'*@D@!NA_W?>C4+(S?[+\1?W]+'X2?XTG]E^(O[^E_E)_C6Q+K>G07B6DMR
MHG=@@7!(W'D#/KBI[Z_M=/A$UW,L,9(4,W<GL/>B[#0P1I?B+^_I?Y2?XTO]
MF>(O[^E_E)_C6NVLV*W"0&X`EDQ@$'`ST!/8GWJ)_$>DQRM$UY'O4D$<G)'4
M#U(]*+L+(S/[+\1?W]+_`"D_QH_LOQ%_?TO\I/\`&M)];MRD=Q$\<ELT,DI.
MX[B%]%[^]5H?%=A,NEL!*!J(/E_(?DP,\_RHU#0K#3/$7]_2ORD_QH_LOQ%_
M?TO\I/\`&M3^VK6"$O>30QDRO&@0EMQ7M]?:B7Q#I<-M'<R7:>5(I=6&3E1U
M/L.U&H61E_V7XB_OZ7^4G^-9?B#3]=319C,VG>7OC^X'S]\>IKNHI$FA21#E
M'7(/J#61XK_Y%Z7_`*Z1?^AK0I.X..A1.F>(B2=^E_E)_C2?V7XB_OZ7^4G^
M-=511S,.70Y7^R_$7]_2_P`I/\:/[+\1?W]+_*3_`!KJJ2E<+'+?V7XB_OZ7
M^4G^-']E^(?[VE?E)_C74T4<P6.6_LSQ%_?TO\I/\:7^S/$7]_2_RD_QKJ*6
MCF'8Y7^R_$7]_2_RD_QH_LOQ%_?TO\I/\:ZDT4<PN4Y?^S/$7]_2_P`I/\:3
M^S/$7]_2ORD_QK:U'5(M.>!98Y6\]Q&A1,@L>@JK_P`)+IOV,W7F.(Q<?9C\
MAR),XQCTSWIW8610_LSQ%_?TK\I/\:3^R_$7]_2_RD_QKJ!TI:.8=CEO[+\1
M?W]+_*3_`!H_LOQ%_?TK\I/\:ZK%)2N%C@[6PUP^(M156T[S1##NR'QC!QCF
MM/\`LOQ%_?TO\I/\:O6/_(VZM_UQA_D:VZ;DQ**.6_LOQ%_?TO\`*3_&C^R_
M$7]_2_RD_P`:ZFBES!8Y;^R_$7][2_RD_P`:/[+\0_WM+_*3_&NII:.8+'*_
MV7XB_OZ7^4G^-']E^(O[^E_E)_C74T4<P6.6_LSQ%_?TO\I/\:#I?B+^_I?Y
M2?XUU-+1S!8Y4:7XB_OZ7^4G^-']E^(O[^E_E)_C754E',%CEO[+\1?W]+_*
M3_&LRXL-='B6R0MIWF_9I=N`^W&1GO7>8K%NO^1PT[_KUF_FM-2!Q*']E^(>
MSZ7CZ2?XT?V7XB_OZ7^4G^-=312Y@L<M_9?B+^_I?Y2?XT?V7XB_OZ7^4G^-
M=311S!8Y;^R_$7]_2_RD_P`:/[,\1?WM+_*3_&NII:.8+'*_V9XB/\>E_E)_
MC1_9?B+^_I?Y2?XUU-%',%CEO[+\1?W]+_*3_&C^R_$7]_2_RD_QKJ:*.8+'
M+?V7XB_OZ7^4G^-']E^(O[^E_E)_C754E',%CA-?T_78]!O#,VF^7LYV"3/4
M>]:":;XB:-"'TO&T8R']/K6IXJ_Y%B__`.N?]16I#_J8_P#='\J?/H+E5SF?
M[+\1?W]+_*3_`!H_LOQ%_?TO\I/\:ZFBES#L<M_9?B+^_I?Y2?XT?V7XB_OZ
M7^4G^-;VI7]MI5C->WDGEVT*[I'(SM'K3K&^M=0MDN+2>.>%QD/&VX&G=AH<
M_P#V7XB_OZ7^4G^-+_9GB+^_I?Y2?XUU%%*X<IRW]E^(O[^E_E)_C1_9?B+^
M_I?Y2?XUU5&*+L=CE?[+\1?W]+_*3_&C^R_$7]_2_P`I/\:ZK%%%PL<K_9?B
M+^]I7Y2?XUF:K8:XEYI*R-IVXW?R$!^NT]>>E=Y6)KG_`"$=$_Z_/_96JHR=
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M`#.B_P#8/;_T8M;/8UC?\SHO_8/;_P!&+6S4L:.8U3PT^H:C?7H\I9VAB^R2
M$?-%(A8Y^AR*CB\/7']JR2W%O%/#/<+<L3.R^6W'&T<'!'!KJSTKF)=7U4W!
M,26?D_;S9A7#%NGWR<_IC\:I-BLD,FT751916\<T;)LF5T#E%W,V58XY8`'&
M*K-I^IBZNK&VBMR'T^&VDDER`O!!8?W@/2KUAKUY/J-K93Q0EFN)[>:1`0#Y
M8R"!GC/IS6<^J75]']MC=8I_L%WL(R5!1RH./PIJXG8OG0[U;UOLQCA@:(I,
MPD)%Q\FU=R]B#W'84L^@W+V%]#OAWSZ?';*WHR@@_AS3+:^N8K?3)[DI/<FP
MDE\SE<X"'!&>^>356_U6^ETUXKO[/MNK'[3&8,@Q\KE3D\CGKQ1J":*D2S0Z
MXR21/)MO(]MN-X)(55\P#&T@#)SGG%=+/HR[K7R&.(KI9W$KE^F>F>G6L\Z[
MJ#:C-#:VC2QVTL<+*(F)8$`LV_.%QGI[5=U74KBPO;8?)#8L/WEPT9<*V0`I
MP1M!SU/>AW!6*4OAZ4ZS=3/%'<6MS,DS%IV385QU4<-C`(-6H=&FC-F6\G]Q
M>RW#?1BV,>_S"JL]_?:AHFIW+-!':A)HTC`/F#;D9)SC\,4CZ[J`OIK:SM#*
MEJ8D9%B+%]P!)W9PN`>,T6871)8Z#=V^T2R1X'VK.TDX\U@5/X8HMM*U.&UT
M(LEN9M.)C=1(<.A39N!]>^*236[^*WN)]ML$^V"S@4YZ[MNYC_0?G23ZSJL#
M7=L8XI9;62/S9HH68")E)W;,YR".@)XYHU!6+-OHL\5Y;3.8B(KJ:8^N'&!C
MWKFKS3KG394MIC\I@GW;=X68/*6\L,H/..QK;?5+EFO)]-A2YD\J!A(F6#JW
M5@F>WH.36[IMTE]I\-PLZ3AA_K$7:"1P>#T.>U*[0[)DMDY>PMW,)A+1J?*/
M5..GX5F>*_\`D7I?^ND7_H:UM]JQ/%?_`"+\W_72+_T-:GJ5T-NBBB@`H/2B
MB@#G?$?VN*XT][;4)X%N+N.W=$`(VG.3SWIC:K.+6\3RIUBM)%A:Z\Q=\C!E
M'`Q[\ULWNGQ7QMC+N'V>99DVG^)>F:B?2+=[6Y@)?9<3><_/\60>/R%4FA.Y
MG7'B&>&XD5--DEABN5M3()`"78#!`],D`U%)XJ$,(26V$=W]I:W,;2?(&4;B
M=V.F".U:K:/;GS.9/GN5NCS_`!C&/P^45!+X=MI)))DEFCF:X-P)%(RK$`$`
M$8P0.E%T*S*EOXG6YELHX[;9]I#$F5]HR&VD*2/F/?Z4W3M9OY+*_GNH+<>1
M=/#'F8*I`.!DG_)J]<Z#'>000W%U<R11D%E)`WD'()P.#GTQ4;^&[=DN%$TZ
MK-<"Z"@@B.3U7([^AS1H+4;`R>(K2WG<&%[2[WE4(<%D/KZ&H#X3@\IHQ<38
M+;SP,;O,WY^O\/TK8TW3X]-@DBC>1]\C2LTAR2S<FKM*_8I(09QSUI:**0PH
MHHH`\P\6>.F\&^,;E%T_[5]IMXVSYFW;C(K,_P"%X/\`]``_^!`_PKJ-4\'Z
M/XI\87SZI%)(T$$0CV2%,`YSTI/^%1^$O^?2X_\``AO\:Z(2HI>\C"2JWT9S
M'_"\7_Z`!_\``@?X4?\`"\7_`.@`?_`@?X5T_P#PJ/PE_P`^EQ_X$-_C1_PJ
M/PE_SZ7'_@0W^-5S8?L+EK=SF?\`A>#?]``_^!`_PH_X7@__`$`#_P"!`_PK
MIO\`A4?A+_GTN/\`P(;_`!I?^%1^$O\`GTN/_`AO\:.;#]@Y:W<Y?_A>+_\`
M0`/_`($#_"C_`(7B_P#T`#_X$#_"NG_X5'X2_P"?2X_\"&_QH_X5'X2_Y]+C
M_P`"&_QHYL/V#EK=SF/^%XO_`-``_P#@0/\`"C_A>+_]``_^!`_PKI_^%1^$
MO^?2X_\``AO\:7_A4?A+_GTN/_`AO\:.;#]@Y:W<Y?\`X7B__0`/_@0/\*/^
M%XO_`-``_P#@0/\`"NG_`.%1^$O^?2X_\"&_QH_X5'X2_P"?2X_\"&_QHYL/
MV#EK=SF/^%XO_P!``_\`@0/\*IR_&%I=6M[_`/L0@PQ/&$\\<[B.>GM79_\`
M"H_"7_/I<?\`@0W^-9L_PP\,1^(+2R6VG\F6"21AY[9)!7'.?>FI8?L)QK=S
M*_X7@X_Y@)_\"!_A1_PO%_\`H`'_`,"!_A73_P#"H_"7_/I<?^!#?XT?\*C\
M)?\`/I<?^!#?XTN?#]@Y:W<YC_A>+_\`0`/_`($#_"C_`(7B_P#T`#_X$#_"
MNG_X5'X2_P"?2X_\"&_QH_X5'X2_Y]+C_P`"&_QHYL/V'RUNYS'_``O%_P#H
M`'_P('^%'_"\&_Z`!_\``@?X5T__``J/PE_SZ7'_`($-_C1_PJ/PE_SZ7'_@
M0W^-'-A^P<M;N<Q_PO!_^@`?_`@?X4?\+Q?_`*`!_P#`@?X5T_\`PJ/PE_SZ
M7'_@0W^-'_"H_"7_`#Z7'_@0W^-'-A^P<M;N<Q_PO%_^@`?_``('^%'_``O%
M_P#H`'_P('^%=/\`\*C\)?\`/I<?^!#?XT?\*C\)?\^EQ_X$-_C1S8?L'+6[
MG,?\+Q?_`*`!_P#`@?X4?\+Q?_H`'_P('^%=/_PJ/PE_SZ7'_@0W^-'_``J/
MPE_SZ7'_`($-_C1S8?L'+6[G&ZG\8VU'39[0Z)Y8E7&XS@XY'M5I/C<Z(J_V
M"3@`9^T#G]*V-<^%WA>PT6ZNH+:X66-,J3<,<<CWJ\GPE\)NBL;2XR0"<7#>
MGUIN>'ML+EK7W.;_`.%X/_T`#_X$#_"D_P"%X-_T`#_X$#_"NG_X5'X2_P"?
M2X_\"&_QH_X5'X2_Y]+C_P`"&_QI<V'[#Y:W<X;Q!\6FUW0KS2SHWDBYC\O?
MYV=OX8KAM'U[5?#\XN-+O9;<G[P'*/\`53P:]8\6_#?PWHWA34M0M+>=;BWB
M+QDSLV#D=LUPOAOX<Z]XCV3>2+*T8?Z^<8)'^RO4_P`JZ*4Z/*[;&,XU.97.
MY\.?&.TN-EOX@@^R2G`%Q$"8V/N.H_6O4H94FA26-@R.`RL.XKDO#?PXT+PZ
MR3"#[7>*/^/B<9(_W1T%=>HPH%<%5TW+W$=5-22]X=1114&@4444`)6)KO\`
MR$=$_P"OS_V1JVZQ-<_Y".B?]?G_`+(U..XF;E%%%(84444`%%%%`!1110`4
M444`%%%%`!6+I/\`R']=_P"NT7_HL5M5BZ3_`,A_7?\`KM%_Z+%-">XUW1/&
M2%V50=/;DG'_`"T%:_VB'_GK'_WT*P+[3K/4/&,27EO',JV#%0XSCYQ5O_A&
M=!_Z!EM_WS0[:`KFI]HA_P">L?\`WT*J_9M/STB_UWG_`'A]_P#O?6JW_",:
M%_T#+?\`[YH_X1G0L9_LRV_[YHT`=+I>DS*5>.+F8SY63:?,/!;(.<FEM]-T
MFVC2***!$2-HU4-P%8Y8?0FF_P#",:%_T#+?_OFD/AG0O^@9;?\`?-%PL']F
M:='9?9[;RH]D3Q1$ONV!NHY)XZ5%9:'I%G:^2$A9FA6*1C(?F`QP.>!GG`J7
M_A&="SC^S+;_`+YH_P"$8T(?\PRV_P"^:+A8>^G:6][]K*H)N,LLI4-CID`X
M./>GW=I87TL<EQL<IT'FX'KR,X/XU#_PC.A?]`RW_P"^:!X9T(]-,MO^^:+H
M6HHTK21+-((X@\X82XD.UL]>,XY]<4KZ9I4MTERRH)5`&Y92N<=,@'G'O33X
M9T+_`*!EM_WS2#PWH!Z:;;'Z+1<=B=K/3I+:6V=(3#*Y=UWCEB<YZ\'-0KI.
ME+:FV"J(RV]B)SN8XQRV<GCCDT?\(QH8_P"89;_]\T?\(QH?_0,M_P#OFC0+
M#SIVF>6T:K$BLJJ?+DVG"_=Z'M5FU6SL[9(+<Q1Q(/E4,/\`&J?_``C.A?\`
M0,MO^^:/^$8T+_H&6_\`WS1H%F:?VB'_`)[1_P#?0K&\4S1-H$P$J$^9'P&'
M]]:F_P"$9T+_`*!EO_WS63XE\/:/!H4TD>FVZMOCP0O^V*%:X.YU/VB'_GK'
M_P!]"C[1#_SUC_[Z%9O_``B^A_\`0,M_^^:/^$7T/_H%V_\`WS1H&II?:(?^
M>L?_`'T*/M$7_/:/_OH5F_\`"+Z'_P!`NW_[YH_X1?0_^@7;_P#?-&@:FE]H
MB_YZQ_\`?0H^T1?\]8_^^A6;_P`(OH?_`$"[?_OFC_A%]#_Z!=O_`-\T:!J:
M7VB+_GK'_P!]"C[1#_SUC_[Z%9O_``B^A_\`0+M_^^:/^$7T/_H&6W_?-&@:
MFE]HA_YZQ_\`?0H^T0_\]8_^^A6;_P`(OH?_`$#+?_OFC_A%]#_Z!EM_WS2L
M@U-+[1#_`,]8_P#OH4?:(?\`GK'_`-]"LP^&-"'_`##+?_OFC_A&-"/_`##+
M?_OBC0-33^T0_P#/6/\`[Z%'VB'_`)ZQ_P#?0K-_X1?0_P#H%V__`'S1_P`(
MOH?_`$"[?_OFGH&II?:(?^>L?_?0H^T0_P#/:/\`[Z%9O_"+Z'_T"[?_`+YH
M_P"$7T/_`*!=O_WS2T#4KV4T0\5ZJQE3!AAP=P]#6U]HB_Y[1_\`?0KEK3P]
MH[^)]3B.G6Y1(82!MZ<&M?\`X1?0_P#H&6__`'S3=A*YI?:(O^>L?_?0H^T1
M?\]8_P#OH5F_\(OH?_0+M_\`OFC_`(1?0_\`H%V__?-*R&:7VB+_`)ZQ_P#?
M0H^T1?\`/6/_`+Z%9O\`PB^A_P#0+M_^^:/^$7T/_H%V_P#WS19`:7VB+_GK
M'_WV*/M$7_/6/_OH5F_\(OH?_0+M_P#OFC_A%]#_`.@7;_\`?-%D!I?:(O\`
MGK'_`-]"C[1%_P`]8_\`OH5F_P#"+Z'_`-`NW_[YH_X1?0_^@7;_`/?-%D!I
M?:(O^>L?_?0H^T1?\]8_^^A6;_PB^A_]`NW_`.^:/^$7T/\`Z!=O_P!\T60&
ME]HA_P">L?\`WV*Q;J:(^+M/;S4P+6;)W#U6K'_"+Z'_`-`NW_[YK(N?#NCK
MXJL81IUOY;6TI*[>IRM-)`[G4_:(?^>T?_?0H^T1?\]8_P#OH5F?\(OH9ZZ7
M;_\`?-+_`,(OH?\`T"[?_OFEH,TOM$7_`#UC_P"^A1]HB_YZQ_\`?0K-_P"$
M7T/_`*!=O_WS1_PB^A_]`NW_`.^:+(6II?:(O^>L?_?0H^T1?\]8_P#OL5F_
M\(OH?_0+M_\`OFC_`(1?0_\`H%V__?-%D,TOM$7_`#UC_P"^A1]HB_YZQ_\`
M?0K-_P"$7T/_`*!=O_WS1_PB^A_]`NW_`.^:+(1I?:(O^>L?_?0H^T1?\]8_
M^^A6;_PB^A_]`NW_`.^:/^$7T/\`Z!=O_P!\T60&E]HB_P">L?\`WT*/M$7_
M`#UC_P"^A6;_`,(OH?\`T"[?_OFC_A%]#_Z!=O\`]\T60:D7BB:)O#5^HE0D
MQ\`,/45J17$/DQ_OH_NC^(>E<WXD\.:-!X=O9(]-MU=8^#M]Q6E'X9T1HD)T
MNWR5'\/M3TL&MS5^T0_\]8_^^A1]HB_YZQ_]]"LW_A%]#_Z!=O\`]\T?\(OH
M?_0+M_\`OFEH&I>D>WE!5VB=3U#$$&GB:$#_`%L?_?0K-_X1C0LX_LRV_P"^
M:/\`A&="QG^S+;_OFC0-32\^'_GM'_WT*7[1#_SUC_[Z%9O_``C&AG_F%V__
M`'S1_P`(OH?_`$"[?_OFGH/4TOM$/_/6/_OH4?:(?^>L?_?0K-_X1?0_^@7;
M_P#?-'_"+Z'_`-`NW_[YHT%J:7VB'_GK'_WT*/M$/_/6/_OH5F_\(OH?_0+M
M_P#OFC_A%]#_`.@7;_\`?-&@:FE]HA_YZQ_]]"L76YHCJ&BXE0XO.?F''R-4
MY\+Z'_T"[;_OFLC6?#VCQWVD*FFVX$EWAOEZC::<;7!W.J^T0_\`/:/_`+Z%
M'VB'_GK'_P!]"LW_`(1?0_\`H%V__?-'_"+Z'_T#+?\`[YJ=`U-+[1#_`,]8
M_P#OH4?:(?\`GK'_`-]"LW_A%]#_`.@7;_\`?-'_``B^A_\`0+M_^^:>@:FE
M]HA_YZQ_]]"C[1#_`,]8_P#OH5F_\(OH?_0+M_\`OFC_`(1?0_\`H%V__?-&
M@:FE]HA_YZQ_]]"C[1#_`,]8_P#OH5F_\(OH?_0+M_\`OFC_`(1?0_\`H%V_
M_?-&@:FE]HA_YZQ_]]"C[1#_`,]8_P#OH5F_\(OH?_0+M_\`OFC_`(1?0_\`
MH%V__?-&@:FE]HA_YZQ_]]"C[1#_`,]8_P#OH5F_\(OH?_0+M_\`OFC_`(1?
M0_\`H%V__?-&@:FE]HA_Y[1_]]"LG2&5M<UQE8$&:+D'(_U8J3_A%]#_`.@7
M;_\`?-5-`L[>RU?6X+6%(HA-%A5&!_JQ3T$]R=O^1T7_`+![?^C%J#7V>6_T
MC3WE>.UNYG$Q1MI?:N57/N?Y5.?^1T7_`+![?^C%J_>Z?;ZA;M!=0K+$3NP>
MH/J#V-+9@94Q>PNK/2=-*1FX,C[YR9`@4`X`)]QQG@5ER>*-1>W"0K"MR$E_
MY9M()9$;:%4#H#ZULKI.E&-K!K+RX8&#J[,1EB.H;.<XX-4[SP[#>O'+836Z
MPK`;=%VEA&,Y+(5(^;ZTTT#N-U'6=4M5OI%%N$L8(I9%922Y8'<H],8]ZK:C
M>W@D<6,BVSG5HHG;!;>I7OS_`"K<%EIBVLMO<213;HECN&D89=0,#=_GO4D^
MF:;<PRQ2P1LDC"9QG'(Z-GMC'6G=!J9LNIO87UU)Y<:PK>117#Y/"L@^;T&&
M(_"JK^(=2F:**WMP'EBDN%VPF0F,-M0$`CKU)J]>3Z,D>I07T:"W81+<._*R
M[QM7^@JQ-8:;>ND,UM\ELBB*4-M`4\8!!SVI7785F1W>I7L6G:<PA2"\O)4A
M*S<B(D$G/J>"`/>L?3M5N-*GO)+UXF@;4I8YY4)PI\M2F/3.,8]:W-2.FR6$
M%O-&EQ!),D*A&R%;/!SGJ#^-07N@:=<Z=+I5L(88Y)EFN$'S%L$$Y[@G`YH3
M5@UN5X=:U'SK$WJQVMO<1J0_EEE9V)PA.?E.,8R.<U1\.7%S9I8++Y4CZA?7
M*S2A2&^4N1DYYY'Y<5T=Q9:=)?0RSJGGC'EJSXY'0A>Y%4]1AT:#3FBDMXY(
MH90_E1MRCLW7@Y')-.ZV"S*=MK>I:BT,5M]EB>1[A3(RE@!&P`P,\YS3M-UJ
M_P!8:W%N;:#_`$5+B7>"VXEB,#I@?*>>>U:]OI^EV,D<4$4$4D>XH@/(#?>(
M'O5=](T0K'^Y@`M5P-K[=BYSAL'IGGFEH.S,>&ZO6LM3>\F2X1=5\F-=I78-
MZCJ#T&:MOK=\,W@^SFS6_P#LAAVDR$;]F[.>N><8Z5I&QTI?-N2L(%RZN[[_
M`)78=#UQGCM40L=+^WS7TMLL,T4F3-(<*S8'SCG&><9QFBZ%J4+;6M1^V6!G
M6W-O>7$MN$C!W+MSAL_@<C%7O%?_`"+TO_72+_T-:O+IMCMMRL"8@<RQ8_A8
MYR1^9JCXK_Y%^7_KI%_Z&M*^I5M#;HHHI#"DZ4M(>AH`S[W7--TZ58KRZ6)V
M^Z&!Y/H..M6#?6ZV8NR_[@@$/M/0]..O>LOQ$CN^D[$9MNHQ%L#.!SS6=)!<
M+;ZM>B2Z:X^U[(QN.%3>O"CZ9YJDA-G6;@:,\UR%U:33W$\YGO$D&I)$NQV`
M6(A=P`]#DU2N/MEL'M2\JZ=%J+H[2[R/+V`J"1\VW=FCE%S'>9ID<T<N?+=7
MP2IVG.".HKC':YM?[,EDNGU`_=$*K(A8%^&4^H&`=W4"H[5(=.L-7B\B=I&U
M%O-4LZA48Y#DC^'Z4<H<QT&OSW4#Z?\`9KF2$37:0R!5!RISGJ.M87_"1:J-
M-8>:IN!=Y$ABX\D3>7C'KV_&MOPR&ETR42;G1+F01%P?N9XQNYQZ5LF%3QM7
M'IBBZ6@6;)!TI:`,"BI*"DI:#TH`P;-U3Q9JI9E7,,.,G'8UM>?%_P`]4_[Z
M%>,?$K0M:UGQHYTFSN;A8[6,2&%\`'G&>17)?\(/XR_Z!&H_]_?_`+*NF-",
MDFY6,)56G;E/I3SHO^>B?]]"CSHO^>B?]]"OFO\`X0?QE_T"-1_[^_\`V5'_
M``@_C+_H$:C_`-_?_LJKZO'^=$^WE_*?2GG1?\]$_P"^A1YT7_/1/^^A7S7_
M`,(/XQ_Z!&H_]_?_`+*C_A!_&7_0(U'_`+^__94OJ\?YT'MY?RGTIYT7_/1/
M^^A1YT7_`#T3_OH5\U_\(/XR_P"@1J/_`']_^RH_X0?QE_T"-1_[^_\`V5/Z
MO'^=![>7\I]*>=%_ST3_`+Z%'G1?\]$_[Z%?-?\`P@_C+_H$:C_W]_\`LJ/^
M$'\9?]`C4?\`O[_]E1]7C_.@]O+^4^E/.B_YZ)_WT*/.B_YZ)_WT*^:_^$'\
M8_\`0(U'_O[_`/94?\(/XR_Z!&H_]_?_`+*E]7C_`#H/;R_E/I3SHO\`GHG_
M`'T*Q;J6,^+]/.]<"UFYW#U6O!?^$'\9?]`C4?\`O[_]E43>#_%:W*6[:7?B
M=U+*IDY*CKCYJ:P\?YT#K2_E/IGSXO\`GJG_`'T*/.B_YZ)_WT*^:_\`A!_&
M7_0(U#_O[_\`94?\(/XQ_P"@1J/_`']_^RI?5X_SH/;2_E/I3SHO^>B?]]"C
MSHO^>B?]]"OFO_A!_&7_`$"-1_[^_P#V5'_"$>,O^@1J/_?W_P"RI_5X_P`Z
M#V\OY3Z4\Z+_`)Z)_P!]"CSHO^>B?]]"OFO_`(0?QC_T"-1_[^__`&5'_"#^
M,?\`H$:C_P!_?_LJ7U>/\Z#V\OY3Z4\Z+_GHG_?0H\Z+_GHG_?0KYK_X0?QC
M_P!`C4?^_O\`]E1_P@_C+_H$:C_W]_\`LJ?U>/\`.@]O+^4^E/.B_P">B?\`
M?0H\Z+_GHG_?0KYK_P"$'\9?]`C4?^_O_P!E1_P@_C'_`*!&H_\`?W_[*CZO
M'^=![>7\I]*>=%_ST3_OH4>?%_SU3_OH5\U_\(/XQ_Z!&H_]_?\`[*C_`(0?
MQE_T"-1_[^__`&5+ZO'^=![>7\I[[XHEC;PU?`2(28_[P]16I%-%Y,?[Q/NC
M^(>E?--QX.\66\#RW&EWZ1*,L7DR/_0JD'@GQBP!&DZB1CKYO_V5/ZO&WQH/
M;N_PGTKYT7_/1/\`OH4>=%_ST3_OH5\U_P#"#^,C_P`PC4?^_O\`]E1_P@_C
M'_H$:C_W]_\`LJ7U>/\`.@]O+^4]V\9ZM/I7A'4;^PFC6Y@C#1DX89R.U<=X
M;^,-E=A+?78?L4IX\^/+1'Z]U_E7F5[X2\3V%E+=7VFWL5M&,R/))E0/<;JP
M<CKN_P`_X5O##0<'=W\S*>(DI+0^MK6[M[NW2:VFCFB<95XVW`_B*G!!&:\$
M\`^&_&HG2ZTN:33+-CEFN1\D@]H^_P"E>\0K(L*"5@T@4!F`P"?7%<56FJ<K
M)W.J$W):JP^EHHK,T"DI:*`$K$US_D(Z)_U^?^R-6W6)KO\`R$-$_P"OS_V1
MJ<=Q,W****0PHHHH`****`"BBB@`HHHH`****`"L72O^0]KO_7:+_P!%BMJL
M72?^0_KO_7:+_P!%BFA/<#QXT7_L'M_Z,6MDUS6H7-U;>+XFMK%KLFP8%5D"
M[?W@]:M?VMJW_0O3_P#@0E#5P3*FJZ9<74^H@0&2*9[;`SPP4G=5K1[&2QO]
M8'D^5;2S*\`&`I&P9('UH_M35O\`H7Y__`A*!JFJC_F7I_\`P(2G9B,NS\.J
MJZ5YVGIE+:5;C=S\QQ@-Z]ZJ06&J65HNZQGFEFTIK3:K#]VX9L`DGI@CGVK?
M_M75?^A?G_\``A*/[5U7_H7Y_P#P(2GKY`8ESHE[-H=Y"UF9'-O:[8V()9D^
M\!GO4NMP,;74;C[*RV\L%LB1DA=WS\K[>GI6M_:VJ_\`0O3?^!"4U]1U*1=K
M^')7'HUPAH]X6AFQ:;<O?2W,.GO:V[W<#"$X!^0?,^!QZ#WQ3=(TBXBU:-KI
M+I9HIY9#*B)Y<@8G&6^\1@C@]ZUO[4U7_H7I_P#P(2C^U-5_Z%Z<_P#;PE&H
MRMJ5I<?\)%;W5G;2/(P1)&D4&((,Y(;JK#)^M4;?3IQHCV7]DR1WR;1+,<8F
M.\$G=G)SUK7.J:L>OA^?_P`"$H_M35?^A>G_`/`A*-0,E-(N#K\S7*W7-[]H
MBFB5=FW'`+GD#L10NCRVVCZ>1IYE,=T9KN`8W2#+8/OC(.*UO[4U7_H7IO\`
MP(2C^U-5_P"A?G_\"$HU`PI-*NEMGN(;*5)#<R2V=MY:ND88`;7!/`8C/'2K
ME_I\\EM=O);S>:;M9H1"HD&X1J#E3U7.16C_`&KJO_0O3_\`@0E']JZK_P!"
M]/\`^!"4M0-+3_M']GV_VJ-(I_+'F)']U3Z"L_Q7_P`B_-_UTB_]#6FC5M5'
M_,O3?^!"5E^)-3U*31)5DT.:-=\9+&=#CYQ2L[CN=C16'_:VK?\`0OS_`/@0
ME']K:M_T+\__`($)19A<W**P_P"UM6_Z%^?_`,"$H_M;5O\`H7Y__`A*.5A<
MVR,TFVL7^UM6_P"A?G_\"$H_M;5O^A?G_P#`A*.5@;6WBDV]1Q6-_:VK?]"_
M/_X$)1_:VK?]"_/_`.!"4687-G9D=J-GTK&_M;5O^A?G_P#`A*/[6U;_`*%^
M?_P(2CE87-L#%%8G]K:M_P!"_/\`^!"4?VMJW_0OS_\`@0E%F%S<HK#_`+6U
M;_H7Y_\`P(2C^UM6_P"A?G_\"$HY6%S<HK#_`+6U;_H7Y_\`P(2C^UM6_P"A
M?G_\"$HL%PLA_P`5;JW_`%QA_D:V\5Q]GJ6I+XFU-QHDQ=HH04\].,`UJ_VM
MJW_0OS_^!"4..H)FW16)_:VK?]"_/_X$)1_:VK?]"_/_`.!"4<K"YMT5B?VM
MJW_0OS_^!"4?VMJW_0OS_P#@0E'*PN;=%8G]K:M_T+\__@0E']K:M_T+\_\`
MX$)1RL+FW16)_:VK?]"_/_X$)1_:VK?]"_/_`.!"4<K"YMT5B?VMJW_0OS_^
M!"4?VMJW_0OS_P#@0E'*QW-NL2ZS_P`)CI_/'V6;^:T?VMJW_0OS_P#@0E9-
MQJ>IGQ18N=#F#K;2@)YZ<C*TU$39V(&!16)_:VK?]"_/_P"!"4?VMJW_`$+\
M_P#X$)4\H7-NBL3^UM6_Z%^?_P`"$H_M;5O^A?G_`/`A*?*PN;=%8G]K:M_T
M+\__`($)1_:VK?\`0OS_`/@0E'*PN;=%8G]K:M_T+\__`($)1_:VK?\`0OS_
M`/@0E'*PN;=%8G]K:M_T+\__`($)1_:VK?\`0OS_`/@0E'*PN;=%8G]K:M_T
M+\__`($)1_:VK?\`0OS_`/@0E'*PN/\`%/\`R+-_S_RS'\Q6I"/W,?\`NC^5
M<IXBU+4Y?#UZDFAS1J8^6,Z''(K2CU751$@&@3D;1_R\)3Y78+ZF[16)_:VK
M?]"_/_X$)1_:VK?]"_/_`.!"4N5A<?XHT:37_#E[I<4RQ-<H$$C#(7D'.*QO
M#?PVT+P\5F,7VV\'_+>X`.#_`+*]!6M_:VK?]"_/_P"!"4O]K:M_T+\__@0E
M4G)+E3$XQ;NT;.WG-+VK$_M;5O\`H7Y__`A*/[6U;_H7Y_\`P(2IY6.YN45A
M_P!K:M_T+\__`($)1_:VK?\`0OS_`/@0E'*PN;E%8?\`:VK?]"_/_P"!"4?V
MMJW_`$+\_P#X$)1RL+FW6)KO_(1T3_K\_P#9&H_M;5O^A?G_`/`A*R=8U+4G
MOM(+Z',A6[RH,Z?,=IXIQ6H-G945A_VMJW_0OS_^!"4?VMJW_0OS_P#@0E*P
M7-RBL/\`M;5O^A?G_P#`A*/[6U;_`*%^?_P(2CE87-RBL/\`M;5O^A?G_P#`
MA*/[6U;_`*%^?_P(2CE87-RBL/\`M;5O^A?G_P#`A*/[6U;_`*%^?_P(2CE8
M7-RBL/\`M;5O^A?G_P#`A*/[6U;_`*%^?_P(2CE87-RBL/\`M;5O^A?G_P#`
MA*/[6U;_`*%^?_P(2CE87-RL72?^0_KO_7:+_P!%BF_VMJW_`$+\_P#X$)4/
MAZ>>?5M;DGM6MI#-%^[9@Q'[L=Q3MH#W)R`?&B?]@]O_`$8*V=H]*Q_^9T7_
M`+![?^C%K9J6"#:/2DVCTIU%`QC;5&2`/K3/-C')9<8SG(Z5A>,@S:/`J1K*
MSWL"B-GVA\N.">P-4;LM;6[V[6,%JQTVX=E1MVSV#>AII7)N=<-I&<4<?W:X
MYM7U'3[9XUO+:Y;[`EQ&P3"Q'<%P<'D'/7VJY=7NI1WDUB-2@ADMK3[0TLD0
M_>L2>V>%&*.4$SIL#T%&!Z"N-?7=5GLKB]@DAMU@MH9C"\>=Q<<J3V%3RZW?
M:9?3I>W$4EK:R1&>7R]NV.0-SCMM*]?>GRL?,=5QG&*0,A8J""PZC/(KD;K7
M;]=,%P)S#=>0]UY`@!41Y.S<2>.!BENM3DL[G4)XF6-II;9&?&[:&4Y('<T<
MK%S(ZTLJD`]Z7`/:N5MKZ[SILVH-&7>2X*R-'M98P,@X!ZXZU8T35+FZU,P/
M<&:WDM1<1LT0C.-V,@`G@BERA<Z/:/04;1Z4HZ4M(H3:/2L3Q6/^*?F_ZZ1_
M^AK6Y6)XK_Y%^;_KI%_Z&M`,VL4;1Z4M%`";1Z4;1Z4M%`#2`!G%1M+$BLS,
MH5>I)&!3-1.W3+HY(Q"_([?*:X%;5O\`A!(71;:W>4VH:2-O,,@,B_>STY--
M1N2W8[\7-L2H$L>6&Y1N&2/7Z5*`#_#BN(FB>VU+Q',S0S"""W58WA`"@@\#
M!X'7COQ6G<ZEJ,8UJX2>(0V(VQ1E,DMM!RQ]L]*.7S!2.DP/2D8':=H&[MFN
M3N]1UJS347-[`XLX([G'DX+[LY0\\#CKUJ>?6K@:O"(;@M`;E+>2-H@%!9<D
M!LY)'':CE87#_A)[F&7$]G$4%ZUHQCD.1M4L7Z=,#I6GIFK?VE>ZA!Y(5;61
M45]V?,!&<^U3-HUB[,3;J=TK3'.>792I/Y$BI;73K:R9S;0K'O"AL=PHP/TH
M=@299VBEVCTH`P*6D4)M'I1M%+10!A67_(VZMQ_RQ@_D:V\#TKQSXB^+M7\,
M>-'32[J*%9[:-G#QALD$XZUS'_"V/%G_`$$;;_OPO^-;QP\YI21BZRB^4^BM
MH]*-H]*^=?\`A;/BS_H)6W_?@?XT?\+9\6?]!*V_[\#_`!JOJD^XOK$#Z*VC
MTHVCTKYU_P"%L>+/^@E;?]^!_C1_PMGQ9_T$;;_OP/\`&CZI/N'UB!]%;1Z4
M;1Z5\Z_\+9\6?]!*V_[\#_&C_A;/BS_H)6W_`'X'^-'U2?</K$#Z*VCTHVCT
MKYU_X6SXL_Z"5M_WX'^-'_"V?%G_`$$;;_OP/\:/JD^X?6('T5M'I1M'I7SK
M_P`+9\6?]!*V_P"_`_QH_P"%L^+/^@E;?]^!_C1]4GW#ZQ`^BMH]*Q;KCQCI
MPX_X])OYK7A__"V?%G_02MO^_`_QJ!_B9XFDNX[QK^W\Z-&17\E<`'KQ^%-8
M2?<3Q$#Z1`!'(%&T>E?.@^+'BS&/[1ML_P#7`?XTO_"V?%G_`$$K;_OP/\:7
MU2?</K$#Z*VCTHVCTKYU_P"%L^+/^@E;?]^!_C1_PMGQ9_T$K;_OP/\`&CZI
M/N/ZQ`^BMH]*-H]*^=?^%L^+/^@E;?\`?@?XT?\`"V/%G_01MO\`OP/\:/JD
M^X?6('T5M'I1M'I7SK_PMCQ9_P!!*V_[\#_&C_A;/BS_`*"5M_WX'^-'U2?<
M/K$#Z*VCTHVCTKYU_P"%L^+/^@E;?]^!_C1_PMGQ9_T$K;_OP/\`&CZI/N'U
MB!]%;1Z4;1Z5\Z_\+9\6?]!&V_[\#_&C_A;'BS_H)6W_`'X7_&CZI/N'UB![
MGXJ`_P"$9ON,_NQ_Z$*U(<&%/]T?RKYRNOB=XGO;62VGU"W:*088"%0:E'Q7
M\5J,#4;;`X'[A:?U2=MQ?6(7/HO:*-H]*^=?^%L>+/\`H(VW_?@?XT?\+8\6
M?]!*V_[\#_&E]4GW']8@>\Z_JR:#H5WJ;PF5;9-YC4@%N?4U0\/>,]#\31`V
M%VOGXRUO+\LB_AW_``KPO4?B-XCUC3Y]/O+Z"2WG79(JP@$CZUS*.\<BR1NR
M2*<AU)!!^O:M(X.ZU>I$L3KHM#ZYX]*7:/2O#/!OQ*\2)=1Z?):2ZVA.-J#]
M\O\`P+H?QKW"%VD@1V1D9E!*-U7V-<M2E*F[2-X5(S5T2;1Z4;1Z4M%06)M'
MI1M'I2T4`-VCTK%UP?\`$PT3_K\_]D:MNL37?^0AHG_7Y_[(U..XF;>T4;1Z
M4M%(8FT>E&T>E+10`FT>E&T>E+10`FT>E&T>E+10`FT>E&T>E+10`FT>E&T>
ME+10`FT>E8NE#_B?:X.WFQ?^BQ6W6+I/_(?UW_KM%_Z+%-">XF?^*T7_`+![
M?^C%K:KFK^._?QA%]AN(86^P-N,L1<$>8.F"*M_9O$7_`$$['_P$;_XNAH5S
M;I*QOLWB+_H)V/\`X"-_\51]F\1?]!.Q_P#`1O\`XJBP[FK-!%.JK*BN%8.`
MPS@CD&FRVEO,^^2)&;84R1_">H^E9GV;Q%_T$['_`,!&_P#BJ/LWB+_H)V/_
M`("-_P#%46\P+<.C:;;I(D-G`B2XW@+]['3\*?=Z997Y1KJVBE9/NEAR*H_9
MO$7_`$$['_P$;_XJC[-XB_Z"=C_X"-_\71\P-)K*V<2!H8SY@"OQ]X#H#]*J
MZIH\&IV=U;D+&;I529PH)90>G\_SJO\`9?$7_03L/_`1O_BZ3[+XB_Z"=A_X
M"-_\71;S`O3Z58W6PW%K%)Y:[5W+T'I]*JZIH<-_$H1A"ZR))D(&5RO0,#U%
M,^S>(O\`H)V/_@(W_P`52?9?$7_03L?_``$;_P"*H^8B?3-%@L(2&(FD,C2[
MF4`*6ZA1V%6+72[&Q<O:VT43$8)08..N/I5'[-XB_P"@G8_^`C?_`!5'V;Q%
M_P!!.Q_\!&_^*H^8S9HK&^S>(O\`H)V/_@(W_P`51]F\1?\`03L?_`1O_BJ5
M@N;58GBO_D7YO^ND7_H:TOV;Q%_T$['_`,!&_P#BJR?$D&NKH<IFU"R9-\>0
MML0?OC_:II`V=?2UB_9O$/\`T$K'_P`!&_\`BZ/LWB+_`*"=C_X"-_\`%46"
MYM45B_9O$7_03L?_``$;_P"*H^S>(O\`H)V/_@(W_P`518+FPZJZ%6P5(P1Z
MUG6_A_2;172WL((U?&Y57@X.1Q[&H/LWB+_H)V/_`("-_P#%4?9O$7_03L?_
M``$;_P"*HMY@:365K(9B\$;&;'F$C[^.F?I2M:6[K*K0QE9O]8"/O_6LS[-X
MB_Z"=C_X"-_\71]F\1?]!.Q_\!&_^+HMY@:4EE;2K*LD,;"50D@(SN4=`?;F
MHO[*L/M7VK[+%Y^01)CD$#`/UJE]F\1?]!.Q_P#`1O\`XNC[-XB_Z"=C_P"`
MC?\`Q=%O,#9_&BL;[-XB_P"@G8_^`C?_`!5'V;Q%_P!!.Q_\!&_^*I6"YM45
MB_9O$7_03L?_``$;_P"*H^S>(O\`H)V/_@(W_P`53L%S:I,UC?9O$7_03L?_
M``$;_P"*H^S>(O\`H)V/_@(W_P`718+E6*QM+SQ=JAN;6"?;#"%\Q`V.#ZUJ
M_P!B:5_T#;/_`+\K_A7.VD&N?\)-J874+,2^5#N8VQP1@XP-U:_V7Q%_T$['
M_P`!&_\`BZ;NNHM^A;_L32O^@;9_]^5_PH_L32O^@;9_]^5_PJI]F\1?]!.Q
M_P#`1O\`XNC[+XB_Z"=A_P"`C?\`Q=&O<++L6_[$TK_H&V?_`'Y7_"C^Q-*_
MZ!MG_P!^5_PJI]F\1?\`03L/_`1O_BZ/LOB+_H)V'_@(W_Q=&O<++L6_[%TK
M_H&V?_?E?\*/[$TK_H&V?_?E?\*J?9O$7_03L/\`P$;_`.+H^R^(O^@G8?\`
M@(W_`,71KW"R[%O^Q-*_Z!MG_P!^5_PH_L32O^@;9_\`?E?\*J?9?$7_`$$[
M'_P$;_XNC[+XB_Z"=A_X"-_\71KW"R[%O^Q-*_Z!MG_WY7_"C^Q-*_Z!MG_W
MY7_"JGV7Q%_T$[#_`,!&_P#BZ/LWB+_H)V'_`("-_P#%T:]PLNQ;_L32O^@;
M9_\`?E?\*Q[G2=-7Q981C3[4(UM*2ODK@\K[5=^R^(O^@G8?^`C?_%UD7-OK
MH\4V(;4;/S?LTNUOLIQC*YXW4U?N#2['1?V+I7_0-L_^_*_X4?V+I7_0-L_^
M_*_X53^S>(B,C4[#';_1&_\`BZ7[+XB_Z"=C_P"`C?\`Q=+7N%EV+?\`8FE?
M]`VS_P"_*_X4?V)I7_0-L_\`ORO^%5/LOB+_`*"=A_X"-_\`%T?9?$7_`$$[
M'_P$;_XNB[[A9=BW_8FE?]`VS_[\K_A1_8NE?]`VS_[\K_A53[+XB_Z"=C_X
M"-_\72?9?$7_`$$['_P$;_XNC7N&G8N?V+I7_0-L_P#ORO\`A1_8FE?]`VS_
M`._*_P"%4_LOB+_H)V/_`("-_P#%TOV7Q%_T$[#_`,!&_P#BZ->X:=BW_8FE
M?]`VS_[\K_A1_8FE?]`VS_[\K_A53[-XB_Z"=A_X"-_\71]F\1?]!.Q_\!&_
M^+HU[A9=BW_8FE?]`VS_`._*_P"%']B:5_T#;/\`[\+_`(53^S>(O^@G8?\`
M@(W_`,52_9O$7_03L?\`P$;_`.+HU[A9=BIXFTG38?#E\\>GVBN(\@K"H(Y'
MM6G%HNE&%"=-L_NC_EBOI]*PO$EOKH\/7IFU&S:/R^0MJ0>H[[JTHK?Q"8DQ
MJ5CC:/\`ET;T_P!^C6VX65]B]_8FE?\`0-L_^_"_X4?V)I7_`$#;/_ORO^%5
M/LWB+_H)V/\`X"-_\51]F\1?]!.Q_P#`1O\`XJC7N&G8S/&>@6TWA#4XM/TN
M!KMX<1"*%0Q;(Z5PGAOX.33;9_$%QY2?\^L!^8CT9NWX5Z:;;Q#T_M*Q_P#`
M1O\`XNC[-XA_Z"5C_P"`C?\`Q=:1JSC%Q3W,Y4XRE=EK2M$TW1;1;;3;.*VC
M'4(O)^IZFM`#'>L7[-XB_P"@G8_^`C?_`!5+]F\1?]!.Q_\``1O_`(JLK=V:
MFS2UB_9O$7_03L?_``$;_P"*H^S>(O\`H)V/_@(W_P`518+FU25C?9O$7_03
ML?\`P$;_`.*H^S>(O^@G8_\`@(W_`,52L%S9K$US_D(Z)_U^?^R-3OLWB+_H
M)V/_`("-_P#%UD:Q;ZX+[2!)J%FS&[^0BV(P=IZ_-S516HFSL*6L7[-XB_Z"
M=C_X"-_\71]F\1?]!.Q_\!&_^*I6'<VJ*Q?LWB+_`*"=C_X"-_\`%4?9O$7_
M`$$['_P$;_XJBP7-JBL7[-XB_P"@G8_^`C?_`!5'V;Q%_P!!.Q_\!&_^*HL%
MS:HK%^S>(O\`H)V/_@(W_P`51]F\1?\`03L?_`1O_BJ+!<VJ*Q?LWB+_`*"=
MC_X"-_\`%4?9O$7_`$$['_P$;_XJBP7-JBL7[-XB_P"@G8_^`C?_`!5'V;Q%
M_P!!.Q_\!&_^*HL%S:K%TK_D/:Y_UUB_]%BC[-XB_P"@G8_^`C?_`!55_#RW
M2:MK8O)HY9?.CRT:%1_JQV)-"6@NI/C_`(K1?^P>W_HP5M5C?\SHO_8/;_T8
MM;-)C0M%%%%AA11118`I&Z<4M1SR"&%Y&!(12QP,G`&:5@*\6H6L][/913H]
MS;A3+$IR4!Z9IIU2S&GF^-S&+9209.V0<$?GQ7*:?'J=K?Z=JEQ9J@NI76X*
M,6?$G*;EQQM(`_&DT^XTRX\-3:5?&Y1XII7D5(FW1_OF(8'';@U7*B5)G8V5
MY!?0>;`^]`Q4DJ5((ZC!%6:Q?#5Y>7EG.;IC*D<Q2"Y,?EF=,##%?S'OBMJD
M4%%%%%@"BBBBP!6)XK_Y%Z;_`*Z1_P#H:UMUB>*_^1?F_P"ND7_H:T(&;5+1
M10`44446`0\#-5!J%M_:'V#SD^U^7YOD_P`6W.,U;;I7"_\`$R^TKX@^Q`+]
MMW9WGS/LY_=XVX^C?A323$V=5'K-A+=O:17`>=&*LH4\$=1G&.*6#6=/N+2.
M[BNXW@DD\I7'0OG&WZYKF]$N5AUG5[1[F9))+R9DMC!A6!488-C^M9S6-S9V
M^D^5;RO;WMS"TJ*O^JE5C\Y'8,.ON*?*A79WUS=0V<#SW,BQ1(-S.QP`*K/J
M]E'9PWC7"?9YL&)P"=^>F`!DU6U":2VTR]EU0P-"`?+$4;$\Y`R.<GITKGM-
MNT33O#5^XD-M:1M#<,8S^Z<H`"1C..V:2BAMLZB36]/BM(KEKI#%+DHR@G=C
MK@`9XJ[!/'<PI-$ZO&XW*R]"*XNP<:;J$6I74$D5G.+KRE,1.PM(&&1_#N%=
M%X:MY+7P_:121-$P#-Y;=5!8D#\B*&DA)LUZ***DH*0TM%,#!LV">+=6RRC,
M,.,G&>#6SYT7_/1/S%>-?$S0-:UOQFS:393W"QVJ"3RVP`<G%<E_P@GC'_H#
MWO\`WV/_`(JNF-",DI.1A*K).R1])>='_P`]$_[Z%'G1_P#/1/\`OH5\V?\`
M"">,?^@/>_\`?8_^*H_X03QC_P!`>]_[['_Q5/ZM'^9"]O+^4^D_.B_YZ)^8
MH\Z+_GHGYBOFW_A!/&/_`$![W_OL?_%4?\()XQ_Z`][_`-]C_P"*H^K0_F#V
MTOY3Z2\Z/_GHG_?0H\Z+_GHG_?0KYL_X03QC_P!`>]_[['_Q5+_P@GC'_H#W
MO_?8_P#BJ/JT?YD'MY?RGTEYT7_/1/S%'G1?\]$_,5\V_P#"">,?^@/>_P#?
M8_\`BJ/^$$\8_P#0'O?^^Q_\51]6A_,'MI?RGTEYT7_/1/S%'G1?\]$_,5\V
M_P#"">,?^@/>_P#?8_\`BJ/^$$\8_P#0'O?^^Q_\51]6A_,'MI?RGTEYT?\`
MST3_`+Z%8MU(A\7Z>0ZX^RS#.1QRM>#?\()XQ_Z`][_WV/\`XJHF\&>*UND@
M;2KP3LI9%\SDJ.N.::PT?YA.O+^4^F!-%C_6)_WT*/.B_P">B?F*^;?^$$\8
M_P#0(O?^^_\`Z]'_``@GC'_H#WO_`'V/_BJ/JT/YT/V\OY3Z2\Z+_GHGYBCS
MH_\`GHG_`'T*^;?^$$\8_P#0'O?^^Q_\52?\()XQ_P"@/>_]]C_XJE]6A_.@
M]O+^4^D_.C_YZ)_WT*/.B_YZ)_WT*^;/^$$\8_\`0'O?^^Q_\51_P@GC'_H#
MWO\`WV/_`(JCZM'^9![>7\I])^=%_P`]$_[Z%'G1_P#/1/\`OH5\V?\`"">,
M?^@/>_\`?8_^*H_X03QC_P!`>]_[['_Q5'U:/\R#V\OY3Z3\Z/\`YZ)_WT*/
M.C/\:?F*^;?^$$\8_P#0'O?^^Q_\51_P@OC'_H#WO_??_P!>CZM#^9"]O+^4
M]-\?>.=1\)>(-.%D(;BTE@)EA?N0>Q'0XK9\-_$?0O$6R(3_`&.\/_+O<$`D
M_P"R>AKP/5=&U71I8HM6M)K>212T:RG=D9JI:V=QJ%RMM:6\MQ.YXCB4L2?P
MK=X6FX;F?MYJ6Q]/>*3GPQ?GMY?]16M"/W"?[H_E7E>C:+XNTKPG>_VWJ(-F
M8?DLW_>2*<C'S]OIS7JD'^I3_='\JX)Q4=#KB[ZDF****DH,4F!2T4`&****
M+`%%%%%@"BBBBP"5B:Y_R$-$_P"OS_V1JVZQ-=_Y"&B?]?G_`+(U..XF;E%%
M%*PPHHHHL`44446`****+`%%%%%@"BBBBP!6+I/_`"'M<_ZZQ?\`HL5M5BZ3
M_P`A_7?^NT7_`*+%-">X?\SHO_8/;_T8M;59%]HJW]^EZE[=6TJQ&+,#XRI(
M//'M47]@3?\`0<U3_OZ/\*-`-NBL3_A'Y_\`H.:I_P!_1_A1_P`(_/\`]!S5
M/^_H_P`*`-NBL3_A'Y_^@YJG_?T?X4?\(_/_`-!S5/\`OZ/\*`-NBL3_`(1^
M?_H.:I_W]'^%'_"/S_\`0<U3_OZ/\*`-K`]*7BL3_A'Y_P#H.:I_W]'^%'_"
M/S_]!S5/^_H_PH`VZ*Q/^$?G_P"@YJG_`']'^%'_``C\_P#T'-4_[^C_``H`
MVZ*Q/^$?G_Z#FJ?]_1_A1_PC\_\`T'-4_P"_H_PH`VZ*Q/\`A'Y_^@YJG_?T
M?X4?\(_/_P!!S5/^_H_PH`VZQ?%?_(OS?]=(O_0UI/\`A'Y_^@YJG_?T?X5#
M<^%C=P-#/K.J/&Q!*F4=CD=O6C0-3HJ2L3_A'Y_^@YJG_?T?X4?\(_/_`-!S
M5/\`OZ/\*-`-NBL3_A'Y_P#H.:I_W]'^%'_"/S_]!S5/^_H_PH`VSSUHP*Q/
M^$?G_P"@YJG_`']'^%'_``C\_P#T'-4_[^C_``H`VZ,#&,5B?\(_/_T'-4_[
M^C_"C_A'Y_\`H.:I_P!_1_A0!MX'I1Q6)_PC\_\`T'-4_P"_H_PH_P"$?G_Z
M#FJ?]_1_A0!M@`4<5B?\(_/_`-!S5/\`OZ/\*/\`A'Y_^@YJG_?T?X4`;=%8
MG_"/S_\`0<U3_OZ/\*/^$?G_`.@YJG_?T?X4`;E&:P_[`F_Z#FJ?]_1_A1_8
M$W_0<U3_`+^C_"E8-0L?^1MU;_KC!_(UMXKGT\+&.ZEN5UG4Q+*`';S1R!T[
M5+_PC\__`$'-4_[^C_"FT@1MT5B?\(_/_P!!S5/^_H_PH_X1^?\`Z#FJ?]_1
M_A2`VZ*Q/^$?G_Z#FJ?]_1_A1_PC\_\`T'-4_P"_H_PIAJ;=%8G_``C\_P#T
M'-4_[^C_``H_X1^?_H.:I_W]'^%`&W16)_PC\_\`T'-4_P"_H_PH_P"$?G_Z
M#FJ?]_1_A0&IMT5B?\(_/_T'-4_[^C_"C_A'Y_\`H.:I_P!_1_A0&IMUB78_
MXK#3O^O6;^:T?\(_/_T'-4_[^C_"H6\+%[N.Y;6=3,L:E5;S1P#U[>U"L#N=
M"**Q/^$?F_Z#FJ?]_1_A1_PC\_\`T'-4_P"_H_PI6`VZ*Q/^$?G_`.@YJG_?
MT?X4?\(_/_T'-4_[^C_"F!MT5B?\(_/_`-!S5/\`OZ/\*/\`A'Y_^@YJG_?T
M?X4`;=%8G_"/S_\`0<U3_OZ/\*/^$?G_`.@YJG_?T?X4`;=':L3_`(1^?_H.
M:I_W]'^%'_"/S_\`0<U3_OZ/\*5D!B^+?`4/B_7+*ZO+QXK2VB*-'$/G<DYZ
M]JZ#1?#VE:!;^1IEE'`N,%@/F;ZGJ:A_X1^;_H.:I_W]'^%']@3_`/0<U3_O
MZ/\`"K<FURWT)Y5>]AWBD#_A&;\@?\L_ZBM:'_4I_NC^58-SX7-W;O!/K.IO
M$XPRF4<_I4H\/3*`!KFJ8`Q_K1_A4Z%=3=I*Q/\`A'YO^@YJG_?T?X4?\(_/
M_P!!S5/^_H_PH`VZ*Q/^$?G_`.@YJG_?T?X4?\(_/_T'-4_[^C_"@#;HK$_X
M1^?_`*#FJ?\`?T?X4?\`"/S_`/0<U3_OZ/\`"@#;HK$_X1^?_H.:I_W]'^%'
M_"/S_P#0<U3_`+^C_"@#;HK$_P"$?G_Z#FJ?]_1_A1_PC\__`$'-4_[^C_"@
M#;K$US_D(Z)_U^?^R-1_8$W_`$'-4_[^C_"H9O"QN'A>76=39H7WH?-'!QC/
M3WH6@,Z*BL/^P)O^@YJG_?T?X4?V!-_T'-4_[^C_``I6#4VZ*Q/^$?G_`.@Y
MJG_?T?X4?\(_/_T'-4_[^C_"F!MT5B?\(_/_`-!S5/\`OZ/\*/\`A'Y_^@YJ
MG_?T?X4`;=%8G_"/S_\`0<U3_OZ/\*/^$?G_`.@YJG_?T?X4`;=%8G_"/S_]
M!S5/^_H_PH_X1^?_`*#FJ?\`?T?X4`;=%8G_``C\_P#T'-4_[^C_``H_X1^?
M_H.:I_W]'^%`&W6-I7_(>US_`*[1?^BQ3?\`A'Y_^@YJG_?T?X59TO25TQ[E
3_M-Q<27#!W>=LG@8'Z"C8#__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>syn-20120331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!-- XBRL document created with Ez-XBRL version 4.0.0.7 [05/10/2012 12:11:36 PM] -->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, May 15, 2012 10:49:18 PM Document Version 1.4-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, May 15, 2012 10:44:13 PM Document Version 1.3-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, May 15, 2012 10:34:36 PM Document Version 1.2-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, May 15, 2012 10:25:36 PM Document Version 1.1-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, May 15, 2012 10:21:06 PM Document Version 1.0-->
<!-- Based on XBRL 2.1  -->
<!--XBRL Document Modified with Ez-Viewer Version 1.0.4.3 on Wednesday, May 16, 2012 02:18:21 AM -->
<xbrli:xbrl xmlns:syn="http://www.adeonapharma.com/20120331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:country="http://xbrl.sec.gov/country/2011-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2011-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:us-types="http://fasb.org/us-types/2011-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink">
	<link:schemaRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:type="simple" xlink:href="syn-20120331.xsd"/>
	<!-- Context Section  -->
	<xbrli:context id="Context_As_Of_31-Dec-2010">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2010-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_3ME_31-Mar-2011">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>
2011-01-01
</xbrli:startDate>
			<xbrli:endDate>
2011-03-31
</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Mar-2011">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2011-03-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Dec-2011">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2011-12-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_3ME_31-Mar-2012">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>
2012-01-01
</xbrli:startDate>
			<xbrli:endDate>
2012-03-31
</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="Context_As_Of_31-Mar-2012">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>
2012-03-31
</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<!-- Unit Section  -->
	<xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
	<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
	<xbrli:unit id="USDPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
	<!-- Element Section  --><dei:EntityRegistrantName contextRef="Context_3ME_31-Mar-2012">Synthetic Biologics, Inc.</dei:EntityRegistrantName>
	<dei:EntityCentralIndexKey contextRef="Context_3ME_31-Mar-2012">0000894158</dei:EntityCentralIndexKey>
	<dei:CurrentFiscalYearEndDate contextRef="Context_3ME_31-Mar-2012">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:EntityFilerCategory contextRef="Context_3ME_31-Mar-2012">Smaller Reporting Company</dei:EntityFilerCategory>
	<dei:TradingSymbol contextRef="Context_3ME_31-Mar-2012">syn</dei:TradingSymbol>
	<dei:DocumentType contextRef="Context_3ME_31-Mar-2012">10-Q</dei:DocumentType>
	<dei:AmendmentFlag contextRef="Context_3ME_31-Mar-2012">false</dei:AmendmentFlag>
	<dei:DocumentPeriodEndDate contextRef="Context_3ME_31-Mar-2012">2012-03-31</dei:DocumentPeriodEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="Context_3ME_31-Mar-2012">Q1</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="Context_3ME_31-Mar-2012">2012</dei:DocumentFiscalYearFocus>
	<us-gaap:Cash contextRef="Context_As_Of_31-Dec-2010" unitRef="USD" decimals="-3">2649000</us-gaap:Cash>
	<us-gaap:Cash contextRef="Context_As_Of_31-Mar-2011" unitRef="USD" decimals="-3">6080000</us-gaap:Cash>
	<us-gaap:Cash contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">6678000</us-gaap:Cash>
	<us-gaap:Cash contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="-3">6802000</us-gaap:Cash>
	<us-gaap:AccountsReceivableNetCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">405000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="-3">440000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:OtherAssetsCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">16000</us-gaap:OtherAssetsCurrent>
	<us-gaap:OtherAssetsCurrent contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="-3">83000</us-gaap:OtherAssetsCurrent>
	<us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">23000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
	<us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="-3">0</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
	<us-gaap:AssetsCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">7122000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="-3">7325000</us-gaap:AssetsCurrent>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">323000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="-3">303000</us-gaap:PropertyPlantAndEquipmentNet>
	<syn:DepositsAndOtherAssetsNoncurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">31000</syn:DepositsAndOtherAssetsNoncurrent>
	<syn:DepositsAndOtherAssetsNoncurrent contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="-3">21000</syn:DepositsAndOtherAssetsNoncurrent>
	<us-gaap:Assets contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">7476000</us-gaap:Assets>
	<us-gaap:Assets contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="-3">8349000</us-gaap:Assets>
	<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">388000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="-3">316000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">29000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="-3">127000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">417000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="-3">443000</us-gaap:LiabilitiesCurrent>
	<us-gaap:Liabilities contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">417000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="-3">443000</us-gaap:Liabilities>
	<us-gaap:PreferredStockValue contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="-3">0</us-gaap:PreferredStockValue>
	<us-gaap:CommonStockValue contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">31000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="-3">33000</us-gaap:CommonStockValue>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">58901000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="-3">60946000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">-51873000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="-3">-53073000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">7059000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="-3">7906000</us-gaap:StockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">7476000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="-3">8349000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_31-Dec-2011" unitRef="USDPerShare" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_31-Mar-2012" unitRef="USDPerShare" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31-Dec-2011" unitRef="Shares" decimals="0">10000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31-Mar-2012" unitRef="Shares" decimals="0">10000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_31-Dec-2011" unitRef="Shares" decimals="0">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_31-Mar-2012" unitRef="Shares" decimals="0">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_31-Dec-2011" unitRef="Shares" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_31-Mar-2012" unitRef="Shares" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31-Dec-2011" unitRef="USDPerShare" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31-Mar-2012" unitRef="USDPerShare" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31-Dec-2011" unitRef="Shares" decimals="0">100000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31-Mar-2012" unitRef="Shares" decimals="0">100000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31-Dec-2011" unitRef="Shares" decimals="0">31374002</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31-Mar-2012" unitRef="Shares" decimals="0">32857609</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31-Dec-2011" unitRef="Shares" decimals="0">31292520</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31-Mar-2012" unitRef="Shares" decimals="0">32776127</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">1233000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">1468000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">231000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">386000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:OperatingExpenses contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">1464000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">1854000</us-gaap:OperatingExpenses>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">-1464000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">-1854000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<syn:WarrantExpenses contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">716000</syn:WarrantExpenses><syn:WarrantExpenses contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">0</syn:WarrantExpenses><us-gaap:OtherNonoperatingIncome contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">56000</us-gaap:OtherNonoperatingIncome>
	<us-gaap:OtherNonoperatingIncome contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">5000</us-gaap:OtherNonoperatingIncome>
	<us-gaap:NonoperatingIncomeExpense contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">-759000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">5000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:IncomeLossFromContinuingOperations contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">-2223000</us-gaap:IncomeLossFromContinuingOperations>
	<us-gaap:IncomeLossFromContinuingOperations contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">-1849000</us-gaap:IncomeLossFromContinuingOperations>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">37000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">649000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
	<us-gaap:NetIncomeLoss contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">-2186000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">-1200000</us-gaap:NetIncomeLoss>
	<us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="Context_3ME_31-Mar-2011" unitRef="USDPerShare" decimals="2">-0.09</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
	<us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="Context_3ME_31-Mar-2012" unitRef="USDPerShare" decimals="2">-0.06</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare contextRef="Context_3ME_31-Mar-2011" unitRef="USDPerShare" decimals="0">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
	<us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare contextRef="Context_3ME_31-Mar-2012" unitRef="USDPerShare" decimals="2">0.02</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_3ME_31-Mar-2011" unitRef="USDPerShare" decimals="2">-0.09</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_3ME_31-Mar-2012" unitRef="USDPerShare" decimals="2">-0.04</us-gaap:EarningsPerShareBasicAndDiluted>
	<syn:WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive contextRef="Context_3ME_31-Mar-2011" unitRef="Shares" decimals="0">25220694</syn:WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive>
	<syn:WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive contextRef="Context_3ME_31-Mar-2012" unitRef="Shares" decimals="0">32003164</syn:WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive>
	<us-gaap:ShareBasedCompensation contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">768000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">508000</us-gaap:ShareBasedCompensation>
	<syn:StockIssuedAsCompensation contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">76000</syn:StockIssuedAsCompensation>
	<syn:StockIssuedAsCompensation contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">0</syn:StockIssuedAsCompensation>
	<syn:StockIssuedForConsultingFees contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">58000</syn:StockIssuedForConsultingFees>
	<syn:StockIssuedForConsultingFees contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">0</syn:StockIssuedForConsultingFees>
	<syn:ChangeInFairValueOfWarrantLiability contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">94000</syn:ChangeInFairValueOfWarrantLiability>
	<syn:ChangeInFairValueOfWarrantLiability contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">0</syn:ChangeInFairValueOfWarrantLiability>
	<us-gaap:Depreciation contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">80000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">20000</us-gaap:Depreciation>
	<us-gaap:ProvisionForDoubtfulAccounts contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">21000</us-gaap:ProvisionForDoubtfulAccounts>
	<us-gaap:ProvisionForDoubtfulAccounts contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">8000</us-gaap:ProvisionForDoubtfulAccounts>
	<us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">-5000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
	<us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
	<us-gaap:GainLossOnSaleOfAccountsReceivable contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">63000</us-gaap:GainLossOnSaleOfAccountsReceivable>
	<us-gaap:GainLossOnSaleOfAccountsReceivable contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">0</us-gaap:GainLossOnSaleOfAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">111000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">43000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">-268000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
	<us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">67000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
	<syn:IncreaseDecreaseInDepositsAndOtherAssets contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">-68000</syn:IncreaseDecreaseInDepositsAndOtherAssets>
	<syn:IncreaseDecreaseInDepositsAndOtherAssets contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">-10000</syn:IncreaseDecreaseInDepositsAndOtherAssets>
	<syn:IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">3000</syn:IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation>
	<syn:IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">23000</syn:IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">154000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">-72000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">-192000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">98000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<syn:IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">40000</syn:IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
	<syn:IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">0</syn:IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">-281000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">-1415000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">1000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
	<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">1000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:RecoveryOfDirectCosts contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">296000</us-gaap:RecoveryOfDirectCosts>
	<us-gaap:RecoveryOfDirectCosts contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">0</us-gaap:RecoveryOfDirectCosts>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">3712000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">1539000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:CashPeriodIncreaseDecrease contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">3432000</us-gaap:CashPeriodIncreaseDecrease>
	<us-gaap:CashPeriodIncreaseDecrease contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">124000</us-gaap:CashPeriodIncreaseDecrease>
	<us-gaap:InterestPaid contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">0</us-gaap:InterestPaid>
	<us-gaap:InterestPaid contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">0</us-gaap:InterestPaid>
	<us-gaap:IncomeTaxesPaid contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">0</us-gaap:IncomeTaxesPaid>
	<us-gaap:IncomeTaxesPaid contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">0</us-gaap:IncomeTaxesPaid>
	<us-gaap:NatureOfOperations contextRef="Context_3ME_31-Mar-2012">&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;1.&amp;#160;&amp;#160;&amp;#160;Organization&lt;/b&gt;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Synthetic Biologics, Inc. (the &amp;#8220;Company&amp;#8221; or &amp;#8220;Synthetic Biologics&amp;#8221;), formerly Adeona Pharmaceuticals, Inc., is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. In the area of synthetic biology, the Company is initially developing a product candidate to treat pulmonary arterial hypertension (PAH). The Company also intends to expand new and existing collaborations in the synthetic biology area. In addition, Synthetic Biologics has several clinical-stage programs that are being funded, or partially funded, by grants, charitable organizations and corporate partners. In this area we are developing, or have partnered the development of, product candidates to treat relapsing-remitting multiple sclerosis (MS), cognitive dysfunction in MS, fibromyalgia and amyotrophic lateral sclerosis (ALS).&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; width: 24%; padding-right: 0.8pt; font-weight: bold;"&gt;&lt;b&gt;Medical Indication&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: center; width: 2%; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; width: 24%; padding-right: 0.8pt; font-weight: bold;"&gt;&lt;b&gt;Product Candidate&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: center; width: 2%; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; width: 48%; padding-right: 0.8pt; font-weight: bold;"&gt;&lt;b&gt;Status&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;PAH&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;Synthetic DNA-based therapy&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;Preclinical&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;Relapsing-remitting MS&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;
&lt;p style="text-align: center; margin: 0pt 0.8pt 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Trimesta&lt;/p&gt;
&lt;p style="text-align: center; margin: 0pt 0.8pt 0pt 0px; font: 10pt times new roman, times, serif;"&gt;(oral estriol)&lt;/p&gt;
&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;All patients enrolled in Phase II clinical trial;&lt;br  /&gt;dosing and monitoring underway&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;Cognitive dysfunction in&lt;br  /&gt;MS&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;
&lt;p style="text-align: center; margin: 0pt 0.8pt 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Trimesta&lt;/p&gt;
&lt;p style="text-align: center; margin: 0pt 0.8pt 0pt 0px; font: 10pt times new roman, times, serif;"&gt;(oral estriol)&lt;/p&gt;
&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;Patient enrollment underway in Phase II&lt;br  /&gt;clinical trial&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;Fibromyalgia&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;Effirma&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;Partnered with Meda AB&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;(oral flupirtine)&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;ALS&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;AEN-100&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;Phase II/III clinical trial preparation underway&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;(gastroretentive zinc acetate)&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:NatureOfOperations>
	<us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="Context_3ME_31-Mar-2012">&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;2.&amp;#160;&amp;#160;&amp;#160;Basis of Presentation&lt;/b&gt;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The accompanying unaudited consolidated interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules and regulations of the United States Securities and Exchange Commission for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The financial information as of December 31, 2011, is derived from the audited financial statements presented in the Company&amp;#8217;s Annual Report on Form 10-K/A for the year ended December 31, 2011. The unaudited consolidated interim financial statements should be read in conjunction with the Company&amp;#8217;s Annual Report on Form 10-K/A, which contains the audited financial statements and notes thereto, together with the Management&amp;#8217;s Discussion and Analysis, for the year ended December 31, 2011.&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Certain information or footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been consolidated or omitted, pursuant to the rules and regulations of the Securities and Exchange Commission for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. It is management's opinion, however, that all material adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair financial statement presentation. The interim results for the period ended March 31, 2012, are not necessarily indicative of results for the full year.&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company has seven subsidiaries, Pipex Therapeutics, Inc. (&amp;#8220;Pipex Therapeutics&amp;#8221;), Effective Pharmaceuticals, Inc. (&amp;#8220;EPI&amp;#8221;), Solovax, Inc. (&amp;#8220;Solovax&amp;#8221;), CD4 Biosciences, Inc. (&amp;#8220;CD4&amp;#8221;), Epitope Pharmaceuticals, Inc. (&amp;#8220;Epitope&amp;#8221;), Healthmine, Inc. (&amp;#8220;Healthmine&amp;#8221;) and Putney Drug Corp. (&amp;#8220;Putney&amp;#8221;). As of March 31, 2012, EPI, Healthmine and Putney are wholly owned and Pipex Therapeutics, Solovax, CD4 and Epitope are majority-owned.&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="Context_3ME_31-Mar-2012">&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;3.&amp;#160;&amp;#160;&amp;#160;Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Principles of Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;All inter-company transactions and accounts have been eliminated in consolidation.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S.A. requires management to make estimates and assumptions that affect the reported amounts reported in the consolidated financial statements and accompanying notes. Such estimates and assumptions impact, among others, the following: the amount allocated to goodwill, the estimated useful lives for property and equipment, fair value of warrants and stock options granted for services or compensation, respectively, estimates of the probability and potential magnitude of contingent liabilities, and the valuation allowance for deferred tax assets due to continuing and expected future operating losses.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events. Accordingly, actual results could differ from those estimates.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;br  /&gt;&lt;b&gt;&lt;i&gt;Accounts Receivable and Allowance for Doubtful Accounts&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Accounts receivable were reported at realizable value, net of allowances for doubtful accounts, which were estimated and recorded in the period the related revenue was recorded. The Company estimated and reviewed the collectability of its receivables based on a number of factors, including the period they were outstanding. Historical collection and payer reimbursement experience was an integral part of the estimation process related to allowances for doubtful accounts associated with Adeona Clinical Laboratory. In addition, the Company regularly assessed the state of its billing operations in order to identify issues, which impacted the collectability of these receivables or reserve estimates. Revisions to the allowances for doubtful accounts estimates were recorded as an adjustment to bad debt expense. Receivables deemed uncollectible were charged against the allowance for doubtful accounts. Recoveries of receivables previously written-off are recorded as credits to the allowance for doubtful accounts.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company records revenue when all of the following have occurred: (1) persuasive evidence of an arrangement exists, (2) the service is completed without further obligation, (3) the sales price to the customer is fixed or determinable, and (4) collectability is reasonably assured.&amp;#160;&amp;#160;The Company recognizes milestone payments or upfront payments that have no contingencies as revenue when payment is received.&amp;#160;&amp;#160;For the three months ended March 31, 2012 and 2011, the Company&amp;#8217;s only stream of revenue was laboratory revenue.&amp;#160;Laboratory revenues are a component of discontinued operations for the three months ended March 31, 2012 and 2011. &lt;i&gt;See Note 4 &amp;#8211; Discontinued Operations of Adeona Clinical Laboratory and Note Receivable.&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;License Revenues&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company&amp;#8217;s licensing agreements may contain multiple elements, such as non-refundable up-front fees, payments related to the achievement of particular milestones and royalties. Fees associated with substantive at risk performance-based milestones are recognized as revenue upon completion of the scientific or regulatory event specified in the agreement. When the Company has substantive continuing performance obligations under an arrangement, revenue is recognized over the performance period of the obligations using a time-based proportional performance approach. Under the time-based method, revenue is recognized over the arrangement&amp;#8217;s estimated performance period based on the elapsed time compared to the total estimated performance period. Revenue recognized at any point in time is limited to the amount of non-contingent payments received or due. When the Company has no substantive continuing performance obligations under an arrangement, it recognizes revenue as the related fees become due.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Revenues from royalties on third-party sales of licensed technologies are generally recognized in accordance with the contract terms when the royalties can be reliably determined and collectibility is reasonably assured. To date, the Company has not received any royalty revenues.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On May 6, 2010, the Company entered into the Meda Agreement for the development and commercialization of Effirma (oral flupirtine) for fibromyalgia.&amp;#160; As consideration for the sublicense, the Company received an up-front payment of $2.5 million upon execution of the Meda Agreement. This payment was recorded as license revenue in 2010. Pursuant to the Company&amp;#8217;s license agreement with McLean Hospital, the Company paid 15% of the $2.5 million payment ($375,000), that was netted against the revenues received from Meda AB. The Company is also entitled to additional milestone payments of $5 million upon filing of an NDA with the U.S. FDA for oral flupirtine for fibromyalgia and $10 million upon marketing approval. The Meda Agreement also provides that the Company is entitled to receive net royalties of 7% of net sales of oral flupirtine approved for the treatment of fibromyalgia covered by issued patent claims in the U.S. and Japan.&amp;#160;The Meda Agreement provides that Meda AB will assume all future development costs for the commercialization of oral flupirtine for fibromyalgia. Pursuant to the terms of the Company&amp;#8217;s agreement with McLean Hospital, the Company is obligated to pay half of all future royalties the Company receives.&amp;#160;&amp;#160;Future milestone payments will be recorded as revenue when payment is received as there are no future deliverables, and it is non-refundable.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;Laboratory Revenues&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company primarily recognized revenue for services rendered upon completion of the testing process. Billing for services reimbursed by third-party payers, including Medicare and Medicaid, were recorded as revenues, net of allowances for differences between amounts billed and the estimated receipts from such payers.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company maintained a sales allowance to compensate for the difference in its billing practices and insurance company reimbursements. In determining this allowance, the Company looked at several factors, the most significant of which is the average difference between the amount charged and the amount reimbursed by insurance carriers over the prior 12 months, otherwise known as the yearly average adjustment amount. The allowance taken was the averaged yearly average adjustment amount for these prior periods and multiplied by the period&amp;#8217;s actual gross sales to determine the actual sales allowance for each period.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company generated reimbursements from&amp;#160;3 significant insurance providers in March 31, 2012 and 2011, as follows:&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2"&gt;Customer&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2"&gt;2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; width: 30%; font-size: 10pt;"&gt;A&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; width: 30%; font-size: 10pt;"&gt;68%&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; width: 30%; font-size: 10pt;"&gt;69%&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;B&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;5%&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;18%&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;C&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;9%&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;5%&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Risks and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company's operations could be subject to significant risks and uncertainties including financial, operational and regulatory risks and the potential risk of business failure. The global economic crisis has caused a general tightening in the credit markets, lower levels of liquidity, increases in the rates of default and bankruptcy, and extreme volatility in credit, equity and fixed income markets. These conditions may not only limit our access to capital, but also make it difficult for our customers, our vendors and us to accurately forecast and plan future business activities.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Cash and cash equivalents include cash and highly liquid short-term investments with original maturities of three months or less.&amp;#160;&amp;#160;At March 31, 2012 and 2011, respectively, the Company had no cash equivalents.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Goodwill&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Goodwill was not amortized, and was tested for impairment at the reporting unit level annually and in interim periods if certain events occur indicating that the carrying value of goodwill was impaired. A reporting unit was an operating segment for which discrete financial information was available and was regularly reviewed by management. The Company had one reporting unit, Adeona Clinical Laboratory, to which goodwill was assigned.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;ASC No. 350 requires a two-step approach to test goodwill for impairment for each reporting unit. The first step tests for impairment by applying fair value-based tests to a reporting unit. The second step, if deemed necessary, measures the impairment by applying fair value-based tests to specific assets and liabilities within the reporting unit. Application of the goodwill impairment tests require judgment, including identification of reporting units, assignment of assets and liabilities to each reporting unit, assignment of goodwill to each reporting unit, and determination of the fair value of each reporting unit. The determination of fair value for a reporting unit could be materially affected by changes in these estimates and assumptions.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;At December 31, 2011, in connection with the Company classifying Adeona Clinical Laboratory as discontinued operations, previously recorded goodwill was considered impaired. &lt;i&gt;See Note 4 &amp;#8211; Discontinued Operations of Adeona Clinical Laboratory and Note Receivable&lt;/i&gt;.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Net Earnings (Loss) per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Net earnings (loss) per share is computed by dividing net earnings (loss) less preferred dividends for the period by the weighted average number of common shares outstanding. Diluted earnings (loss) per share is computed by dividing net income (loss) less preferred dividends by the weighted average number of common shares outstanding including the effect of common share equivalents.&amp;#160;Since the Company reported a net loss for the three months ended March 31, 2012 and 2011, all common equivalent shares would be anti-dilutive; as such there is no separate computation for diluted loss per share. The number of options and warrants for the purchase of common stock, that were excluded from the computations of net loss per common share for the three months ended March 31, 2012 were 3,843,465 and 2,414,922, respectively, and for the three months ended March 31, 2011 were 2,273,072 and 2,554,650, respectively.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Research and Development Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company expenses research and development costs as incurred. Research and development expenses consist primarily of license fees, manufacturing costs, salaries, stock-based compensation and related personnel costs, fees paid to consultants and outside service providers for laboratory development, legal expenses resulting from intellectual property prosecution and other expenses relating to the design, development, testing and enhancement of the Company&amp;#8217;s product candidates.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Payment Arrangements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Generally, all forms of stock-based payments, including stock option grants, warrants, restricted stock grants and stock appreciation rights are measured at their fair value on the awards&amp;#8217; grant date typically using a Black-Scholes pricing model, based on the estimated number of awards that are ultimately expected to vest. Stock-based compensation awards issued to non-employees for services rendered are recorded at either the fair value of the services rendered or the fair value of the stock-based payment, whichever is more readily determinable. The expense resulting from stock-based payments are recorded in research and development expense or general and administrative expense in the consolidated statement of operations, depending on the nature of the services provided.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Reclassifications&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;To conform prior period amounts to current year classifications, the Company has reclassified assets, liabilities, revenues and expenses associated with the sale of Adeona Clinical Laboratory to discontinued operations. These reclassifications had no impact on the Company&amp;#8217;s previously reported financial condition, results of operations or cash flows.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="Context_3ME_31-Mar-2012">&lt;table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="text-align: justify; vertical-align: top;"&gt;
&lt;td style="text-align: left; width: 0.25in;"&gt;&lt;b&gt;4.&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;b&gt;Discontinued Operations of Adeona Clinical Laboratory and Note Receivable&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-indent: -0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-indent: -0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On March 8, 2012, the Company sold all of its interest in Adeona Clinical Laboratory, LLC (the &amp;#8220;Lab&amp;#8221;) to Hartlab, LLC, an entity controlled by the Lab&amp;#8217;s former owner. In connection with the sale of the Lab, the consideration received was (i) the immediate assignment of the Lab&amp;#8217;s outstanding accounts receivable up through the date of closing, plus (ii) $700,000 payable pursuant to the terms of a two-year non-recourse promissory note bearing interest at 5.7% per annum secured by all of the assets of the Lab. The note and all unpaid interest are due on March 1, 2014.&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;In accordance with ASC Topic 205-20 &amp;#8220;&lt;i&gt;Presentation of Financial Statements&amp;#8212;Discontinued Operations&lt;/i&gt; &amp;#8221; (ASC 205-20), the Company determined that all the criteria had been met and classified the Lab as discontinued operations and its results of operations, financial position and cash flows are separately reported for all periods presented. The assets of the discontinued operations are presented separately under the caption &amp;#8220;Assets of discontinued operations&amp;#8221; in the accompanying Consolidated Balance Sheets at March 31, 2012, and December 31, 2011, and consist of the following &lt;i&gt;(in thousands&lt;/i&gt; &lt;i&gt;):&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-indent: -0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-indent: -0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-style: italic; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2"&gt;March 31, 2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2"&gt;December 31, 2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;Assets of discontinued operations:&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt; width: 62%; font-size: 10pt;"&gt;Property and equipment, net&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; width: 1%; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; width: 15%; font-size: 10pt;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; width: 1%; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; width: 17%; font-size: 10pt;"&gt;23&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt; font-size: 10pt;"&gt;Total assets&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"&gt;23&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The summarized statement of operations data for Adeona Clinical Laboratory for the three months ended March 31, 2012 and March 31, 2011 are as follows &lt;i&gt;(in thousands):&lt;/i&gt;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="6"&gt;March 31,&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-style: italic; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2"&gt;2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2"&gt;2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; width: 62%; font-size: 10pt;"&gt;Laboratory fees, net&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 16%; font-size: 10pt;"&gt;115&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 16%; font-size: 10pt;"&gt;323&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;Operating Costs and Expenses:&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-left: 9pt; font-size: 10pt;"&gt;General and administrative&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;27&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;35&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt; font-size: 10pt;"&gt;Cost of&amp;#160; laboratory services&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;116&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;251&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt; font-size: 10pt;"&gt;Total operating costs and expenses&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;143&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;286&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;Income (loss) from discontinued operations&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;(28&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;)&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;37&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;Other Income:&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&amp;#160;Gain on the sale of Adeona Clinical Laboratory&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;677&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;Net income from discontinued operations&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"&gt;649&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"&gt;37&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
	<us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="Context_3ME_31-Mar-2012">&lt;table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="text-align: justify; vertical-align: top;"&gt;
&lt;td style="text-align: left; width: 0.25in;"&gt;&lt;b&gt;5.&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;b&gt;Selected Balance Sheet Information&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Accounts receivable consisted of the following at March 31, 2012 and December 31, 2011 &lt;i&gt;(in thousands):&lt;/i&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2"&gt;March 31, 2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2"&gt;December 31, 2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; width: 62%; font-size: 10pt;"&gt;Accounts receivable&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 15%; font-size: 10pt;"&gt;736&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 17%; font-size: 10pt;"&gt;692&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;Bad debt allowance - customer&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;(296&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;(287&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; padding-bottom: 2.5pt; font-size: 10pt;"&gt;Accounts receivable, net&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"&gt;440&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"&gt;405&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Property and Equipment consisted of the following at March 31, 2012, and December 31, 2011 &lt;i&gt;(in thousands)&lt;/i&gt;:&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2"&gt;March&amp;#160;31,&amp;#160;2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2"&gt;December&amp;#160;31, 2011&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; width: 62%; font-size: 10pt;"&gt;Manufacturing equipment&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 15%; font-size: 10pt;"&gt;400&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 17%; font-size: 10pt;"&gt;400&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; font-size: 10pt;"&gt;Computer and office equipment&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;159&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;159&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; padding-bottom: 1pt; font-size: 10pt;"&gt;Laboratory equipment&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;136&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;136&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;695&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;695&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;Less accumulated depreciation&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;(392&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;(372&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; padding-bottom: 2.5pt; font-size: 10pt;"&gt;Property and equipment, net&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"&gt;303&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"&gt;323&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;Depreciation expense for the three months ended March 31, 2012 and 2011 was $20,000 and $80,000, respectively.&lt;/p&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock><us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="Context_3ME_31-Mar-2012">&lt;table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="text-align: justify; vertical-align: top;"&gt;
&lt;td style="width: 0in;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 0.25in;"&gt;&lt;b&gt;6.&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;During 2001, Pipex Therapeutics&amp;#8217; board of directors and stockholders adopted the 2001 Stock Incentive Plan (the &amp;#8220;2001 Stock Plan&amp;#8221;). This plan was assumed by Pipex in the October 2006 merger with Sheffield. As of the date of the merger, there were 1,489,353 options issued and outstanding under the 2001 plan. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2001 plan shall not exceed 250,000. All awards pursuant to the 2001 Stock Plan shall terminate upon the termination of the grantee&amp;#8217;s employment for any reason. Awards include options, restricted shares, stock appreciation rights, performance shares and cash-based awards (the &amp;#8220;Awards&amp;#8221;). The 2001 Stock Plan contains certain anti-dilution provisions in the event of a stock split, stock dividend or other capital adjustment, as defined in the plan. The 2001 Stock Plan provides for a Committee of the Board to grant awards and to determine the exercise price, vesting term, expiration date and all other terms and conditions of the awards, including acceleration of the vesting of an award at any time. As of March 31, 2012, there were 1,066,007 options issued and outstanding under the 2001 Stock Plan.&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On March 20, 2007, the Company&amp;#8217;s board of directors approved the Company&amp;#8217;s 2007 Stock Incentive Plan (the &amp;#8220;2007 Stock Plan&amp;#8221;) for the issuance of up to 2,500,000 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. This plan was approved by stockholders on November 2, 2007. The exercise price of stock options under the 2007 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company&amp;#8217;s common stock on the date the option is granted. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2001 plan shall not exceed 250,000. Options become exercisable over various periods from the date of grant, and generally expire ten years after the grant date. As of March 31, 2012, there are 1,031,394 options issued and outstanding under the 2007 Stock Plan.&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On November 2, 2010, the board of directors and stockholders adopted the 2010 Stock Incentive Plan (&amp;#8220;2010 Stock Plan&amp;#8221;) for the issuance of up to 3,000,000 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. The exercise price of stock options under the 2010 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company&amp;#8217;s common stock on the date the option is granted. Options become exercisable over various periods from the date of grant, and generally expire seven to ten years after the grant date. As of March 31, 2012, there are 1,746,064 options issued and outstanding under the 2010 Stock Plan.&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;In the event of an employee&amp;#8217;s termination, the Company will cease to recognize compensation expense for that employee. There is no deferred compensation recorded upon initial grant date, instead, the fair value of the stock-based payment is recognized ratably over the stated vesting period.&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company has applied fair value accounting for all stock-based payment awards since inception. The fair value of each option or warrant granted is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes assumptions used in the months ended March 31, 2012 and 2011 are as follows:&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="3"&gt;Three&amp;#160;Months&amp;#160;Ended&amp;#160;March&amp;#160;31,&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;"&gt;2012&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;"&gt;2011&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; font-size: 10pt;"&gt;Exercise price&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;$1.14 &amp;#8211; $2.47&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;$1.21 &amp;#8211; $2.22&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; width: 62%; font-size: 10pt;"&gt;Expected dividends&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; width: 18%; font-size: 10pt;"&gt;0%&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; width: 18%; font-size: 10pt;"&gt;0%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; font-size: 10pt;"&gt;Expected volatility&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;108% &amp;#8211; 174%&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;185% &amp;#8211; 188%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; font-size: 10pt;"&gt;Risk free interest rates&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;0.37% &amp;#8211; 1.98%&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;2.81% &amp;#8211; 3.58%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; font-size: 10pt;"&gt;Expected life options&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;10 years&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;5 years &amp;#8211; 7 years&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; font-size: 10pt;"&gt;Expected forfeitures&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;0%&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;0%&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company records stock-based compensation based upon the stated vested provisions in the related agreements, with recognition of expense recorded on the straight line basis over the term of the related agreement. The vesting provisions for these agreements have various terms as follows:&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 3%; padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 3%; padding-right: 0.8pt;"&gt;&amp;#9679;&lt;/td&gt;
&lt;td style="text-align: justify; width: 94%; padding-right: 0.8pt;"&gt;immediate vesting,&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt;"&gt;&amp;#9679;&lt;/td&gt;
&lt;td style="text-align: justify; padding-right: 0.8pt;"&gt;one-half vesting immediately and the remainder over three years&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt;"&gt;&amp;#9679;&lt;/td&gt;
&lt;td style="text-align: justify; padding-right: 0.8pt;"&gt;monthly over three years,&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt;"&gt;&amp;#9679;&lt;/td&gt;
&lt;td style="text-align: justify; padding-right: 0.8pt;"&gt;quarterly over three years,&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt;"&gt;&amp;#9679;&lt;/td&gt;
&lt;td style="text-align: justify; padding-right: 0.8pt;"&gt;annually over three years,&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt;"&gt;&amp;#9679;&lt;/td&gt;
&lt;td style="text-align: justify; padding-right: 0.8pt;"&gt;one-third immediate vesting and remaining annually over two years,&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt;"&gt;&amp;#9679;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: justify; padding-right: 0.8pt;"&gt;one-eighth immediate vesting with remaining vesting over two years,&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt;"&gt;&amp;#9679;&lt;/td&gt;
&lt;td style="text-align: justify; padding-right: 0.8pt;"&gt;one-half immediate vesting with remaining vesting over nine months; and&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="padding-right: 0.8pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-right: 0.8pt;"&gt;&amp;#9679;&lt;/td&gt;
&lt;td style="text-align: justify; padding-right: 0.8pt;"&gt;one quarter immediate vesting with the remaining over three years.&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;During the three months ended March 31, 2012, the Company granted 1,300,000 options to employees and consultants having a fair value of approximately $3 million based upon the Black-Scholes option pricing model.&amp;#160; During the same period of 2011, the Company granted 324,502 options to employees having a fair value of approximately $433,000 based upon the Black-Scholes option pricing model.&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;A summary of stock option activities as of March 31, 2012, and for the year ended December 31, 2011, is as follows:&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2"&gt;Options&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font: bold 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font: bold 10pt times new roman, times, serif;" colspan="2"&gt;Weighted &lt;br  /&gt;Average &lt;br  /&gt;&amp;#160;Exercise &lt;br  /&gt;Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font: bold 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font: bold 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font: bold 10pt times new roman, times, serif;" colspan="2"&gt;Weighted Average Remaining &lt;br  /&gt;Contractual &lt;br  /&gt;Life&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font: bold 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font: bold 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font: bold 10pt times new roman, times, serif;" colspan="2"&gt;Aggregate &lt;br  /&gt;Intrinsic &lt;br  /&gt;Value&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font: bold 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; width: 48%; font-size: 10pt;"&gt;Balance &amp;#8211; December 31, 2010&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%; font-size: 10pt;"&gt;2,539,091&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 10%; font-size: 10pt;"&gt;1.32&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 10%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; font-size: 10pt;"&gt;Granted&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;557,002&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;1.26&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; font-size: 10pt;"&gt;Exercised&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;(23,333&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;)&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;0.57&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; padding-bottom: 1pt; font-size: 10pt;"&gt;Forfeited or expired&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;(93,750&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;0.59&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; font-size: 10pt;"&gt;Balance &amp;#8211; December 31, 2011&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;2,979,010&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;1.34&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; font-size: 10pt;"&gt;Granted&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;1,300,000&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;2.35&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; font-size: 10pt;"&gt;Exercised&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;(289,343&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;)&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;0.23&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; padding-bottom: 1pt; font-size: 10pt;"&gt;Forfeited or expired&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;(146,202&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;0.80&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; padding-bottom: 2.5pt; font-size: 10pt;"&gt;Balance &amp;#8211; March 31, 2012 &amp;#8211; outstanding&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"&gt;3,843,465&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"&gt;1.79&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"&gt;7.18 years&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"&gt;2,230,000&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; padding-bottom: 2.5pt; font-size: 10pt;"&gt;Balance &amp;#8211; March 31, 2012 &amp;#8211; exercisable&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"&gt;2,323,320&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"&gt;1.62&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"&gt;5.73 years&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"&gt;1,814,000&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The options outstanding and exercisable as of March 31, 2012, are as follows:&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; padding-bottom: 1pt; font-size: 10pt;" colspan="13"&gt;&lt;b&gt;Options&amp;#160;Outstanding&amp;#160;&lt;/b&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; padding-bottom: 1pt; font-size: 10pt;" colspan="9"&gt;&lt;b&gt;&amp;#160;Options&amp;#160;Exercisable&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" colspan="2"&gt;Weighted&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;Weighted&amp;#160;Average&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" colspan="2"&gt;Weighted&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;Weighted&amp;#160;Average&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; font-size: 10pt;" colspan="2"&gt;Range&amp;#160;of&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" colspan="2"&gt;Average&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;Remaining&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" colspan="2"&gt;Average&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;Remaining&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="2"&gt;Exercise&amp;#160;Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="2"&gt;Options&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="2"&gt;Exercise&amp;#160;Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;"&gt;Contractual&amp;#160;Life&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="2"&gt;Options&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="2"&gt;Exercise&amp;#160;Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;"&gt;Contractual&amp;#160;Life&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; width: 12%; font-size: 10pt;"&gt;$0.09 - $4.57&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 12%; font-size: 10pt;"&gt;3,753,466&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 12%; font-size: 10pt;"&gt;1.69&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; width: 13%; font-size: 10pt;"&gt;7.29 years&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 11%; font-size: 10pt;"&gt;2,233,321&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 11%; font-size: 10pt;"&gt;1.44&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; width: 13%; font-size: 10pt;"&gt;5.86 years&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt;"&gt;$4.58 - $9.05&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;89,999&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;5.93&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; padding-bottom: 1pt; font-size: 10pt;"&gt;2.51 years&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;89,999&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;5.93&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; padding-bottom: 1pt; font-size: 10pt;"&gt;2.51 years&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 2.5pt; font-size: 10pt;"&gt;$0.09 - $9.05&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"&gt;3,843,465&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"&gt;1.79&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: center; font-size: 10pt;"&gt;7.18 years&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"&gt;2,323,320&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"&gt;1.62&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: center; font-size: 10pt;"&gt;5.73 years&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The options outstanding and exercisable as of March 31, 2011, are as follows:&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;/p&gt;
&lt;p style="margin: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="13"&gt;&lt;b&gt;&amp;#160;Options&amp;#160;Outstanding&lt;/b&gt;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="9"&gt;&lt;b&gt;&amp;#160;Options&amp;#160;Exercisable&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" colspan="2"&gt;Weighted&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;Weighted&amp;#160;Average&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" colspan="2"&gt;Weighted&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;Weighted&amp;#160;Average&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; font-size: 10pt;" colspan="2"&gt;Range&amp;#160;of&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" colspan="2"&gt;Average&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;Remaining&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" colspan="2"&gt;Average&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;Remaining&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="2"&gt;Exercise&amp;#160;Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="2"&gt;Options&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="2"&gt;Exercise&amp;#160;Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;"&gt;Contractual&amp;#160;Life&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="2"&gt;Options&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="2"&gt;Exercise&amp;#160;Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;"&gt;Contractual&amp;#160;Life&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; width: 12%; font-size: 10pt;"&gt;$0.09 - $4.57&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 12%; font-size: 10pt;"&gt;2,721,921&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 12%; font-size: 10pt;"&gt;1.22&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; width: 13%; font-size: 10pt;"&gt;6.75 years&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 11%; font-size: 10pt;"&gt;2,183,073&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 11%; font-size: 10pt;"&gt;1.32&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; width: 13%; font-size: 10pt;"&gt;6.27 years&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1pt; font-size: 10pt;"&gt;$4.58 - $9.05&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;89,999&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;5.93&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; padding-bottom: 1pt; font-size: 10pt;"&gt;3.51 years&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;89,999&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;5.93&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; padding-bottom: 1pt; font-size: 10pt;"&gt;3.51 years&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 2.5pt; font-size: 10pt;"&gt;$0.09 - $9.05&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"&gt;2,811,926&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"&gt;1.37&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: center; font-size: 10pt;"&gt;6.65 years&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"&gt;2,273,072&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"&gt;1.50&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: center; font-size: 10pt;"&gt;6.16 years&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;b&gt;&lt;i&gt;Options of Subsidiary&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;During 2004 and 2007, CD4 granted 30,000 options. On August 5, 2009, 10,000 of these options expired. As of March 31, 2012, a total of 20,000 options were outstanding and exercisable with an exercise price of $0.20 and a remaining contractual life of 0.12 years.&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;As of March 31, 2012, Epitope has 50,000 options outstanding and 20,000 options exercisable with an exercise price of $0.001 and a remaining contractual life of 6.25 years.&amp;#160;&amp;#160;These options were granted during 2008, vest annually over 5 years, and have a fair value of $50, which was determined using the Black-Scholes model with the following assumptions: expected dividend yield of 0%; expected volatility of 200%, risk free interest rate of 2.47% and an expected life of 10 years.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<syn:StockPurchaseWarrantsTextBlock contextRef="Context_3ME_31-Mar-2012">&lt;table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="text-align: justify; vertical-align: top;"&gt;
&lt;td style="text-align: left; width: 0.25in;"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;b&gt;Stock Purchase Warrants&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: justify; vertical-align: top;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On March 15, 2012, the Company entered into a consulting agreement for a financial communications program, for a period of twelve months that began on February 20, 2012. As compensation for such program, the consultant is paid a monthly fee and will be issued a performance warrant exercisable for 250,000 shares of the Company&amp;#8217;s common stock based on achievement of certain milestones. Upon initiation of the program, 50,000 of the performance warrants vested. The performance warrant is exercisable for a period of two years from the date the agreement was executed for an exercise price equal to the price of the Company&amp;#8217;s common stock on the date of execution. The fair value of the warrant approximated $61,000 and was measured using the Black-Scholes valuation model. The assumptions used by the Company are summarized in the following table:&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 75%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;Exercise price&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;" colspan="2"&gt;$ &amp;#160;&amp;#160;&amp;#160;&amp;#160;2.20&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; width: 81%; font-size: 10pt;"&gt;Expected dividends&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 15%; font-size: 10pt;"&gt;0&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;Expected volatility&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;108&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;Risk free interest rate&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;0.37&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;Expected life of warrant&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;2 years&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;Expected forfeitures&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;0&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On December 20, 2011, the Company entered into a consulting agreement for financial advisory services, for a period of twelve months. As compensation for such services, the consultant is paid a monthly fee and on February 2, 2012, was issued a warrant exercisable for 100,000 shares of the Company&amp;#8217;s common stock. The warrant is exercisable upon issuance for a period of five years from the date of issue at an exercise price equal to the price of the Company&amp;#8217;s common stock on the date of issue. The fair value of the warrant approximated $200,000 and was measured using the Black-Scholes valuation model. The assumptions used by the Company are summarized in the following table:&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;table style="width: 75%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;Exercise price&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;" colspan="2"&gt;$&amp;#160;&amp;#160;&amp;#160;&amp;#160; 1.14&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; width: 81%; font-size: 10pt;"&gt;Expected dividends&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 15%; font-size: 10pt;"&gt;0&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;Expected volatility&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;174&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;Risk free interest rate&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;0.71&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;Expected life of warrant&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;5 years&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;Expected forfeitures&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;0&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On April 6, 2011, the Company entered into a Common Stock Purchase Agreement with an institutional investor. As part of this agreement, the Company issued a warrant to purchase 844,391 shares of common stock. The warrants have an exercise price of $1.00 and a life of fifteen months. The warrants vested immediately and expire August 10, 2012. As of March 31, 2012, 344,391 of these warrants remained outstanding.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;br  /&gt;On January 28, 2011, the Company entered into a Common Stock Purchase Agreement with three institutional investors. As part of this agreement, the Company issued warrants to purchase 1,428,572 shares of common stock. The warrants have an exercise price of $1.40 and a life of fifteen months. The warrants vested immediately and expire May 1, 2012. As of March 31, 2012, 746,429 of these warrants remained outstanding.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On July 2, 2010, the Company entered into a Common Stock Purchase Agreement with a single investor. As part of this agreement, the Company issued warrants to purchase 60,606 shares of common stock to the placement agent, or its permitted assigns. The warrants have an exercise price of $1.32 and a life of 5 years. The warrants vested on January 1, 2011 and expire December 31, 2015. Since these warrants were granted as part of an equity raise, the Company has treated them as a direct offering cost. The result of the transaction has no affect to equity. As of March 31, 2012, 18,182 of these warrants remained outstanding.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;A summary of warrant activities as of March 31, 2012, and for the year ended December 31, 2011, is as follows:&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2"&gt;Warrants&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font: bold 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font: bold 10pt times new roman, times, serif;" colspan="2"&gt;Weighted &lt;br  /&gt;Average&amp;#160;Exercise Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font: bold 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; width: 64%; font-size: 10pt;"&gt;Balance &amp;#8211; December 31, 2010&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 15%; font-size: 10pt;"&gt;1,131,078&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 15%; font-size: 10pt;"&gt;3.49&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; font-size: 10pt;"&gt;Granted&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;2,272,963&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;1.25&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; font-size: 10pt;"&gt;Exercised&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;(15,615&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;)&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;1.03&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; padding-bottom: 1pt; font-size: 10pt;"&gt;Expired&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;(129,240&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;2.08&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; font-size: 10pt;"&gt;Balance &amp;#8211; December 31, 2011&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;3,259,186&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;1.95&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; font-size: 10pt;"&gt;Granted&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;350,000&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;1.90&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; font-size: 10pt;"&gt;Exercised&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;(1,194,264&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;)&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;1.24&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; padding-bottom: 1pt; font-size: 10pt;"&gt;Expired&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; padding-bottom: 2.5pt; font-size: 10pt;"&gt;Balance &amp;#8211; March 31, 2012 - outstanding&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"&gt;2,414,922&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"&gt;2.36&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: justify; padding-bottom: 2.5pt; font-size: 10pt;"&gt;Balance &amp;#8211; March 31, 2012 &amp;#8211; exercisable&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"&gt;2,214,922&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"&gt;2.37&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The warrants outstanding as of March 31, 2012, are as follows:&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;/p&gt;
&lt;table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="2"&gt;Exercise&lt;br  /&gt;Price&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="2"&gt;Warrants&lt;br  /&gt;Outstanding&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="2"&gt;Warrants&lt;br  /&gt;Exercisable&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="2"&gt;Weighted&amp;#160;Average&lt;br  /&gt;Remaining&lt;br  /&gt;Contractual&amp;#160;Life&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="2"&gt;Aggregate&lt;br  /&gt;Intrinsic Value&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 16%; font-size: 10pt;"&gt;1.00&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 16%; font-size: 10pt;"&gt;369,391&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 16%; font-size: 10pt;"&gt;369,391&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; width: 18%; font-size: 10pt;"&gt;0.36 years&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; width: 16%; font-size: 10pt;"&gt;443,000&lt;/td&gt;
&lt;td style="text-align: left; width: 1%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;1.14&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;100,000&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;100,000&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;4.84 years&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;106,000&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;1.32&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;18,182&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;18,182&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;3.75 years&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;16,000&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;1.40&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;721,429&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;721,429&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;0.08 years&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;577,000&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;2.20&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;250,000&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;50,000&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;1.96 years&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;2.22&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;517,257&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;517,257&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;4.66 years&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;3.30&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;61,207&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;61,207&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;3.30 years&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;3.75&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;50,000&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;50,000&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;3.88 years&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 1pt; font-size: 10pt;"&gt;6.36&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;327,456&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;327,456&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;0.61 years&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"&gt;2,414,922&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"&gt;2,214,922&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"&gt;1.81 years&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;"&gt;1,142,000&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</syn:StockPurchaseWarrantsTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Context_3ME_31-Mar-2012">&lt;table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="text-align: justify; vertical-align: top;"&gt;
&lt;td style="width: 0in;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 0.25in;"&gt;&lt;b&gt;8.&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;b&gt;Stockholders&amp;#8217; Equity&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;During the three months ended March 31, 2012, the Company issued 289,343 shares of common stock, in connection with the exercise of stock options, for proceeds of approximately $68,000. The Company also issued 1,194,264 shares of common stock in connection with the exercise of warrants, for proceeds of approximately $1.5 million.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:NotesAndLoansReceivableNetNoncurrent contextRef="Context_As_Of_31-Dec-2011" unitRef="USD" decimals="-3">0</us-gaap:NotesAndLoansReceivableNetNoncurrent>
	<us-gaap:NotesAndLoansReceivableNetNoncurrent contextRef="Context_As_Of_31-Mar-2012" unitRef="USD" decimals="-3">700000</us-gaap:NotesAndLoansReceivableNetNoncurrent>
	<us-gaap:IncreaseDecreaseInNotesReceivableCurrent contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">0</us-gaap:IncreaseDecreaseInNotesReceivableCurrent>
	<us-gaap:IncreaseDecreaseInNotesReceivableCurrent contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">700000</us-gaap:IncreaseDecreaseInNotesReceivableCurrent>
	<syn:ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">4000000</syn:ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises>
	<syn:ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">0</syn:ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises>
	<syn:ProceedsFromIssuanceOfCommonStockForStockOptionExercises contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">8000</syn:ProceedsFromIssuanceOfCommonStockForStockOptionExercises>
	<syn:ProceedsFromIssuanceOfCommonStockForStockOptionExercises contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">68000</syn:ProceedsFromIssuanceOfCommonStockForStockOptionExercises>
	<syn:ProceedsFromIssuanceOfCommonStockForWarrantExercises contextRef="Context_3ME_31-Mar-2011" unitRef="USD" decimals="-3">0</syn:ProceedsFromIssuanceOfCommonStockForWarrantExercises>
	<syn:ProceedsFromIssuanceOfCommonStockForWarrantExercises contextRef="Context_3ME_31-Mar-2012" unitRef="USD" decimals="-3">1471000</syn:ProceedsFromIssuanceOfCommonStockForWarrantExercises>
	<!-- Footnote Section -->
	<link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
	</link:footnoteLink>
	<us-gaap:SubsequentEventsTextBlock contextRef="Context_3ME_31-Mar-2012">&lt;table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 6pt;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="text-align: justify; vertical-align: top;"&gt;
&lt;td style="width: 0in;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; width: 0.25in;"&gt;&lt;b&gt;9.&lt;/b&gt;&lt;/td&gt;
&lt;td style="text-align: justify;"&gt;&lt;b&gt;Subsequent Event&lt;/b&gt;s&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On May 1, 2012, the Company was informed by Berman &amp;amp; Company, P.A. (&amp;#8220;Berman &amp;amp; Company&amp;#8221;), the Company&amp;#8217;s independent registered accounting firm, that during a regular Public Company Accounting Oversight Board (&amp;#8220;PCAOB&amp;#8221;) inspection of Berman &amp;amp; Company, the PCAOB issued a comment that the audit opinion included in the Company&amp;#8217;s Annual Report on Form 10-K for the year ended December 31, 2011 was issued by a partner at Berman &amp;amp; Company who was not authorized under the PCAOB rules to issue the opinion or act as our named engagement partner with respect to the Form 10-K audit (or prior 2011 Form 10-Q interim reviews) after the original engagement partner rotated off the account under the Securities and Exchange Commission&amp;#8217;s independence rules as it pertains to partner rotation (S-X Rule 2-01 - Qualifications of Accountants).&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Company received funds from the exercise of warrants but will not issue any shares under any of its outstanding registration statements on Form S-3 until such time as it receives guidance from the SEC whether the issue disclosed herein affects the Company&amp;#8217;s ability to continue to issue securities thereunder. The Company intends to return all of the funds to the warrant holders. The Company has sought guidance from the SEC staff regarding this matter and intends to file a waiver request to the extent it becomes necessary.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;On May 10, 2012, Jeffrey J. Kraws was appointed as the independent, non-executive Chairman of the Board. For his service as independent, non-executive Chairman of the Board, Mr. Kraws will receive annual compensation of $150,000. Additionally, Mr. Kraws was granted options to purchase 100,000 shares of the Company&amp;#8217;s common stock with an exercise price equal to our per share market price on the date of issue. These options will vest pro rata, quarterly over a two year period with the first quarterly issuance of 12,500 options vesting immediately. The Company measured the fair value of the stock options at approximately $166,000 using a Black-Scholes valuation model; these warrants were indexed to the Company&amp;#8217;s own stock.&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;The Black-Scholes assumptions used in calculating the fair value of the stock options are as follows:&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="width: 40%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="width: 68%; font-size: 10pt;"&gt;Exercise price&lt;/td&gt;
&lt;td style="width: 2%; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; width: 30%; font-size: 10pt;"&gt;$1.70&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;Expected dividends&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;0%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;Expected volatility&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;171%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;Risk free interest rate&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;1.28%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: #ccffcc; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;Expected life of options&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;7 years&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="background-color: white; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;Expected forfeitures&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;0%&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:SubsequentEventsTextBlock>
	<xbrli:context id="Context_As_Of_14-May-2012"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2012-05-14</xbrli:instant></xbrli:period></xbrli:context>
	<dei:EntityCommonStockSharesOutstanding contextRef="Context_As_Of_14-May-2012" unitRef="Shares" decimals="0">33016175</dei:EntityCommonStockSharesOutstanding>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>syn-20120331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Viewer on Tuesday, May 15, 2012 10:49:18 PM Document Version 1.4-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, May 15, 2012 10:44:13 PM Document Version 1.3-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, May 15, 2012 10:34:36 PM Document Version 1.2-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, May 15, 2012 10:25:36 PM Document Version 1.1-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, May 15, 2012 10:21:06 PM Document Version 1.0-->
<!--XBRL Document Modified with Ez-Viewer Version 1.0.3.6 on Tuesday, May 15, 2012 02:39:17 PM -->
<!--XBRL Document Modified with Ez-Viewer Version 1.0.4.5 on Tuesday, May 15, 2012 04:15:54 PM -->
<!--XBRL Document Modified with Ez-Viewer Version 1.0.4.3 on Wednesday, May 16, 2012 02:18:21 AM -->
<schema targetNamespace="http://www.adeonapharma.com/20120331" elementFormDefault="qualified" xmlns:syn="http://www.adeonapharma.com/20120331" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:country="http://xbrl.sec.gov/country/2011-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2011-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:num="http://www.xbrl.org/dtr/type/numeric">
	<annotation><appinfo>
			<link:roleType roleURI="http://www.adeonapharma.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
				<link:definition>001 - Document - Document and Entity Information</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.adeonapharma.com/role/StatementOfFinancialPositionClassified" id="StatementOfFinancialPositionClassified">
				<link:definition>002 - Statement - Consolidated Balance Sheets</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.adeonapharma.com/role/Balancesheetparenthetical" id="Balancesheetparenthetical">
				<link:definition>003 - Statement - Consolidated Balance Sheets [Parenthetical]</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.adeonapharma.com/role/StatementOfIncomeAlternative" id="StatementOfIncomeAlternative">
				<link:definition>004 - Statement - Consolidated Statements of Operations</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.adeonapharma.com/role/StatementOfCashFlowsIndirect" id="StatementOfCashFlowsIndirect">
				<link:definition>005 - Statement - Consolidated Statements of Cash Flows</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.adeonapharma.com/role/Organization" id="Organization">
				<link:definition>006 - Disclosure - Organization</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.adeonapharma.com/role/BasisOfPresentation" id="BasisOfPresentation">
				<link:definition>007 - Disclosure - Basis of Presentation</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.adeonapharma.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
				<link:definition>008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.adeonapharma.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivable" id="DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivable">
				<link:definition>009 - Disclosure - Discontinued Operations of Adeona Clinical Laboratory and Note Receivable</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.adeonapharma.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
				<link:definition>010 - Disclosure - Selected Balance Sheet Information</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.adeonapharma.com/role/StockBasedCompensation" id="StockBasedCompensation">
				<link:definition>011 - Disclosure - Stock-Based Compensation</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.adeonapharma.com/role/StockPurchaseWarrants" id="StockPurchaseWarrants">
				<link:definition>012 - Disclosure - Stock Purchase Warrants</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:roleType roleURI="http://www.adeonapharma.com/role/StockholdersEquity" id="StockholdersEquity">
				<link:definition>013 - Disclosure - Stockholders' Equity</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
			<link:linkbaseRef xlink:type="simple" xlink:href="syn-20120331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="syn-20120331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="syn-20120331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="syn-20120331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:roleType roleURI="http://www.adeonapharma.com/role/SubsequentEvents" id="SubsequentEvents"><link:definition>014 - Disclosure - Subsequent Events</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
		</appinfo></annotation>
	<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
	<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
	<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
	<import namespace="http://fasb.org/us-gaap/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd"/>
	<import namespace="http://xbrl.sec.gov/invest/2011-01-31" schemaLocation="http://xbrl.sec.gov/invest/2011/invest-2011-01-31.xsd"/>
	<import namespace="http://xbrl.sec.gov/country/2011-01-31" schemaLocation="http://xbrl.sec.gov/country/2011/country-2011-01-31.xsd"/>
	<import namespace="http://xbrl.sec.gov/currency/2011-01-31" schemaLocation="http://xbrl.sec.gov/currency/2011/currency-2011-01-31.xsd"/>
	<import namespace="http://xbrl.sec.gov/exch/2011-01-31" schemaLocation="http://xbrl.sec.gov/exch/2011/exch-2011-01-31.xsd"/>
	<import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
	<import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
	<import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
	<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
	<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
	<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
	<import namespace="http://xbrl.sec.gov/dei/2011-01-31" schemaLocation="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd"/>
	<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
	<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
	<element name="DocumentAndEntityInformationAbstract" id="syn_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="DepositsAndOtherAssetsNoncurrent" id="syn_DepositsAndOtherAssetsNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="BalanceSheetParentheticalAbstract" id="syn_BalanceSheetParentheticalAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive" id="syn_WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="StockIssuedAsCompensation" id="syn_StockIssuedAsCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="StockIssuedForConsultingFees" id="syn_StockIssuedForConsultingFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="ChangeInFairValueOfWarrantLiability" id="syn_ChangeInFairValueOfWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="IncreaseDecreaseInDepositsAndOtherAssets" id="syn_IncreaseDecreaseInDepositsAndOtherAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation" id="syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" id="syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="ProceedsFromIssuanceOfCommonStockForStockOptionExercises" id="syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="ProceedsFromIssuanceOfCommonStockForWarrantExercises" id="syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises" id="syn_ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="StockPurchaseWarrantsAbstract" id="syn_StockPurchaseWarrantsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="StockPurchaseWarrantsTextBlock" id="syn_StockPurchaseWarrantsTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
	<element name="WarrantExpenses" id="syn_WarrantExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" nillable="true"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>syn-20120331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Viewer on Tuesday, May 15, 2012 10:49:18 PM Document Version 1.4-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, May 15, 2012 10:44:13 PM Document Version 1.3-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, May 15, 2012 10:34:36 PM Document Version 1.2-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, May 15, 2012 10:25:36 PM Document Version 1.1-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, May 15, 2012 10:21:06 PM Document Version 1.0-->
<!--XBRL Document Modified with Ez-Viewer Version 1.0.3.6 on Tuesday, May 15, 2012 02:39:17 PM -->
<!--XBRL Document Modified with Ez-Viewer Version 1.0.4.5 on Tuesday, May 15, 2012 04:15:54 PM -->
<!--XBRL Document Modified with Ez-Viewer Version 1.0.4.3 on Wednesday, May 16, 2012 02:18:21 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#StatementOfFinancialPositionClassified" roleURI="http://www.adeonapharma.com/role/StatementOfFinancialPositionClassified"/>
	<calculationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StatementOfFinancialPositionClassified">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_Cash" order="20" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent" order="40" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_OtherAssetsCurrent" order="60" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" order="80" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" order="20" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" order="40" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent" order="60" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_DepositsAndOtherAssetsNoncurrent" xlink:label="loc_syn_DepositsAndOtherAssetsNoncurrent"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_syn_DepositsAndOtherAssetsNoncurrent" order="80" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" order="20" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" order="40" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock" order="60" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" order="80" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" order="20" use="optional" weight="1"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" order="40" use="optional" weight="1"/>
	</calculationLink>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#StatementOfIncomeAlternative" roleURI="http://www.adeonapharma.com/role/StatementOfIncomeAlternative"/>
	<calculationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StatementOfIncomeAlternative">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" order="20" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" order="40" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_WarrantExpenses" xlink:label="loc_syn_WarrantExpenses"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_syn_WarrantExpenses" order="20" use="optional" weight="-1"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ChangeInFairValueOfWarrantLiability" xlink:label="loc_syn_ChangeInFairValueOfWarrantLiability"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_syn_ChangeInFairValueOfWarrantLiability" order="40" use="optional" weight="-1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="60" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:label="loc_us-gaap_GainOrLossOnSaleOfStockInSubsidiary"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_GainOrLossOnSaleOfStockInSubsidiary" order="80" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_OtherNonoperatingIncome" order="100" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="20" use="optional" weight="1"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" order="40" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations" order="20" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" order="40" use="optional" weight="1"/>
	</calculationLink>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#StatementOfCashFlowsIndirect" roleURI="http://www.adeonapharma.com/role/StatementOfCashFlowsIndirect"/>
	<calculationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StatementOfCashFlowsIndirect">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations" order="20" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" order="40" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" order="60" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedAsCompensation" xlink:label="loc_syn_StockIssuedAsCompensation"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_syn_StockIssuedAsCompensation" order="80" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedForConsultingFees" xlink:label="loc_syn_StockIssuedForConsultingFees"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_syn_StockIssuedForConsultingFees" order="100" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_WarrantExpenses" xlink:label="loc_syn_WarrantExpenses"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_syn_WarrantExpenses" order="120" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ChangeInFairValueOfWarrantLiability" xlink:label="loc_syn_ChangeInFairValueOfWarrantLiability"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_syn_ChangeInFairValueOfWarrantLiability" order="140" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_Depreciation" order="160" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts" order="180" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="200" use="optional" weight="-1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfAccountsReceivable" xlink:label="loc_us-gaap_GainLossOnSaleOfAccountsReceivable"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnSaleOfAccountsReceivable" order="220" use="optional" weight="-1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" order="240" use="optional" weight="-1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="260" use="optional" weight="-1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInNotesReceivableCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInNotesReceivableCurrent"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInNotesReceivableCurrent" order="280" use="optional" weight="-1"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="loc_syn_IncreaseDecreaseInDepositsAndOtherAssets"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_syn_IncreaseDecreaseInDepositsAndOtherAssets" order="300" use="optional" weight="-1"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation" order="320" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable" order="340" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" order="360" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" order="380" use="optional" weight="-1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="20" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" order="20" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises" order="40" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_syn_ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises" order="60" use="optional" weight="1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RecoveryOfDirectCosts" xlink:label="loc_us-gaap_RecoveryOfDirectCosts"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RecoveryOfDirectCosts" order="80" use="optional" weight="-1"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashPeriodIncreaseDecrease"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" order="20" use="optional" weight="1"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" order="40" use="optional" weight="1"/>
		<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" order="60" use="optional" weight="1"/>
	</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>syn-20120331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Viewer on Tuesday, May 15, 2012 10:49:18 PM Document Version 1.4-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, May 15, 2012 10:44:13 PM Document Version 1.3-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, May 15, 2012 10:34:36 PM Document Version 1.2-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, May 15, 2012 10:25:36 PM Document Version 1.1-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, May 15, 2012 10:21:06 PM Document Version 1.0-->
<!--XBRL Document Modified with Ez-Viewer Version 1.0.3.6 on Tuesday, May 15, 2012 02:39:17 PM -->
<!--XBRL Document Modified with Ez-Viewer Version 1.0.4.5 on Tuesday, May 15, 2012 04:15:54 PM -->
<!--XBRL Document Modified with Ez-Viewer Version 1.0.4.3 on Wednesday, May 16, 2012 02:18:21 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
	<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
	<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
	<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
	<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
	<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
	<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#DocumentAndEntityInformation" roleURI="http://www.adeonapharma.com/role/DocumentAndEntityInformation"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#StatementOfFinancialPositionClassified" roleURI="http://www.adeonapharma.com/role/StatementOfFinancialPositionClassified"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#Balancesheetparenthetical" roleURI="http://www.adeonapharma.com/role/Balancesheetparenthetical"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#StatementOfIncomeAlternative" roleURI="http://www.adeonapharma.com/role/StatementOfIncomeAlternative"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#StatementOfCashFlowsIndirect" roleURI="http://www.adeonapharma.com/role/StatementOfCashFlowsIndirect"/>
	<definitionLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/DocumentAndEntityInformation">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_2"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityRegistrantName_2" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_3"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityCentralIndexKey_3" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_4"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_4" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_5"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityFilerCategory_5" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_6"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_TradingSymbol_6" order="50" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_7"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_7" order="60" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_8"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentType_8" order="70" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_9"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_AmendmentFlag_9" order="80" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_10"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentPeriodEndDate_10" order="90" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_11"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_11" order="100" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_12"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_dei_DocumentFiscalYearFocus_12" order="110" use="optional"/>
	</definitionLink>
	<definitionLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StatementOfFinancialPositionClassified">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_2"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AssetsAbstract_2" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_3"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_Cash_3" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_5"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_OtherAssetsCurrent_5" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_6"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_6" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_7"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_AssetsCurrent_7" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8" order="50" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_9"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_9" order="60" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_DepositsAndOtherAssetsNoncurrent" xlink:label="loc_syn_DepositsAndOtherAssetsNoncurrent_10"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_syn_DepositsAndOtherAssetsNoncurrent_10" order="70" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_11"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_2" xlink:to="loc_us-gaap_Assets_11" order="80" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_13"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_AccountsPayableCurrent_13" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_14"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_14" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_15"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_LiabilitiesCurrent_15" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_16"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_Liabilities_16" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_17"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_StockholdersEquityAbstract_17" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_18"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_17" xlink:to="loc_us-gaap_PreferredStockValue_18" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_19"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_17" xlink:to="loc_us-gaap_CommonStockValue_19" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_20"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_17" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_20" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_21"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_17" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_21" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_22"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_17" xlink:to="loc_us-gaap_StockholdersEquity_22" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_23"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_12" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_23" order="50" use="optional"/>
	</definitionLink>
	<definitionLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/Balancesheetparenthetical">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_3" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_4"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_4" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_5"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_5" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_6"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_6" order="50" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_7"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_7" order="60" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_8"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_8" order="70" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9" order="80" use="optional"/>
	</definitionLink>
	<definitionLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StatementOfIncomeAlternative">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_2"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_2" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_5"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2" xlink:to="loc_us-gaap_OperatingExpenses_5" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_WarrantExpenses" xlink:label="loc_syn_WarrantExpenses_8"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7" xlink:to="loc_syn_WarrantExpenses_8" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ChangeInFairValueOfWarrantLiability" xlink:label="loc_syn_ChangeInFairValueOfWarrantLiability_9"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7" xlink:to="loc_syn_ChangeInFairValueOfWarrantLiability_9" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_10"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_10" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome_12"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7" xlink:to="loc_us-gaap_OtherNonoperatingIncome_12" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_13"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_13" order="50" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_14"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_14" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_15"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_15" order="50" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_16"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetIncomeLoss_16" order="60" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_17"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_17" order="70" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_18"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_17" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_18" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_19"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_17" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_19" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_20"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_20" order="80" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive" xlink:label="loc_syn_WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive_21"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_syn_WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive_21" order="90" use="optional"/>
	</definitionLink>
	<definitionLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StatementOfCashFlowsIndirect">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_3"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_3" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_4"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_4" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_6"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_ShareBasedCompensation_6" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedAsCompensation" xlink:label="loc_syn_StockIssuedAsCompensation_7"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_syn_StockIssuedAsCompensation_7" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedForConsultingFees" xlink:label="loc_syn_StockIssuedForConsultingFees_8"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_syn_StockIssuedForConsultingFees_8" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_WarrantExpenses" xlink:label="loc_syn_WarrantExpenses_9"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_syn_WarrantExpenses_9" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ChangeInFairValueOfWarrantLiability" xlink:label="loc_syn_ChangeInFairValueOfWarrantLiability_10"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_syn_ChangeInFairValueOfWarrantLiability_10" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_11"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_Depreciation_11" order="50" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_12"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_12" order="60" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_13"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_13" order="70" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfAccountsReceivable" xlink:label="loc_us-gaap_GainLossOnSaleOfAccountsReceivable_14"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_GainLossOnSaleOfAccountsReceivable_14" order="80" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_15"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_15" order="90" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_16"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_15" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_16" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_17"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_15" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_17" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInNotesReceivableCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInNotesReceivableCurrent_18"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_15" xlink:to="loc_us-gaap_IncreaseDecreaseInNotesReceivableCurrent_18" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="loc_syn_IncreaseDecreaseInDepositsAndOtherAssets_19"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_15" xlink:to="loc_syn_IncreaseDecreaseInDepositsAndOtherAssets_19" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation_20"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_15" xlink:to="loc_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation_20" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_21"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_15" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_21" order="50" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_22"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_15" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_22" order="60" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_23"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_15" xlink:to="loc_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_23" order="70" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_24" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_25"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_25" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_26"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_25" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_26" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_27"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_25" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_27" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_28"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_28" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises_29"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_28" xlink:to="loc_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises_29" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises_30"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_28" xlink:to="loc_syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises_30" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises_31"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_28" xlink:to="loc_syn_ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises_31" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RecoveryOfDirectCosts" xlink:label="loc_us-gaap_RecoveryOfDirectCosts_32"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_28" xlink:to="loc_us-gaap_RecoveryOfDirectCosts_32" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_33"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_28" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_33" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashPeriodIncreaseDecrease_34"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CashPeriodIncreaseDecrease_34" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_35"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_Cash_35" order="50" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_36"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_36" order="60" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_37"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_36" xlink:to="loc_us-gaap_InterestPaid_37" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_38"/>
		<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_36" xlink:to="loc_us-gaap_IncomeTaxesPaid_38" order="10" use="optional"/>
	</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>syn-20120331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Viewer on Tuesday, May 15, 2012 10:49:18 PM Document Version 1.4-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, May 15, 2012 10:44:13 PM Document Version 1.3-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, May 15, 2012 10:34:36 PM Document Version 1.2-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, May 15, 2012 10:25:36 PM Document Version 1.1-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, May 15, 2012 10:21:06 PM Document Version 1.0-->
<!--XBRL Document Modified with Ez-Viewer Version 1.0.3.6 on Tuesday, May 15, 2012 02:39:17 PM -->
<!--XBRL Document Modified with Ez-Viewer Version 1.0.4.5 on Tuesday, May 15, 2012 04:15:54 PM -->
<!--XBRL Document Modified with Ez-Viewer Version 1.0.4.3 on Wednesday, May 16, 2012 02:18:21 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2008-03-31.xsd#negated" roleURI="http://xbrl.us/us-gaap/role/label/negated"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
	<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_DocumentAndEntityInformationAbstract" xlink:label="loc_syn_DocumentAndEntityInformationAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_DocumentAndEntityInformationAbstract" xlink:to="lab_syn_DocumentAndEntityInformationAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement Of Financial Position [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash at beginning of period</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash at end of period</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, Net, Current</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivable - net</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, Net, Current, Total</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other Assets, Current</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xml:lang="en-US">Assets Of Discontinued Operations</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xml:lang="en-US">Assets of discontinued operations</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total Current Assets</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total Current Assets</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net, Total</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net, Beginning Balance</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net, Ending Balance</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent" xml:lang="en-US">Notes, Loans and Financing Receivable, Net, Noncurrent</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent" xml:lang="en-US">Long-term note receivable</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:to="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_DepositsAndOtherAssetsNoncurrent" xlink:label="loc_syn_DepositsAndOtherAssetsNoncurrent"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_DepositsAndOtherAssetsNoncurrent" xml:lang="en-US">Deposits and Other Assets Noncurrent</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_DepositsAndOtherAssetsNoncurrent" xml:lang="en-US">Deposits and other assets</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_syn_DepositsAndOtherAssetsNoncurrent" xml:lang="en-US">Deposits and other assets</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_DepositsAndOtherAssetsNoncurrent" xml:lang="en-US">Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and also includes aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet due to materiality considerations. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_DepositsAndOtherAssetsNoncurrent" xlink:to="lab_syn_DepositsAndOtherAssetsNoncurrent"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total Assets</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total Assets</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Stockholders Equity [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Stockholders' Equity</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current, Total</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued liabilities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current, Total</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total Current Liabilities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total Current Liabilities</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total Liabilities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total Liabilities</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders Equity Attributable To Parent [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity:</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued, Total</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued, Beginning Balance</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued, Ending Balance</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.001 par value; 100,000,000 shares authorized, 28,127,644 issued and 28,209,126 outstanding and 23,420,189 issued and 23,338,707 outstanding</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.001 par value; 100,000,000 shares authorized, 32,857,609 issued and 32,776,127 outstanding and 31,374,002 issued and 31,292,520 outstanding</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued, Total</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued, Beginning Balance</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued, Ending Balance</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid In Capital, Common Stock</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional paid-in capital</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid in Capital, Common Stock, Beginning Balance</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid in Capital, Common Stock, Ending Balance</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit), Beginning Balance</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit), Ending Balance</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders Equity Attributable To Parent</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total Stockholders' Equity</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total Stockholders' Equity</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Stockholders Equity</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total Liabilities and Stockholders' Equity</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total Liabilities and Stockholders' Equity</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_BalanceSheetParentheticalAbstract" xlink:label="loc_syn_BalanceSheetParentheticalAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_BalanceSheetParentheticalAbstract" xml:lang="en-US">Balance Sheet Parenthetical [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_BalanceSheetParentheticalAbstract" xml:lang="en-US">Balance Sheet Parenthetical [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_BalanceSheetParentheticalAbstract" xml:lang="en-US">Balance Sheet Parenthetical</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_BalanceSheetParentheticalAbstract" xlink:to="lab_syn_BalanceSheetParentheticalAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par Or Stated Value Per Share</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value (in dollars per share)</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, shares outstanding</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding, Beginning Balance</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding, Ending Balance</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par Or Stated Value Per Share</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value (in dollars per share)</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued, Total</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding, Beginning Balance</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding, Ending Balance</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Costs and Expenses:</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense, Total</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total Operating Costs and Expenses</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total Operating Costs and Expenses</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) From Continuing Operations Before Income Taxes, Extraordinary Items, Noncontrolling Interest</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Loss from Continuing Operations</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Loss from Continuing Operations</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other Income (Expense):</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_WarrantExpenses" xlink:label="loc_syn_WarrantExpenses"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_WarrantExpenses" xml:lang="en-US">Warrant Expenses</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_WarrantExpenses" xml:lang="en-US">Warrant expense</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_syn_WarrantExpenses" xml:lang="en-US">Warrant expense</label>
		<label xlink:type="resource" xlink:label="lab_syn_WarrantExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">The amount of expenses incurred for warrant during the period.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_WarrantExpenses" xlink:to="lab_syn_WarrantExpenses"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ChangeInFairValueOfWarrantLiability" xlink:label="loc_syn_ChangeInFairValueOfWarrantLiability"/>
		<label xlink:type="resource" xlink:label="lab_syn_ChangeInFairValueOfWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xml:lang="en-US">The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</label>
		<label xlink:type="resource" xlink:label="lab_syn_ChangeInFairValueOfWarrantLiability" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xml:lang="en-US">Change in fair value of warrant liability</label>
		<label xlink:type="resource" xlink:label="lab_syn_ChangeInFairValueOfWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Change in fair value of warrant liability</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ChangeInFairValueOfWarrantLiability" xlink:to="lab_syn_ChangeInFairValueOfWarrantLiability"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Gain (Loss) On Sale Of Property Plant Equipment</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Loss on the sale of equipment</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Gain (Loss) on Sale of Property Plant Equipment, Total</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Loss on sale of equipment</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:label="loc_us-gaap_GainOrLossOnSaleOfStockInSubsidiary"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xml:lang="en-US">Gain (Loss) on Sale of Stock in Subsidiary</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xml:lang="en-US">Gain on the sale of Adeona Clinical Laboratory</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:to="lab_us-gaap_GainOrLossOnSaleOfStockInSubsidiary"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xml:lang="en-US">Other Nonoperating Income</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xml:lang="en-US">Other income</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncome" xml:lang="en-US">Other income (expense)</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncome" xlink:to="lab_us-gaap_OtherNonoperatingIncome"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total Other Expense, net</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total Other Income (Expense), net</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xml:lang="en-US">Income (Loss) From Continuing Operations Attributable To Parent</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xml:lang="en-US">Net Loss from Continuing Operations</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xml:lang="en-US">Net loss</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xml:lang="en-US">Net Loss from Continuing Operations</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xml:lang="en-US">Income (Loss) From Discontinued Operations, Net Of Tax, Attributable To Parent</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xml:lang="en-US">Net Income from Discontinued Operations</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xml:lang="en-US">Net income from discontinued operations</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable To Parent</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Loss</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Loss</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US">Net Income (Loss) Per Share - Basic and Dilutive:</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xml:lang="en-US">Income (Loss) From Continuing Operations, Per Basic and Diluted Share</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xml:lang="en-US">Continuing operations (in dollars per share)</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xml:lang="en-US">Income (Loss) From Discontinued Operations, Net Of Tax, Per Basic and Diluted Share</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xml:lang="en-US">Discontinued operations (in dollars per share)</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net Loss Per Share (in dollars per share)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net Income (Loss) Per Share - Basic and Dilutive (in dollars per share)</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive" xlink:label="loc_syn_WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive" xml:lang="en-US">Weighted Average Number Of Common Shares Outstanding During Period Basic and Dilutive</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive" xml:lang="en-US">Weighted average number of shares outstanding during the period - Basic and Dilutive (in shares)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_syn_WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive" xml:lang="en-US">Weighted average number of common shares outstanding during the period - Basic and Dilutive (in shares)</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive" xml:lang="en-US">The average number of shares or units issued and outstanding that are used in calculating basic and diluted EPS.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive" xlink:to="lab_syn_WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement Of Cash Flows [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Operating Activities [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash Flows From Operating Activities:</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activites:</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-Based Compensation</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation, Total</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedAsCompensation" xlink:label="loc_syn_StockIssuedAsCompensation"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockIssuedAsCompensation" xml:lang="en-US">Stock Issued As Compensation</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockIssuedAsCompensation" xml:lang="en-US">Stock issued as employee compensation</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_StockIssuedAsCompensation" xml:lang="en-US">The noncash expense that accounts for the value of stock options distributed to employees as compensation.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockIssuedAsCompensation" xlink:to="lab_syn_StockIssuedAsCompensation"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedForConsultingFees" xlink:label="loc_syn_StockIssuedForConsultingFees"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockIssuedForConsultingFees" xml:lang="en-US">Stock Issued For Consulting Fees</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockIssuedForConsultingFees" xml:lang="en-US">Stock issued for consulting fees</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_StockIssuedForConsultingFees" xml:lang="en-US">The fair value of restricted stock or stock options granted to nonemployees as payment for consulting fees.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockIssuedForConsultingFees" xlink:to="lab_syn_StockIssuedForConsultingFees"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ChangeInFairValueOfWarrantLiability" xml:lang="en-US">Change In Fair Value Of Warrant Liability</label>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation, Total</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xml:lang="en-US">Provision For Doubtful Accounts</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xml:lang="en-US">Provision for uncollectible accounts receivable</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xml:lang="en-US">Provision for Doubtful Accounts</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfAccountsReceivable" xlink:label="loc_us-gaap_GainLossOnSaleOfAccountsReceivable"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnSaleOfAccountsReceivable" xml:lang="en-US">Gain (Loss) On Sale Of Accounts Receivable</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfAccountsReceivable" xml:lang="en-US">Gain on the settlement of accounts payable</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfAccountsReceivable" xml:lang="en-US">Gain on the settlement of accounts payable</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfAccountsReceivable" xlink:to="lab_us-gaap_GainLossOnSaleOfAccountsReceivable"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) In Operating Capital [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase (Decrease) In Accounts Receivable</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Accounts receivable</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Accounts receivable</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xml:lang="en-US">Increase (Decrease) In Other Current Assets</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xml:lang="en-US">Other current assets</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xml:lang="en-US">Other current assets</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInNotesReceivableCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInNotesReceivableCurrent"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInNotesReceivableCurrent" xml:lang="en-US">Increase (Decrease) In Notes Receivable, Current</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInNotesReceivableCurrent" xml:lang="en-US">Note receivable</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInNotesReceivableCurrent" xml:lang="en-US">Note receivable</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInNotesReceivableCurrent" xlink:to="lab_us-gaap_IncreaseDecreaseInNotesReceivableCurrent"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="loc_syn_IncreaseDecreaseInDepositsAndOtherAssets"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_IncreaseDecreaseInDepositsAndOtherAssets" xml:lang="en-US">Increase Decrease In Deposits and Other Assets</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_IncreaseDecreaseInDepositsAndOtherAssets" xml:lang="en-US">Deposits and other assets</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_IncreaseDecreaseInDepositsAndOtherAssets" xml:lang="en-US">The aggregate net change during the reporting period in moneys given as security, collateral, or margin deposits. Also includes, net change in other operating assets not otherwise defined in the taxonomy.</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_syn_IncreaseDecreaseInDepositsAndOtherAssets" xml:lang="en-US">Deposits and other assets</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_IncreaseDecreaseInDepositsAndOtherAssets" xlink:to="lab_syn_IncreaseDecreaseInDepositsAndOtherAssets"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation" xml:lang="en-US">Increase (Decrease) In Assets Of Disposal Group Including Discontinued Operation</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation" xml:lang="en-US">Assets of discontinued operations</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation" xml:lang="en-US">The increase (decrease) during the reporting period in assets of discontinued operations.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Increase (Decrease) In Accounts Payable</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Accounts payable</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Total</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Increase (Decrease) In Accrued Liabilities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Accrued liabilities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Accrued liabilities</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xml:lang="en-US">Increase (Decrease) In Liabilities Of Disposal Group Including Discontinued Operation</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xml:lang="en-US">Liabilities of discontinued operations</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xml:lang="en-US">The increase (decrease) during the reporting period in liabilities of discontinued operations.</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xml:lang="en-US">Liabilities of discontinued operations</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Operating Activities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Used In Operating Activities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Used In Operating Activities</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Investing Activities [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash Flows From Investing Activities:</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US">Proceeds From Sale Of Property, Plant, and Equipment</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US">Proceeds from the sale of equipment</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US">Proceeds from the sale of equipment</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Investing Activities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Investing Activities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided By Investing Activities</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Financing Activities [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash Flows From Financing Activities:</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" xml:lang="en-US">Proceeds From Issuance Of Common Stock For Stock Option Exercises</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" xml:lang="en-US">Proceeds from issuance of common stock for stock option exercises</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" xml:lang="en-US">The cash inflow from the additional capital contribution to the entity for stock option exercised.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" xlink:to="lab_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises" xml:lang="en-US">Proceeds From Issuance Of Common Stock For Warrant Exercises</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises" xml:lang="en-US">Proceeds from issuance of common stock for warrant exercises</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises" xml:lang="en-US">Proceeds from issuance of common stock for warrant exercises</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises" xml:lang="en-US">The cash inflow from the additional capital contribution to the entity for warrant exercises.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises" xlink:to="lab_syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises" xml:lang="en-US">Proceeds From Issuance Of Common Stock Excluding Stock Option and Warrant Exercises</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises" xml:lang="en-US">Proceeds from issuance of common stock</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises" xml:lang="en-US">The cash inflow from the additional capital contribution to the entity excluding stock option and warrant exercised during the period.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises" xlink:to="lab_syn_ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RecoveryOfDirectCosts" xlink:label="loc_us-gaap_RecoveryOfDirectCosts"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RecoveryOfDirectCosts" xml:lang="en-US">Recovery Of Direct Costs</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RecoveryOfDirectCosts" xml:lang="en-US">Cash paid as direct offering costs</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RecoveryOfDirectCosts" xml:lang="en-US">Cash paid as direct offering costs</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RecoveryOfDirectCosts" xlink:to="lab_us-gaap_RecoveryOfDirectCosts"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Financing Activities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided By Financing Activities</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided By Financing Activities</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashPeriodIncreaseDecrease"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashPeriodIncreaseDecrease" xml:lang="en-US">Cash Period Increase Decrease</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashPeriodIncreaseDecrease" xml:lang="en-US">Net increase (decrease) in cash</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashPeriodIncreaseDecrease" xml:lang="en-US">Net increase in cash</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease" xlink:to="lab_us-gaap_CashPeriodIncreaseDecrease"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental disclosures of cash flow information:</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPaid" xml:lang="en-US">Interest Paid</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestPaid" xml:lang="en-US">Cash paid for interest</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_InterestPaid" xml:lang="en-US">Cash paid for interest</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid" xlink:to="lab_us-gaap_InterestPaid"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Income Taxes Paid</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Cash paid for taxes</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Cash paid for taxes</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NatureOfOperations" xml:lang="en-US">Nature Of Operations [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NatureOfOperations" xml:lang="en-US">Nature of Operations [Text Block]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xml:lang="en-US">Business Description and Basis Of Presentation [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Disclosure Of Compensation Related Costs, Share-Based Payments [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockPurchaseWarrantsAbstract" xlink:label="loc_syn_StockPurchaseWarrantsAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockPurchaseWarrantsAbstract" xml:lang="en-US">Stock Purchase Warrants [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockPurchaseWarrantsAbstract" xml:lang="en-US">Stock Purchase Warrants [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockPurchaseWarrantsAbstract" xlink:to="lab_syn_StockPurchaseWarrantsAbstract"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockPurchaseWarrantsTextBlock" xlink:label="loc_syn_StockPurchaseWarrantsTextBlock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_syn_StockPurchaseWarrantsTextBlock" xml:lang="en-US">Stock Purchase Warrants [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_syn_StockPurchaseWarrantsTextBlock" xml:lang="en-US">Stock Purchase Warrants [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_syn_StockPurchaseWarrantsTextBlock" xml:lang="en-US">The entire disclosure for stock purchase warrants.</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_syn_StockPurchaseWarrantsTextBlock" xlink:to="lab_syn_StockPurchaseWarrantsTextBlock"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders Equity Note Disclosure [Text Block]</label>
		<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract"/>
		<label xlink:type="resource" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Subsequent Events [Abstract]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock"/>
		<label xlink:type="resource" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Subsequent Events [Text Block]</label>
		<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock"/>
	</labelLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>syn-20120331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Viewer on Tuesday, May 15, 2012 10:49:18 PM Document Version 1.4-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, May 15, 2012 10:44:13 PM Document Version 1.3-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, May 15, 2012 10:34:36 PM Document Version 1.2-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, May 15, 2012 10:25:36 PM Document Version 1.1-->
<!--XBRL Document Modified with Ez-Viewer on Tuesday, May 15, 2012 10:21:06 PM Document Version 1.0-->
<!--XBRL Document Modified with Ez-Viewer Version 1.0.3.6 on Tuesday, May 15, 2012 02:39:17 PM -->
<!--XBRL Document Modified with Ez-Viewer Version 1.0.4.5 on Tuesday, May 15, 2012 04:15:54 PM -->
<!--XBRL Document Modified with Ez-Viewer Version 1.0.4.3 on Wednesday, May 16, 2012 02:18:21 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#DocumentAndEntityInformation" roleURI="http://www.adeonapharma.com/role/DocumentAndEntityInformation"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#StatementOfFinancialPositionClassified" roleURI="http://www.adeonapharma.com/role/StatementOfFinancialPositionClassified"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#Balancesheetparenthetical" roleURI="http://www.adeonapharma.com/role/Balancesheetparenthetical"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#StatementOfIncomeAlternative" roleURI="http://www.adeonapharma.com/role/StatementOfIncomeAlternative"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#StatementOfCashFlowsIndirect" roleURI="http://www.adeonapharma.com/role/StatementOfCashFlowsIndirect"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#Organization" roleURI="http://www.adeonapharma.com/role/Organization"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#BasisOfPresentation" roleURI="http://www.adeonapharma.com/role/BasisOfPresentation"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.adeonapharma.com/role/SummaryOfSignificantAccountingPolicies"/>
	<roleRef xlink:type="simple" roleURI="http://www.adeonapharma.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivable" xlink:href="syn-20120331.xsd#DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivable"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#PropertyAndEquipment" roleURI="http://www.adeonapharma.com/role/PropertyAndEquipment"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#StockBasedCompensation" roleURI="http://www.adeonapharma.com/role/StockBasedCompensation"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#StockPurchaseWarrants" roleURI="http://www.adeonapharma.com/role/StockPurchaseWarrants"/>
	<roleRef xlink:type="simple" xlink:href="syn-20120331.xsd#StockholdersEquity" roleURI="http://www.adeonapharma.com/role/StockholdersEquity"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
	<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/DocumentAndEntityInformation">
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_DocumentAndEntityInformationAbstract" xlink:label="loc_syn_DocumentAndEntityInformationAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_DocumentAndEntityInformationAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_3"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityRegistrantName_3" order="0" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_4"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityCentralIndexKey_4" order="10" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_5"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_CurrentFiscalYearEndDate_5" order="20" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_6"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityFilerCategory_6" order="30" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_7"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_TradingSymbol_7" order="40" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_8"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_8" order="50" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_9"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_DocumentType_9" order="60" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_10"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_AmendmentFlag_10" order="70" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_11"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_DocumentPeriodEndDate_11" order="80" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_12"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_DocumentFiscalPeriodFocus_12" order="90" use="optional"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_13"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_dei_DocumentFiscalYearFocus_13" order="100" use="optional"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StatementOfFinancialPositionClassified">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_3"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_AssetsAbstract_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_4"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_Cash_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_6"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_OtherAssetsCurrent_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_7"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_8"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_AssetsCurrent_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_10"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_DepositsAndOtherAssetsNoncurrent" xlink:label="loc_syn_DepositsAndOtherAssetsNoncurrent_11"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_syn_DepositsAndOtherAssetsNoncurrent_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_12"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3" xlink:to="loc_us-gaap_Assets_12" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_14"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_AccountsPayableCurrent_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_15"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_16"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_LiabilitiesCurrent_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_17"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_Liabilities_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_18"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_StockholdersEquityAbstract_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_19"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_18" xlink:to="loc_us-gaap_PreferredStockValue_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_20"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_18" xlink:to="loc_us-gaap_CommonStockValue_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_21"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_18" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_21" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_22"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_18" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_22" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_23"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_18" xlink:to="loc_us-gaap_StockholdersEquity_23" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_24"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_24" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/Balancesheetparenthetical">
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_BalanceSheetParentheticalAbstract" xlink:label="loc_syn_BalanceSheetParentheticalAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_BalanceSheetParentheticalAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_4"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_5"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_PreferredStockSharesIssued_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_6"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_7" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_8"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_8" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_9"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CommonStockSharesIssued_9" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_10"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_10" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StatementOfIncomeAlternative">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_3"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_OperatingExpensesAbstract_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_4"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_6"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3" xlink:to="loc_us-gaap_OperatingExpenses_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_WarrantExpenses" xlink:label="loc_syn_WarrantExpenses_9"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8" xlink:to="loc_syn_WarrantExpenses_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ChangeInFairValueOfWarrantLiability" xlink:label="loc_syn_ChangeInFairValueOfWarrantLiability_10"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8" xlink:to="loc_syn_ChangeInFairValueOfWarrantLiability_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_11"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome_13"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8" xlink:to="loc_us-gaap_OtherNonoperatingIncome_13" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_14"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_14" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_15"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_16"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_16" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_17"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NetIncomeLoss_17" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_18"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_18" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_19"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_18" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_20"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_18" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_21"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_21" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive" xlink:label="loc_syn_WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive_22"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_syn_WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive_22" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StatementOfCashFlowsIndirect">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_2"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_4"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_5"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_7"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_us-gaap_ShareBasedCompensation_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedAsCompensation" xlink:label="loc_syn_StockIssuedAsCompensation_8"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_syn_StockIssuedAsCompensation_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockIssuedForConsultingFees" xlink:label="loc_syn_StockIssuedForConsultingFees_9"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_syn_StockIssuedForConsultingFees_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_WarrantExpenses" xlink:label="loc_syn_WarrantExpenses_10"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_syn_WarrantExpenses_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ChangeInFairValueOfWarrantLiability" xlink:label="loc_syn_ChangeInFairValueOfWarrantLiability_11"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_syn_ChangeInFairValueOfWarrantLiability_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_12"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_us-gaap_Depreciation_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_13"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_14"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_14" order="70" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GainLossOnSaleOfAccountsReceivable" xlink:label="loc_us-gaap_GainLossOnSaleOfAccountsReceivable_15"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_us-gaap_GainLossOnSaleOfAccountsReceivable_15" order="80" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_16"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_16" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_17"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_16" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_18"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_16" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInNotesReceivableCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInNotesReceivableCurrent_19"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_16" xlink:to="loc_us-gaap_IncreaseDecreaseInNotesReceivableCurrent_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="loc_syn_IncreaseDecreaseInDepositsAndOtherAssets_20"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_16" xlink:to="loc_syn_IncreaseDecreaseInDepositsAndOtherAssets_20" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation_21"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_16" xlink:to="loc_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation_21" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_22"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_16" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_22" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_23"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_16" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_23" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_24"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_16" xlink:to="loc_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_24" order="70" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_25"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_25" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_26"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_26" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_27"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_26" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_27" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_26" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_29"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_29" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises_30"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_29" xlink:to="loc_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises_30" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises_31"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_29" xlink:to="loc_syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises_31" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises" xlink:label="loc_syn_ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises_32"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_29" xlink:to="loc_syn_ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises_32" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RecoveryOfDirectCosts" xlink:label="loc_us-gaap_RecoveryOfDirectCosts_33"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_29" xlink:to="loc_us-gaap_RecoveryOfDirectCosts_33" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_34"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_29" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_34" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashPeriodIncreaseDecrease_35"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_CashPeriodIncreaseDecrease_35" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_36"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_Cash_36" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_37"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_Cash_37" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_38"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_38" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_39"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_38" xlink:to="loc_us-gaap_InterestPaid_39" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_40"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_38" xlink:to="loc_us-gaap_IncomeTaxesPaid_40" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/Organization">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_NatureOfOperations_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/BasisOfPresentation">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/SummaryOfSignificantAccountingPolicies">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivable">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/PropertyAndEquipment">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StockBasedCompensation">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StockPurchaseWarrants">
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockPurchaseWarrantsAbstract" xlink:label="loc_syn_StockPurchaseWarrantsAbstract_0"/>
		<loc xlink:type="locator" xlink:href="syn-20120331.xsd#syn_StockPurchaseWarrantsTextBlock" xlink:label="loc_syn_StockPurchaseWarrantsTextBlock_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_StockPurchaseWarrantsAbstract_0" xlink:to="loc_syn_StockPurchaseWarrantsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/StockholdersEquity">
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
	</presentationLink>
	<roleRef xlink:type="simple" roleURI="http://www.adeonapharma.com/role/SubsequentEvents" xlink:href="syn-20120331.xsd#SubsequentEvents"/>
	<presentationLink xlink:type="extended" xlink:role="http://www.adeonapharma.com/role/SubsequentEvents"><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract"/>
		<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock"/>
		<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="loc_us-gaap_SubsequentEventsTextBlock" order="10" use="optional"/>
	</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001144204-12-029753-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-12-029753-xbrl.zip
M4$L#!!0````(`/>)KT!I.'87<TH``#T0`P`0`!P`<WEN+3(P,3(P,S,Q+GAM
M;%54"0`#@L>R3X+'LD]U>`L``00E#@``!#D!``#L77N3VS:2_SM;M=\!ZZO+
MQE6C!R7-V_&6/(]D*AY[UF-G<W5UE8)(2$),$ER`'(WRZ:\;("F2HD1*HL:3
MC9V*/4,"W3\TNAL-H`&^^L>CYY(')A47_O<OK';W!6&^+1SN3[Y_\>GC=>OD
MQ3]>__4OK_[6:I%?WGQX2QQA1Q[S0V)+1D/FD!D/I^3J]Y9^&U,B@W87_CLF
M_]L][%C=3J]K]8C5.[.LL_X1N;O]/])JQ51UM<N$Z"UP'O,,U9\YFS%)@.3'
MB"F'S@_(+9T3Z_"`&*+=L\'IF74"1!=4?HY16.U!DWP&9U9_!9]^@WSZ`R.D
M,CZ]!OGT#E?SL9KD8YUU5_'IIGS(&ZJ`+CS5''MMBVRJ)!FR[4&[C[3^Q1P_
M"^LHAM4%73P!9&1X&W-Y'$F7G^'?!$S"5V=J#@8Q#</@K-.9S69MZC#ATV!*
MI4?;MO"T4G?[?>M%7,'E_N=<#236%G(");O]#KX>01N3XOC6X6F%;.&CCGF9
M%ETB/>OKLM;IZ6E'OTV+*EY6$(A:G5]NW][;4^;1%O=52'T[AX6OP5XLSY48
M]*SC=35,B:2"+WP_\LK+.Z'LA/.`=:!0"THQR>VT7G6E?`6'!9+9Z)A6@COM
M4&E+X;+.F-IABST&+O5I*.3\&GY/"$DV7DGAJ`-O4X@L7,-*\X$BN5X/2WO]
MT/1Z6M06D1_*>;ZL8G9[(AXZ\4M40JO5M5H+-;0C*<&%KZH7ORVIZ#!>7@=>
ME!1GC_:TO#R^*:G`_0>FPO(JYEU))9]R6Y77T:]*JBANEU>`%V7%PT"N*`]O
M2BI$JC6A-$CKC*D:Z3Z,7ZRNTJ)AN+H:O)1\%(5,9:JACJO2.OI-":]'=XU9
M_O(6?07XNV]>H=<X4]H??&!CHKW(66P9ZWU-)Y`B8#+DP#_CU30!1/7]"\6]
MP$V?3;4M@3]M)2ZS_:B<%QT-`UW_A?!#]AB2>V:'Z,"-2_XF]LEV_):#2<<E
M?QVJ7]^/?^U;K4MF(]6N;E-2`P8)'L[UD^01=_`AC!J2Z#;GFYCT^,7-3R]>
M=^'/R>G`.CQYU2E6-EPZ2VQB+B`5+IP\8^TZ0WB&,%M6#[H*AIM.\>V"[()(
M\B260(5,^K=7*)%;*E$BUK.5"+18AI?@HHU,M/IV,S+)OO\FTP(G5Z>?D^/B
M[>YR3'7KV4LRIUM+,FE2MXKV]H>1R9/96^_92J1@;[TM[*WWE/;V?"69TZTE
MF6RN6SCV??+YJH$OPE<HJ7N8=$!4\#I^[C&J(LE>Q]VG7R;DDW?)[TBCC.2G
M^\LE>G',?@;OMB!WQZ3&F9)U^`,(^W6FZ#N,U3'2WI+S4GU\>,E\X7&_C&Q=
M`>5(=/+HBPW'/KMRF9Z(9KOM%43)9U=:BSZP"5>A!%UX1SU&XA[_@$'02M]Q
M/_?#*0NY3=YPX8H)A+8'Y,:WVZ\ZJPAK.(N7%X!(4O?&=]CC3VQ>CVW6/E:2
M2AE=Z,E#>,V53=W_851>&3=0CU?+.&/#:!6I0J.NN<OD!3R?P/2LIB0]ZD(E
M\H$%`F)4?P+AI1=0?YYM88YNRO.CI+CP=3_W1L*MQPVB6D,W5S>EF*Q9?(2P
MN!Y!B!'_:2AFZZ8$A_#$P:?7+IW4HSBFKF*&9*[V$L@[[:PVZM.%'\QCSI%:
M8F1ZW92YAF>J'K-_%I@LD5G!"-5K`S;X=QFCE(QF$\_:SBZHFI;279ZB$'0B
MN@QZ7^(PFX.NPNRNU0>N1X-3,,97G2SA#3FE`>M:3D?=D^ZNG-(P<#VGH^.3
MAMK4J^!TTNVMYS2T]9*)^L!LQA_HR&7O6!A[H2;:.N@>Y@"LX]<0L'JB&0RZ
MVP%[#P.2'"K%0M6@G*RC')IE)CMAJ">2D_XF&,R;]^-+K@*AJ/N#%%$`0[,;
MH<.'IXB(^Q%SW@<8GD!$T*"\>GFLVX-YDC;5D_^^VM.@V(^M7J]$\#ORKB>>
MXW[OL";O.[,2-[]S(2@<^L[5OR,>X)`%-MV$&/H%]5O'KR%@]634[VX(#`*U
MLTL("14/%;S/V/P[X=O-*4[?TKCJL&L(5SV!]3;$E=>]1DQJ<'Q4HM8;<ZOK
MXPOQ5!FW>"B\HW,<!QMT'_V3D])!-\]I9S`U;:4PYM8#(\'GON5TQ%V.*_U-
M#FFG13CEO)I`5$]"5N]X"TC[D<[`RF-I&$3=H+&_)8@]BV`[MCLWNC"VL3$#
M(3CWH;`__TS=J'RVO&&K<Z/9$H?=$&P<EU4AN!">)_QF!1`/G:M8[,"_II_L
MU^<_=!R.P2AU[RAW;OP+&O"0NIDZ34CD\.2TFQ=*-=]&8=:<?7=/!T>[P/S`
M0LI]YEQ1Z4/8K\#_1E[D8AK')1MSFS?B65N'ULEQOH^K&3>*LYXX6X?][FXX
MM82GPG685!@)A^5KIYL&<-W#_,B]S&8G%#5G1Z?=HTU09+PX!+Q[DDPQM*UB
MVB#"+</AC1#F1X,[*M_+^Q"53SO&9.=G&TFFNT89O#@2M;M=:]5HM(I_XY#+
M1?M$D,VFWS`*IT+RWYFSL73C7<,,RBYN+Y@_JX`6N38&L$263P/P1JFH*>E5
MH#*L&D%45US-('H?A;AWC4MN3R*H#+_FL#4DLE78,K'+TSO`&LR;!;N+Z]L!
M['Z=7GEPO]:C;(UM4W_7!+8F75W?ZA\/NMW>&E@ESF4K2'5%U>^='$*<=;HC
MI,:=7=_JG?8.>^MZL(93V9.WZ_>.CX^LWO$6X'Y@/I/4A?!PZ'C<UZDG(7]@
M5X\!\U6=#(&JO<!>8<I=P;%A=%6+@H.CDZW1?6"*46E/H?`E>V"NT)L1C4FN
M5U@K6<NN46!5:R@G1UL"B_?W_$G\LDZV1I5^#8X&^9W>(H^=$53IT,GA)@AN
M?%MX[*U0ZEH*[\)L?4+A=.]3O6%C(9DI]Y$^,G7U"%HH)!@OE?.;D'EZ(P=J
M2N&Z4/4&4(.-ER],;"3-UI(X]PCW&8FE:K5FJ8_W+1;<P_L7E9@'V)RM',>;
M1"7$7V_)L7JUN919+BT#Q"`2DS'RVKVIAR4I*,M\EO-0ML)2(83#C:$LOVYL
M5&D=%Q;X5O)J#-%&XJD'I]K\&I!4KU?(C*CFVCS(:L]46/3;"61I,HYZQ\+W
M8_!AP_CT&NXH?Q1I\JU)M]U=X/WC-0W9`=D7:V_5ELK:GFNJP5!C0;@)J[`*
MX5^.P4ZL*W6]5YA%KV9=;05W3+ZABML8M7(W"IFS>LEDK83*%DPP%;[;SDYC
MMP;T9,VJL0X4-^MHO\U:K_E[[;?\TF$#L+Y`,^OU(W1C;W\M3?8P$^:%"OLR
ML@JV#4.L;S"#S2#JD)GQR10>#!]`_A/V+O)&3+X?QPL[Q36=RTC"W^:81(XB
M?]C4,DI7F'J'O5[WZ'00A_.-8?LRS:VQH-;M]JVC_30WW=..NY\Y>'@)0EQM
M9@W,\@I+6N5\FH%2&=K7AH*"UNN59GEWJ)H62CKS7<FE$1SU)L0;8;@6$GBI
MR,4([YHUL1)P>%(FCB5&3:'96"BKD5Q,J3]A-_XUY5)O-[T?QZL+2;9#`S.1
MTT$JGAK\&L963UAU<26F=ZDOS>$-F5/A=%F6^"Y<J_+;:W*]D^*!XS51H$:7
M(AJ%X\A-$J(;6)?/+\NO8]8DJJKDG^U`_4"YCV'?>_^>NJ!#N3,6Z0&+!J:-
M^56>>FSW@[1^@FP#*)=/XNTNRZ/^6EDNLVP>X?8RK$`'$Q')($"X9.;?&W\?
M$K0LJ[CR4LEU'S"KDM67EA]W1:D7G^/L_C7G<#9<$2H$G'78[@-GU7+;TO)B
M/90XVBX7+C]@U8`TCQ:A65VN^X!9N1;7;1+F%D=$&UAO7M."+0`]>?.JHJ5]
MM*_:%\4GSAIPTLM;KNM9-@ZPR@:.>TT#+)Q(:V)#_[0&R`+;?>"LD.5IU1"R
M`F6Y=F=*/;%/&:QSB]O"^C(MK3</;;B5F9T=O-Y#SV,<YKR9?U+,@2$ZV1H>
MVB%_:,I&>B=6<5NI)O/]8:X<?P?681.@H;S-F*/7_4MF.=EC]@VX].(DM2[K
M/4+>Y+SD=GA7],R-O@^W85VNI<@EG/<'N+Y\MT0+DQ_QP.0<G8UD=G@A5"/+
M/*?%+,<2-HT`J2^A:@PK9'C-?>K;#>M:_]CJU5&W$N;[PUR5K'G8/VT"LZZC
M]WB*`V`#<AWTER^Z*F?6'*;*VQ,&VT!*<AKQA/#N@LD%B`O"NW"L;WMK.*8I
MGGMH9H[VCGPW:>QJON]H&$D8_#9,8WO]K1N>!T2%<[Q[W*-RPOTST@U"^/_Q
MG(RAVAFQ\/>0>V#J/IL1&&BI?V`>'!`%^C8^?_'M)#Q'6B/\P6I_2[W@_+^L
MH^YYV4_OY83Z_'>-$RMU1DGU3H`__?4OC<):(%C%`673HBZ?`)??(AC7QO-S
MLB/;E1>+DN_@.3&H3GJ][GE\36;ZQ#HG0F8+E)#*%'YY`,BDQZ0[)T/]K0QR
MIS^68;,(ZH`F&;X'A"M"R8B+D-E3'PGASI?F#13L*/X,"*)S%D<&B!@3E0*X
M?#=LC?0'0W`)B0::!9#U'<)]7SSH<QG$X0J]3LO##X;,\4B-QQP.GAN$!EBU
MF$2D"'==>*28:@-"S9B"N\IS'.DFSP_TZUA4V!(.1L.I"XV.P2(;2@(IG,B&
M&!,W_AV\3S,4),1/YI`@<CV!>=[`!=P&5";3.8:*S->?+_GN;OCCRS;YF.$#
MPA/`"4HX"@FQQP";BAV/_[)'KH,@$*/KTI%(3(^;QBPU0C=/MY7&]S0<D)+.
M)5.J0$:8V>`2VX660B^V5$@G#-LWD=0#-%-H$B8?C1@B&$<^C)0'J#D!-,](
M)GDXFI,)[D*")MB@&EQG*$+1A1F:+K2%#+`13-/PF4PZ!C4'>V:F>R@C<<UP
M2A_2&D8S"@ITL-PM:M$ODKDT4$"L)9G'0RU0#W>9`P"I;)=)H0#`=[?WH.JV
MF&#'HY+-%;3/7`0,`K^]!SO@([#'.74GG.H&46\N0I@/3$&\>&D#"C1#<?CV
M_F7[2;W":F=D^B1F/>-..$6JW?\^)Z!7#I,MK6.!8F<D^6D3YL1FKJL":NL/
M3'7-[P&JH?D]`T0F*![P6Q.H>K$00A&<9PLZ2<$8X4B$H?#.R,BE]F=B`2@E
M7.Z<DZPD;89C]CF)F]@;0`MC'"V).3T@V_9)$)K&M6;,/!L)URD,,[?H4Z!#
M;WS\MV0P"9TRL.O`K,)2UG?EU+^,*.YB\[I(S.N/+8G!R=:2P#//D5K3_$XH
M=]+U,MBK)05#RH8=L*/4-R-YOW)@GS]GV'<PSXZ'Q2_<OWMHW%>27]IH/Y0$
M)+?W3R.ZBC@DH9X+0Y#TM@')1XF/0EHK"FJ<^W<"(S+@#_,!]V41PW-5U*'K
MPMN0,TP28SX>%64X_\%YEV+DYB8-VB'"A4C<C$Z2D`[6=H324Q4(3V$ZPD.!
MJ<D$(W4YH\MN]ZL_^P\D^;2=>K%BSI13RZ\.[JN#2^,KX]QBWZ8G\8E_RKJY
MG/[D7=Y7-_9G(/FTG7J=6=UYS@*[&H^Y])XUQ+MTL4Y_ROF6.90,WWPUVAHD
MC4<?NU'`\70W>_F<P3X;V_UC].T?GN33=NKP[1/%C%O"NWJ'&='/&6(2275N
MEB:-))`LH'%BX-?9X28>>D(AWA:2A5`49SV_<]\FU&9X'>9_A+ONZ,TB_#V3
M,[.4`9!+$'@3*=Q^59=,V9('6&#HZ[/0"E/FF`)PNMI'0/S&775!_=,D$/0J
M$@@T;-PFS@+7@OG2F00-2.!)Z9;N<8ZH_7DB!3@=W'04\HS,ICQD.V]^XLXZ
MM>.4`[/H12.'QQ<[Z&TAO+!6;[C#K)V,3;X7[MFBZ7IZO4UO-H\8\V,':5;>
MD*QTH#0S$2TU2?[())!@_KB7K,C$7"3ISO$]"PPOO5_]R=<P](VY6K.&'D"P
MS2XR%I`1$L#?))O@!P#TICD47*Y]S^Q(FM0X+'_U:.MCP9A4X'&E4PTP"6*Y
ME=S'1`[C\;&F;@G2QR\<R\@V/$-!KJ$8P0^6ZF)#]/4N@P>(YT,*C]RW?MEP
M=WM?/;]M#L[>\#P+%&@/*WI?J]8ELQE>:T'ZU@'!%#6=P@.1``QJ#AD#79,S
M$]M0J;D$QD,N-+V0;60=GRLR]/T(JID;JS`'*%&PGSI#K:M8<<ZH)`P32I:!
MF:R9;<Q9347D.F#08%=4@X2ZOR5KE*D%;(KZ`+O(-I\XI1RMIDI0.J]'Z,24
M*<R,0P$])B8,?UG`N*4^G>@*.21X="(REJT-TJ?N'$:H@WJR>Q[*^-5$RU!<
M0"`-^I,S3NC3L1`A*@MFNMFNP`^;`R$L@8,+UT=JC,FM,LK]CUR+@3)GC8!>
MX*8FYH4%D501]4.=BU4UR&T]K,GD(KPV&>K&PH^N2>B;$T>@U24B(]#$>,3+
M#X6)P+&[;`AC,8L/N5&=P2C9%'/X,`LM$Q`B\`4*??A59]Q!D<@-=;M$&BSK
M1#8;OXH\=L4,\]Y"=+9>:O!_APH!3-"0PE3,,#OO($["`\P>C3,*J8,Z:;KY
M.Q1\G"$(S(Q^`'O\W*/>`ER4?9GI+H^"((S[PF2[8H/'E,LRM<JUW3CDI"^2
M%B?N*-!)XK%#NL5KHA-OU#LP/*%+$KY<:[1)L0*(T)`BN7$$$D`7]]65->#*
M&@@JDO35)(_4)RH:*>YPZ$TL?L<#]H@:DF;P)JG)F:SCY4+YI..K\9C96B5*
MTXUSM*[N;O*5[T&^#_2QI&C\)E_\XG*`Z;'*Y@P<91D'*%&`%_`0S+L..%,R
M7_U'1MUPZL&<N:3&XF6VDG94=U'H@UN[E-$$ND$&!9GJM]E*X!.U)RI:(4@L
M"R)+&PUT-A4X&(B9#Q:LWY5T:2ID%)_VV;%,D()'?Q/@SN<M32-CN8LEA<W7
M#/(7F(%>\S%(W0^'Z:!V!P,1]*)Z#LL,_8IEAOO(\]#O0O=DVD(6C2%):Y[%
MVL->\I436>$/7"]9+H(2D,M%&EHD*S`\E<)Z>3QM=O5>V6(^D!YJ6\EQBE!2
M7U%[D5E/DSNE%L,\<SE8=CQ#RL1H.'K_&:2VK%J?E`XOKH`^QE/JSZI/.(1G
M5_]!)KD0OG1.870(HV:\T6Z[J43[OCUL0WCW[XCCA&81_.($P:.?&6:RF+XQ
M6JU4Y`7QLI0.A75,8.82.NK'T<DSFI\^B+E5-RDQG'2]4,\`VN0^@J%R-1(.
MY>WP`!ECX(TS>&6.#XUAT!0SH'1FU@,T,HS?A:U10"LG0C@S[KJF0L+$(9%B
M$.82%^(=$_@&\3%S<Q`H.6-^8,+S!_UI7.BWF;G^SX!4^KNO(H:I3^1@T\V!
MJ`=NHTN5>D*3W#RI)RN!";-PRK1H=#PI`Q2CY!9#9!$(O>E!<4:"25\XIS+J
M@VJ`/>DN;H(X2%<W$6\\V4()Z=DHXG+BS[21D#ZBC/&:(B?29ZKBNR*25$;V
MB#"Q.1'N0R0S*W@+TV,\X?5G,-Q;^AE;O.BE%:;$'IFT.7@[E0DK?HN<"19(
MIIY@3BZC"L]'425\.@*+A4FLXGA.2%M;5D,3A6#&`N$WG!K[R2DSF/M&Z>H%
M=*-6"B[MR,,K<FT6VZ\^T(8V:X@[&<*5YIHLN66:JN>_#HM7.M`WZ44%$!''
MS-D$NJV7`./EA-@[^+AB!D.JE^B;\/'$&O&$9(F.H;_CX.]0Y`\(H;#``%X@
MTA-N,UTU;!P.$I+)ZJE0&9_V)74TS:-;'A;3^R@SU]CI9<:<J28W2B;AZ9]V
M]$S%)1?BFH$.9D8D;5,N_UV_T[[Z`&@:JTF$:KR\DT@U">`2+=<4%\.#63-#
MW5L,</$JBQD,]2>CX5_04]#G&55I\?R)TR+)!\YF\9E*//8'MIVX>P#+<ZU4
MQ!S@02].?'TAMEX"`S,0.`+RY*:?`KJY:8Q87)?=)C^"'Q!29R/$;).5N(#.
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MO,B21Y*[T_OK#P!)B9(EM]66;=G65FW&;4LD"`(@`.+E!L>\P=N4*`U8/EPT
M-%9&$5)=,9>^0,+VER%LPWV`SFBOY<]FY)<PP9_`R8$;DL5$P80'-E\R\NZ@
MHG<%N*]*\N">4#;`^9KKWU+B`*DM3`3S+2<=6(NLV&*0AKL_0=\]G[YA+^U7
M*$+#I4/W#AP+U2!EXA$"(Z#6?Z.%(\A2@.!E]Y44-5+71Q4/57V7:X$&`A@T
MFX!N'/UK6+,R`5[VU(N.9!U\67'$!%#BS^%Y&&PF?LCKG2E'O4F@QLBEBO^R
M_RHKD41HZI5H/@7H!<SQ@F71!=3S+]1H!4`3H58&)X*TUV#NY0(4*[R+T-^1
M6DFX\_S$#)G0+5(&[>H="1K*B@*`?E'7#M%MP#GF4$6W8>Y=!JU=WIL7W2'[
M'JP^Q#H$<RFCDO/9C8\3_;4!S6\K/U*%!'4?!5B1A3.F1DT]\SB9E5Y"F\6L
M?`6O_(&7C_VX2(AMOV5F_3YFU('!*\'"DY+&I\&2<Z"=$0PG+@YBO/X&C(7-
M\Y2HS"K0)XZ&;P4<XA)6R,R_";CRS,R=!QU:D93JX*XV!$-TT#AX(^ZU`HY5
M2$C37BY:4CK,.$X>RPA#":1C?G(K8`MT\1DJ9S)!I2V1.>J2VG]P7'1DM!GU
MO,@JB'CI!1HMW5&ASB_"[RBSZ6899+7*=S<'5?H'B;BI*:"6"RK/2>):N>1(
M)..%5(06O-3FZ-(<V8KL48:N&_@Q,0EB%+;9/U#DF9HI7=89$!L.%@-HXV0(
M95APYKRQ8IBE'-6+04U,*_[Q8,H(4*M)#2VWG`A%(0H]7GB1#Z+$38WB+.`G
MV+4V^SL!1)(M>6_.X6R;/@J7L884`28640[DL<5#]@5519G2W+*R49!05>1'
M,A.O<+"VYOP4#40,-V?A"SR9/#FV0+:8"Y-FI2N1;OF]EN%N,XA<'FET0L-9
MDD\`<$A60@,B,L]JC7DG3%FCR(;LFE-#503I',2<%N[2`11+$$E"(IBV4-P\
M*%T+ME.*/]QH731+*$&1^-$-<LD)Z%'.LRAPT#,.FEDHU1W:B7C^">P@!<&A
M?Y:*6DDE3CD"8H-LG?;&OOGDLK-RR"I*")`4.9HX45[.8N\_>Z!=/;`AJ5:=
M-)8H-E\&*TJ.ECEQ6E['&IM9V$INS'R.SEQR)^FC064`LI5<,1K&K%)EJ)08
M"*`=IG(D/2=(!$6&65]&O*/)V:JU:`#C>;<]P./-I102/,'X#SY9F@=8>I7H
MB@+2TD.87BJ4'0J(1)![A,@V^Y*)(RO6(XPC4*4>3G[C`/Y_^>%"@(!.+W"!
M)13MP0L-;6I!&LJ7SWNC@=7I=%ZI>"P$V^-1E'%7Q'IZC#82`2KW,>V%0_<[
MEG[#PSURE7]*^9/P;B7']@%T9Y`]$ZZ*_((%_O'A,A$'>-'&?OD@8VLS-+)"
M(D1FS^U.>G!@A>^<7.ET^MXYKEQ!AFQI%0M91S5,;@V,=9I+5)@A7Z@A&F=L
M1%N`7\>",0NV!$/=9]&!B\7=-"FF%D1>(7CR6KG0T*D8T7V!ZXAY:%Y'TN+_
MZ@"P[;1%FEEG>HEJ3QE>Y,FK01E9J.X-3!Z>4#U@#7,N-S^V0:OT+Z6\(MH\
M9BC#!)CI(L][N4E`<B#3W9GR5NM%)?N5(R+"?$-:OIE#S82XZ[0S[C%;76D7
M`5<1A`FV\=(T(,>?=$<(>B]M')S%`928FHD!?O;6)GJTYC+,U%"D-+6E;L<#
M=)&@Y"@PQR)9DUS?+K39.^7)SXRB[BY(`IE:']UMI&Y*9(W!0%ZXR3\$F#(K
MCG9]N!3>(]&M(P4O`E]%]Q@`I`,C\+I!J7GIF`/BK$6D=%4RJB6$9\$L)HG,
MX1A'9P.B21U!R64`!2.HF`F>*&HQQO$\,:]U%JB)$R7(LK6@/-,XDUAF&G=;
ML@*JUL;EY9DP9D_+:M?WOTNC49=OC6_?\+$Y'#:I.W^,$)&71RI#17:S-8'7
MU&)8F?%EC*(8]76:KHUU@64H@&H,%P"8NP&SN\KS:,D@F7N,2/CN^?>>-A0Q
MIAOM"P65<94DIY0JA[$3SG>`]-Y)+6;ZZ#!ZST(-F;3'Y?XH]Y+0W*JM]?1Y
M*F_Z;P+L:2_I`Z@BMJ&46XF>R5(/SLT=9"WI!*@;:U7(1=)BE9+%)'&2+PDH
MO12))G2D=*R`%+1"3[L3JDN3\$U-4)E767=<J\*ZLD9J?H;^4\JH4I'4$,Y1
MN82W>553<;$`MH?]T"G325TE$?;RD]EUXKJ&Q8Z'?F2NG/TYU`S[0B=R18/*
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MKS%L9^)[_EQ,V`0>%[)!UL2ACF6.#L2`18-QQ\E'JU,,*7Y<W94"/ES_G@?`
MH'?<5<$=?RX%//%`+G_JE!C?/@8ZS6[*9\[2E;?]UX[W/5@NHLF#I;+>HH#/
M.;OS,:])AF9X:EJ+L@)57IX,SA74P4_#0RN4?2#ES;*,J\-8#0I+I1`CYB\#
M2M0,R:4Y<=0-X?527>Y26B8\ARYC#).3WE1\2P<'HW\7_KSCWM0/U%;28`Y&
M,\,R72HMPB>8;$8I'J[CZ=N[>%N<N.=F[5RD^Q$HV%V3T$,?L*OPG>/R,TZT
MBA%"97-X@I"XFL]$/W$+K$D4C?R&-;^"J$7)?8+Z".M+Y^B6^8$`F"A_-=+E
MANAVSPB4]I&'P_P[[<NHV#6=SJ5-QTA-*3X]LY`FHV0-<+^J3.G#@W88\M?K
ME_%&/EUF@:'S+RRL1=4;\1J,ASK%&]/#1"!OO<P,>5D'4T3R6((WL:B=^Z#N
M)N,23OI*3,R8.H55SJO,28DK--$%I9H`+_XH;SY.1[\Q89808=S@9186E<67
M)'&'_"8.@Y,WEIC:@"5V"RH8T@AW<)3'Z:HRFDQGW\69C=</1L9P.@H+N1+#
M4M+`66O2&;!FGX(OM50G1)6&U^]V;R<)L%?OV1]^F_4&G20!W6'1O=\":ES$
MX=H4K00$FJ`J0Z?QU6AZ`^0FS42`E]DX(`X29E^&?86)7**_I":"[C%';Z`*
MDCMVB/K>E`:WD.)57F)<"<UB<]#5J.@>%8LK.ZN*RY_HD@9(GD9=!#J)M!J8
M`>\21E?=)G7428P^`PXYE<)^G-IO1I:H+%)CK/14&"M%5*M#Z`I@Q7("JWN4
M?3F&L?!Q;YHDCIFK2]>S*"2'E7>-]V3=NHR(B>T.73H/91X5+Y!"098#T.IX
MN*;TR'DP=91;#I:*OG@\OUHJQE,"%<@.S.MRP,*B1#7+S-2-XYU2HM6L\1`?
M*+&2L.M<M43Y.`LJ6-7"_N`1^^@$:/6&[.5O?AA27BJ[NG4"?JZJ&2*%QTAQ
M8Z2$B!2=>+M4@F8*9BU)9"_G+;0SD`=4&1QZEIJ!9TIIJM`D><&,7@D5ZY24
M8<#08N!1`B%,%UOX(%P"YFD@*Z?"8P!O`6&F<D128L9\(VTW)37T!`6&I4*2
M=1D.`A_!?D(^K$6QSPJ`9&H-_;T^73"1JC5%!(/9]Y91CMWD5@4J"YEP)2MM
M<87B)/=BJO:%0(PW0YYW"=IT/2>IXZIR3S%Y+`%Z)^0FMK`*E$Y5H"HB/U2Y
MX+BBMP%(J`/O8R!22-\<<315SQKW>U9_.)!XM/IVW[KH=K.FL:RXN]G(MARY
M:W5'/:LS4CMD#09]:SCHI$<^4QG]%=070AFBYH.1?/`>DP_.54BGJM[(:B0A
M%42)4;6:I^&0;XE*,&"V9L&S\6BJ_K(189YD]*DD9`!NB3&Z2ZK(3+-8&".J
M*N42LRKSP2S,IKS;KDXE#5$+<_7[E%A)R4NR4!K6GXJKP*%@!9D<UX%(PBJ1
MY8RJ`\:2+)#K-^@'-_"$<;%HY:#00"\!)0@NJ7&0JDP''T*=[T4S4VD)8PQ5
MC$MEK4PY6@Q6>EX=4D_>;N\6`T&U35&4W+)0S>@GNAG]X33TNDB`*R*C=T1&
M7U3JS&62KWNV,N!7G4,KCW-T']&!9[*=3DHRC6>SDJ(LI(AEF-3A2V=.%`BR
M).63-]DBC.@#X5@K``>@1DPRJ5?Y%70%/*RT;MB_*@H?)IJ&!LG+X66UO.AA
M@68+B!J=0?\.XR);5Y-;7Y=OP>_G_I3C-4XJ?SW._$BT"SF9U!800.3ZN;RS
MB4LN`O^B%[W-K@JEE1Q%9=M%/B5?\?G"]1^XRE!93;))5V,"L2I(?JPZ!8RJ
M-L;K?N&CJYNK:FAAS@15W?<#V0]$&)G0E"5&NI>28%DAF$<TZ46`N5QXP.A!
M`6Q]H4A^ABFF?0`YR>KW^JF\&J9))?Y,9X$IAY>(;M5&>XZLD9E!G3H)ZN>E
MW(%&I%P3ROU53@`>IZS[YNL"O:DLES@-#%4%U&R`?JA=3`9#JTG]08Q$RD$+
MY16W6=XU*4VD*K32N9\MDZ)K2SWB?<&$FGPOD;[(#K*[JN_59&D\3?WY.H/A
M9E+V87*Q8!0RS6W>D>G=D6QK4LM^LV+TJ?KU'T2X\`$QOP;^<A%^TH>/Z;M*
M7%<?XD8P3ZALG\I0D636BOS%FY)DIB@TCH3'MY^4GY)+_D_J*9D*V.VTNP/A
M961"OYWA^,<CK#1(Z8&J]2GFP[-9O!;!*CQT\+]AK4X;%YV5'O*_\J?=B*^#
M`["+ZAUX<H]UCPQ3(,(Q/-6%^P2%(&`]CY!J]JR[+_SMM_?L)0YD=.F`WU-]
M/4#R_9<31&":T?/H'Y%E$V01K,"G_%WE8#->)LF&`A]5N7O0*2B7-,]AK\6O
M&L"*E8ND&$B<9H].]Y?BE;KYFO,IBO+,=4\>(*9#S\FID;M<H*_'7]Y(D'3M
M9Y1J\(K%%NX2)X:9GX\Z'2RX@5H6O9KM(Q77/Y"WCG2<R71_F#:@-$\?>T8A
M`U(;K6MX0CH:U:Z!NCEHCUZ0PPNOQ.=X)[A412.,^HSJ4BQ9LO+.X:"DOL&C
M2X],\63L@,H=X7$D"4HZLOK%:M=Q*AR?5FL1X=7P-Q\L%%CP``X@D^ICY>Q+
MIH?6+_$Y?!47^XXIJULD=Q.-CAG,Q%XB"'+R5VD.-BH>Q6VU9!"?H`M"4B9D
M@RRN:N\DZH_:_3576:KR1)BO05@YG<*2V"92*XANM*\XI:?@]:;KQB$:<<M%
ME1Z=(M%"Z`*>O&A.LXQ+JDT<:>\:>W89CUTPKHEZ78/.[*CPWC1@WCDND<K5
M+:>;YFPHE:4<F"O7D+(0DO2UK11.C>GJ)0$`2AX\GB(/_<"K-QDSH+YGVP$`
M..XT9AD/CY_?,(Q@%9-MHO9/)[DUS6$'7?+I('5%1!U@U05Y4N5Y)INL^YC(
M?[-FL=7DR9"_-(=]L]NPXZ2H$UC,OI/I<HE=?XF/O&$7B\1@'Q;F&'\IZ'[D
M\:@LKU62=UQ&LFR61/R\HMD4?>GI!D7SM3:DUS4;60DFFSVR1T7S=7L'W:3]
MIK%GH>^V!P72(G<=WZC>LC1^2I";FJ5B*J-1J6.(R_,(K1KJ*IZEZ)#9GO&W
MQE>S`5MR]1,15L*5?'07?A3#3\USJ99CP<4HNA@=\IZL\<^7BPS,1*91X<:X
M'EF!)V(CKT-5A3\+,[I.S-`_5Z-^F#;JC]GN;'PU34VWIJ9;)37=BNUH\Z3C
MJGSP&KQ47J-K>SMKC1TU+!K/M@>5PE>FY-RQXZY74EVMJ;UY:+=?E76#UAD7
M>P>L'E#4##VU*%KV.<ZF?R^3&<!@^:B"\G;OM#^Q'6W04T-7X6,^P5\+`ZM/
M9G^[HX;L\[26<@I?W>7[IO=HN>M`Z<_\6;(<,^E+)P-L:QSM\EIF/W.M(R?;
M'I:BIXI1UNS`V^Y@G?V^HQTX[`58*2:7UU])`:5)K/+I/(R&OM9R>+^"N]:&
MP[?A\/$!9&PM#+5/J8H:E%M8%%Y[*OK9R^YX>XA>G0PZ>KO5XAO'VM$8T@UZ
MZB^O/U->NI3:C2.M(?!C$=45Z5#QIU^Q*JQ*LGX\H;O1?M>1UW!43@5H[(^J
M=Z""@.AZG6:-9&X.KG,YN-8%Q?Z1%*U\HFW=Q"P/^Q=;B<<F;'SK+2CI(]A%
MV'AS1-5;!C?H>4H*1%*T:=L*3*ER3E?+Q<*E-`3'594.J-!!\EY2!ZHIW;1)
MZ:9!5:6;KK@K*QFF*E"P3TD_D343U:6'WC&UR[O,J?^C"GB@#I8MX;%2"22_
M$,@V"3;[370Z[A2;7%SMV-=P%%D%33&-\RJFL8-KAIB?'DW=R)&A:S!S7-D'
MA54*1KUR00%GF+E16#U@>+%.)!U-YL8VOM=W#A9=OJ;B;OX]J7JMN$_IMG+E
MM-WA+[L7NXK'61>WT6`>8V-V=1>TBOD#G'1E/%,YAU[9HC_GYRGL]SN-L_;`
M6]`IEX"PUR(?N^AW\KB_8A<6=ZHLV$==%JR4:Z&@R&B1;R%Q+;S9F6?F1-T(
MC<=`>0P2B+!D1_Q'XT.HW(>0PG3C3$C8[O=4&[*XH.+)&,6%#H5^IYQNU#@4
M#H*[?3D4UKNSW\L>J('L9C>;8?N\37CEN&Y?[4&YV(YSN97>-5YJ8'H7>PJ,
M0D&;4'SCMGEKEW15-Q&\)[$#]3BI'K')<SY1PO#)R.KAQ6X+/C1X.?095I9E
M?\/&],YDLIPO9=?D*4]:L#9R=.T%1*_DS6%S]5,9YD?[P_S>3ZXR3NYJ&CZ<
MW\5#KW.0ZN+-%AA;4.<"[[6/2_U@'--Q^^MR5=GI_@;;5C[ORKZ1^.7S,7VF
MCK[8QUS<<?<AOW5OB<#MG\WNO>K7S[/W1B_TKYS4#RK!>'7K!/P=-@S_HOJ%
MGWT$N([W-H.]RSH8<X/%AY4%BU.;=]HU9F[LFN'KPHJ[N'+](*\,NIT.L-P7
ML>`_L.MDX"SX$G8\:=0YPEM))YC*SF'`TI$?R()4(2+TUG=!WL(74W\1J8::
M."8C=&-Q!>QX>\?9%V#`E8ZYQI/X>_R+_?85-L$4(5O@:R@#G#!<SF4?5PFM
M:DOY&0#""U\8:LCF/+B!S]2S%'A]-A/<G;;99=)&4W6GQ<_R86HF&G!VC__8
M5G]\8?4&/>8O9*\)`=-BFW1T'!N-<)/NFK0$A%)V[8RH?I>WI$MHF"A$44'3
M$[HD:$IT8=M;T,E`[,G?])PQ<IFS,(0HG54A[/L#N^;L)G"HY2>,@5U0?8\S
M/E^X_@./%Z@[I&*?418NKT,Q%4[PP*9RZ]5KLLVN:BJ?LRY<@NMB:UP0XQ,.
M4W8')((!K_"]<P_$$:ZT\LWLK!I$=FK%/5@N5,$!_95J&HM?R:5Q@P1#M3:*
M"J"^J1XV4G5"']!^*2$0E.;#-1;I@(@"0?DA<A>L8JQ:B`#*&L'80K5INH]K
MZYJ$AEIIEH;E]%G27<4`'@R.@.V=@$S%B@NP2-&:"G=)<"P"_TZ$DN8D9OB=
M:GWB*+C#A2LBO8BIN!-3CF0)=$:%3";.0E#OI"G*"*EF8U];/J/FN&K4A%2S
M`!($4QY*!"/US$44)>3TCL0`["_MCT8'(@F^B[OP2M!_\&`BJ&&SF'`+CI&0
MJMGA,Q9J`T)UIR9^U`V7Y3)D$VC5&G8JXF;LU(.6YK347JN.U-S5O:[54WHV
M1)TGW\%X$:09E(-:'F3C1U)RH#,<`HV/2LJ!!)O[:`I]F(,C[J<.2AFN>I1J
MQYQBVKR#8X%DI@Z*O'=PQ(T/CU'!X1$KFKAMQ-(`!#8J]UG7&J@NY(EHG@"I
M`_E(QH)G3/&J6IN+&):4K+:P/_F?2T`QM9/._+9&W,3LBS;QG>,BJ^O?3,&%
M(ZQ^`W0G5%E(R33T;5I.P3KD56<`0\JG]`%!\YM'.09:+5T@ZJ3AM#X\=/OK
M^/P0/%PYF_6FPN&<T@I@P7_`#W08=B6U2-F3%A#)\:C9+<57YB[#CIH=OV%"
MV?(^T>=H-W,$%_SQ02]:!HNIDY3C_A&Z`MAV[D0TLR/%Y<P1`7+,=QXQV*9E
M]G!-T6Z*CM3Y1A(./\BE(?R*MLY08?BL`+[F5,9!40$90D`F`6`8!EV&<4MT
MJO-@ZFVT"+E[-[(HN/L@SQ/4)#R&H`$^9I$"2AY5^/9ZJ>](H0]?]R[ZI83^
M:,]"?\^B/LV^=D<*^_(6@=TI$.HI@1X_54*@]\@=T`CT;05Z.:&<VJF3$LH[
ME5$A*O5D(VTMK$9]T%"'I815:M-.35A]REI-7LP>*7HP#,Z4Y@HG+9Q:$S`J
M\5#&1!7_QA/_RM!QVI,)5H6>@U@H0`$%$@2-+AX$?)I^&<<,T-E)UJ\`EA=`
MY,FVHV$31MR96@F9I^C;E`H+Z7K$"6-8IPPL(2#5!TFJ\A6Z-=4VD:3:4]O[
M;\8VWDJ%U$7Q;6#0D1E(B`.R;V&O\["I9&V(QP.=$<1=4CZF]X,[P)I*?L"`
M\![MHSYG8%L0Y7/"OBEVM(1@RY!,8I2%>$O1NIK`T8GG%XW90B&,#\S]*7<E
M`.GGR".F17.86/@;N=73+4[WD0/19$.<8)A^3[%?H(4L0O0[$6#R]T>D1./G
MU=R)#:^TFWUY'("#9Y_L>'&KF1\5$,OF`7H?4SKRSN/+BA`D[\'MMMV//6*V
M_98][[;[ZW*.]P-4U\X"U5TER3IFTV!7/;+)M#&WKIADY<D@&JUZX''1R)T7
MQP)6/8)JXVV]\UU0Q%T1K2MBO0<>L3OC%RD6L4?]=7NZ#Y#&@PQ(X_$6^UD=
MT^9"^U6$W\'PYJBBPYI`T4;#9VUOI#W@L-/NC3)(;%_D8'&O0'7;8SL-5*\]
MV&9K]\.JKIC%5[F'9E;IJ#DL%`/E+3(W<E0`6%VX--Y,,+AG7$08<75@#CTP
M,SYV1)Y8C)'IEI&^KS#E=$DYQ^17<5R(X;="]\Q*=$0@X_&8<P/'`,7@6?JN
MC)QA.B!`.^QBWUL\?N"@>0&2QN,XN0@3IQGZ"+7/;64BZ8N)'6H)9.J.`B9+
M@&*WSAV/?<8JMF&O?I<-O"UVIU;NEL>"#'LODF#;0)J(G?;X*9G<FXQT,1Q=
ME(T\U,KR17_M!&(^YU.!3D%%34_VA!2B;$L\[00YQ8/B[?*MX\YB[HHQY,J+
M*\F0<T?0K8;B5]0#2YV$)XH]<OPFOO\8+>=.57\NG0`D;X.9E4$=SUO2]62#
MF%5!%-V*8,I69#3)(2F#Y%\I%-[[1XW`LMKNAJ@D1^YM#BZ5QJ:1&4=NG@(N
MJS\5R^'/0\567@:^1:)ML,C425"$R$2[2(@PD8GMVMINU:2";)28E0Z9T)?=
MMM53,5@Z&B7RD^"DE8@DL(E(=&9NU"F,]`==F8,\?=YC<^&Z.:9AWG4Y2U^7
M)TACQNI"9\YUX"+,A[=)^>OI=?O6H-/-7\UFT/=[%)CV%-CW;A-6-<,E"Y?S
M.4:,9F+'F(.)>F"34]A"7F03DHB.\:/X4DE\*_4<+0RL:`SH]1*[N1=?7U;P
M\Z-^Y0,6:90C/950JT5L"5BR./X'H058&"&Y#AA[31("2-6YX>DOC4@1?;N>
M^OW+(U?M>T7EV>R;WJJOL4*4VA3,;0ZP\J3CIG_X3<R:S=K39EW>W`3\!O78
MU!9\@JT17B@FZ:__!U65PV+K<%$?_<*X!=T\S+Q:R^H=ZPIF'J@JZ%/K2\4J
M2]'`76O0N[`Z%^MJ[#8%5M=AT&[W]M:RY>#(VQD='A+>!I>G4?GW5VG0KUGT
M<=4!'`Q&5J=33K@\':KCPHW=[I:K&WHNB-D[8/6`HF;HJ4]4EK2Q3T<HONSV
MK%ZO7+&VW('65;4\+I1TVH-RO<<:9F_04T-9N*N2I<7U57^1L:J<"BO)K.UU
MDK(I=OOVY47/&@VV:U775!I^(O)!T)?K;E'O=@4[AS<'K\>VA&.#]VA17A>-
M?1,']3IG[7&I(%WK8G1AK7>YGZ^"9K=[_08Q=0"L'E#4##V-UW<G3*_#ZQK2
MSLUP[35-@VH!6#V@J!EZZJ)%GJ+?%XNU]QO';\H?4+)K2</M#7IJ*`P;QV_]
M?8\O[?[0ZI:,1F@\OY5Y?L>[\KDW;LAZ+N'8X#U:E->@I?>Z[G%Y#N%,H5?S
M)Z,<=`GBJE'#OUU,M[;SGS7N]ZS^L)Q;H6G!6/E&V.W1=K>;I[P'^^:*4=L>
M/UH*[;RW9$]LT;6ZO?+^X%WT)ZW8A&NL[<89T:"G0<\QH.>T;`2CS<UQ'KW[
MUH:Z5@_#SKL'.8./8D?V9B,,M_-`GO(>[)LK!NU1K[$1:L$6UMCNU\)&V$-A
MK#0D.R@']"WN%1>FNJMAV2*S0UQ!<:,-FRWE'OK[K/KTX[%WCKSXT5-*=&SF
M4$XJ<]BR)Q).?(T?=+&A&*>?#7=L&M'7^L7M_?]Z]I(S[`-!%T40KF#J8T8I
MS8>^XOX_A07<L\57=FPZ56/;G.EJ=!6C8UQ+"OYX5%6.J3XH;@BF+FLI1S"'
M$I=?'>_&:!+HSXX1U:?-!+N4,7O@@;A277TPVM!'39:RGCXJD(E5U"Y=0;B.
MV4[P\.1:F+6(.-H)DBJJYGI:2&DHIV`VHVYI,O%3:Y;6:,,;+FBX8!=<L+]K
MSAV52,SVKRWL_ON\T^Y<L!9[WB];/.F<2TX6HA.+PF`09;F:?,>,RB>6D2W$
MH-T>EHM^K"?RL@S8*QIYU.Y>/'IY>*1L4C@PQO)A'$%3;?FI&+3;_7(E,>J)
MO(W99-`>#[?M_+ME>MW.LT7*W2T15<&I/<;3^Z+=V2YN_WA5OKJDIHTOK(N+
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M6*#C?=@DN>YDKIC1DYVVW95DWCZQ3<U']\>%B/P%9[=.R`9I?&=1G=F.C3'?
MZ=@;H7[8[@XTZA,4Q9^^I:B(B$%3XS2FU[$%UAA0H>-Y,+3[P'PPSI@:UB(P
M;IT[#K#,'!&P.\==2C!A[>C^!MS<`R:F'`3A7'@P]C+$H8&$V3L4GZVKR:WO
M`J[G_I2[<N'XHTR^(52%X7(NH7R#Q,XG!**X$U,.TS\([DZ)TEZ\37Z^\UTG
M$JZ('B3A=UY8<%B%W]DLX)P)E,NXK,")"-QNNS]Z(9'J)8-H1-J=%0K^Z?4R
M;-TXSN+-!Q%.7#]<!OSS[+T_7W`O=!#8KQP@X-/W?AB%5[=.P-\Y(9]^<1[F
M<"J$WX`@W[G^Y/O/__'O__93^."]N8K@KR]+H"9X[A].@%N1/$8;#']\Y;._
M/'LO/_^S]_O'?_;L%I!@"XGOV<]T6IG)/Y+$6T"1;TJ2N.*.^*RCM*.G9/[D
MLE[6P@<`-S7OU<4-"*"!\#('S:B=.4(>5STT2.F!:#.8W@VFMV/-Z`5>CJ>M
M_DFN"4+/T[P::204O[T?Q62?0AS.62G![8&6X"A]D)$=[X&1`@>2``2&#S(.
MF#!<NA%)I1L0),C*,&&`XD]XCC<1('XG_GR^]&!_I6!=!#Z(U;FEGEO`W#[)
MJ^B>NR`YYP#O;0BS.A&[YC<@?WR/_<*O@R7H1GA&$%ATND\,\4+#A4N`/)X`
M`5<0`K$R`7,[`H\)F@)D]PQ$'\JX>^&Z,!<\$2[Y5`(%P\VIQ^"]I/74<81S
M==5I%J(L"Y4:HA$E:6;<M4=O"4R8$78->>@:I1XNR9G<"GXG408O3X`'X.QB
M<P'"/_(]#DK/WQ?P')QGD9!+5'/$"QR8&E`>T"$=5J@+?<M_`)&275AZ3WPI
MZN&<\.<TS12/"/R0[#B>:##*9(F'!`VQ<E+S/_$D!J*1"U"']T88@P_QO/".
MG`C0(1>5/F;Q0;TT9P&(^B'F>.JPYT.;<$7;#>#.N8-'5/'QBT-*K--!+"<S
MCEYX$=Z^?DBQ!R;*PA/`@V#<()=DCFZ2$,7YL_6W8$JEV(X&A\RPK<B?GFNK
M?DP1]YI#I=*@GD?C3I^S/+TV[U.W7;)20]F%[#<D1!'<N#`LYF-63=X@UJLP
M0*ZFL5Z#HH'+[?1C8+XX^(76^AU.+)V=\^6^FC[;G?'V$&VQ;Y7P:'YN5+X)
M>C([URE[EW.4+*?]`DKS.IG=ZSZAVV^]#\KU^PBJ^XR+"/3B=6L^KCVL0,UY
MA/T*[?Z=E,,YC&_WL\<^\`F?7_-`F^#VTSP#B5_`F=Z)T`>;'N:Y`S4Z?,0E
ML,;D3T;8V.9/.16TJP,MP]@)4&3XVYVG&/[2@"PPNY=DZ,/$9)MGL3`3@(,\
M*QQ^(VB9$^W4Y*9)RIG;786D,[&W&[NXUG;QIF8QL]MVN78+]3[N&[NXL8M/
MV2X>5<"LC5U\$+MX5"Y!]RA9[E3MXL?C+X_MH&SLXL8N/J)I,1H.5&R7#3<P
MQ=]+RRX3PG&9W-ZJV"KA`7`17:V"W2@\O#KV`[*Z%TX027L/#-?8GD_/NF(W
MP^0+/=NXW[=Z%[9A,Q?:QJ$*H,H-]K+;'1UFIX7K3,PBSKW829`:2EY_,S&?
M\ZF``]1]4$%]&"*H(PIM,Z8@)X2MIX"/(PWCX66\&=[G)Z%LQ6%]NR?`ZX"Q
MUXI`_NIXTKDQKHI&HENID.2125B63F(<FF1B6WT`=S#J5D`H_0H)Y7?G@=GK
MB634'P+P%T=`)/N44G]=NMJ]UJE`2#%T'KG\R<(IE^B&'6O8&1907.P_<YV)
MA,2YH=']@`D8:(%AG!&2CA.&@+TL7:TET5XW0Z(Z/#67-OV$IU5E=I-$8_>L
M(LE!FUT)]"9FJ#$5U^HDV$,8_UQB?&C@`)QI]&'P;A1P<NW!]W-\T6%3F'>"
M+\]X(&-NPTB"#HA<NI'V$$8P6^A,R+F'(WFPX?#.A(X(.6D15]ECRQYWZ\E4
M->/@RF:X5"[5!\-T8;A]=R(2,$Q.CX"NC'Q&QS5N.!(Q,/@4MB=+EO"O"#=J
M)K#74*7QT30#V''^M/SBGLHZ(R#NM,0,5=2)RP-@I6JV&7Y\J,46SB!'>BJA
M5HO9$K`4E29G*<52U^*-@8Y=_D\N<5@=OO;G_8GENI(?PWZ16_B=X]*E7GS9
M9K]=$8KK;/$C+3Q6Z'2W+1M6W1F5BVBJ9^VLG18>*\1@K]TO5PIEBW7ORPL7
M\U,N@+]*=?5D?&^8DMVU+H;ERJD\':[CPH[=[I:K"K(SHJ[NF%A[6WXZA/W2
M'EA#NX+=>W4R*+';G=VR^=Y%].9%D#[*3.QMU?3=J,EU*:OUTNY>6-W^=J4A
MBO&VCI,:[+_MMDO&UE>"L[J<0)L8)^ONZ8]+%/>L[N#"LL?E*ER=C]IU41.U
MJ[$ERA"U3`)N2#J?I&N2Y=A8$J4M"<N^Z%O=8041?J=D3'1/(SRY,29VH\ZV
M]J_+-O@_+/X/<`:5J2.89V*D[XY9R[S$+T%?-2HAN?^BGGV[;UV4;-1S<@4E
M#U_4L]ON':1@\BX/ZG,Q#_8.6#V@J!EZCO_\,G\RLGJ/4V[N_R3K-B=934ZR
M@Y2=KTMQYUV$;:;">%/E;O-C*`.^46CDCB-,#Y1*DYGLN,,T=]M7V#4B\IK6
MPFOC0Y.4F"?9F.>*K8]/TF/.`5LJ+-:(EU<AL2;ZONI"Y*EO:]`$_AA0?'ES
M$_`;E>X>(^\3X$YXH9BP_\'R,[M>XT$*=50=0SHL;EY;\LJPR@#<8RL@4HC%
MWO`"$T,;1#:(W"\BQX4E;=J]HB8ZIXK+JD5CO]\K'5"QCPC[758L*8G#@B-E
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MII4?;YI`74IY]+HCJS]H=J'9A687.NVA_83#K]F(JC?BI.L+[2BU?X.#N-(Y
MSJ]"P2ZF:ZH?'=>.-%4\ZK4C=GM<Q9%]RENRI\(JMF7WNZ7]*KNMKO+3Z_#!
M>T/=%G6S15T&X!N`\LZ%'W[^CW__MY^68>O&<1;RT5O?!:2$'ZEEWQ]^Q#^(
M<.+ZX3+@\5ML`A#"'U_Y["_/WLO/_^S]_O&?/;OUNQ.TL-+)LY]I]6:!#UD\
MI!7YBS<EBX>HNB,QHO#M)Y7W,/<@+FJ2U64`P'Q%1J4`=H2G]J3,9NN7V]V!
M^?XU?AC+MH;7)0;5T*<',K=04LRX:X_>,KF=:R8YY0H]'Y;4NI+:5%)[6]D=
M5G4OS!;HR6DIVAU?6+U^KZ!]J,6$AQSA<=G^4O71Y4D_4'A!-AKU%_@$0(==
M%!>!/^%\2N,Y"_CKAYC+KK3/AV.4);+/IH;%<4-?`Q073B[J:+H!1+IFT:/`
MV.T!FPO7A9&,[IL_O2XM-E+"!I\)+[WI;[[CA5_YA(L[)+H_>/2'[TV608!]
M6//DS&7XS\\SE#0?^`0EC?V,+3TAG_G[U8=G;,HG`+L;_N59J_?LYTX"Z"93
M5@QC+`W7PCCJX/^V`/23-PDXR'=`"?WWDT=#)*^^7P-L6G!OCLY-)]T5I"61
M6@I</#F_*);X!03+)^`[+!'X>2:;&!/-?_PQ<9=XVM!?GXFW8=?4(:L+.87;
M([W?46NI$JQ#K/.1+3O8"G_Q`V.H"G=NO/FV%<"PCT4\LBW#/:^B>@8J`?U6
M1%0]2]C]D5T*^[GP_V>KQ7[Q_<@#B<>NE%;0:M%OKO"^OYFI'W^#/]@/^BIZ
M6(`^!@"3FO1,?1OXJ*7=1M'BS>O7]_?W[1_7@=OV@YO7W4ZG]QI_?HT//J.Q
M7Z\,GC8XEM<A_W,)0O?C'3?-DH,;&$,TNT[(P+BHS,"(MXS1GB7#KOH@-K,I
M=J'Q[]6\.)!5\]D#T^6!Y=HM]TX()@#H]7,P%JX?V#L>P"BRB#'^7S]HL2_M
MRS9[J4W%;N=MT:/Q(_;;5ZG)##,3)YWR!0H,H(^`WX@PX@&`X$PF_M*+T`J;
MB6".[SL1FTJ[S,$GEZX3L"_+:U=,XE5<)F]]!A8*T?_"WOE.,$U!_.7]Y>=W
M)G@`1;A00@[,F>+%XRKH;6U7.61%(?`$(/[N@*(1@>$F/!Q.>*AYP)-@8!7A
MX-+SEH[+OO*%'\";'DC>8`[;VOH;65KX&OKLE/FYTHI-;IZ$![;.80LGB#QX
M```J6@J[O_7I/1"S`'%TZP?B7_#^$J8(C&4&2Q?(*E)V)/V@5P:0.9.(BM8N
M`^8Y2#G<NW%N..%#`T&F)%B<B%\<"(=(UB>1]9+L20'_TGKTS_\-2`-R$'-X
M_T[P^_`5<V:1@@\`!F8`M.7,&?B1@TW*_=E,;HFD"V-U<*0!+44"%N=X4P;Z
MX:WCW=#VS&&IL+X"*IUPA1/$.<P(@MH!ZL&5I69'#+V\:OU_]A6>9MU6QV8M
M]M^PS6(&@IV,>B0U1;%H5K]JGX,0,AT4`5E2L$\SV)B0S>"E0J<#NUY&0$NN
M2Q0KJ1''4.X,N;/X!;PC,G65I5P)Y*:$2!I(+6',:5>M'D.QX;)P.;DEH-7V
M*@A#=K,44ZKX'@-Y]?$],!&'CY*B)$A3Z<2`-<'W''C>F<V`\,-"WG>NA2NB
M!Z0?5&&$AURFV2U,J!3GX;3*M),'.021!^\$/%H&,"/@R)=T+_&JF$YADBG'
M2WJ86UAOZ"]17N8O%=`&S(05.(.I](V)$&@AB@CM4Q..F0"*=V`^P!QP`Q[^
M8<SZI!Y&B-MK#J*3R&7"P]`)'@Y&_WF?#G$P=_3)_%<^FP7\@?VUS?X6./<A
M26IGL?`1RU.D3:*XY.BT@"N\%O#-9!D!UMG[6T>0X%>$0&=@&ZF=X;[!W'=B
M(HF\Y"`6^SV(H4)V5"P"1$"'&.PI#!<Z^BQ];LOPT3:[!#48OP7Z?$B-`E#<
MR/Z+VMU)TE3=0#!5#<QP7!;Q4LJA2><.`!\+DP66Q&9`C0`EC(^'%DAO.2SN
MX'<>J6=\>51/05"0.$%>)'9!D:0@I+7?(6$O`F`])W(L!D,'P`\N""&D?(=%
M][X\N6$BX4\3MRKH-/!F\KQ0MAE.!P0P@.7JB7`.9#@!:L94D(<US;IS[J#3
M="H'ABUC=U@*5R,JY4=&E2#KK!U291:V#*5J]0XOM5I7$Q`3@&T<2N[EW)]R
M]RT.&1KEZ^]!*A$-_4``_,*M\>_5OIS%(7?`LS6]?0[0U5QM_3*46BB8E1-0
MGB-]P_$HR6S8?V#W.-MG,X.=K2:O@T'_H!T,*@K:4FL9%I:A_9B2Q&N<"I77
MC-5%QM7`O4YAV5B[/5J]D:]!0N;''V@_`0-/Q9V8HJ:U9NG5(BT_]O/%P4,"
MU^/ISD<1Y^H[[(,ARA[96Z!J=P3U583?0</G7-K8J,@$JKC^`9'5[H[K3EA@
MP--!J8['PR)L5!#,50,"BQ$V\X,9%V":\IK++#,0ZM$+![J6P*L,\49=/3`Q
MS=[GV_T6&';J\D$]#:.`4-)_H2P'W4^@(3*YY?/T50G8_^T;_^[U^T]_>_8S
M7NB.+_KV8/S3Z^S+/^NOTJ-+LR.>RT./2/0S@M/J#%IV/QY(_:+_UN^]3BV0
MECSEXLU'FL2X1;HBT\SHI;,FQL'$27*1)4<P[[(ZSW[N]3KVT!X-?GJ]V:P`
MH`89_X4__P]02P,$%`````@`]XFO0#S^X_\K"```V6<``!0`'`!S>6XM,C`Q
M,C`S,S%?8V%L+GAM;%54"0`#@L>R3X+'LD]U>`L``00E#@``!#D!``#M76U3
MVS@0_GPW<__!EWYM7IP`1S-PG31`)S.T88"^?.LH]H9HZD@Y28;D?OU)3@P)
MMF4E,41.[Q/%:+6[S[/22BO9/7D_'0?./3".*3FMN+5&Q0'B41^3N]/*E]N+
MZG'E_=]__'[R9[7Z_</UI7-&O7`,1#B?9)LA!M]YP&+DG/];_8KA`9A#B7,;
M`O?1[*WS"<T<]_"MTVRX3<=MM`_>M=UCY^K34R]?YYH=MW90K1:GYZ#MMC+T
MM`K4TSIHMXXR]#0+U-,\S-;C%JG';3>R]#36U+,D66O5CK+U-IKMEHR+OY3>
M+70<U`XU.F1`'+8/#[;6T5(ZOH%/EK4</7GB'DL0G4ZL)<#DYP!Q<.0H(_RT
M,A)BTJ[7'QX>:M,!"VJ4W=6;C4:K'C>LS%NVIQROM'YHQ6W=^O=/ES?>",:H
MB@D7B'A/4JJ;-#GWW;MW]>BOLBG';1[)7U(/B6C<Y]KE9+90OU7C9E7UJ.HV
MJRVW-N5^16+PVPFC`5S#T(GTM\5L`J<5CL>30-D=/1LQ&,IG,U)5.#9:<^DW
M-P()4.3TAQ>82$<Q"JXHQ\KF;H`XCPBK.$K!E^O>BAO(!TK09(38&-4\.JZK
M1G7#'NN1W1X*O#"($+J45J[8#U,!Q%?*YT]5[\7I5^I_.PFHMZ(S4'11M@K:
M0F7$R1#Q041,R*MW"$TD0:Y;AT#P^(G"UZTVW`4_;Q:/?W0X!\&[(6/2MEA!
M@`801&I_I+>KO[J=7<1'&O.B/R^L6F*OPU8-1,R+.Y'_3%"W&M^+%G4>CL=1
M;U4L*8SEAXR.=1#%>FF*H0YE/K#32E/FW)!+&^A$]8^"BO,`^&XD9#[>`<8=
MSZ,A$?P:/,#W:!#`9Q`&H:$3*P,G>K\77!W8Q55?C("9#MZ4QF7@)<W'!1M'
M=K$Q-[(_/,-\0CD*/C(:3GK$"T*UG)9//4H$)B'X_0FP""#3*7>C3LO`[C:8
M+:+@V,8HR&74#G;TM#Q'VK),=<6HC`DQNPH0$1WBG_\3XHE:7<F)6X._5LQJ
M5O0.VYFB/E,!7-IZ21%9S:V?*?%RIS\C<:M),P.@Z(R6V$S)!S_.8*(V&\J:
MI:RJY<%(S$K\S1RV,X?<".K]'-%`VL;5(!<SS1!):;R+N1B&(#'U(VN^HB`$
M[12<;+WC(,J&/#D+I[AJ9X;LTO&8$B-*$DU+PT?223LS8<?W\=R.*X3]'NFB
M"18H6#)?MVC,%RX-829`V+G#NP:!,`'_'#$BMR>\XWGA6($-_AD,L8=U2QD#
MX=)0:`*$G:GU$J,!#F3\18NRM1)MKNA.O3$S?-<A9@K_\X!;<72-9%LV/]-:
M&J>SD_JS,XO"SE]ZQ*-CZ`0"&)&]W\.&IR[)?E[CK"6I]?4KM?/J%;D[GTZ`
M<.UP3;9]_8GE(Q!I1"!CM^./,<%<L`BYA4D:Z_,D=SPP,XEX/A)S$;!SR7\-
M'"0F(VGW&=Q#0*,"43YM>KFRD);CO9T;@\^4T-C!^5253U>VS-95HF^(,?0(
M6MI$E=9JQQ&2B^%R62CA8?Y0KA90?NN.$+F#'KE`F$4[U?YP84F\6DA;?9I*
MEHD`(R3R!^N:I!24&>7&YY)RWB<W*)"&KQ3E'RORN@1IUD%9^%P7%SMW]LKZ
M/ENV/UJ)]\A-..#8QXCI=H8FTF7D,Q<1._?X4:T_Z7#>W8@4B;*1ENGY@BBW
M81=3<_-4D%U(Y[OSLWYI]N-AOVZ?9"!LHT<?8$@9S-O=HBGP\ZG<6DB",)%C
MJB<#(CJADI(R5H*(0[EQ!:[+*2^I=<=CP#Q$G@^&%Z6B!#6HS9'3S#N6;J%`
M/'FKVS:MM-OU[)YF]/I!;&LE8M7RU*M<7$+0'\J1UQ&"X4$HU,V(6WH-$\JB
M[;X4T);DB]-1OEC8"E$+:LKJ$O1%0!]XC_B8@2<VK"DG^WF-FG)2ZRXF/66%
MW&C=8^G+A]D7#GZ//!;+.I[`]WEG0VMTLNLIY,66ASL<]&L2^']V^%6S0Z&!
M\CJIXW6OS,FI&CX@B4N7CM5:-?))=VTN7:#T3&<!\2HW3.<E(LYE7'5X#A'Z
M]J7E(0>&HBMF>31<4";3`@\#9?4%9)[G:$7VA8P4,`HOC.W1F=I6L&<=LKF%
M+41^P4.VK1A9Y]3-M2R]G\%$;K)P7E)?:59:LM*=CIFQ[.0L\D]](D%.KF<T
M'(AA&,3OTFJ8THJ5GCD]*#&3EAV;_2HGVUNSN^91=U.SMK#B"D/RU?<U2$X1
MWCN"TP"*R2WNTE!AA14&<OMW!O.?/;(6O4;BI2?8#*288MNN("6MC\[]%Z]K
MY[Z`;B2^AQ2G@113K%E464)Q]![Q4W3F?SG"N(L]I#H+K)ANS<JKB)N>28/2
MWT3.V(D:BY>6N?5`6K#6*FX=9<C:!E\G,:9TD[[WC.^-X(V#P;[SK(P5Q16:
M;;SFBF5+2_P:\,3$6E9Y2K6<R9@T>_?22'P_Z4V`%#/\LF=025N6C'B9N7QC
M!:4EOFB@X]`H;F'VHG=L>N0>^+9W;-(ZV4G]U@/PHWL!*>6LY<],Z<NYQKW8
M&?0:2E.JN^:0V7G])@.$Q5=IMXOKM$ZVGM67,5>'N>J[Q_WATC=#+BB+?O8C
M?,^GP#R<?=2Z<7=V!J^&M^49>W,0BX[BC3E^/%;>GM]$5WO/;1*\HB]S;<;K
M^72Q.E@*/CF+%L6U:??[S;\QR':^H7D-'KT'-E,+2W7?NDNYMLJ=WKZT%.?`
MD'^M;"?+Y\A98)CZSS<+&N8T0CNF+]^=Q)M4:^RP2O!*66$`I*ZVUTA&I0<@
M=<@;S[QI;^6<//YO'?*7_P!02P,$%`````@`]XFO0/N!ZB>%#0``!L,``!0`
M'`!S>6XM,C`Q,C`S,S%?9&5F+GAM;%54"0`#@L>R3X+'LD]U>`L``00E#@``
M!#D!``#M75M3XS@6?IZMVO^0I5\G)$Z@NTG!3J6!=%%+`P5TS^R32[&51#N.
ME9%L(//K5[)CR,6695N.Y"Y>ND.BR_G.)TM'1^?(I[^]S+W6$R048?_LP#KL
M'K2@[V`7^=.S@^^/H_;G@]_^_<]_G/ZKW?[CR_UUZP([X1SZ0>L;*S-!T&T]
MHV#6NOR[_0/!9TA:V&\]AI"Z8/EKZQM8MJSC7UN]KM5K6=W!T<G`^MRZ^_;6
MRH^XYY9U>-1NJ^OG:&#U,_KI*^RG?S3H?\SHIZ>PG]YQ=C^6RGZL03>KGV[!
M?M9J'O8//V;WV^T-^FQ<?.+]5NCCZ/!8T`<;$,>#XZ/*??1Y'[]#UU_OY>,;
M$NLS4V)KF/3B(?_/,:"PQ9XRGYX=S()@,>ATGI^?#U_&Q#O$9-KI=;O]3E+P
M("XY>*%HH_1S/REK=?[X=OW@S.`<M)%/`^`[;[5X,VGUK).3DT[T*RM*T8!&
M]:^Q`X+HN<^5JY59@O_53HJU^5=MJ]?N6X<OU'V5BY5Q@]=NUALX[L0_'C!U
M_7(*B$.P!^_AI+7Z^/W^:K<>\H..B^:=59D.\#S6%1=B$"P7\.R`HOG"@\EW
M,P(GF1@3`;CHQUSH#[RU3A5QV&?H\T'3=N$$A%Z@4+C=ME6)BN<`^?5(&C==
M3="HC?8<SL>0J)1RH]U*(LZ8-,0)Q[#]"EVAH&FM5Q+7Q\%0Z7.S:C`6*I$H
MKW6Z]-M\\NSVXRGC0S(A#WWWT@]0L+SR)YC,HXGJH+6-CDL%7(A]L)@!5NK0
MP?-.!$_83D49'P(00-[X[62$?#8#(^#=88IXV^<>H#1:28I(*]EB1;F_`(\O
M%W0&8;``A'4W@P%R@%=$U.Q&U&GUBIF@<SCT`DA\QM@3+*G+W7;4R7@.Z&SD
MX6=ZY;N(0"<H*>-N.[&,;'Y'?C0`KIE`&Z+"EP#Z+A]A\;>\R:J/!._SEU,/
M.QL]>=Q$P"1U1HAF@PF@XVA*"&E["L""30V6U8%>0)-ON`*M=M=:V00?5E_;
MKRI@\.`5^TB37CPPAE[4MYU=V.[&>M(C\R,8OXT5D;Q10=M*9'TC=4@VI6;3
M<M+>:H8N9/=,")Y+J"SI$N>(V\+$A>3L@-4(*9,$+[C,?**(9_V!@_V`#<-+
M+ZK&GA0XY1_>?O<PA>[904!"6)HH"IW#*7[JN!#%'+$/V]2PK^QX--_#*:(!
M`7YP`^9IY&05M7OUT)-JLY0C2B!Z0I6UP]5^U'[.)"?`8[,7?/D/7`KUOE76
M[C=(\;NR)YKO[5WSYR'A"^\(4;;N_A<"<NF[%PQ,AO*SBMM'C="_0/R$@KZF
MP3]"'B3G3)8I)N*AOU'2/FZ$XM,E3W1^M'>=/Q+`'9,/R_D8>QG:WBAC?VR$
MGK=E3C1\K&M*Q_,Y]A\"[/SYP&Q(2&_#@'N:N)#B^5U0T?[4""ZD@"0$?=P[
M08D-_\B:S:!BO8C]N1%*WQ(Y4>^GO:MWR*1PN20C#V0-]8TR]DDC%+PM<Z+A
MS]H&\!TD"+MBNR6UK&UU&Z'R3.$3W9]HTWUL2<6"C=AW:3MO87G;JFE'6Q,'
MJ0#>-DZ:B>`FK3P-KZ5MJQG[5H'XKQ1D;%Y/.YM>L)H<8Y+>UW<7V;N+S#07
M67FBAI3"@`['W)GD!`*B-@LVP%F6*;AZ5UEY]7.WOT#I_&?-[K%=]:6K>25J
MYO.@86@[#@[]@-Y#!Z(G_KS>P&#E11(-=$$US:XR62YR()CT`-P&,TAB7/G4
M[!;6[$*3)215</6.XZK+P.WD`M$%IL#[2G"XN/(=+^2^#O8M7\:0'T+W=@%)
M=%8H\225;E2SQT[Z.:L"4+W3NBK]LHPF&/2Z\HJ1]":S>L=U>;W?$<P&1K"\
M\T!\(/]7B!;<KF'SM8`&437-OCY95G(@J/=]ER?I!@>0,A&O,?`WE]0;[#NY
MSXQ,=<W^0UG2)*&H\8OO1-VP+^P+N.`[<B[$VIHJY$&FFFYO8AX!LAC4N\RK
MKBFYBXEN)V*Q963=8ZC.:UY>R=<(C)''=!8]E]%)U0Q[3#S*)]1@*;&QEVVB
M"8[&,IB,,L-7&[<[L.03J_QF=;.";>GU&112OW@+NPO,+`\#8<;]&EPIQM+K
MV)9>YX(:TK*QF>1U*,18&AR];@<%5*6#,FDN7)-0CAS;TNLU4,L*1V.2BZ"4
M;2%2@E[O@0*RQ.#,<C/`"60/>8SS!_!"T9%<2FG;TAU!)%1UEHLA%8=!]L-:
M?%D>*=M%;4MWR%$)1M)`F&06#%T7Q9W?`>1>^>=@@0+@K8DM,NQR*]L]W3%+
M)3B3@V62X7`/`Z8-Z%X"XB-_2IE5&LY#C^T>W0NF=@>)5JS\RG9/=]13"1;E
M8)EM;Q2R,^R>;F]%"9;289AD2>29317\3':O\4X+&8@Y)QM[BG7+3M]]#V][
M#V_[><+;-O<`=X#<D@BC&]F?=Y!$>1W2FZ&L!AH4#B<-R"3#?%/H.!=G&`8S
M3-#?;W-?+GW;%1N0>2H-Q"0+/$W8*TK#PE3%E1J0H"H%PB3S.DU0<7Z?9,T&
M)+7*(S')]%[;<9=8QR1J-R!-MA@:DX*(=E))I98O0:T&)-+*H5"?1:N0I=Q5
M*Z-&`S)N\Q&8%$U4,!E=IEH#DG8E8>1$).T_?V[WQJUWM\*[6^'G<2NLPOG]
MZ>7+`OH4RB309=9ID/-`A,$D?\%7Z#-!O:'O#MTY4RD7DD]#*[$%+.74U.PQ
M$.H_G;)\0`8=B-]#"IE*9DS:"_@$/1RE!.2S)JRGV7U0@K,\."8]:COPBDR!
MFIT%):A)@V"2ZRVVO*XQI2,&]SS./V/BOB:@T2]P@@F,RSV"%T@O7QAF!@'Y
M@"RC!8`G%;":3)5,OND56XJ9R2E:VVKLM4%>B7JU8-(H8T+BY$&(T:P>!PD[
M*+=N@SP;,EC4>'U3LZ%^!X1?`2J8>5-*:79-2*EL4]OI()28+:EJ/9\!?\J>
MTA%`)/(IWDY6W2<'_&EQ#I(U-7L=2JI?#IA)=LE7I@T^%=_Z#\!CXFXDG+YF
MFXIV`E(-Z,X<+,%G<8`F+3U1[N,N:I'5F5Y#=SY;!>8$B$PZL<I$6,8ZT)W3
M5H$N(2:3#JGR#=A*>P#=&6YJ;?GUG#83GK9-B5,O'Z$W,+B=L(W',`@(&H<!
M=\<^XGNXP"3:TT:WWDIS7*$/W1ETY8="1=`F/>Y,Z#=LHCEYO9SN++M"V[-M
MP4TZ:TY"\9.`A2^`(H=[_)`7!M"5V$E+MJ`[U:X(8P4@F70ZG;]:,$!;6/(B
M=DJWJ3M9KPB'91=?`72#CC.*K!Q5!TBIUG5G$:H>*J658)+G(D<IY1<$_?F'
MRA:"]9S#:O?PI#M6(9K.^`!\8F-H"F]"#NQVL@K#V8[`N0@)^S>^5WQ#SNB5
M=>D^664=Z$]'S"=5/>*<V_/W'_&T^_Z^]XBG]XBGGR?BB5\@S(;X'<%/B#TH
M7Y;?F317_NMQ^-!ACV:<^2AQ!%BXL0;%2)4"9Y+]4;<74+,?MQ0]I9V$1H57
M-<M%J-=97-\XJ:83DV:*H?N_D`9\7J1<5(;*0=%UL&^`'[&Z9:..[C1'H*D<
M936IQZ3#WV0K"%VV;^!':*L7PF>;C:D5=%\O7Q-1&:9HE@KJ"Z")$E7B-*(A
MS6%*6%[W%?-[(2I/`VIF_#RB1I@P`X:&'A=[!#.CR415=-\]KX.N-"6HF3(5
MAOQIOEY^;[SLXJXQ^K+>,$'=-]+OC3-)99@4:G$!%P0Z*,_X6"^F_9K[O=H<
MV\A-BGJ(`%+6.YNY+W`X#B:AE]PV+B!35$UW*.%^R<W3A$E!%GN+`M;\DKZ]
M#@!YG9@4H[$M]>Y+\@H,@]W*NH,;]0Z!='V8]*84I@8"V2[X`L;_KP%?76DK
MX8&2;T1W@.-^AT,QO:A_];G*85%H7I"IKCMBLB`YL@RG`S7KM&,;-\^;6+WN
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MU:#DX;9[>EUD2EDO!MLDAUF&Y"/D`]]1-+4+&K-[S;D0O1RZ&MTPZW,-#SKC
M;^YZS9SCD6@C3*+_;Z,N+U\@<5!V<%C9YNR>YJO+RO&R:[5744!]0;,R4KW&
MMU5G>+LINZ_Y(K-]LIL&OL8PVUR1+E]6>\.U8<=,"%5T2S9O]_6ZUO8W!`HH
MQ"23G9_C/T&RY)X%GF-\CJGP"#.UO-W7?.^="I9S$39@6YV"6(G-9?>-S+`L
M1W`QV":=@D1B1Q<8;'L)!2QG5[+[S;D\3XS"-))RZ+#[S?%*)?*:='3T$"X6
M\:4&P$MNR;CR)YC,(\>WQ'93L@6[WYR;Z0I`,BF<.KF._@X@T3U$Z\7LON;;
MYPIH.NM,;Q.-0;Z\M3<)Y%*R4=+N:_;'*&!E!U#.#B[E4J#3#F][S!8F]L?_
M`5!+`P04````"`#WB:]`8+9UG!(@``#QR`$`%``<`'-Y;BTR,#$R,#,S,5]L
M86(N>&UL550)``."Q[)/@L>R3W5X"P`!!"4.```$.0$``-U=:V_D-I;]O`OL
M?^#V+I!NH/SNIS?)P,_`6*?+:#N9602+0)98+DYDJ2*I;%=^_?(AJ?0B14H4
M2>^'07I<O.2]U#V'Y"5Y^?W?7AY#\`23%,71#V\.=O??`!CY<8"BAQ_>_')W
MN?/YS=]^_+=__?[?=W;^<?KM&IS'_OH11AGX&9=9(!B`9Y0MP<5?.[\B^`P3
M$$?@;@W3P-O,P,_>!AQ\F('#_8-#<+!__/[+\<%G<//SMI9?6<O@8/?]SHZ^
M=MX?'QQQVCG2V,[1^^.CCYQV#C6V<_B!W\Z!SG8.CO=Y[>PKME.1W#W:_<AO
M=__P^`C[Q2?2[H@VWN]^$+2!'>+#\8?WH]LX(FW\'091M96/6TL./N-.!"=%
M*R&*_KCW4@@PRJ+TAS?++%L=[^T]/S_OOMPGX6Z</.P=[N\?[14%W["2QR\I
MJI5^/BK*'NS]X^?K6W\)'[T=%*69%_E;*5)-E]S!ER]?]NBON&B*CE,J?QW[
M7D9QWZL7X)8@_V^G*+9#_K1S<+AS=+#[D@9O<!_\R_=)',)O<`%H^\?99@5_
M>).BQU5(]*9_6R9PT:U$F"1[1'XO@@]>!@/2P.<=W`9KX#_R/[\!I-`OWZ[*
M6F@-ZW1OG>X\>-Z*51)Z]S`LJGJS-XEV7XCY!Q^KVEV39MLJ-OOR2ZTN)F1,
MQQN8H#BXB(8IVY`VK/5MYB79"+TK\L8TOXLS+QRD<T72F+9?X;#^+>7,]2NF
M:SBL7[>26K7-VIHJ=V:M%RF+7>/V:YK!EPQ&`:%"]E<B*2!VQH=D0"!UXDIC
MOU9=2,:&.*E;FFZB'3+2[1_E](O_\'LQ@IY$F``RE&VNHD6</-*1Y>0^S1+/
MSXIJJ.JT\M^E1?=R!8EH3<4$IO$Z\:&2Q:SCZ]IX]_+:D)$6"Y+9,8QV?KE]
M\V,Y@_"B`#!!4)$$OQ6R__L]:UZG/7CF?A^7#O__QJP@;YPV9=2NMC$G21T9
M7N(7&N%_]EB3E]CS8SQ-6V4[-?];)/&C(A@*36+%?MA30'EU!K7PTGMJ33&/
MPO`_V(-A5LZL""$<[.P?%#.R_,^_XT$U@T2O.^]^RY@5`N`4-`)WKI)-;RD+
M@-]H$0L8UJFK"5\6.T#AN3U?WX*?XA$57N%_IC*^NBULQU^KR@K\@!0#M)P+
MCJM#:2L>W'(-KA>W_4+5DU/H[S[$3WL!1,R)\3^:OHO_]#OC^F_P`1&*C[*O
MWF,7RW*+&O%;@:)-!\B'XFTY0`J:]]H)5#;ALWTN47ALKS],ZZ]G&".)%U[A
ME<K+?\.-T&&;90U[;%M5SO?/"P):$N"B-IU6I]9F_9;C&FW'Y?G%5)Y[MDX2
MW.0E2GTO_!_H)1=1<([YGN.\W.+&_%>@<-,9\J*`E06D,%X4!8`4M^/&DREO
MRIO[W*7JT+V^,BT;7Z(0)F>XO8<X$7-QO:1A)FZJR6$T6@P4Y6R2L":%S?)O
MIS.TV;?;$Z;RT[O$(UO1MYO'^[C5Y[GZ]3+&?+.I6O,CY[\#5L"..X[5T90'
M=G[FJN]U?^.)YZKQXV,<W6:Q_\?MTL-?:+[.R'XK440\<14)FI[%BHW@30ZI
M%*!B,\`$0472Z@S7D$6&9[\2SM8Q%9;QM*E04@2>[W"U'#S4BACS_(9BW!T`
M\KL=3QZGH2G/[/K`51_L_+I3>=L);BD@K5V&'H]^ZV6,^5M3M>;G+'\'I(`=
MCQNKHRF?Z_S,5:?K_L93<UQYP$6P\.\N:YSUFJIRR845M+S<UZ^U:7;L=(TN
MFNSVBZD]E\466-N7^&]=VUOB\L8]N$MEKC_DP9_<+6AQNYZL7WO3'LUUF2ZO
MYON+&<\F43-YO]Z6MN35577[O((&-)WQ:%V:V_'FEIOP?;GM(Q9.(\P7ERCR
M(A]A;,4IZCE,IR1NY\2"V"#^<8#Y`I2"H)"T>JA.FVFQLFE63C](N"+W/(2,
M'YI#UTF:PBR5P%&CH%'$M)1L+=5H`2<@(*FK74?N_NI-E^5\<G/.>>:E2X%+
MTI^-.F*N4&O7%?_9GL>956K5NE\R1#'@9>`>/J`H(GLMF/59M9/IN[W%,U1;
MB%?7`CU-HK<*BR9F:Y@P.(SX?KR.LO0;]"%Z(N=6O\(LW\H7#2HB,;-#C-B`
M%HGGQ<&V_`Q@B1G(92P.0`,M2<KR8`=$<`H+LLH-+V-?8@;H]3#+`ZX$/EK#
MKPPXS$%\GBUAPJ8$_<#N*&P4SIW*-EV'%@*LE`/`E=?9%C3':&@2;7Q7;6),
MX*>FUV#SQ3E*5W'JA3\E\7IU%?GAFFQ:X[]BLS,4K6$PQ],/>HM)8F@=7JF%
MM=U`XSGKP/D"5`5!*6DA:CBEG7@^&E3MC`5VFE]>CG'H[J7H*&\VC6=9B%I$
M79^#.3`H]BE*YW:%FH`76S$T<]6BJWF@2F'/'IQN$L)KV>8&=R:]TOOG&JU(
M)!5/AP7H$HH9!5N/`4TW*8K/`!5@M[(+$;JVL0?'@:90&^#6!HO+2^T?@[N^
M-!EJF\"JTS(\=^J%)*62S>#<!/9=T".A?.-,\K`,Q35I68K?S+'TUSB#*5;C
M.O:B>LCB*^Z#WKF0E+A1UI8TJ.EZ5&P&J!3UNWRW#[M:*T*UK<@>HP\T\SJ.
M'G8RF#R""%=0"1[:!9**%S8!I>2"PW,#P179]24-58(/0HQ(B9G+"=1O0.LL
M3"Y"\5"-NEE%@`YC8FJ,9V79\0KTETI:I&["F9<D&\*H3UZXAB0,XCVR30!R
M>3]=0"P8@"P&V1(E`5CA"12"*5C$"4@AKI;<?EFM$]PN_FNV]/`$(8$`OJR@
MGS'!>T)IV3J)2%0%=]!J%2+ZR[.7!"FN<<,2)BTRFC\4@@TYWH5+WL--C/L5
M&U)$8[":_L8GG(\6(,2T23H<%_'"-`:(AC"P%M[#0T*3K@&_,([9-,-?AUA(
M:KQG<Q60+B',0(!+S\A/4=E7^9<DG(PMQ7;C(N&&!HE";&R`V^NJ"/<AMOD1
M%TZ0%Y+>P72;HJ"()NU6<%HTT=EC6/@OUF.D`OSI@V87O<6_$0TBDH\I%/31
MNUV+>:<D.;J6<TJ6H$W'H7H#4#8B3PKG8LQ&FKAA&Q="2\K*F8\EB8-(%D!P
MC;Q[A#D-T;D=O1>XC$-,;2E9,&4;B:-OTE48!9*"8:W)^U:4#D558<"DG3A+
M-Y&)W^4VVL6+JF,V$:7LE>9/`]UX&[*"DC\'U!"P<@*HI33WQ$E>TH5=$F7=
M5ZRD[4,^PSO;J6,]W8[..]##\7*C^$S6,*@PB!1$.3*F4<I5O<-W2%E0*>P&
M5I4M"+>%+2)62\>[@ELQ`#J@V^/]5F:T_;"UC5<I?W$+H%(JU_?RK^WC4[?6
MEJ;"/3AT#8!RR+,&.3'6G(`8UTO=PM0P-2V!2`(]5B[R#HB]N!)M40H^=,53
M3K(L0??KC%ZPN(OQ>H9RL`MAEL&V%8&48]O7<E5C)TY%2VYP773'BFKU*]G2
M$@"BJ[3ATVQ=ZK9/X.2EBOQRM.`,7*4IGD?;/,"FIGW*M/_/_=W]_0.RD\CV
M'/\+'.S/]O?I_T#*4N=YZVP9)V0#;$:VY"!`U%:VSSIIHD#)@V_COYLC9]UT
M&.+8\38=)KEUHHU+:NV#;'Q&,WC7?)LWLH^"6T7-WD%O*]HZ'U'+[#DU\V:5
M]^4T:"U@7"'E'GZ>'1Q^FGU\_[Y*O/BOA_M?\"\?JQS,?CJ:O3_<GQU\_E(3
M.)H='7V>?=K_-#%IR][NG[SCC@YGGS_@CMNO]0/^ZZ=/'TF7MCKNZ&!V].D]
MKNZP)G`P._QR./MPN._":#<.)4Z,<V--<&J$&VN,2V,;;ZAHY6+@C1,&=WJ"
M@&88\L(;#P57T9FW0MBQ*YJ)MGSZA<WN_<@8T]J+*(4`D0)7$<CE9K4,V!8W
MA$::M<)2.R@"/I.S2UI:OA'B?"/'.&UB6UVB/'D>:>V<R9.(.5K\!C,/13"X
M\!+B3.F)[Z\?UR%Y\_@<+I"/1"%)"6&CM"AE3-,-"R%02(&W%3F0"[ZSQXJ#
MK*J:$+!2MB:@#NNO0.=3^I9C;#ZMJ2Z1N3S[-<E<@?IL[BLI[2?9WD<:M7_D
MTJ81=XM4[NRM&5IV3VT%-I92W@$J':>GW:U#^2U#!R\SR!U'Z19UZO*"^.`*
M[]*"$P=:9.UI'1]1N*=@ABL-&^72Y0N)$S1B%`V^'Y[3XBVYF<G&^"7,D.^%
M@L,R<G+&;HC+F,`9#0`5`C4IJV=D7IT],E>N-1MD[Z*N-%BJ-W7ED6+K#!#6
M:I[0!P,"NG%P`Q/ZEJ'TL2!N!19/"@F,ZCWH@&7!/`%,FFT-D0>"V*.5KAPF
M&F1@OFE;[M:"MR@"01R&'I[5X`DWV[#MB,/9.\S1YYWB\QV]KFD+=.RUT)-R
M8UP:;"U!BR#K,*(77/G+KULA5P"E9$P.I-;Y!I>0PW,Q,6*X_F47*6QG7A$E
MN9!UA)3*RZ+#K7.KTD;448$X1MA&1-V59-#0\".[2!`_@BXK:1T3XD?#><"P
M^@2Z#G/J$)GVZ-K@4\Z:OI!C6VX3V>C27ILD7\APGHZ'[+6<CQZP/)61MG6*
M6F'=5C^@X^BJ=)1IKV(]JN"+@C.9#JU$*UHI+$-%4K;`)+%FJX/(H=7G(#/<
M7'=*.)0`&0ZL.%O:]"XW>1)VD<!=HW6AP/[U2&7]Y1:89O8K]72^$PEJ>MR_
M%[O6UL<M3>06QT(QNP@6+TBZ/<F)1?$P2QQ=#NO^+(ZMA/6;Y](B6(84>BG-
M[O+W*O+C1U@^XBZ1N80G893-^&HW78J5!&51)S*33*2^2=_O<9RFV_=YC<'W
M7HO4[!<O*QBEL/5<?(?/\V7,OOXJ4+WU7&F9@;XH[(3G#S/A+$[SAQT*,<NI
M>7J=J/4@:Z\'F4/`3S#"RH0G47`2/*(($44R]`1SU00XZ),TBH9^,YH.E4M0
M1ZK+%'YE#QCCK/%J,K86JM/:8!+?DA!IHEP6'R9OA*80V[[$*IW#)QC&]"FU
M?J2+Y0S?`Q6;T+Z[QLI3IZI(V,?X*$N"K82]NY]ZOX03(2DIA+0O#,K`P^*D
M5F4R:WD2*S5Y=6C&VJ$ONQXBFJ_:@NQ4VEN=;$M/LJT%5*[C-+W$AIRQY]NQ
M2N7[[>DI7,0)9.7NO!>87KS@:4*<!"CRDLT57B#3Y[6P).XDK-_#591!["#]
M09EI6K40V)FJ^SC1E;>DO7>`M`BV38)MFX`U"O+RM-D9J#4,:,OL[=-MVZ!H
MW':LR52/DG;`@MN1MFC0\4XP'[B;E*"Z@W_3LI/)%Z&C\GE'IG$^W$@$$OME
M#;\%W6]*^R'HK4Q!B&]SL7=.Q!B'6,5>[VV:8SG**.UI[2>?9=UL\'W>OWM)
MXI5+GJ[U1E<I8W=UV^HUOWA>PN(*0TU/J#]Z\86I&=$'>KE[N2;4[&U.NL^;
M]X1;BYTES%\@)D\,PV)O!+'W;`/ZF/)S;DNP3@C)D7=]V8ZWQ;=[.5U2O0#,
M`]M@C)\M<<_A4?G20PD]2CI?Y&T4^0*Z,G/(2DIS0<,Y%+32Y3#8.Q+HI7AD
M""#[U[NV<Q2/4/NM5[P#_/L3VV=`$29@VEX*$KB*$W+$VDNK+Z%M7^[.'["^
MA^2EZQ5]Z!K7]HRR)6Y*S]/3-CJ^FW9:9T%H:Z13%[B];6<6X"QZ3#6-R+3>
MU*!\C4:9(AJ%#JF2CPKB#6YU>B@BZXYY=.N%6*6;A,`CV]R$A"C_7",:MQ7M
M>,I58';C4]:HUFX;%BR"'?,($&DP7X!"'M`*0%F#Q<W0H1;2E7?,>#@EYI$Q
M?D)[Y+9%=7RO./]>,?][39#=76Z&J.VS27PRH[O`2NS1V@Q6HPZSI#A/JJK1
MXXA7T>WZ/D4!\A)1PC49:>-TV&^.)+:H*!F?M\)V:7"@90T./`E@''G@#+=$
M4S7AEN.$^)?E?&4*KM@%+UD_-+@12^)([?"+:#N6(V%V4Y:K=G>@K",(:'&'
M5E%Y-)6^<CNR@[0%;_-0A>4KJCW^W=J1[7%N!Z+V0Z+UCD3I5:/S#H;D^<<1
MJ/.7!X4B:&WZ/E3W9N]SC'!B0T%Y(\')DQ6C#DBX=LYAS'$%8TG5I=[(&V3K
M5Y@!\X<)M)VIX%@48A%WST#H^@QN'6<8?BK!.LF=H]1G>L%@JQ;^)O/%G?=2
M1?E=_(WN)I##;UA`F#)=7QL6*7-<UT@P:[6!BK?/`('$?$$.@<V<)EJ]/42L
MSGMI(>@>5SA9O_&H8GQ0-3YVD@DU4(>8,'7PAL'E'\RVZHN6?+5R9I=Y#14%
M",QYRBWVD=%_HOF/["I40L-KBS,T&_JI[?`,_\9&E[E=8&\M;3N1;HZ1BK?&
MBO1LIUZ*?'*?"(5K_"4D#I/*UF"4Q>3-:OI.^=1<F6MP!J@TNS[&Y)TX8#K<
MQC:'E\:"G::UZ`E:/H"JZ*--B*DZJ$NQ)*QS0]V^7*##ZW0L\L0W?6A`:D;=
MO`UFRQE%=79%Q>[M@L#)+*.C?5\]D-+G^&[&5\92P+#:G8VIC*(%J6C**R`)
M75UTWAU!>`6$,0HS8T(*[I!(S[QF^)3=J:GZT"FZL_-RT?;&=AHNBT`S(8%A
M)JDL,9RD'$F$*2XX--QZ@^AA298NV".]!_AU_7@/D_DB3^K8S.=X3J^(W-#;
M(355<+=WD(3F!LS=M=/9*:U[97GE(*\=L.K)G*'(%MIZ*@.P-@!KI,/G+=WU
M,])/7MY/$>NG>-&1\[;C\A*7&IBT<0*TV6%^GC+8T7Z3>0IUTJZC=RBY;I:`
M=82R(FDZ[9AJ%Y:WV];D/AON*-\+_77(3JS=EWT9Y+/_BYM;F[<NM?-][<*F
M?K(W-PDN<[EBA;UT>1G&SS*I5(5B1J>_/08TG7Z;@I<,/5@`4`DG`M*#38FE
M33$Y^Y-QK>;43\JOC.XW$S5NDO@)!3`XW?R"V>XJ*C-4G?@8MNR]=8FL(>J5
MF=ZY5C>V:]U"?;&H!IQNP%M2$U[.O*ND)]O6Y@3VM!A?`2$-EW59:SL9R6"/
M[MAY'>K.Y@!\$OQSG6;THCXYOT(Z"86PMFE\%^N#^"3-&26!B3JLB91*,^3(
M2]D0:,<]\,^OD5`L=&06@Z3LR"@_PT'^2O[MDSXL)NO;RR4>:\0Z+TT)U"9S
M38I2@U/W/#8&`[S4(-<Y.E>2U0E9MX#9Z3I/Z=;LEA3<H25!M:C%Z;FTZN0&
MZ\X]5=V?5G6IZ+-BG]^W^MR)#,]B=V\M),2^/CATS&XGTYC(2=J#.W%Y8X%=
MD<J=KIL_-0=.4LO(&Z9]$;%*`7Q<A?$&PJE1*!/*4['CCN:!BNB0G5\8S@-N
MOD]RGJ4TOQD)7Y:IA^C#:'A<9_O/`7FS@)PIQOV`Q_^B'U+2*=6^L!B3ZP52
M-<36CR(=@+Z,DS/<>^N0#/&7D)L.42AB`]9=B@N1C07`5@(0$>OHEC<B!SC!
M@+\U8C&-$8K8EK&"P+N>.(SDP$V03^":`SEI(/J!Y.!B:,;,4`/TRMO0*&!'
M?[B!;RZN.!"W""JYM&F<?'!7$2!R^5OK\P4HLFE>=^>#,[=4.(<KO#)$?0N$
M6C&CRX*&@JUS5I6?[2T`["HI-=574-&)27V78S:G\IU>:0X[-`B0XK8Q+9W'
MZ_MLL0Y/\GF8`$M",:/8ZC&@Z2-E<3I+*`1`(6$/?H/M6-#-;#\.0^AGB-RR
M*^?1V+$@>B(W[^S=QAIEE\3W,8EG&;`T\2V%%'O)1@M5OI6N(D"]A+#5)*.=
MQD@F&"UDP;=)0#,NMZB\845./9AE8;E]7A("GDS;90/CAME,Q<G'5E\:3@&P
MC%Y#H6G$S_-TXI4=@C-OA?#L2NXE;ME*3%\JD3>NX^Y(GFK]O$RUCI='E=?)
M6!5.;-6-LI2M_=+&KEJ*4<@>7ZNDA+>\Q:;NK1WW/%1=U288E49N*7'+`)0:
M"SC0<VKT'FC:B4O3]BEML$L+\J.R$FBLCLLDE^,9>1LFRDXH.:N-R&UQVV-Q
MET&RHS!-;)D+`R;M$A=(V<:,\',C/.U&C"4#C498GB1PH2,Q/>#CQB8;?(TS
M6&&H7$$E1N!489D5N(9),@.5K\P09@5+N$0/TD:2@HY.%?398)<<Q$CJ)X@>
M&`W>U6^W=`Y7<8JR]"0**"MQ9P%*XL8V)A4,XF*]D"5(+Z3I&I4-0[8F`B/-
MJUD24TOTSP84#@.,,(7>R'MX2"BKL%.[;&>Y<F$Q*9(P5MZK>XPCN$G!`WJ"
M$3D1D$(\I4#99@;(I@>N*_'"&3E3\.@E#^2>>*[0+C@)TYCDQ`S7`7D+N](D
MB6?0SFQ%-:(X8S\](^Q+`5R@");/YF7>2QS%CQO51^HTL*TY/S)UAD*5Q:KG
M*90I3"/7LIKGBW/ZWJ$7_I3$Z]45]3)R`[(K/X@T$0^IVR)+#^L*V9@.`^1\
M`8KJ`:T?E`UP,O:X0O)Z>B?O!O)$IVQ&7TLC@1Y[)=XR[1HEO+YNLGA:3"N'
MB&EP#(&X$,V^81MY@T+9A:PC<>RM*:I![!O]V[2Z(MA\HTXFW&16?$)"RP=!
M[0_BQ*$R:>S(A[.;P+%,!`EFI^OMQJ(J%S3%[=-!VR!Y1B"RH"+L&"GTFU;8
M$$YJPW!JT&2!=0K@H$:*!7B0T;AJJE0_S=)I<`,6UT\C.D6202HMO.*5E,9^
MJG;(*UA3:;1\X,(JE.HP9R)B#KB*O67E6)(5KRU',ZR+J8T$LTN%2AQ-9=2U
MY::>PN@UY"T269H;9\HVV6=TC%OF9B8FWD1U`/JL\\M5]`137:G31)6YP#=B
M8Q5YIZS,M4Q'6HQOID[KLM;-U&D2'BT)7!EW-GKOT8<PH"G]V9T+_!=,+=GF
M!G^Y["0*+OY<H]6C^.242BVF;T4JF-=Q"8]*,V<M;D@5-<P`K6-&MY++:JS>
MG-1A*WTTDUXQ(O;B^3Z<T#2I.8(%PPS?IE2%8,?E2F7\N3A)T#(Y<'52H&<R
M\!IF`,Y:.F9),L)..>O<G.6,G]VXPSB7*/(B7].R1%29"PPD-E81GV5EKV19
MHF9\<UG29:V;RQ()CY8$KHP[#]X&J\Y/2/8GW!(LWTX@*:$NXX3^=TX385V\
MP,1'*3<UV^#JC&UQC3!8O`@I*JN^J4-3B)$T+NQ?K$I0UFEG\VJ*'J`S>%3T
M0.7Q%VKWHI%.#<`)>T!F%TMC%Y`]*YHH$D4+S%/;M8P7!(@(>R'^G5VV)QL/
M-"TDZ8,LIL6PIBC;\+LHL'@J<"PY5#=K1C/#I!279XK306^MJIRBM@Y#1]!:
MD6!O2D;+8#*>SU3,[N>RY]SL*6E,$Y&_/L-U\;>$Y1JYN]4SCM,VC_!4*9O+
M=M/1]<5+OI5?&2Y.HD`7A<M6[PZMRW?(0*HO&ZC/8TETW<0(H(,*-?21D!Y=
M)<+A=FLB1UCZ3FUZ2WRGR9E!^V%(EUE4D8>4F%65A,P%\,A[+1B0&W*^*H%^
M=A:GPF0NW>6-AN%X*C<]OBC'CJ&2DH`6M1=#D]6<ALE6'J*O+@1,]7BQ@!1-
MOFX;U)(O3&F#R3B?T/&;H3RQU[L8;M<29G<UO*XGK/X:8NFREAJR;\RVWN36
MN;E+,'YWP`+/4,WHC*UY*%O`*P(AHSPB5+YSF&*E02NSBSV&4+*!8*;KG@5]
M1CQ=VN*!X39P%3<)\7X,-"$M`0"#SQFN5RN6M]H+B[>?KZ)%G#S2!:C,H^22
M-9A]\%#:K-9C1Q7)[?O>H"+LQ#Z[)@/)W:$P3M<)NTI$5_YTW8^V=5G>:5?T
MT-:3A(KN:?*.>0;)$U0W>/4CP%>MF.$[XS4%VS<[V<^`_&[S^K=0R^T"DP3L
M45[8WDUO+<J:O=3==M/VY>T.'S6:K2%^A'?>"TQ[P50O:3H'0T/-CLO2Y`UN
M6L0ZK/J4K3MK1DI:3*"@0UG#N1*Z?+8C+4*GPYH#5YZ,!:\U;^(0^7)G-`5"
M1B$G5)Z3*8@$$(K2T\[UA(<<7H<)DFPRJ1$F8=N/AM:[]_U0,!@9]C(\UY\O
MRCOPP@APN[#92&^7LJV(`"U$-F^VQ<!O=_`E`Z?8F#]LGH56T#]6T-]H!)/K
M,*U()=];S/GWZ3I%$4S3<YCZ"2HV4$^]%*7D#A9,BYUUTL&T?P7^/Z`RH_@8
M9&S3_XI*0*46ND]/ZV'W*[<U.8(L$Y;'2I:;Q.1P)V]B=H2'&PQ1HH<(+9!/
M+DZVQE(9'$M68#9`*6M4*WRW%02=$R4G`&K)/*-Q226W;(4EU7S2X*/E79F2
M2/;R6F(EF36@:DUFGSY7-K.5N;XS,QU+9%]/9^?&$LP=BXT^=3[,G5NOH0_T
M9:.XK2@B3GR6GI?;/C+CY^BJ32-[;$=T.'[5N6>]^2EQD6W-C@S)KZU?#+.$
M%O!TT(8>Y)CCD7GRX$7H+ZK2&=8*3TD"+U\85%<$\T5^!LD+;_%?Z`ZKS*Q`
M3_U&&457E[3>(:S4.P.UFNF86EM^XN5H63O85N_$U.+5=I!)CM$*K";1Z$65
MG>-'IUY(;D3<+B',MEPHM\)7J<;:020)`X6'=7)Y0"NH#*3.+/H=L-76R219
MYQ4=3Y+V7+/1`*8&O:BT@E%*>>0;)`_<!?2"P^W22^"]E\+@QMO(3@-&5FP\
M5C"J$[H6TOD<.*:7+LLJ05XGNX(T`[3:'5HO*"IV8LA_37UB.MXP'C!=X0<-
M:'&0-TZK"DL&(T;5["9S<+M!`).Y#$Q.&S!Q8J(P:;<,8@]GYA2:@#.80'I0
M,SB_`[W1?(/]:8D;R"\TB^8)_3+&,C'TJ=Z:Q](;[X5`D2O![K!MR@Y3U_2E
MW*EZ]U[.E_2ZMV@XDQ"RZ^#"E1K/,ZR.+J_)%)DL'\JVW.7Y-_`@N+W74\DQ
MMRJLS%-PV,Q6)`>87@1;/9="%%K&80"3E*3SSC9?XPS*W)@3"YJ-3_49T0F8
M7.`[P$0`D7%B66K('*-1)BDW:\65Y'S,-EK4-J+EZW``0W);J%79FOLYMW^L
MR\KOAIEI'W(*^[[JCFIRR^4^A7^N\43AXDDR6,L5D899YVZ!6`\59+:W$HJZ
M`:O<'3;OL;J]/]#3]?8<1VYCCB>CTW5:FFCV'7>(J<_P/O=I]']NS346_1'_
M&_^'!,;P+_\'4$L#!!0````(`/>)KT#]+>.^)Q$``'$(`0`4`!P`<WEN+3(P
M,3(P,S,Q7W!R92YX;6Q55`D``X+'LD^"Q[)/=7@+``$$)0X```0Y`0``[5U;
M<]NV$G[NF3G_0<=]K2Q+<M+8D[0CWSJ:.I;&=MJ>)PY,01).*4(%2-O*KS\`
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M>#3!U$;+.1*MCDVZZ,A&G40^G6(R/CC(P9+Y:'I#;`$&0=:8<B)Y7UJ(<\^I
MLDBKR;&@W!?(DI[#YQ@[2\1$=W/L$!-96415,RG/JD.Q&BWPP'(PLP5BSSBG
M+7?YE"?C)>+S&XN^\*$](0R;3DX9=_D4E''$9L@FWS./F`A=84_CA(^F8X:Y
M4#*S*''D19%S%PO$5J/I`YG98C292,P-IDE=,3G8LS&UB$DPSX2A'L=TN3-,
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M]DEW?0;]<?VSL=EG/X9W/R'IXQL:W4#6,(H#%I4;,3/@*/ZX`V'TR+QNT?&/
M3&US3JP-^E-&%YF-&8A"4Q1I4296TR]'@L+E0D*ZE(SDF4_H-L6,K1>Q!-D]
MP9\Q>Z*1H0>#I!A+>"C^R'70W#0V>D"(JG%)P2\L^D%AR+%Y/*//G0DF/GSB
M#]NHB9\,WWGO\8Q(G[6=.[2(&X&JID;_4!"+(!%%+4%X)6;5V/U2",Z0-12K
MS.OO>)5H^*VVQFFM++\K?6#Z;N6VOW295/!&G*.1]5^,F-AL7PEE%.97-3<^
MU`2!!`4"$'I``^"&6)A="EEFE"6[?Z2E\;$FIH^7/;!ZOW*K/S(D+Q`?5HLG
M:BGL'6EC_%P32V]+'=CX%&IJIXL%M;U0R8,X(&`^<AUY)R2%3)[G$PB-3S5!
M0TN5`*(/E4,4[-X?!5L%&.$FQEE-S+XE=&#@CY4;>""DF$A);BRD<O=(&Z-[
M4A,;[X@=6/EG,#?>A`P3=C&Q;8TNU!DZKV?OB!]8_Q.8]?U]E2_8C?@M[LR;
MV-[H'LRY5Q.%6!4"),Z`D9`[7'T<-JV-;EW.L@D*O!VJXD'XW-F.>.XM#*J9
M+0$7HXJ1*R&"FH7\/8J:Q^N3#?H>27V/I-8,PP'GV.$:<TJT82UBJDK1&X*=
M3/A*0$S^,W@$=M?V\1BMA6T(,NOL+?Z6SW2'G76(,VF,)9"!1W)UD4Q10AU2
MKQ?$(V>.F6^3=&!W&X-'AW7AC!5='9*O%XB^7J/I%>%+RI'U&Z/N<FB;EBO#
M?[%)C!JC.#=3\$"V]A@OHJ+Z9J&.SJ/K#X'^T-'Q;!"_2:V^J\B(FK.5SU8I
M9D%:[]A"?EY,D-LKUJ@$")/(P`/ONHBF**&^Z:C7L)1YY%RH=TN1'=V$W%';
M3!VM.N3P%P&ZF.MJH[Z%J0K\^$Q"O)11%JE!:!^2B*,.&?R50AI^NEJH[W7J
M-6A]W5(74?A;B&S+9_C*8??RITX+YRU!3\0B#O&FD]VO*S0B2+HLZG')D4>K
MIIQ]@R/^&*WD:J(?V(@2&%WHZ%0F\)+#';NJ-2>6Q<1!+F0J+;SC:8PN=!BK
M',C5VC5EC&?".\X4T`&N$H".5ZNTX->A+.AZP!I=Z.A4N8A*?4H+18%"F6LW
MEF0^Z!A5"4`GJU=:,`MXDAX'PGKJ_H$L-RFI(J:UT86.7J4`I0IEQ6K2D!U7
M*"4Y#=+MID8/.C*5"\\X-9JRD1I,)L07?(S(9&A?HB41BT5(Y:2-="JQT8..
M9>5"7$^QIMPSWF,'$1M/KA&SB3WCX@3A+EQ+?H9^A:?$)$DK=3JQT8,.B^7R
M`3W%FG)=&%?/),/NS.C!1\5R8!RO2#,N$].VJ05BH4:O`:$Q'25+NW7<]H0*
ML\C5A>R*WG^M.3](SN,PYY0R&JET[]G?FC4T="RIG/K>T[[?T[X/$\/H`5HX
M]HAYZDZ\X]<8,^];6.U8@HI!K=+$M55JI`_X'S\/7&=.&?G^M@:F8K]-")YR
MGA_S&%6:$H6(4W3(N9L9:)\(/!N]*,@;-9H28HA3,KF<@R8E>*9Z4:BCNC0E
MG!"*E.58OC6HP9/1L^"NIT]3KGUV:I9H+=L)5.!9Z3FQCM&C*6G,.UJFKM8*
M"O#\]$+8;G2`SU#>$ZYZBW1BF2+P=/1"$&]ILL>49IC*$KMO1U3N=+X(&YDT
MTD,4%.]QPPRC0FW#]XCA>\2P9ABN/^2T9]>O\N$)K%,S0DE3J[A@DA8-`?<W
M;`L=K8$]&4P6Q/;J#\N5:JUQ`L0IE.#!P$3PXO%.5ZDAJ-\+1(0UYT+3*_R,
M+>I]#9J.>2(=>&0P!^)I"C4E"+QCFBQS-W@<,`>P<4HT(WW?WUO>4LYOA*$N
M_7(+0M&WQ[8N\)0R[+=[1*^87[\*:PGEB8W8REOSY+>D@E)H(^2;#6UQ0L$\
M_52PEUYK%6[<KQU*FVY`/52H1X/AY]MA/0@U-HZIM+4*6.IH`W\-%9N`M'[,
M+6&]B&D%'G'4,G@4JW@U"F_TE&^\%0'E<H[LF9A;;A!AWA7':+H6/<BXBTL]
MU*2$#R;F1$]3M^*3:U%,2SJR(6++!6AD/R`+RR=.0]5=0D]>JD]N6@S@2V7D
M<(?L*L)/OR56I=NU6-(^/YX"O@A#`=P3=&K*%;#2.GEV5?"%&`J`G:C5WM++
M#^RP5^C,!E^4H=RS5[@,0[V_[([J&O^H]AUV1E-QQ!PX#B-/KB.O*![I/5Y2
MYD4^O%=NM/VC0!_P)1_RNU%!M<O[GFGK4=IJUQ3LO%DE:1T)MX,O"Y'I*+XM
M>C,6B.`+RB#7[0)Q8LIH-K%<<4;1B+AH<H"O#9$%[0Q*-26]*'UU%,;8LD-:
MLFANGO#5);)X0-[M1H+R#;DHS+)6%G6O7-SARUZ4[6BYS="4N\H4@^9?R@ZA
M8$9I2UBX2`9<#=CXJP-,9G/I^H(MFN$[=_&$V6BZ3O_<SOR\<IGXK_]:6T1'
MF2^IN'4HK8-#J)^1[A+EZUQ::=I#2;65K\C<6/2%#X7^#(L=+^33;1MILCW9
MMD/VGG2;9R3%&U(QS;YGWKYGWAXJAO+Y).')8T:?B9@=+U;?.)X,[4UNT\`4
M\[E?944CLR(SLUKEZN92KR%^LN];`O`[HES8YKY$:$R:;[TN$:"OHO;G9<6L
MTI1S_6#R/Y<[<CKG4DUA$9-X#]*\&>N1EK?>[:,[\$SH,GUT3P9J2D)-$'3!
M$W'&EFD%'M9)F^A8`O#LYGW!K-B.JXP`OJ3&AJJ\CY']+\T'/`7GQ/;@:<G5
MP)QF`_BU*@WF&\K$IH^[EE3Y!BLSFY-(P-.<0<".,P/\9%]B\CIX_G-UL,:H
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MI\R5DCQO]*`CM67F"&;3NQFE5Q0Z#^UGS,OZZB*!F=&#CLZ6\-E%BG[P:6*E
MW32;&$^\).^8FRYQ+-2Y0\S`Q>A!1UQS`JZ\9LZB.7@.:=433"D3B]&##L:6
MZC/9%&](1>5XG6^(C6RSI"4I@9G1@P[6EK`DI>AWH)FLX1E2IN'*)\DW7_W+
MW-P;RKS_CSQQKU\Q,XDZY34O.Z,/';W-B>KN*:F("<`7H-P^LDGX+>X?VZR,
M/G3(ME+?B%._O%4F7Q7`?&YQ_;J.`83<76RYRG(53?9&'SJ`6YW[9#`)_'I4
MSM9%9O<($58R_B3KLEQ2GIA>$-O>Z$-'<TOQD50=X6\-J]ZOEK)/-?K0L=M2
MW2.;XN55H(4\X7@*>^6JMJ/8"1ZB)C+ZT%'83`_C)NK1C*BJU#$%2J-?I\AG
M('%IXV_I>8`0@3D'#1)T!#([2"46>_9!NK;!EM8'=[FT//61%90Y&]I3RA8^
M#AH%Y_0X&'WHL&$6H#,H!7]77E86A?]NW!B1I**HX69&'SR0EP$G54I$5!_P
MF$R9M9J\!P-3`8VT-$ZA0W-E8+JCTAZO""NL4#IB,V23[WX*2_45E_P4,ED)
MEEK$U*R;I"0"J49ZAQR7X=%4JY;=;F/PJJ2)YE0=`./4V-\\5^%XD+6(N;SE
M?6/]/BSRZ'#A<K$IXOP*<Y.1()`88]Y'@=2%$.3O!-VR,ZOEL,JE9B.&W8.[
M6"`9;WP@,YM,B2F3*W8L^#X2<QW(DDRJ,_KT&-1RQ&FKUHA1%E_F<S0=>*TO
M!2MA"1F`HTPZXTI,/O)KL=#GN-57R8D5V7LL()0LK#,J,W("&:I149)3H+G\
MU:)<;,1T!G%1UN##.SM^BC%?@B4:,1L$F8R1)-#JGP4.'4!E]3XQ]T[0>N<3
MWO*,INOK)61MPFXZP[X4_C#K=BAJ<8$L>5?_,,?8>7-)O=4[`QOP05X66AI!
M6`U;-&*8>YD<NV6"059RW\9>QLE&DGMLR4P`+\7`*\[[)&4=HY7N""_&&&J=
MUQ/Y(BRRYC)?A#/X!%`83/6B7]`NS9D,QBXSYT+-=597IF.UNGKQ-M>$D9M*
MDW%0Z@N5-(32B<!&AX[!MAQ?2YOF^/2<6D(3+C>RS@KB:;5M&>3!6>MQM21"
MH.?5XD3*=MK4Y@&^X*0"H-I*9M"P\F$F6]_C:<2&G"R6LI*%_+=O]T.MH.P3
MQ_^X@OOU,PZ5IE5,NCO-.WL,%V]U]4NU![-H[UHI+0H2B&-E5!2],Z2*!OIB
M/QF)W?.?4G?E;;YZG'WNR$[D1E3\Y?]02P,$%`````@`]XFO0,D.SGXA"```
M(3H``!``'`!S>6XM,C`Q,C`S,S$N>'-D550)``."Q[)/@L>R3W5X"P`!!"4.
M```$.0$``.U;6V_;.!9^[@+['[A^V9>19<5)IC&2#M(D'AA(ZZ#)M`46BP$M
M'=O$R*1+4HD]OWX/*<F2K4ODV,4VA5\:6>?RG0MY>#GJ^6^+64@>02HF^$7+
M:W=:!+@O`L8G%ZT_'OK.V]9O[_[YC_-_.<[7]Y]NR;7PHQEP33X@SYA!0)Z8
MGI*;OYW/#)Y`$L')0P0JH,M?R`>Z)-[)+^2HXQT1K],[/NMY;\G=ATS+YQB9
M>.UCQ]D?SG'/ZU;@=/>(TSWN=4\K<([VB'-T4HWC[1/'ZW6J<#I;XN0DV]WV
M:35NYZC7Q7'QJ\'=`>.X?5*#@0/BI'=RO#-&UV!\@8#G44XS3[RW&$1RF:(H
M?PHS2C25$]`?Z0S4G/IPT9IJ/>^Y[M/34YL&(#B=3ZF<T;8O9JY1U>EV/9R(
M(1C3^D+.KF%,HU!?M+Y%-+1VM@C.7*YZ:LF;ZK,":\Q/W;:0$V3I>.[7#[?W
MUMQ4<\CX7VO<BY$,4_ZN:\@CJB!E-]1`KP3RS"=N3%RQAC5ZO]ZBXKQ25L/,
MN-*4^YD1!:,3%[VSLS/74E-6#A.J(:A4?N9*$8*;L*52D7(FE,Y74F.J1E8B
M(9AP>T['<U8!3T4<JG6U&!(E&T4:5"KFBXAKN5P/J`*_/1&/;D(L0?,C*;&"
M5\DEU!+!`%BY#!)*V&'A3\OY#:5$@/%'4+I<)*:5"''*?%4N8TDE(HKYY0)(
M*,^.7LY!E:;&4LHP]%Q6@""E1$#"N'*@G;I(S;(PE^`_,S"I].W8'%-?.["8
MAY13+>2RC[]7D1.<1[-R)8&6KG'-128'N4`R/YL6^ODID:$\#Y&HQW+XYIQR
M+C356$_?G=/YG/&Q,._?O#DW,[-GM#^@$#$/?WP:U!<V:TM:OR]Y<,,UT\L!
MZD0.@]$B#*-8RQ&C)_`!C!EGUCHLB,3)%H?<(^4!B?60G*)S=U-#7G&D(!CR
M=_89TZM0CY4RE2Z13%BJI#+%S65\&OI16`>4O$K#OF,J[M$INV`-QWW&L2HS
M&MX)9:V^"JE2R;IEDM*0MSH]1YB3E1)\OA)<B9`%9N:0]S0TBP*YGP)H=<@-
MN$E$E`G(G.(2H*>@&5H1IZ.:7)V!;O,,D/_<Y97^]Y"1M=DRP`/7#"Y##1+K
M.'N$PAPI<E3GY;@N+RN"(F),AG.0UN/#'%G/R!55TWXHGM2`!PS78UW(2)&C
M.B,GS3-BU!*K]Y`1<(=R0CG[.[>8K[VICOBI6;&9\D.A(@GX(R]WB*Q9#Q13
MP_%=SL%T)2@2JN/\ZV:<K;@9R'D%AX!C<8EF,RJ7P_$]FW#<W/@4=Z2^/<8Q
M/KG#<N`S<_:S9:89;W5:WFZF)=%H$I/323*E)-5ZR!6>*3!TPH0E0H35$CD<
M7UKN*U1K=C&W="2D/7;AR>*CT/`)?&"/=!0FZ_?N:JHS?+:9X3Q8;ETW&8_Q
M2`I(,D1[F#&8)`,]#`!P[Z3`"&J3D9MO$9N;Y3G.:2FE,DU>IS`1(<2]PN8&
M^7"2W-R)"?\O7$H@N!*S.7"56Z`J:-4Y\`HY,!H<JX+D=1PBGT3^+I+^%,/S
MA4J)RX3*!;Y`JH[[46G<2:J!I"H.84_"/A5A`%*9NJ*7N9BOOZ\.>+<TX(GT
MOTDL_]-%V_QCVA"?8$SL_7[/7#M>M!2;S<U*'+^;V@M8M>1.V@[Y$_UK+V9A
MRF%TUS0:;)HV0Y+@IBJ2:]GZ]@,JL4L([K6R%HJ[%X\P]MMZM)ZN'\R?D(ZV
M]0=%(/P!7<$AOJTK&[/B^SCTHI/,2,&W".?!S2-DJ\/FVW<E%>JX>"Y)I4@L
M]O.4IW,W;7#@4];V,%T0'"Q":L)+^\%5_<VXE7PK?*NG1L3\<E(YQ[QRO".G
MZ[47*HB3OXT!JV&SI0&IW)8&E'>-&T*G`@;SI`E:;?.V`M0"E@JZ$&J5OG$R
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M\A$DG0".[A'(X?A*S#`/]WBB`36,M`FN^=+Y.C*VWEE;3`?+QY1>LS#*>O$F
M`/O4N18I*[K5N-AGJ.PMT4"I"#U3Q?M6XWD-R\Y#/'/E>XWQG/5](4WS/0I-
MSZL/:<-MP\<2KE?@YM64\@D,>)\R^9F&$0S'R17K+:,C%JXN%8VWC9A?@=,#
M[DO`8^8UQ'\'O+PJ9YXWE_A^[B-R\+W\CZT?CJ^90K=H:/4@6QC9JE36DZP+
MSHO4O<J!DPY\!ON+WLMUOH;!=R>%#Q"HOA0S4SF-_M5Z:,HI%E+[=S@W2F\6
M('VF\D7WY1I>P1!KXEQ2=%\8FJ+TSQ"6FT4R-7*9Q]J\0Z@::WP%X2MMPQ9W
MZ\^P_3@[]5)#'V"AWX=(>,:A'%_L4?R_'GHZ??]_VU6OQI;9*^<':X%0/^;J
MD6N=J/#XF2%IG#EWX^L#?/P?4$L!`AX#%`````@`]XFO0&DX=A=S2@``/1`#
M`!``&````````0```*2!`````'-Y;BTR,#$R,#,S,2YX;6Q55`4``X+'LD]U
M>`L``00E#@``!#D!``!02P$"'@,4````"`#WB:]`//[C_RL(``#99P``%``8
M```````!````I(&]2@``<WEN+3(P,3(P,S,Q7V-A;"YX;6Q55`4``X+'LD]U
M>`L``00E#@``!#D!``!02P$"'@,4````"`#WB:]`^X'J)X4-```&PP``%``8
M```````!````I($V4P``<WEN+3(P,3(P,S,Q7V1E9BYX;6Q55`4``X+'LD]U
M>`L``00E#@``!#D!``!02P$"'@,4````"`#WB:]`8+9UG!(@``#QR`$`%``8
M```````!````I($)80``<WEN+3(P,3(P,S,Q7VQA8BYX;6Q55`4``X+'LD]U
M>`L``00E#@``!#D!``!02P$"'@,4````"`#WB:]`_2WCOB<1``!Q"`$`%``8
M```````!````I(%I@0``<WEN+3(P,3(P,S,Q7W!R92YX;6Q55`4``X+'LD]U
M>`L``00E#@``!#D!``!02P$"'@,4````"`#WB:]`R0[.?B$(```A.@``$``8
M```````!````I('>D@``<WEN+3(P,3(P,S,Q+GAS9%54!0`#@L>R3W5X"P`!
@!"4.```$.0$``%!+!08`````!@`&`!0"``!)FP``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Discontinued Operations of Adeona Clinical Laboratory and Note Receivable<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</a></td>
        <td class="text"><table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0">
<tr style="text-align: justify; vertical-align: top;">
<td style="text-align: left; width: 0.25in;"><b>4.</b></td>
<td style="text-align: justify;"><b>Discontinued Operations of Adeona Clinical Laboratory and Note Receivable</b></td>
</tr>
</table>
<p style="text-indent: -0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-indent: -0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On March 8, 2012, the Company sold all of its interest in Adeona Clinical Laboratory, LLC (the &#8220;Lab&#8221;) to Hartlab, LLC, an entity controlled by the Lab&#8217;s former owner. In connection with the sale of the Lab, the consideration received was (i) the immediate assignment of the Lab&#8217;s outstanding accounts receivable up through the date of closing, plus (ii) $700,000 payable pursuant to the terms of a two-year non-recourse promissory note bearing interest at 5.7% per annum secured by all of the assets of the Lab. The note and all unpaid interest are due on March 1, 2014.</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In accordance with ASC Topic 205-20 &#8220;<i>Presentation of Financial Statements&#8212;Discontinued Operations</i> &#8221; (ASC 205-20), the Company determined that all the criteria had been met and classified the Lab as discontinued operations and its results of operations, financial position and cash flows are separately reported for all periods presented. The assets of the discontinued operations are presented separately under the caption &#8220;Assets of discontinued operations&#8221; in the accompanying Consolidated Balance Sheets at March 31, 2012, and December 31, 2011, and consist of the following <i>(in thousands</i> <i>):</i></p>
<p style="text-indent: -0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-indent: -0.5in; margin: 0pt 0px 0pt 0.5in; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="font-style: italic; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">March 31, 2012</td>
<td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">December 31, 2011</td>
<td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-size: 10pt;">Assets of discontinued operations:</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;" colspan="2">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;" colspan="2">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt; width: 62%; font-size: 10pt;">Property and equipment, net</td>
<td style="padding-bottom: 1pt; width: 1%; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; width: 1%; font-size: 10pt;">$</td>
<td style="border-bottom: black 1pt solid; text-align: right; width: 15%; font-size: 10pt;">-</td>
<td style="text-align: left; padding-bottom: 1pt; width: 1%; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; width: 1%; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; width: 1%; font-size: 10pt;">$</td>
<td style="border-bottom: black 1pt solid; text-align: right; width: 17%; font-size: 10pt;">23</td>
<td style="text-align: left; padding-bottom: 1pt; width: 1%; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt; font-size: 10pt;">Total assets</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">-</td>
<td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">23</td>
<td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
</tr>
</table>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">The summarized statement of operations data for Adeona Clinical Laboratory for the three months ended March 31, 2012 and March 31, 2011 are as follows <i>(in thousands):</i></p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i>&#160;</i></p>
<table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="6">March 31,</td>
<td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-style: italic; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">2012</td>
<td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">2011</td>
<td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; width: 62%; font-size: 10pt;">Laboratory fees, net</td>
<td style="width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">$</td>
<td style="text-align: right; width: 16%; font-size: 10pt;">115</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
<td style="width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">$</td>
<td style="text-align: right; width: 16%; font-size: 10pt;">323</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; font-size: 10pt;">Operating Costs and Expenses:</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-left: 9pt; font-size: 10pt;">General and administrative</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">27</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">35</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt; font-size: 10pt;">Cost of&#160; laboratory services</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">116</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">251</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 9pt; font-size: 10pt;">Total operating costs and expenses</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">143</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">286</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; font-size: 10pt;">Income (loss) from discontinued operations</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">(28</td>
<td style="text-align: left; font-size: 10pt;">)</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">37</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; font-size: 10pt;">Other Income:</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;&#160;Gain on the sale of Adeona Clinical Laboratory</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">677</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">-</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">Net income from discontinued operations</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">649</td>
<td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">37</td>
<td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
</table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the facts and circumstances leading to the completed or expected disposal, manner and timing of disposal, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the segment in which the disposal group was reported, and the classification (whether sold or classified as held for sale) and carrying value of the assets and liabilities comprising the disposal group. Includes all disposal groups, including those classified as components of the entity (discontinued operations).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e957-107759<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2941-110230<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1436-107760<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6390789&amp;loc=d3e2443-110228<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 144<br><br> -Paragraph 43-48<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1474-107760<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e1020-107759<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1510-107760<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e1012-107759<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>16
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7T)A;&%N8V5?4VAE971S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0V]N<V]L:61A=&5D7T)A;&%N8V5?4VAE971S7U!A/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7U-T871E;65N='-?;V9?3W!E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N<V]L:61A=&5D7U-T871E;65N='-?;V9?0V%S/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^3W)G86YI>F%T
M:6]N/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#`V+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0F%S
M:7-?;V9?4')E<V5N=&%T:6]N/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`W+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^4W5M;6%R>5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`X+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^1&ES8V]N=&EN
M=65D7T]P97)A=&EO;G-?;V9?061E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`Y+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^4V5L96-T961?0F%L86YC95]3:&5E=%]);F9O<FUA
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#$P+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W1O8VM"
M87-E9%]#;VUP96YS871I;VX\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3$N:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y3=&]C:U]0=7)C:&%S95]787)R86YT<SPO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970Q,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K:&]L9&5R<U]%<75I
M='D\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,3,N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=6)S
M97%U96YT7T5V96YT<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q-"YH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@(#PO>#I%>&-E;%=O<FMS:&5E=',^#0H@(#QX
M.E-T>6QE<VAE970@2%)E9CTS1")7;W)K<VAE971S+W)E<&]R="YC<W,B+SX-
M"B`@/'@Z06-T:79E4VAE970^,#PO>#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O
M=&5C=%-T<G5C='5R93Y&86QS93PO>#I0<F]T96-T4W1R=6-T=7)E/@T*("`\
M>#I0<F]T96-T5VEN9&]W<SY&86QS93PO>#I0<F]T96-T5VEN9&]W<SX-"B`\
M+W@Z17AC96Q7;W)K8F]O:SX-"CPO>&UL/CPA6V5N9&EF72TM/@T*/"]H96%D
M/@T*("`\8F]D>3X-"B`@(#QP/E1H:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D
M('=I=&@@36EC<F]S;V9T($5X8V5L(%A0(&]R(&YE=V5R+CPO<#X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S8X-#)C9#$T7S@X
M8SA?-#)E,U]A,3%F7V4U,C,V-S`Y9&9D.0T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B\V.#0R8V0Q-%\X.&,X7S0R93-?83$Q9E]E-3(S-C<P.61F
M9#DO5V]R:W-H965T<R]3:&5E=#`Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%4T%!13X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY$;V-U;65N="!A;F0@16YT:71Y($EN9F]R
M;6%T:6]N/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L
M(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%Y(#$T
M+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M;G1I='D@4F5G:7-T<F%N="!.86UE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#Y3>6YT:&5T:6,@0FEO;&]G:6-S+"!);F,N/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@0V5N
M=')A;"!);F1E>"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/C`P,#`X.30Q-3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-U<G)E;G0@1FES8V%L(%EE87(@16YD($1A=&4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/BTM,3(M,S$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!&
M:6QE<B!#871E9V]R>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M4VUA;&QE<B!297!O<G1I;F<@0V]M<&%N>3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5')A9&EN9R!3>6UB;VP\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/G-Y;CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($-O;6UO
M;B!3=&]C:RP@4VAA<F5S($]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS,RPP,38L,3<U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!4>7!E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XQ,"U1/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;65N9&UE;G0@1FQA
M9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^9F%L<V4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M
M96YT(%!E<FEO9"!%;F0@1&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^36%R(#,Q+`T*"0DR,#$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!&:7-C86P@4&5R:6]D
M($9O8W5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y1,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C
M=6UE;G0@1FES8V%L(%EE87(@1F]C=7,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/C(P,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7S8X-#)C9#$T7S@X8SA?-#)E,U]A,3%F7V4U,C,V-S`Y9&9D
M.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V.#0R8V0Q-%\X.&,X
M7S0R93-?83$Q9E]E-3(S-C<P.61F9#DO5V]R:W-H965T<R]3:&5E=#`R+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%4%E!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY#;VYS
M;VQI9&%T960@0F%L86YC92!3:&5E=',@*%531"`D*3QB<CY);B!4:&]U<V%N
M9',L('5N;&5S<R!O=&AE<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,CQB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%S<V5T
M<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M87-H/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8L.#`R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V
M+#8W.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^06-C;W5N=',@<F5C96EV86)L92`M(&YE=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-#0P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-#`U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^.#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^07-S971S(&]F(&1I<V-O;G1I;G5E
M9"!O<&5R871I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y4;W1A;"!#=7)R96YT($%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-RPS,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XW+#$R,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R='D@86YD(&5Q=6EP;65N
M="P@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,#,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,C,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DQO;F<M=&5R;2!N;W1E(')E8V5I=F%B;&4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C<P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1E<&]S:71S(&%N9"!O=&AE<B!A<W-E=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!!
M<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L,S0Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPT
M-S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^3&EA8FEL:71I97,@86YD(%-T;V-K:&]L9&5R<R<@17%U
M:71Y/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D%C8V]U;G1S('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,Q-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,X.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06-C<G5E9"!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!#=7)R96YT($QI86)I
M;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-#,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,3<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y4;W1A;"!,:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-#0S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-#$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T;V-K:&]L9&5R<R<@17%U:71Y.CPO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F
M97)R960@<W1O8VLL("0P+C`P,2!P87(@=F%L=64[(#$P+#`P,"PP,#`@<VAA
M<F5S(&%U=&AO<FEZ960L(&YO;F4@:7-S=65D(&%N9"!O=71S=&%N9&EN9SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C
M:RP@)#`N,#`Q('!A<B!V86QU93L@,3`P+#`P,"PP,#`@<VAA<F5S(&%U=&AO
M<FEZ960L(#,R+#@U-RPV,#D@:7-S=65D(&%N9"`S,BPW-S8L,3(W(&]U='-T
M86YD:6YG(&%N9"`S,2PS-S0L,#`R(&ES<W5E9"!A;F0@,S$L,CDR+#4R,"!O
M=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^061D:71I;VYA;"!P86ED+6EN(&-A<&ET86P\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C8P+#DT-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4X+#DP,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C=6UU;&%T960@9&5F
M:6-I=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-3,L,#<S*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4Q
M+#@W,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y4;W1A;"!3=&]C:VAO;&1E<G,G($5Q=6ET>3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-RPY,#8\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#`U.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L($QI86)I
M;&ET:65S(&%N9"!3=&]C:VAO;&1E<G,G($5Q=6ET>3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`X+#,T.3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-RPT-S8\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S8X-#)C9#$T7S@X8SA?-#)E
M,U]A,3%F7V4U,C,V-S`Y9&9D.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B\V.#0R8V0Q-%\X.&,X7S0R93-?83$Q9E]E-3(S-C<P.61F9#DO5V]R
M:W-H965T<R]3:&5E=#`S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%0TU!0SX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#$^/'-T<F]N9SY#;VYS;VQI9&%T960@0F%L86YC92!3:&5E=',@6U!A
M<F5N=&AE=&EC86Q=("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL('!A
M<B!V86QU92`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`P,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T
M;V-K+"!S:&%R97,@875T:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C
M:RP@<VAA<F5S(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!R969E<G)E9"!S=&]C:RP@<VAA<F5S(&]U='-T86YD:6YG/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K
M+"!P87(@=F%L=64@*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`P,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S
M=&]C:RP@<VAA<F5S(&%U=&AO<FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$P,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3`P+#`P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C
M:RP@<VAA<F5S(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,S(L.#4W+#8P.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,Q+#,W-"PP,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<VAA<F5S
M(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M,BPW-S8L,3(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,S$L,CDR+#4R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?-C@T,F-D,31?.#AC.%\T,F4S7V$Q,69?934R,S8W
M,#ED9F0Y#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8X-#)C9#$T
M7S@X8SA?-#)E,U]A,3%F7V4U,C,V-S`Y9&9D.2]7;W)K<VAE971S+U-H965T
M,#0N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5:4T%%/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/D-O;G-O;&ED871E9"!3=&%T96UE;G1S(&]F($]P97)A=&EO;G,@*%531"`D
M*3QB<CY);B!4:&]U<V%N9',L(&5X8V5P="!3:&%R92!D871A+"!U;FQE<W,@
M;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DUA<BX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^36%R+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY/<&5R871I;F<@0V]S=',@86YD($5X<&5N
M<V5S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y'96YE<F%L(&%N9"!A9&UI;FES=')A=&EV93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Q+#0V.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PR,S,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!D
M979E;&]P;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S@V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5&]T86P@3W!E<F%T:6YG($-O<W1S(&%N9"!%>'!E;G-E<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PX-30\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#0V-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO<W,@
M9G)O;2!#;VYT:6YU:6YG($]P97)A=&EO;G,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#$L.#4T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#$L-#8T*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/=&AE<B!);F-O
M;64@*$5X<&5N<V4I.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y787)R86YT(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@W,38I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#:&%N9V4@:6X@9F%I<B!V86QU92!O9B!W
M87)R86YT(&QI86)I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#DT*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3&]S<R!O;B!T:&4@<V%L92!O9B!E<75I<&UE;G0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@:6YC;VUE/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-38\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!/=&AE
M<B!);F-O;64@*$5X<&5N<V4I+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@W-3DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3F5T($QO<W,@9G)O;2!#;VYT:6YU:6YG($]P
M97)A=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L.#0Y
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#(L,C(S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3F5T($EN8V]M92!F<F]M($1I<V-O;G1I;G5E9"!/<&5R871I
M;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-#D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE
M="!,;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$L,C`P
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M)"`H,BPQ.#8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/DYE="!);F-O;64@*$QO<W,I(%!E<B!3:&%R
M92`M($)A<VEC(&%N9"!$:6QU=&EV93H\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=&EN=6EN9R!O<&5R871I;VYS("AI
M;B!D;VQL87)S('!E<B!S:&%R92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^)"`H,"XP-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B0@*#`N,#DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$:7-C;VYT:6YU960@;W!E<F%T:6]N
M<R`H:6X@9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#`N,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!,;W-S(%!E<B!3:&%R92`H:6X@
M9&]L;&%R<R!P97(@<VAA<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B0@*#`N,#0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XD("@P+C`Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@879E<F%G92!N=6UB97(@
M;V8@<VAA<F5S(&]U='-T86YD:6YG(&1U<FEN9R!T:&4@<&5R:6]D("T@0F%S
M:6,@86YD($1I;'5T:79E("AI;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS,BPP,#,L,38T/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4L,C(P+#8Y-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C@T,F-D,31?.#AC.%\T
M,F4S7V$Q,69?934R,S8W,#ED9F0Y#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+S8X-#)C9#$T7S@X8SA?-#)E,U]A,3%F7V4U,C,V-S`Y9&9D.2]7
M;W)K<VAE971S+U-H965T,#4N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5!6$%'/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/D-O;G-O;&ED871E9"!3=&%T96UE;G1S(&]F($-A
M<V@@1FQO=W,@*%531"`D*3QB<CY);B!4:&]U<V%N9',L('5N;&5S<R!O=&AE
M<G=I<V4@<W!E8VEF:65D/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M36%R+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y-87(N(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D-A<V@@1FQO=W,@1G)O;2!/<&5R871I;F<@06-T
M:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M)"`H,2PX-#DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XD("@R+#(R,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!I;F-O;64@9G)O;2!D:7-C;VYT:6YU
M960@;W!E<F%T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-C0Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^061J=7-T;65N=',@=&\@<F5C;VYC:6QE(&YE="!L
M;W-S('1O(&YE="!C87-H('5S960@:6X@;W!E<F%T:6YG(&%C=&EV:71E<SH\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O
M8VLM8F%S960@8V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XU,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XW-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&ES<W5E9"!A<R!E;7!L;WEE92!C;VUP
M96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4W1O8VL@:7-S=65D(&9O<B!C;VYS=6QT:6YG(&9E97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N="!E>'!E;G-E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S$V/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#:&%N9V4@:6X@9F%I
M<B!V86QU92!O9B!W87)R86YT(&QI86)I;&ET>3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/CDT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y$97!R96-I871I;VX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^.#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W9I<VEO;B!F;W(@=6YC;VQL
M96-T:6)L92!A8V-O=6YT<R!R96-E:79A8FQE/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DQO<W,@;VX@<V%L92!O9B!E<75I<&UE;G0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'86EN(&]N('1H
M92!S971T;&5M96YT(&]F(&%C8V]U;G1S('!A>6%B;&4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@V,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0VAA;F=E<R!I;B!O
M<&5R871I;F<@87-S971S(&%N9"!L:6%B:6QI=&EE<SH\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@<F5C96EV
M86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#,I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3$Q*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3W1H97(@8W5R<F5N="!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#8W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(V.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3F]T92!R96-E:79A8FQE/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@W,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5P;W-I=',@86YD(&]T:&5R(&%S
M<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^07-S
M971S(&]F(&1I<V-O;G1I;G5E9"!O<&5R871I;VYS/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S('!A>6%B;&4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#<R*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!L:6%B
M:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q.3(I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y,:6%B:6QI=&EE<R!O9B!D:7-C;VYT:6YU960@;W!E<F%T:6]N<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0P*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!#87-H(%5S
M960@26X@3W!E<F%T:6YG($%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#$L-#$U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#(X,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V%S:"!&;&]W<R!&
M<F]M($EN=F5S=&EN9R!!8W1I=FET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M('1H92!S86QE
M(&]F(&5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.970@0V%S:"!0<F]V:61E9"!">2!);G9E<W1I;F<@06-T:79I=&EE
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M0V%S:"!&;&]W<R!&<F]M($9I;F%N8VEN9R!!8W1I=FET:65S.CPO<W1R;VYG
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F
M<F]M(&ES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!F;W(@<W1O8VL@;W!T:6]N
M(&5X97)C:7-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y0<F]C965D<R!F<F]M(&ES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!F;W(@
M=V%R<F%N="!E>&5R8VES97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$L-#<Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!I<W-U86YC92!O9B!C;VUM;VX@
M<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V%S:"!P86ED(&%S(&1I<F5C="!O9F9E<FEN9R!C;W-T<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#(Y-BD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@0V%S:"!0<F]V:61E
M9"!">2!&:6YA;F-I;F<@06-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PU,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS+#<Q,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!I;F-R96%S92!I;B!C87-H
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C0\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#0S,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S
M:"!A="!B96=I;FYI;F<@;V8@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XV+#8W.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(L-C0Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%T(&5N9"!O9B!P97)I;V0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L.#`R/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPP.#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^4W5P<&QE;65N=&%L(&1I<V-L;W-U<F5S(&]F(&-A<V@@9FQO=R!I
M;F9O<FUA=&EO;CH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V%S:"!P86ED(&9O<B!I;G1E<F5S=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@<&%I9"!F;W(@=&%X97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C@T,F-D,31?.#AC.%\T
M,F4S7V$Q,69?934R,S8W,#ED9F0Y#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+S8X-#)C9#$T7S@X8SA?-#)E,U]A,3%F7V4U,C,V-S`Y9&9D.2]7
M;W)K<VAE971S+U-H965T,#8N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY/<F=A;FEZ871I;VX\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!8V-O=6YT:6YG(%!O;&EC
M:65S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3F%T=7)E(&]F($]P97)A=&EO;G,@6U1E>'0@0FQO8VM=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=M
M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[)SX\8CXQ+B8C,38P.R8C,38P.R8C,38P.T]R9V%N:7IA
M=&EO;CPO8CX\+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V
M,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G
M:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
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M=')O<&AI8R!L871E<F%L('-C;&5R;W-I<R`H04Q3*2X\+W`^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V
M,#L\+W`^#0H\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&)O<F1E<BUC
M;VQL87!S93H@8V]L;&%P<V4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[)SX-"CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E
M>'0M86QI9VXZ(&-E;G1E<CL@=VED=&@Z(#(T)3L@<&%D9&EN9RUR:6=H=#H@
M,"XX<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&(^365D:6-A;"!);F1I8V%T
M:6]N/"]B/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!W:61T:#H@,B4[('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L
M:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@=VED=&@Z(#(T)3L@<&%D9&EN9RUR
M:6=H=#H@,"XX<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^/&(^4')O9'5C="!#
M86YD:61A=&4\+V(^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([('=I9'1H.B`R)3L@<&%D9&EN9RUR:6=H=#H@,"XX<'0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P
M="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!W:61T:#H@-#@E.R!P861D
M:6YG+7)I9VAT.B`P+CAP=#L@9F]N="UW96EG:'0Z(&)O;&0[)SX\8CY3=&%T
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M8V%L+6%L:6=N.B!T;W`[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('!A9&1I;F<M<FEG:'0Z
M(#`N.'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('!A9&1I;F<M<FEG
M:'0Z(#`N.'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[/"]T
M9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#LG
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@<&%D9&EN9RUR
M:6=H=#H@,"XX<'0[)SY296QA<'-I;F<M<F5M:71T:6YG($U3/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('!A9&1I;F<M<FEG:'0Z
M(#`N.'!T.R<^)B,Q-C`[/"]T9#X-"CQT9#X-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CL@;6%R9VEN.B`P<'0@,"XX<'0@,'!T(#!P>#L@9F]N
M=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/E1R:6UE
M<W1A/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!M87)G
M:6XZ(#!P="`P+CAP="`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R<^*&]R86P@97-T<FEO;"D\+W`^#0H\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@<&%D9&EN9RUR
M:6=H=#H@,"XX<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CL@<&%D9&EN9RUR:6=H=#H@,"XX<'0[)SY!;&P@<&%T
M:65N=',@96YR;VQL960@:6X@4&AA<V4@24D@8VQI;FEC86P@=')I86P[/&)R
M("`O/F1O<VEN9R!A;F0@;6]N:71O<FEN9R!U;F1E<G=A>3PO=&0^#0H\+W1R
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[)SX-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('!A9&1I;F<M<FEG:'0Z(#`N
M.'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('!A9&1I;F<M<FEG:'0Z
M(#`N.'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('!A9&1I;F<M<FEG
M:'0Z(#`N.'!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ('1O<#LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@<&%D9&EN9RUR:6=H=#H@,"XX<'0[)SY#;V=N:71I=F4@
M9'ES9G5N8W1I;VX@:6X\8G(@("\^35,\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&-E;G1E<CL@<&%D9&EN9RUR:6=H=#H@,"XX<'0[)SXF(S$V
M,#L\+W1D/@T*/'1D/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!M87)G:6XZ(#!P="`P+CAP="`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^5')I;65S=&$\+W`^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&UA<F=I;CH@,'!T(#`N.'!T
M(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[)SXH;W)A;"!E<W1R:6]L*3PO<#X-"CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R!P861D:6YG+7)I9VAT.B`P+CAP=#LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!P861D:6YG+7)I9VAT.B`P+CAP=#LG/E!A=&EE;G0@96YR;VQL;65N="!U
M;F1E<G=A>2!I;B!0:&%S92!)23QB<B`@+SYC;&EN:6-A;"!T<FEA;#PO=&0^
M#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[)SX-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('!A9&1I;F<M<FEG
M:'0Z(#`N.'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('!A9&1I;F<M
M<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('!A9&1I
M;F<M<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y
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M96YT97([('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('!A9&1I;F<M<FEG:'0Z
M(#`N.'!T.R<^4&%R=&YE<F5D('=I=&@@365D82!!0CPO=&0^#0H\+W1R/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[)SX-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!C96YT97([('!A9&1I;F<M<FEG:'0Z(#`N.'!T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('!A9&1I;F<M<FEG:'0Z(#`N
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M=&5X="UA;&EG;CH@8V5N=&5R.R!P861D:6YG+7)I9VAT.B`P+CAP=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!P
M861D:6YG+7)I9VAT.B`P+CAP=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R!P861D:6YG+7)I9VAT.B`P+CAP=#LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!P861D:6YG+7)I9VAT.B`P+CAP=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!P861D:6YG+7)I9VAT.B`P+CAP
M=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!T;W`[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R<^04Q3/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!C96YT97([('!A9&1I;F<M<FEG:'0Z(#`N.'!T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R<^045.+3$P,#PO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!P861D:6YG+7)I9VAT.B`P
M+CAP=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M8V5N=&5R.R!P861D:6YG+7)I9VAT.B`P+CAP=#LG/E!H87-E($E)+TE)22!C
M;&EN:6-A;"!T<FEA;"!P<F5P87)A=&EO;B!U;F1E<G=A>3PO=&0^#0H\+W1R
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[)SX-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('!A9&1I;F<M<FEG:'0Z(#`N
M.'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('!A9&1I;F<M<FEG:'0Z
M(#`N.'!T.R<^*&=A<W1R;W)E=&5N=&EV92!Z:6YC(&%C971A=&4I/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('!A9&1I;F<M<FEG
M:'0Z(#`N.'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([('!A9&1I;F<M<FEG:'0Z(#`N.'!T.R<^)B,Q-C`[/"]T
M9#X-"CPO='(^#0H\+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?-C@T,F-D,31?.#AC.%\T,F4S7V$Q,69?934R,S8W
M,#ED9F0Y#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8X-#)C9#$T
M7S@X8SA?-#)E,U]A,3%F7V4U,C,V-S`Y9&9D.2]7;W)K<VAE971S+U-H965T
M,#<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY"
M87-I<R!O9B!0<F5S96YT871I;VX\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^36%R+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!8V-O=6YT:6YG(%!O;&EC:65S(%M!
M8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0G5S:6YE<W,@1&5S8W)I<'1I;VX@86YD($)A<VES(&]F(%!R97-E
M;G1A=&EO;B!;5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CQB/C(N)B,Q-C`[
M)B,Q-C`[)B,Q-C`[0F%S:7,@;V8@4')E<V5N=&%T:6]N/"]B/CPO<#X-"CQP
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M(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R!M87)G:6XZ(#!P="`P<'@[(&9O
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M8W1I;VYS('1O($9O<FT@,3`M42!A;F0@07)T:6-L92`Q,"!O9B!296=U;&%T
M:6]N(%,M6"X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y
M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@;6%R9VEN.B`P<'0@,'!X.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q
M-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@8F%C
M:V=R;W5N9"UC;VQO<CH@=VAI=&4[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/CPO<#X-"CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&)A8VMG<F]U;F0M8V]L
M;W(Z('=H:71E.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY4:&4@9FEN86YC:6%L(&EN9F]R
M;6%T:6]N(&%S(&]F($1E8V5M8F5R(#,Q+"`R,#$Q+"!I<R!D97)I=F5D(&9R
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M:"!T:&4@0V]M<&%N>28C.#(Q-SMS($%N;G5A;"!297!O<G0@;VX@1F]R;2`Q
M,"U++T$L('=H:6-H(&-O;G1A:6YS('1H92!A=61I=&5D(&9I;F%N8VEA;"!S
M=&%T96UE;G1S(&%N9"!N;W1E<R!T:&5R971O+"!T;V=E=&AE<B!W:71H('1H
M92!-86YA9V5M96YT)B,X,C$W.W,@1&ES8W5S<VEO;B!A;F0@06YA;'ES:7,L
M(&9O<B!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,2X\+W`^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!B86-K9W)O=6YD+6-O
M;&]R.B!W:&ET93L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@8F%C:V=R;W5N9"UC;VQO<CH@
M=VAI=&4[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@
M<F]M86XL('1I;65S+"!S97)I9CLG/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&IU<W1I9GD[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R!M87)G
M:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
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M:6]N+"!H;W=E=F5R+"!T:&%T(&%L;"!M871E<FEA;"!A9&IU<W1M96YT<R`H
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M="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@;6%R9VEN.B`P<'0@,'!X
M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^
M/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN
M.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L
M('-E<FEF.R<^5&AE($-O;7!A;GD@:&%S('-E=F5N('-U8G-I9&EA<FEE<RP@
M4&EP97@@5&AE<F%P975T:6-S+"!);F,N("@F(S@R,C`[4&EP97@@5&AE<F%P
M975T:6-S)B,X,C(Q.RDL($5F9F5C=&EV92!0:&%R;6%C975T:6-A;',L($EN
M8RX@*"8C.#(R,#M%4$DF(S@R,C$[*2P@4V]L;W9A>"P@26YC+B`H)B,X,C(P
M.U-O;&]V87@F(S@R,C$[*2P@0T0T($)I;W-C:65N8V5S+"!);F,N("@F(S@R
M,C`[0T0T)B,X,C(Q.RDL($5P:71O<&4@4&AA<FUA8V5U=&EC86QS+"!);F,N
M("@F(S@R,C`[17!I=&]P928C.#(R,3LI+"!(96%L=&AM:6YE+"!);F,N("@F
M(S@R,C`[2&5A;'1H;6EN928C.#(R,3LI(&%N9"!0=71N97D@1')U9R!#;W)P
M+B`H)B,X,C(P.U!U=&YE>28C.#(R,3LI+B!!<R!O9B!-87)C:"`S,2P@,C`Q
M,BP@15!)+"!(96%L=&AM:6YE(&%N9"!0=71N97D@87)E('=H;VQL>2!O=VYE
M9"!A;F0@4&EP97@@5&AE<F%P975T:6-S+"!3;VQO=F%X+"!#1#0@86YD($5P
M:71O<&4@87)E(&UA:F]R:71Y+6]W;F5D+CPO<#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S8X-#)C9#$T7S@X8SA?-#)E,U]A
M,3%F7V4U,C,V-S`Y9&9D.0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B\V.#0R8V0Q-%\X.&,X7S0R93-?83$Q9E]E-3(S-C<P.61F9#DO5V]R:W-H
M965T<R]3:&5E=#`X+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O
M;&EC:65S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@
M,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^06-C;W5N=&EN9R!0;VQI8VEE<R!;06)S=')A8W1=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-I9VYI9FEC
M86YT($%C8V]U;G1I;F<@4&]L:6-I97,@6U1E>'0@0FQO8VM=/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=M87)G:6XZ(#!P
M="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[)SX\8CXS+B8C,38P.R8C,38P.R8C,38P.U-U;6UA<GD@;V8@4VEG;FEF
M:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<SPO8CX\+W`^#0H\<"!S='EL93TS
M1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\8CX\:3Y0<FEN8VEP
M;&5S(&]F($-O;G-O;&ED871I;VX\+VD^/"]B/CPO<#X-"CQP('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO
M<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@
M,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CLG/D%L;"!I;G1E<BUC;VUP86YY('1R86YS86-T:6]N<R!A;F0@86-C
M;W5N=',@:&%V92!B965N(&5L:6UI;F%T960@:6X@8V]N<V]L:61A=&EO;BX\
M+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ
M(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J
M=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\8CX\:3Y5<V4@;V8@17-T:6UA=&5S
M/"]I/CPO8CX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y
M.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@
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M;W-E(&5S=&EM871E<RX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J
M=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\8G(@("\^/&(^/&D^06-C
M;W5N=',@4F5C96EV86)L92!A;F0@06QL;W=A;F-E(&9O<B!$;W5B=&9U;"!!
M8V-O=6YT<SPO:3X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^06-C;W5N
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M:3X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@
M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R<^/&(^/&D^4F5V96YU92!296-O9VYI=&EO;CPO:3X\
M+V(^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R
M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^5&AE($-O;7!A;GD@<F5C;W)D
M<R!R979E;G5E('=H96X@86QL(&]F('1H92!F;VQL;W=I;F<@:&%V92!O8V-U
M<G)E9#H@*#$I('!E<G-U87-I=F4@979I9&5N8V4@;V8@86X@87)R86YG96UE
M;G0@97AI<W1S+"`H,BD@=&AE('-E<G9I8V4@:7,@8V]M<&QE=&5D('=I=&AO
M=70@9G5R=&AE<B!O8FQI9V%T:6]N+"`H,RD@=&AE('-A;&5S('!R:6-E('1O
M('1H92!C=7-T;VUE<B!I<R!F:7AE9"!O<B!D971E<FUI;F%B;&4L(&%N9"`H
M-"D@8V]L;&5C=&%B:6QI='D@:7,@<F5A<V]N86)L>2!A<W-U<F5D+B8C,38P
M.R8C,38P.U1H92!#;VUP86YY(')E8V]G;FEZ97,@;6EL97-T;VYE('!A>6UE
M;G1S(&]R('5P9G)O;G0@<&%Y;65N=',@=&AA="!H879E(&YO(&-O;G1I;F=E
M;F-I97,@87,@<F5V96YU92!W:&5N('!A>6UE;G0@:7,@<F5C96EV960N)B,Q
M-C`[)B,Q-C`[1F]R('1H92!T:')E92!M;VYT:',@96YD960@36%R8V@@,S$L
M(#(P,3(@86YD(#(P,3$L('1H92!#;VUP86YY)B,X,C$W.W,@;VYL>2!S=')E
M86T@;V8@<F5V96YU92!W87,@;&%B;W)A=&]R>2!R979E;G5E+B8C,38P.TQA
M8F]R871O<GD@<F5V96YU97,@87)E(&$@8V]M<&]N96YT(&]F(&1I<V-O;G1I
M;G5E9"!O<&5R871I;VYS(&9O<B!T:&4@=&AR964@;6]N=&AS(&5N9&5D($UA
M<F-H(#,Q+"`R,#$R(&%N9"`R,#$Q+B`\:3Y3964@3F]T92`T("8C.#(Q,3L@
M1&ES8V]N=&EN=65D($]P97)A=&EO;G,@;V8@061E;VYA($-L:6YI8V%L($QA
M8F]R871O<GD@86YD($YO=&4@4F5C96EV86)L92X\+VD^/"]P/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q
M-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R
M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R<^/&D^3&EC96YS92!2979E;G5E<SPO:3X\+W`^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[
M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF
M(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M
M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
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M="!R96-E:79E9"!A;GD@<F]Y86QT>2!R979E;G5E<RX\+W`^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V
M,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G
M:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[)SY/;B!-87D@-BP@,C`Q,"P@=&AE($-O;7!A;GD@96YT97)E
M9"!I;G1O('1H92!-961A($%G<F5E;65N="!F;W(@=&AE(&1E=F5L;W!M96YT
M(&%N9"!C;VUM97)C:6%L:7IA=&EO;B!O9B!%9F9I<FUA("AO<F%L(&9L=7!I
M<G1I;F4I(&9O<B!F:6)R;VUY86QG:6$N)B,Q-C`[($%S(&-O;G-I9&5R871I
M;VX@9F]R('1H92!S=6)L:6-E;G-E+"!T:&4@0V]M<&%N>2!R96-E:79E9"!A
M;B!U<"UF<F]N="!P87EM96YT(&]F("0R+C4@;6EL;&EO;B!U<&]N(&5X96-U
M=&EO;B!O9B!T:&4@365D82!!9W)E96UE;G0N(%1H:7,@<&%Y;65N="!W87,@
M<F5C;W)D960@87,@;&EC96YS92!R979E;G5E(&EN(#(P,3`N(%!U<G-U86YT
M('1O('1H92!#;VUP86YY)B,X,C$W.W,@;&EC96YS92!A9W)E96UE;G0@=VET
M:"!-8TQE86X@2&]S<&ET86PL('1H92!#;VUP86YY('!A:60@,34E(&]F('1H
M92`D,BXU(&UI;&QI;VX@<&%Y;65N="`H)#,W-2PP,#`I+"!T:&%T('=A<R!N
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M97,L(&%N9"!I="!I<R!N;VXM<F5F=6YD86)L92X\+W`^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\
M+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ
M(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
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M9G)O;2!S=6-H('!A>65R<RX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O
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M8W1U86P@<V%L97,@86QL;W=A;F-E(&9O<B!E86-H('!E<FEO9"X\+W`^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P
M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY4:&4@
M0V]M<&%N>2!G96YE<F%T960@<F5I;6)U<G-E;65N=',@9G)O;28C,38P.S,@
M<VEG;FEF:6-A;G0@:6YS=7)A;F-E('!R;W9I9&5R<R!I;B!-87)C:"`S,2P@
M,C`Q,B!A;F0@,C`Q,2P@87,@9F]L;&]W<SH\+W`^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P
M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^
M#0H\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#@P)3L@8F]R9&5R+6-O;&QA<'-E
M.B!C;VQL87!S93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S
M+"!S97)I9CLG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA
M;&EG;CH@8V5N=&5R.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B
M;VQD.R<@8V]L<W!A;CTS1#(^0W5S=&]M97(\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW
M96EG:'0Z(&)O;&0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z
M(&)O;&0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<@8V]L<W!A;CTS1#(^
M,C`Q,CPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T
M97AT+6%L:6=N.B!C96YT97([(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG
M:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,CXR,#$Q/"]T9#X-"CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4]
M,T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I
M9'1H.B`Q)3L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('=I9'1H.B`S,"4[(&9O;G0M
M<VEZ93H@,3!P=#LG/D$\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,B4[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M=VED=&@Z(#$E.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@=VED=&@Z(#,P)3L@9F]N
M="US:7IE.B`Q,'!T.R<^-C@E/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M<VEZ93H@,3!P=#LG/CPO=&0^
M#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#(E.R!F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I
M9'1H.B`Q)3L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('=I9'1H.B`S,"4[(&9O;G0M
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M="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M<VEZ93H@
M,3!P=#LG/C4E/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!F;VYT+7-I>F4Z(#$P<'0[)SX\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M<VEZ93H@,3!P
M=#LG/C$X)3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="US:7IE.B`Q,'!T.R<^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G
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M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([(&9O;G0M<VEZ93H@,3!P=#LG/CDE/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[
M)SX\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([(&9O;G0M<VEZ93H@,3!P=#LG/C4E/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SX\
M+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P
M="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[)SX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM
M97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\8CX\:3Y2:7-K<R!A;F0@
M56YC97)T86EN=&EE<SPO:3X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X
M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^
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M97,N/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R
M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^/&D^0V%S:"!A;F0@0V%S
M:"!%<75I=F%L96YT<SPO:3X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X
M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^
M0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<R!I;F-L=61E(&-A<V@@86YD(&AI
M9VAL>2!L:7%U:60@<VAO<G0M=&5R;2!I;G9E<W1M96YT<R!W:71H(&]R:6=I
M;F%L(&UA='5R:71I97,@;V8@=&AR964@;6]N=&AS(&]R(&QE<W,N)B,Q-C`[
M)B,Q-C`[070@36%R8V@@,S$L(#(P,3(@86YD(#(P,3$L(')E<W!E8W1I=F5L
M>2P@=&AE($-O;7!A;GD@:&%D(&YO(&-A<V@@97%U:79A;&5N=',N/"]P/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@
M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R<^/&(^/&D^)B,Q-C`[/"]I/CPO8CX\+W`^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\8CX\:3Y';V]D=VEL
M;#PO:3X\+V(^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T
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M;V1W:6QL('=A<R!A<W-I9VYE9"X\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM
M97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[
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M=&AE<V4@97-T:6UA=&5S(&%N9"!A<W-U;7!T:6]N<RX\+W`^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V
M,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G
M:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[)SY!="!$96-E;6)E<B`S,2P@,C`Q,2P@:6X@8V]N;F5C=&EO
M;B!W:71H('1H92!#;VUP86YY(&-L87-S:69Y:6YG($%D96]N82!#;&EN:6-A
M;"!,86)O<F%T;W)Y(&%S(&1I<V-O;G1I;G5E9"!O<&5R871I;VYS+"!P<F5V
M:6]U<VQY(')E8V]R9&5D(&=O;V1W:6QL('=A<R!C;VYS:61E<F5D(&EM<&%I
M<F5D+B`\:3Y3964@3F]T92`T("8C.#(Q,3L@1&ES8V]N=&EN=65D($]P97)A
M=&EO;G,@;V8@061E;VYA($-L:6YI8V%L($QA8F]R871O<GD@86YD($YO=&4@
M4F5C96EV86)L93PO:3XN/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/&(^/&D^
M3F5T($5A<FYI;F=S("A,;W-S*2!P97(@4VAA<F4\+VD^/"]B/CPO<#X-"CQP
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T(#!P
M>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG
M/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[
M(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL
M('1I;65S+"!S97)I9CLG/DYE="!E87)N:6YG<R`H;&]S<RD@<&5R('-H87)E
M(&ES(&-O;7!U=&5D(&)Y(&1I=FED:6YG(&YE="!E87)N:6YG<R`H;&]S<RD@
M;&5S<R!P<F5F97)R960@9&EV:61E;F1S(&9O<B!T:&4@<&5R:6]D(&)Y('1H
M92!W96EG:'1E9"!A=F5R86=E(&YU;6)E<B!O9B!C;VUM;VX@<VAA<F5S(&]U
M='-T86YD:6YG+B!$:6QU=&5D(&5A<FYI;F=S("AL;W-S*2!P97(@<VAA<F4@
M:7,@8V]M<'5T960@8GD@9&EV:61I;F<@;F5T(&EN8V]M92`H;&]S<RD@;&5S
M<R!P<F5F97)R960@9&EV:61E;F1S(&)Y('1H92!W96EG:'1E9"!A=F5R86=E
M(&YU;6)E<B!O9B!C;VUM;VX@<VAA<F5S(&]U='-T86YD:6YG(&EN8VQU9&EN
M9R!T:&4@969F96-T(&]F(&-O;6UO;B!S:&%R92!E<75I=F%L96YT<RXF(S$V
M,#M3:6YC92!T:&4@0V]M<&%N>2!R97!O<G1E9"!A(&YE="!L;W-S(&9O<B!T
M:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$R(&%N9"`R,#$Q
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M('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q,B!W97)E(#,L.#0S
M+#0V-2!A;F0@,BPT,30L.3(R+"!R97-P96-T:79E;'DL(&%N9"!F;W(@=&AE
M('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q,2!W97)E(#(L,C<S
M+#`W,B!A;F0@,BPU-30L-C4P+"!R97-P96-T:79E;'DN/"]P/@T*/'`@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q
M-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R
M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R<^/&(^/&D^4F5S96%R8V@@86YD($1E=F5L;W!M96YT($-O
M<W1S/"]I/CPO8CX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P
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M96UE;G1S/"]I/CPO8CX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J
M=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z
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M=FEC97,@<')O=FED960N/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
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M;&]W<RX\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
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M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D1I<V-O;G1I;G5E
M9"!/<&5R871I;VYS(&]F($%D96]N82!#;&EN:6-A;"!,86)O<F%T;W)Y(&%N
M9"!.;W1E(%)E8V5I=F%B;&4\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^36%R+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY$:7-C;VYT:6YU960@3W!E<F%T:6]N<R!A
M;F0@1&ES<&]S86P@1W)O=7!S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&ES<&]S86P@1W)O=7!S+"!)
M;F-L=61I;F<@1&ES8V]N=&EN=65D($]P97)A=&EO;G,L($1I<V-L;W-U<F4@
M6U1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M=&%B;&4@<W1Y;&4],T0G;6%R9VEN+71O<#H@,'!X.R!F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XM8F]T=&]M.B`P
M<'@[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('9E<G1I8V%L+6%L:6=N.B!T
M;W`[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@
M,"XR-6EN.R<^/&(^-"X\+V(^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!J=7-T:69Y.R<^/&(^1&ES8V]N=&EN=65D($]P97)A=&EO;G,@;V8@
M061E;VYA($-L:6YI8V%L($QA8F]R871O<GD@86YD($YO=&4@4F5C96EV86)L
M93PO8CX\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=T97AT
M+6EN9&5N=#H@+3`N-6EN.R!M87)G:6XZ(#!P="`P<'@@,'!T(#`N-6EN.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q
M-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UI;F1E;G0Z("TP+C5I;CL@;6%R
M9VEN.B`P<'0@,'!X(#!P="`P+C5I;CL@9F]N=#H@,3!P="!T:6UE<R!N97<@
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M:61E<F%T:6]N(')E8V5I=F5D('=A<R`H:2D@=&AE(&EM;65D:6%T92!A<W-I
M9VYM96YT(&]F('1H92!,86(F(S@R,3<[<R!O=71S=&%N9&EN9R!A8V-O=6YT
M<R!R96-E:79A8FQE('5P('1H<F]U9V@@=&AE(&1A=&4@;V8@8VQO<VEN9RP@
M<&QU<R`H:6DI("0W,#`L,#`P('!A>6%B;&4@<'5R<W5A;G0@=&\@=&AE('1E
M<FUS(&]F(&$@='=O+7EE87(@;F]N+7)E8V]U<G-E('!R;VUI<W-O<GD@;F]T
M92!B96%R:6YG(&EN=&5R97-T(&%T(#4N-R4@<&5R(&%N;G5M('-E8W5R960@
M8GD@86QL(&]F('1H92!A<W-E=',@;V8@=&AE($QA8BX@5&AE(&YO=&4@86YD
M(&%L;"!U;G!A:60@:6YT97)E<W0@87)E(&1U92!O;B!-87)C:"`Q+"`R,#$T
M+CPO<#X-"CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-
M"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,'!T
M(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CLG/DEN(&%C8V]R9&%N8V4@=VET:"!!4T,@5&]P:6,@,C`U+3(P("8C.#(R
M,#L\:3Y0<F5S96YT871I;VX@;V8@1FEN86YC:6%L(%-T871E;65N=',F(S@R
M,3([1&ES8V]N=&EN=65D($]P97)A=&EO;G,\+VD^("8C.#(R,3L@*$%30R`R
M,#4M,C`I+"!T:&4@0V]M<&%N>2!D971E<FUI;F5D('1H870@86QL('1H92!C
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M;B`F(S@R,C`[07-S971S(&]F(&1I<V-O;G1I;G5E9"!O<&5R871I;VYS)B,X
M,C(Q.R!I;B!T:&4@86-C;VUP86YY:6YG($-O;G-O;&ED871E9"!"86QA;F-E
M(%-H965T<R!A="!-87)C:"`S,2P@,C`Q,BP@86YD($1E8V5M8F5R(#,Q+"`R
M,#$Q+"!A;F0@8V]N<VES="!O9B!T:&4@9F]L;&]W:6YG(#QI/BAI;B!T:&]U
M<V%N9',\+VD^(#QI/BDZ/"]I/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M:6YD
M96YT.B`M,"XU:6X[(&UA<F=I;CH@,'!T(#!P>"`P<'0@,"XU:6X[(&9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\
M+W`^#0H\<"!S='EL93TS1"=T97AT+6EN9&5N=#H@+3`N-6EN.R!M87)G:6XZ
M(#!P="`P<'@@,'!T(#`N-6EN.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'1A8FQE('-T>6QE/3-$
M)W=I9'1H.B`X,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[(&9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)R!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=F;VYT+7-T>6QE
M.B!I=&%L:6,[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N
M.B!C96YT97([(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[
M)R!C;VQS<&%N/3-$,CY-87)C:"`S,2P@,C`Q,CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H
M=#H@8F]L9#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$
M,CY$96-E;6)E<B`S,2P@,C`Q,3PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@
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M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<@8V]L<W!A;CTS
M1#(^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD
M+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ
M(#%P=#L@<&%D9&EN9RUL969T.B`Y<'0[('=I9'1H.B`V,B4[(&9O;G0M<VEZ
M93H@,3!P=#LG/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0L(&YE=#PO=&0^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@=VED=&@Z(#$E.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F
M=#L@=VED=&@Z(#$E.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M
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M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
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M8F]T=&]M.B`R+C5P=#L@<&%D9&EN9RUL969T.B`Y<'0[(&9O;G0M<VEZ93H@
M,3!P=#LG/E1O=&%L(&%S<V5T<SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#(N-7!T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O
M=6)L93L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)#PO
M=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@
M9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^
M+3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN
M9RUB;W1T;VTZ(#(N-7!T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[
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M(&5N9&5D($UA<F-H(#,Q+"`R,#$R(&%N9"!-87)C:"`S,2P@,C`Q,2!A<F4@
M87,@9F]L;&]W<R`\:3XH:6X@=&AO=7-A;F1S*3H\+VD^/"]P/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R<^/&D^)B,Q-C`[/"]I/CPO<#X-"CQT86)L
M92!S='EL93TS1"=W:61T:#H@.#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA
M<'-E.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I
M9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG(&-O;'-P86X]
M,T0V/DUA<F-H(#,Q+#PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG
M/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=F;VYT+7-T>6QE.B!I=&%L
M:6,[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT
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M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T
M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
M<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+7=E:6=H=#H@8F]L9#LG(&-O;'-P86X],T0R/C(P,3$\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UW96EG:'0Z(&)O;&0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT
M<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@=VED=&@Z(#8R)3L@9F]N="US:7IE.B`Q,'!T.R<^3&%B;W)A=&]R
M>2!F965S+"!N970\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M<VEZ93H@,3!P=#LG/B0\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@
M,38E.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ,34\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$V
M)3L@9F]N="US:7IE.B`Q,'!T.R<^,S(S/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M
M8V]L;W(Z('=H:71E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
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M;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CPO
M='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!P861D:6YG+6QE9G0Z(#EP=#L@9F]N="US:7IE.B`Q,'!T
M.R<^1V5N97)A;"!A;F0@861M:6YI<W1R871I=F4\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US
M:7IE.B`Q,'!T.R<^,C<\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXS-3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^
M#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[('!A9&1I;F<M;&5F=#H@
M.7!T.R!F;VYT+7-I>F4Z(#$P<'0[)SY#;W-T(&]F)B,Q-C`[(&QA8F]R871O
M<GD@<V5R=FEC97,\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
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M(#%P=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z
M(#$P<'0[)SXR-3$\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L
M;W(Z('=H:71E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P=#L@
M<&%D9&EN9RUL969T.B`Y<'0[(&9O;G0M<VEZ93H@,3!P=#LG/E1O=&%L(&]P
M97)A=&EN9R!C;W-T<R!A;F0@97AP96YS97,\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T
M('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M<VEZ93H@,3!P
M=#LG/C$T,SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I
M9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXR.#8\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M
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M=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^*#(X/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z
M(#$P<'0[)SXI/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M<VEZ93H@,3!P=#LG/C,W/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P
M<'0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O
M=6YD+6-O;&]R.B!W:&ET93L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*
M/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T
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M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y
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M;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
M9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXV-S<\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@
M<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T
M.R<^+3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D
M9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T
M9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C
M9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z
M(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
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M;G,\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ
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M)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
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M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\
M+W1D/@T*/"]T<CX-"CPO=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
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M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/E-E;&5C=&5D($)A;&%N8V4@4VAE970@26YF;W)M871I;VX\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,CQB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/<F=A;FEZ
M871I;VXL($-O;G-O;&ED871I;VX@86YD(%!R97-E;G1A=&EO;B!O9B!&:6YA
M;F-I86P@4W1A=&5M96YT<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U<'!L96UE;G1A;"!"86QA;F-E
M(%-H965T($1I<V-L;W-U<F5S(%M497AT($)L;V-K73PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'1A8FQE('-T>6QE/3-$)VUA<F=I;BUT;W`Z
M(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CL@;6%R9VEN+6)O='1O;3H@,'!X.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP
M861D:6YG/3-$,#X-"CQT<B!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y
M.R!V97)T:6-A;"UA;&EG;CH@=&]P.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@=VED=&@Z(#`N,C5I;CLG/CQB/C4N/"]B/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3LG/CQB/E-E;&5C=&5D
M($)A;&%N8V4@4VAE970@26YF;W)M871I;VX\+V(^/"]T9#X-"CPO='(^#0H\
M+W1A8FQE/@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P
M/@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^/"]P/@T*/'`@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT
M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^06-C;W5N
M=',@<F5C96EV86)L92!C;VYS:7-T960@;V8@=&AE(&9O;&QO=VEN9R!A="!-
M87)C:"`S,2P@,C`Q,B!A;F0@1&5C96UB97(@,S$L(#(P,3$@/&D^*&EN('1H
M;W5S86YD<RDZ/"]I/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU
M<W1I9GD[(&UA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@
M<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-"CQT86)L92!S='EL
M93TS1"=W:61T:#H@.#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<@8V5L
M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>3L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M
M86QI9VXZ(&-E;G1E<CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@
M8F]L9#LG(&-O;'-P86X],T0R/DUA<F-H(#,Q+"`R,#$R/"]T9#X-"CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M
M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E
M<CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG(&-O;'-P
M86X],T0R/D1E8V5M8F5R(#,Q+"`R,#$Q/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I
M9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G
M8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('=I
M9'1H.B`V,B4[(&9O;G0M<VEZ93H@,3!P=#LG/D%C8V]U;G1S(')E8V5I=F%B
M;&4\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!W:61T:#H@,24[(&9O;G0M<VEZ93H@,3!P=#LG/B0\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,34E.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXW,S8\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@=VED=&@Z(#$E.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$W)3L@9F]N="US
M:7IE.B`Q,'!T.R<^-CDR/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!W:61T:#H@,24[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO
M=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H
M:71E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US
M:7IE.B`Q,'!T.R<^0F%D(&1E8G0@86QL;W=A;F-E("T@8W5S=&]M97(\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[
M(&9O;G0M<VEZ93H@,3!P=#LG/B@R.38\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ
M93H@,3!P=#LG/BD\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
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M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#LG/BD\+W1D/@T*/"]T<CX-"CQT<B!S
M='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S
M=&EF>3L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!F;VYT+7-I>F4Z(#$P<'0[
M)SY!8V-O=6YT<R!R96-E:79A8FQE+"!N970\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
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M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P
M=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M<VEZ93H@,3!P=#LG/B0\+W1D/@T*/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA
M;&EG;CH@<FEG:'0[(&9O;G0M<VEZ93H@,3!P=#LG/C0P-3PO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N
M-7!T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CPO
M=&%B;&4^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P
M<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#LF(S$V
M,#LF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y
M.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[)SY0<F]P97)T>2!A;F0@17%U:7!M96YT(&-O;G-I
M<W1E9"!O9B!T:&4@9F]L;&]W:6YG(&%T($UA<F-H(#,Q+"`R,#$R+"!A;F0@
M1&5C96UB97(@,S$L(#(P,3$@/&D^*&EN('1H;W5S86YD<RD\+VD^.CPO<#X-
M"CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE
M<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.SPO<#X-"CQT86)L
M92!S='EL93TS1"=W:61T:#H@.#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA
M<'-E.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I
M9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@
M9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG(&-O;'-P86X]
M,T0R/DUA<F-H)B,Q-C`[,S$L)B,Q-C`[,C`Q,CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H
M=#H@8F]L9#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&9O
M;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$
M,CY$96-E;6)E<B8C,38P.S,Q+"`R,#$Q/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M=V5I
M9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G
M8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('=I
M9'1H.B`V,B4[(&9O;G0M<VEZ93H@,3!P=#LG/DUA;G5F86-T=7)I;F<@97%U
M:7!M96YT/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$U)3L@
M9F]N="US:7IE.B`Q,'!T.R<^-#`P/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F;VYT+7-I>F4Z
M(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q-R4[(&9O
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M;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M
M<VEZ93H@,3!P=#LG/C$U.3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^
M#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&IU<W1I9GD[('!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@
M,3!P=#LG/DQA8F]R871O<GD@97%U:7!M96YT/"]T9#X-"CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P
M="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P
M<'0[)SXQ,S8\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R
M:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^,3,V/"]T9#X-"CQT9"!S='EL93TS
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M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M<VEZ93H@,3!P=#LG/C8Y-3PO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R
M;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T
M=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#LG/DQE<W,@86-C=6UU;&%T960@
M9&5P<F5C:6%T:6]N/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,7!T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E
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M="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P
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M=#L@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R
M:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^,S`S/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#(N-7!T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T
M(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^
M)#PO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU
M<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T
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M9&5D($UA<F-H(#,Q+"`R,#$R(&%N9"`R,#$Q('=A<R`D,C`L,#`P(&%N9"`D
M.#`L,#`P+"!R97-P96-T:79E;'DN/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C@T,F-D,31?.#AC.%\T,F4S7V$Q,69?
M934R,S8W,#ED9F0Y#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8X
M-#)C9#$T7S@X8SA?-#)E,U]A,3%F7V4U,C,V-S`Y9&9D.2]7;W)K<VAE971S
M+U-H965T,3$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY3=&]C:RU"87-E9"!#;VUP96YS871I;VX\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$:7-C;&]S=7)E(&]F
M($-O;7!E;G-A=&EO;B!296QA=&5D($-O<W1S+"!3:&%R92UB87-E9"!087EM
M96YT<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D1I<V-L;W-U<F4@;V8@0V]M<&5N<V%T:6]N(%)E;&%T
M960@0V]S=',L(%-H87)E+6)A<V5D(%!A>6UE;G1S(%M497AT($)L;V-K73PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'1A8FQE('-T>6QE/3-$
M)VUA<F=I;BUT;W`Z(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL
M('1I;65S+"!S97)I9CL@;6%R9VEN+6)O='1O;3H@,'!X.R<@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<B!S='EL93TS1"=T97AT+6%L
M:6=N.B!J=7-T:69Y.R!V97)T:6-A;"UA;&EG;CH@=&]P.R<^#0H\=&0@<W1Y
M;&4],T0G=VED=&@Z(#!I;CLG/CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@=VED=&@Z(#`N,C5I;CLG/CQB/C8N/"]B/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3LG/CQB/E-T;V-K+4)A
M<V5D($-O;7!E;G-A=&EO;CPO8CX\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\
M<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY$=7)I
M;F<@,C`P,2P@4&EP97@@5&AE<F%P975T:6-S)B,X,C$W.R!B;V%R9"!O9B!D
M:7)E8W1O<G,@86YD('-T;V-K:&]L9&5R<R!A9&]P=&5D('1H92`R,#`Q(%-T
M;V-K($EN8V5N=&EV92!0;&%N("AT:&4@)B,X,C(P.S(P,#$@4W1O8VL@4&QA
M;B8C.#(R,3LI+B!4:&ES('!L86X@=V%S(&%S<W5M960@8GD@4&EP97@@:6X@
M=&AE($]C=&]B97(@,C`P-B!M97)G97(@=VET:"!3:&5F9FEE;&0N($%S(&]F
M('1H92!D871E(&]F('1H92!M97)G97(L('1H97)E('=E<F4@,2PT.#DL,S4S
M(&]P=&EO;G,@:7-S=65D(&%N9"!O=71S=&%N9&EN9R!U;F1E<B!T:&4@,C`P
M,2!P;&%N+B!4:&4@=&]T86P@;G5M8F5R(&]F('-H87)E<R!O9B!S=&]C:R!W
M:71H(')E<W!E8W0@=&\@=VAI8V@@<W1O8VL@;W!T:6]N<R!A;F0@<W1O8VL@
M87!P<F5C:6%T:6]N(')I9VAT<R!M87D@8F4@9W)A;G1E9"!T;R!A;GD@;VYE
M(&5M<&QO>65E(&]F('1H92!#;VUP86YY(&]R(&$@<W5B<VED:6%R>2!D=7)I
M;F<@86YY(&]N92UY96%R('!E<FEO9"!U;F1E<B!T:&4@,C`P,2!P;&%N('-H
M86QL(&YO="!E>&-E960@,C4P+#`P,"X@06QL(&%W87)D<R!P=7)S=6%N="!T
M;R!T:&4@,C`P,2!3=&]C:R!0;&%N('-H86QL('1E<FUI;F%T92!U<&]N('1H
M92!T97)M:6YA=&EO;B!O9B!T:&4@9W)A;G1E928C.#(Q-SMS(&5M<&QO>6UE
M;G0@9F]R(&%N>2!R96%S;VXN($%W87)D<R!I;F-L=61E(&]P=&EO;G,L(')E
M<W1R:6-T960@<VAA<F5S+"!S=&]C:R!A<'!R96-I871I;VX@<FEG:'1S+"!P
M97)F;W)M86YC92!S:&%R97,@86YD(&-A<V@M8F%S960@87=A<F1S("AT:&4@
M)B,X,C(P.T%W87)D<R8C.#(R,3LI+B!4:&4@,C`P,2!3=&]C:R!0;&%N(&-O
M;G1A:6YS(&-E<G1A:6X@86YT:2UD:6QU=&EO;B!P<F]V:7-I;VYS(&EN('1H
M92!E=F5N="!O9B!A('-T;V-K('-P;&ET+"!S=&]C:R!D:79I9&5N9"!O<B!O
M=&AE<B!C87!I=&%L(&%D:G5S=&UE;G0L(&%S(&1E9FEN960@:6X@=&AE('!L
M86XN(%1H92`R,#`Q(%-T;V-K(%!L86X@<')O=FED97,@9F]R(&$@0V]M;6ET
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M,S$L(#(P,3(L('1H97)E('=E<F4@,2PP-C8L,#`W(&]P=&EO;G,@:7-S=65D
M(&%N9"!O=71S=&%N9&EN9R!U;F1E<B!T:&4@,C`P,2!3=&]C:R!0;&%N+CPO
M<#X-"CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T
M:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG/B8C,38P.R8C,38P.SPO
M<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@
M,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CLG/D]N($UA<F-H(#(P+"`R,#`W+"!T:&4@0V]M<&%N>28C.#(Q-SMS
M(&)O87)D(&]F(&1I<F5C=&]R<R!A<'!R;W9E9"!T:&4@0V]M<&%N>28C.#(Q
M-SMS(#(P,#<@4W1O8VL@26YC96YT:79E(%!L86X@*'1H92`F(S@R,C`[,C`P
M-R!3=&]C:R!0;&%N)B,X,C(Q.RD@9F]R('1H92!I<W-U86YC92!O9B!U<"!T
M;R`R+#4P,"PP,#`@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!T;R!B92!G<F%N
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M92!O9B!S=&]C:R!O<'1I;VYS('5N9&5R('1H92`R,#`W(%-T;V-K(%!L86X@
M:7,@9&5T97)M:6YE9"!B>2!T:&4@8V]M<&5N<V%T:6]N(&-O;6UI='1E92!O
M9B!T:&4@0F]A<F0@;V8@1&ER96-T;W)S+"!A;F0@;6%Y(&)E(&5Q=6%L('1O
M(&]R(&=R96%T97(@=&AA;B!T:&4@9F%I<B!M87)K970@=F%L=64@;V8@=&AE
M($-O;7!A;GDF(S@R,3<[<R!C;VUM;VX@<W1O8VL@;VX@=&AE(&1A=&4@=&AE
M(&]P=&EO;B!I<R!G<F%N=&5D+B!4:&4@=&]T86P@;G5M8F5R(&]F('-H87)E
M<R!O9B!S=&]C:R!W:71H(')E<W!E8W0@=&\@=VAI8V@@<W1O8VL@;W!T:6]N
M<R!A;F0@<W1O8VL@87!P<F5C:6%T:6]N(')I9VAT<R!M87D@8F4@9W)A;G1E
M9"!T;R!A;GD@;VYE(&5M<&QO>65E(&]F('1H92!#;VUP86YY(&]R(&$@<W5B
M<VED:6%R>2!D=7)I;F<@86YY(&]N92UY96%R('!E<FEO9"!U;F1E<B!T:&4@
M,C`P,2!P;&%N('-H86QL(&YO="!E>&-E960@,C4P+#`P,"X@3W!T:6]N<R!B
M96-O;64@97AE<F-I<V%B;&4@;W9E<B!V87)I;W5S('!E<FEO9',@9G)O;2!T
M:&4@9&%T92!O9B!G<F%N="P@86YD(&=E;F5R86QL>2!E>'!I<F4@=&5N('EE
M87)S(&%F=&5R('1H92!G<F%N="!D871E+B!!<R!O9B!-87)C:"`S,2P@,C`Q
M,BP@=&AE<F4@87)E(#$L,#,Q+#,Y-"!O<'1I;VYS(&ES<W5E9"!A;F0@;W5T
M<W1A;F1I;F<@=6YD97(@=&AE(#(P,#<@4W1O8VL@4&QA;BX\+W`^#0H\<"!S
M='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
M(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS
M1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY/;B!.;W9E
M;6)E<B`R+"`R,#$P+"!T:&4@8F]A<F0@;V8@9&ER96-T;W)S(&%N9"!S=&]C
M:VAO;&1E<G,@861O<'1E9"!T:&4@,C`Q,"!3=&]C:R!);F-E;G1I=F4@4&QA
M;B`H)B,X,C(P.S(P,3`@4W1O8VL@4&QA;B8C.#(R,3LI(&9O<B!T:&4@:7-S
M=6%N8V4@;V8@=7`@=&\@,RPP,#`L,#`P('-H87)E<R!O9B!C;VUM;VX@<W1O
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M;V8@<W1O8VL@;W!T:6]N<R!U;F1E<B!T:&4@,C`Q,"!3=&]C:R!0;&%N(&ES
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M('1H92!G<F%N="!D871E+B!!<R!O9B!-87)C:"`S,2P@,C`Q,BP@=&AE<F4@
M87)E(#$L-S0V+#`V-"!O<'1I;VYS(&ES<W5E9"!A;F0@;W5T<W1A;F1I;F<@
M=6YD97(@=&AE(#(P,3`@4W1O8VL@4&QA;BX\+W`^#0H\<"!S='EL93TS1"=M
M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM
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M:6YG('!E<FEO9"X\+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[
M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF
M(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M
M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
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M('5S960@:6X@=&AE(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q,B!A;F0@
M,C`Q,2!A<F4@87,@9F]L;&]W<SH\+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ
M(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[)SXF(S$V,#LF(S$V,#L\+W`^#0H\=&%B;&4@<W1Y;&4],T0G=VED
M=&@Z(#@P)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N=#H@,3!P
M="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#%P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&9O;G0M<VEZ93H@,3!P
M=#L@9F]N="UW96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,SY4:')E928C,38P
M.TUO;G1H<R8C,38P.T5N9&5D)B,Q-C`[36%R8V@F(S$V,#LS,2P\+W1D/@T*
M/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^
M#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z
M(#$P<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M
M86QI9VXZ(&-E;G1E<CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@
M8F]L9#LG/C(P,3(\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M=V5I9VAT.B!B;VQD.R<^,C`Q,3PO=&0^#0H\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!F;VYT+7-I>F4Z(#$P<'0[)SY%
M>&5R8VES92!P<FEC93PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([(&9O;G0M<VEZ93H@,3!P=#LG/B0Q+C$T("8C.#(Q,3L@)#(N-#<\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXD,2XR,2`F(S@R,3$[("0R+C(R/"]T9#X-"CPO='(^#0H\
M='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&IU<W1I9GD[('=I9'1H.B`V,B4[(&9O;G0M<VEZ93H@,3!P=#LG/D5X<&5C
M=&5D(&1I=FED96YD<SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&-E;G1E<CL@=VED=&@Z(#$X)3L@9F]N="US:7IE.B`Q,'!T
M.R<^,"4\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([('=I9'1H.B`Q."4[(&9O;G0M<VEZ93H@,3!P=#LG/C`E/"]T
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M;G1E<CL@9F]N="US:7IE.B`Q,'!T.R<^,3`X)2`F(S@R,3$[(#$W-"4\+W1D
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M+7-I>F4Z(#$P<'0[)SXP+C,W)2`F(S@R,3$[(#$N.3@E/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="US:7IE.B`Q,'!T.R<^
M,BXX,24@)B,X,C$Q.R`S+C4X)3PO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$
M)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R!V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@9F]N
M="US:7IE.B`Q,'!T.R<^17AP96-T960@;&EF92!O<'1I;VYS/"]T9#X-"CQT
M9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="US:7IE.B`Q,'!T
M.R<^,3`@>65A<G,\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
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M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([(&9O;G0M<VEZ93H@,3!P=#LG/C`E/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="US:7IE.B`Q,'!T.R<^
M,"4\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=M87)G:6XZ
M(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J
M=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W
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M86)L92!S='EL93TS1"=W:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E.B!C
M;VQL87!S93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CLG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#LG/@T*/'1D('-T>6QE/3-$
M)W=I9'1H.B`S)3L@<&%D9&EN9RUR:6=H=#H@,"XX<'0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`S)3L@<&%D9&EN9RUR:6=H=#H@,"XX
M<'0[)SXF(SDV-SD[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J
M=7-T:69Y.R!W:61T:#H@.30E.R!P861D:6YG+7)I9VAT.B`P+CAP=#LG/FEM
M;65D:6%T92!V97-T:6YG+#PO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!T;W`[)SX-"CQT9"!S='EL93TS1"=P861D:6YG+7)I
M9VAT.B`P+CAP=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUR:6=H=#H@,"XX<'0[)SXF(SDV-SD[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y.R!P861D:6YG+7)I9VAT.B`P+CAP=#LG/F]N
M92UH86QF('9E<W1I;F<@:6UM961I871E;'D@86YD('1H92!R96UA:6YD97(@
M;W9E<B!T:')E92!Y96%R<SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!T;W`[)SX-"CQT9"!S='EL93TS1"=P861D:6YG+7)I
M9VAT.B`P+CAP=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUR:6=H=#H@,"XX<'0[)SXF(SDV-SD[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y.R!P861D:6YG+7)I9VAT.B`P+CAP=#LG/FUO
M;G1H;'D@;W9E<B!T:')E92!Y96%R<RP\+W1D/@T*/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R<^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUR:6=H=#H@,"XX<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M<FEG:'0Z(#`N.'!T.R<^)B,Y-C<Y.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@<&%D9&EN9RUR:6=H=#H@,"XX
M<'0[)SYQ=6%R=&5R;'D@;W9E<B!T:')E92!Y96%R<RP\+W1D/@T*/"]T<CX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R<^#0H\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUR:6=H=#H@,"XX<'0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z(#`N.'!T.R<^)B,Y-C<Y.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@<&%D9&EN9RUR
M:6=H=#H@,"XX<'0[)SYA;FYU86QL>2!O=F5R('1H<F5E('EE87)S+#PO=&0^
M#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[)SX-
M"CQT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`P+CAP=#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@,"XX<'0[)SXF(SDV
M-SD[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!P
M861D:6YG+7)I9VAT.B`P+CAP=#LG/F]N92UT:&ER9"!I;6UE9&EA=&4@=F5S
M=&EN9R!A;F0@<F5M86EN:6YG(&%N;G5A;&QY(&]V97(@='=O('EE87)S+#PO
M=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[
M)SX-"CQT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`P+CAP=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@,"XX<'0[)SXF
M(SDV-SD[)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J
M=7-T:69Y.R!P861D:6YG+7)I9VAT.B`P+CAP=#LG/F]N92UE:6=H=&@@:6UM
M961I871E('9E<W1I;F<@=VET:"!R96UA:6YI;F<@=F5S=&EN9R!O=F5R('1W
M;R!Y96%R<RP\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@=&]P.R<^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@,"XX
M<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M<FEG:'0Z
M(#`N.'!T.R<^)B,Y-C<Y.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@:G5S=&EF>3L@<&%D9&EN9RUR:6=H=#H@,"XX<'0[)SYO;F4M:&%L9B!I
M;6UE9&EA=&4@=F5S=&EN9R!W:71H(')E;6%I;FEN9R!V97-T:6YG(&]V97(@
M;FEN92!M;VYT:',[(&%N9#PO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!T;W`[)SX-"CQT9"!S='EL93TS1"=P861D:6YG+7)I
M9VAT.B`P+CAP=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUR:6=H=#H@,"XX<'0[)SXF(SDV-SD[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!J=7-T:69Y.R!P861D:6YG+7)I9VAT.B`P+CAP=#LG/F]N
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M9&5D($UA<F-H(#,Q+"`R,#$R+"!T:&4@0V]M<&%N>2!G<F%N=&5D(#$L,S`P
M+#`P,"!O<'1I;VYS('1O(&5M<&QO>65E<R!A;F0@8V]N<W5L=&%N=',@:&%V
M:6YG(&$@9F%I<B!V86QU92!O9B!A<'!R;WAI;6%T96QY("0S(&UI;&QI;VX@
M8F%S960@=7!O;B!T:&4@0FQA8VLM4V-H;VQE<R!O<'1I;VX@<')I8VEN9R!M
M;V1E;"XF(S$V,#L@1'5R:6YG('1H92!S86UE('!E<FEO9"!O9B`R,#$Q+"!T
M:&4@0V]M<&%N>2!G<F%N=&5D(#,R-"PU,#(@;W!T:6]N<R!T;R!E;7!L;WEE
M97,@:&%V:6YG(&$@9F%I<B!V86QU92!O9B!A<'!R;WAI;6%T96QY("0T,S,L
M,#`P(&)A<V5D('5P;VX@=&AE($)L86-K+5-C:&]L97,@;W!T:6]N('!R:6-I
M;F<@;6]D96PN/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0@,'!X.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q
M-C`[/"]P/@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^02!S=6UM87)Y
M(&]F('-T;V-K(&]P=&EO;B!A8W1I=FET:65S(&%S(&]F($UA<F-H(#,Q+"`R
M,#$R+"!A;F0@9F]R('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$Q
M+"!I<R!A<R!F;VQL;W=S.CPO<#X-"CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T
M(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CLG/B8C,38P.SPO<#X-"CQT86)L92!S='EL93TS1"=W:61T:#H@,3`P)3L@
M8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N=#H@,3!P="!T:6UE<R!N
M97<@<F]M86XL('1I;65S+"!S97)I9CLG(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3LG/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!C96YT97([(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW
M96EG:'0Z(&)O;&0[)R!C;VQS<&%N/3-$,CY/<'1I;VYS/"]T9#X-"CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z(#$P<'0[
M(&9O;G0M=V5I9VAT.B!B;VQD.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT.B!B;VQD(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA
M;&EG;CH@8V5N=&5R.R!F;VYT.B!B;VQD(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[)R!C;VQS<&%N/3-$,CY796EG:'1E9"`\8G(@("\^
M079E<F%G92`\8G(@("\^)B,Q-C`[17AE<F-I<V4@/&)R("`O/E!R:6-E/"]T
M9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT.B!B
M;VQD(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O
M;G0Z(&)O;&0@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&9O;G0Z(&)O;&0@
M,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CLG(&-O;'-P86X]
M,T0R/E=E:6=H=&5D($%V97)A9V4@4F5M86EN:6YG(#QB<B`@+SY#;VYT<F%C
M='5A;"`\8G(@("\^3&EF93PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#%P=#L@9F]N=#H@8F]L9"`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,7!T.R!F;VYT.B!B;VQD(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@
M8V5N=&5R.R!F;VYT.B!B;VQD(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[)R!C;VQS<&%N/3-$,CY!9V=R96=A=&4@/&)R("`O/DEN=')I
M;G-I8R`\8G(@("\^5F%L=64\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[(&9O;G0Z(&)O;&0@,3!P="!T:6UE<R!N97<@<F]M86XL
M('1I;65S+"!S97)I9CLG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE
M/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-C8V9F8V,[('9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y
M.R!W:61T:#H@-#@E.R!F;VYT+7-I>F4Z(#$P<'0[)SY"86QA;F-E("8C.#(Q
M,3L@1&5C96UB97(@,S$L(#(P,3`\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q)3L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[('=I9'1H.B`Q,"4[(&9O;G0M<VEZ93H@,3!P=#LG/C(L-3,Y+#`Y
M,3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z
M(#$E.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)3L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O
M;G0M<VEZ93H@,3!P=#LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R!W:61T:#H@,3`E.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ+C,R
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@
M,24[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$P)3L@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W
M:61T:#H@,24[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$E.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q
M)3L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$P)3L@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!W:61T:#H@,24[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^
M#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E
M.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@:G5S=&EF>3L@9F]N="US:7IE.B`Q,'!T.R<^1W)A;G1E9#PO
M=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z
M(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXU-3<L,#`R/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^,2XR-CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4]
M,T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[
M(&9O;G0M<VEZ93H@,3!P=#LG/D5X97)C:7-E9#PO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
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M<VEZ93H@,3!P=#LG/C`N-3<\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-
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M9F]N="US:7IE.B`Q,'!T.R<^1F]R9F5I=&5D(&]R(&5X<&ER960\+W1D/@T*
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[(&9O
M;G0M<VEZ93H@,3!P=#LG/B@Y,RPW-3`\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ
M93H@,3!P=#LG/BD\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X
M="UA;&EG;CH@<FEG:'0[(&9O;G0M<VEZ93H@,3!P=#LG/C`N-3D\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P
M861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!P861D:6YG
M+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P
M861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!P861D:6YG
M+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*
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M;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^
M,BPY-SDL,#$P/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE
M.B`Q,'!T.R<^,2XS-#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T
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M;CH@<FEG:'0[(&9O;G0M<VEZ93H@,3!P=#LG/C$L,S`P+#`P,#PO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M<VEZ93H@,3!P=#LG/C(N,S4\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
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M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N
M="US:7IE.B`Q,'!T.R<^*#(X.2PS-#,\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M<VEZ93H@,3!P=#LG/BD\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@
M9F]N="US:7IE.B`Q,'!T.R<^,"XR,SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC
M;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!P861D:6YG+6)O='1O;3H@
M,7!T.R!F;VYT+7-I>F4Z(#$P<'0[)SY&;W)F96ET960@;W(@97AP:7)E9#PO
M=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H
M=#L@9F]N="US:7IE.B`Q,'!T.R<^*#$T-BPR,#(\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O
M;G0M<VEZ93H@,3!P=#LG/BD\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T
M97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI
M9#L@=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M<VEZ93H@,3!P=#LG/C`N.#`\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!P
M861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!P
M861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\
M+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-C8V9F8V,[
M('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!J=7-T:69Y.R!P861D:6YG+6)O='1O;3H@,BXU<'0[(&9O;G0M
M<VEZ93H@,3!P=#LG/D)A;&%N8V4@)B,X,C$Q.R!-87)C:"`S,2P@,C`Q,B`F
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M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R
M+C5P=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M<VEZ93H@,3!P=#LG/B0\+W1D/@T*/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X
M="UA;&EG;CH@<FEG:'0[(&9O;G0M<VEZ93H@,3!P=#LG/C$N-SD\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`R+C5P=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
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M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,BXU<'0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU
M<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[
M)SXD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P
M<'0[)SXR+#(S,"PP,#`\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N
M9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT
M9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z
M(#$P<'0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K
M9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
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M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ
M(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXR+#,R,RPS,C`\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R
M+C5P=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z
M(#$P<'0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I
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M="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B
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M;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N
M.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^,2PX,30L,#`P/"]T9#X-"CQT
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M;VYS(&]U='-T86YD:6YG(&%N9"!E>&5R8VES86)L92!A<R!O9B!-87)C:"`S
M,2P@,C`Q,BP@87)E(&%S(&9O;&QO=W,Z/"]P/@T*/'`@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*
M/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'@[)SXF(S$V,#L\+W`^#0H\=&%B;&4@
M<W1Y;&4],T0G=VED=&@Z(#$P,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P
M<V4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E
M;G1E<CL@<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T.R<@
M8V]L<W!A;CTS1#$S/CQB/D]P=&EO;G,F(S$V,#M/=71S=&%N9&EN9R8C,38P
M.SPO8CX\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
M(&9O;G0M<VEZ93H@,3!P=#LG/CQB/B8C,38P.SPO8CX\+W1D/@T*/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA
M;&EG;CH@8V5N=&5R.R!P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z
M(#$P<'0[)R!C;VQS<&%N/3-$.3X\8CXF(S$V,#M/<'1I;VYS)B,Q-C`[17AE
M<F-I<V%B;&4\+V(^/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&-E;G1E<CL@9F]N="US:7IE.B`Q,'!T.R<@8V]L<W!A;CTS1#(^)B,Q-C`[
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M,T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
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M;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
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M,T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M<VEZ93H@,3!P=#LG(&-O;'-P
M86X],T0R/D%V97)A9V4\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([(&9O;G0M<VEZ93H@,3!P=#LG/E)E;6%I;FEN9SPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M<VEZ93H@,3!P=#LG
M(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@9F]N="US:7IE.B`Q,'!T.R<@8V]L<W!A;CTS1#(^079E
M<F%G93PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N
M="US:7IE.B`Q,'!T.R<^4F5M86EN:6YG/"]T9#X-"CPO='(^#0H\='(@<W1Y
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M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&9O;G0M<VEZ93H@
M,3!P=#LG(&-O;'-P86X],T0R/D]P=&EO;G,\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E
M<CL@9F]N="US:7IE.B`Q,'!T.R<@8V]L<W!A;CTS1#(^17AE<F-I<V4F(S$V
M,#M0<FEC93PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P
M=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P
M="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+7-I>F4Z(#$P<'0[
M)SY#;VYT<F%C='5A;"8C,38P.TQI9F4\+W1D/@T*/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&9O;G0M<VEZ93H@,3!P=#LG(&-O
M;'-P86X],T0R/D]P=&EO;G,\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="US
M:7IE.B`Q,'!T.R<@8V]L<W!A;CTS1#(^17AE<F-I<V4F(S$V,#M0<FEC93PO
M=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@
M=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+7-I>F4Z(#$P<'0[)SY#;VYT<F%C
M='5A;"8C,38P.TQI9F4\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K
M9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@=VED=&@Z(#$R)3L@9F]N="US:7IE.B`Q
M,'!T.R<^)#`N,#D@+2`D-"XU-SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!W:61T:#H@,24[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q,B4[
M(&9O;G0M<VEZ93H@,3!P=#LG/C,L-S4S+#0V-CPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT+7-I>F4Z(#$P
M<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
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M86QI9VXZ(&-E;G1E<CL@=VED=&@Z(#$S)3L@9F]N="US:7IE.B`Q,'!T.R<^
M-RXR.2!Y96%R<SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED
M=&@Z(#$Q)3L@9F]N="US:7IE.B`Q,'!T.R<^,BPR,S,L,S(Q/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$E.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="US:7IE.B`Q
M,'!T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M('=I9'1H.B`Q,24[(&9O;G0M<VEZ93H@,3!P=#LG/C$N-#0\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@
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M;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T.R<^)#0N-3@@+2`D.2XP-3PO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T
M;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z(#$P<'0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXX.2PY.3D\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#%P=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT
M+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^-2XY,SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ
M(#%P=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
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M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXX.2PY.3D\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T
M97AT+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^-2XY,SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T
M;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
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M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([('!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N="US:7IE
M.B`Q,'!T.R<^)#`N,#D@+2`D.2XP-3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`R+C5P=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B
M;&4[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU
M<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T
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M;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^#0H\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT
M+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^,2XW.3PO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ
M(#(N-7!T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="US
M:7IE.B`Q,'!T.R<^-RXQ."!Y96%R<SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#(N-7!T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T
M(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z
M(#$P<'0[)SXR+#,R,RPS,C`\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,BXU<'0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T
M97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X-"CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[
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M8FQE/@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*
M/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@
M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R<^5&AE(&]P=&EO;G,@;W5T<W1A;F1I;F<@86YD(&5X97)C:7-A8FQE(&%S
M(&]F($UA<F-H(#,Q+"`R,#$Q+"!A<F4@87,@9F]L;&]W<SH\+W`^#0H\<"!S
M='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[
M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SX\
M+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P>#LG/B8C,38P.SPO<#X-"CQT
M86)L92!S='EL93TS1"=W:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E.B!C
M;VQL87!S93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CLG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG
M;CH@8V5N=&5R.R!F;VYT+7-I>F4Z(#$P<'0[)R!C;VQS<&%N/3-$,3,^/&(^
M)B,Q-C`[3W!T:6]N<R8C,38P.T]U='-T86YD:6YG/"]B/CPO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^/&(^)B,Q-C`[/"]B/CPO=&0^
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M;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M<VEZ93H@,3!P=#LG(&-O
M;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&-E;G1E<CL@9F]N="US:7IE.B`Q,'!T.R<@8V]L<W!A;CTS1#(^5V5I9VAT
M960\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M
M<VEZ93H@,3!P=#LG/E=E:6=H=&5D)B,Q-C`[079E<F%G93PO=&0^#0H\=&0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M<VEZ93H@,3!P=#LG
M(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@9F]N="US:7IE.B`Q,'!T.R<@8V]L<W!A;CTS1#(^5V5I
M9VAT960\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O
M;G0M<VEZ93H@,3!P=#LG/E=E:6=H=&5D)B,Q-C`[079E<F%G93PO=&0^#0H\
M+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M<VEZ93H@
M,3!P=#LG(&-O;'-P86X],T0R/E)A;F=E)B,Q-C`[;V8\+W1D/@T*/'1D('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M<VEZ93H@,3!P=#LG(&-O
M;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&-E;G1E<CL@9F]N="US:7IE.B`Q,'!T.R<@8V]L<W!A;CTS1#(^079E<F%G
M93PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="US
M:7IE.B`Q,'!T.R<^4F5M86EN:6YG/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CL@9F]N="US:7IE.B`Q,'!T.R<@8V]L<W!A;CTS1#(^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF
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M<VEZ93H@,3!P=#LG(&-O;'-P86X],T0R/D5X97)C:7-E)B,Q-C`[4')I8V4\
M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[
M('1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="US:7IE.B`Q,'!T.R<@8V]L<W!A
M;CTS1#(^3W!T:6]N<SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
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M=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT
M+6%L:6=N.B!C96YT97([(&9O;G0M<VEZ93H@,3!P=#LG/D-O;G1R86-T=6%L
M)B,Q-C`[3&EF93PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#%P=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI
M9VXZ(&-E;G1E<CL@9F]N="US:7IE.B`Q,'!T.R<@8V]L<W!A;CTS1#(^3W!T
M:6]N<SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P
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M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C
M96YT97([(&9O;G0M<VEZ93H@,3!P=#LG/D-O;G1R86-T=6%L)B,Q-C`[3&EF
M93PO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z
M("-C8V9F8V,[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M8V5N=&5R.R!W:61T:#H@,3(E.R!F;VYT+7-I>F4Z(#$P<'0[)SXD,"XP.2`M
M("0T+C4W/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W
M:61T:#H@,24[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$E.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q
M)3L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$R)3L@9F]N="US:7IE.B`Q
M,'!T.R<^,BPW,C$L.3(Q/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!W:61T:#H@,24[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!F;VYT+7-I>F4Z(#$P<'0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('=I9'1H.B`Q)3L@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q,B4[(&9O;G0M<VEZ
M93H@,3!P=#LG/C$N,C(\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('=I9'1H.B`Q)3L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T
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M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,24[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$Q)3L@
M9F]N="US:7IE.B`Q,'!T.R<^,2XS,CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([('=I9'1H.B`Q,R4[(&9O;G0M<VEZ93H@,3!P=#LG/C8N,C<@
M>65A<G,\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O
M;&]R.B!W:&ET93L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R.R!P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXD-"XU."`M("0Y+C`U/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^
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M9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXU+CDS/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T
M97AT+6%L:6=N.B!C96YT97([('!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M
M<VEZ93H@,3!P=#LG/C,N-3$@>65A<G,\+W1D/@T*/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO
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M<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I
M9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXU+CDS/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!C96YT97([('!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O
M;G0M<VEZ93H@,3!P=#LG/C,N-3$@>65A<G,\+W1D/@T*/"]T<CX-"CQT<B!S
M='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!F;VYT+7-I>F4Z(#$P<'0[)SXD,"XP
M.2`M("0Y+C`U/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!P861D:6YG+6)O='1O;3H@,BXU<'0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E
M>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXR+#@Q,2PY,C8\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`R+C5P=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT
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M+#`W,CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D
M9&EN9RUB;W1T;VTZ(#(N-7!T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M<VEZ93H@,3!P=#LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@
M<FEG:'0[(&9O;G0M<VEZ93H@,3!P=#LG/C$N-3`\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,BXU<'0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXU
M<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!C96YT97([(&9O;G0M<VEZ93H@,3!P
M=#LG/C8N,38@>65A<G,\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL
M93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=M
M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
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M97)I9CLG/D1U<FEN9R`R,#`T(&%N9"`R,#`W+"!#1#0@9W)A;G1E9"`S,"PP
M,#`@;W!T:6]N<RX@3VX@075G=7-T(#4L(#(P,#DL(#$P+#`P,"!O9B!T:&5S
M92!O<'1I;VYS(&5X<&ER960N($%S(&]F($UA<F-H(#,Q+"`R,#$R+"!A('1O
M=&%L(&]F(#(P+#`P,"!O<'1I;VYS('=E<F4@;W5T<W1A;F1I;F<@86YD(&5X
M97)C:7-A8FQE('=I=&@@86X@97AE<F-I<V4@<')I8V4@;V8@)#`N,C`@86YD
M(&$@<F5M86EN:6YG(&-O;G1R86-T=6%L(&QI9F4@;V8@,"XQ,B!Y96%R<RX\
M+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P
M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M)SY!<R!O9B!-87)C:"`S,2P@,C`Q,BP@17!I=&]P92!H87,@-3`L,#`P(&]P
M=&EO;G,@;W5T<W1A;F1I;F<@86YD(#(P+#`P,"!O<'1I;VYS(&5X97)C:7-A
M8FQE('=I=&@@86X@97AE<F-I<V4@<')I8V4@;V8@)#`N,#`Q(&%N9"!A(')E
M;6%I;FEN9R!C;VYT<F%C='5A;"!L:69E(&]F(#8N,C4@>65A<G,N)B,Q-C`[
M)B,Q-C`[5&AE<V4@;W!T:6]N<R!W97)E(&=R86YT960@9'5R:6YG(#(P,#@L
M('9E<W0@86YN=6%L;'D@;W9E<B`U('EE87)S+"!A;F0@:&%V92!A(&9A:7(@
M=F%L=64@;V8@)#4P+"!W:&EC:"!W87,@9&5T97)M:6YE9"!U<VEN9R!T:&4@
M0FQA8VLM4V-H;VQE<R!M;V1E;"!W:71H('1H92!F;VQL;W=I;F<@87-S=6UP
M=&EO;G,Z(&5X<&5C=&5D(&1I=FED96YD('EI96QD(&]F(#`E.R!E>'!E8W1E
M9"!V;VQA=&EL:71Y(&]F(#(P,"4L(')I<VL@9G)E92!I;G1E<F5S="!R871E
M(&]F(#(N-#<E(&%N9"!A;B!E>'!E8W1E9"!L:69E(&]F(#$P('EE87)S+CPO
M<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S8X
M-#)C9#$T7S@X8SA?-#)E,U]A,3%F7V4U,C,V-S`Y9&9D.0T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B\V.#0R8V0Q-%\X.&,X7S0R93-?83$Q9E]E
M-3(S-C<P.61F9#DO5V]R:W-H965T<R]3:&5E=#$R+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W1O8VL@4'5R8VAA<V4@5V%R
M<F%N=',\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S
M,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY3=&]C:R!0=7)C:&%S92!787)R86YT<R!;06)S=')A8W1=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K
M(%!U<F-H87-E(%=A<G)A;G1S(%M497AT($)L;V-K73PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'1A8FQE('-T>6QE/3-$)VUA<F=I;BUT;W`Z
M(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CL@;6%R9VEN+6)O='1O;3H@,'!X.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP
M861D:6YG/3-$,#X-"CQT<B!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y
M.R!V97)T:6-A;"UA;&EG;CH@=&]P.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@=VED=&@Z(#`N,C5I;CLG/CQB/C<N/"]B/CPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3LG/CQB/E-T;V-K(%!U
M<F-H87-E(%=A<G)A;G1S/"]B/CPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&IU<W1I9GD[('9E<G1I8V%L+6%L:6=N.B!T;W`[)SX-
M"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU
M<W1I9GD[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL
M93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[)SX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM
M97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY/;B!-87)C:"`Q-2P@,C`Q
M,BP@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@8V]N<W5L=&EN9R!A9W)E
M96UE;G0@9F]R(&$@9FEN86YC:6%L(&-O;6UU;FEC871I;VYS('!R;V=R86TL
M(&9O<B!A('!E<FEO9"!O9B!T=V5L=F4@;6]N=&AS('1H870@8F5G86X@;VX@
M1F5B<G5A<GD@,C`L(#(P,3(N($%S(&-O;7!E;G-A=&EO;B!F;W(@<W5C:"!P
M<F]G<F%M+"!T:&4@8V]N<W5L=&%N="!I<R!P86ED(&$@;6]N=&AL>2!F964@
M86YD('=I;&P@8F4@:7-S=65D(&$@<&5R9F]R;6%N8V4@=V%R<F%N="!E>&5R
M8VES86)L92!F;W(@,C4P+#`P,"!S:&%R97,@;V8@=&AE($-O;7!A;GDF(S@R
M,3<[<R!C;VUM;VX@<W1O8VL@8F%S960@;VX@86-H:65V96UE;G0@;V8@8V5R
M=&%I;B!M:6QE<W1O;F5S+B!5<&]N(&EN:71I871I;VX@;V8@=&AE('!R;V=R
M86TL(#4P+#`P,"!O9B!T:&4@<&5R9F]R;6%N8V4@=V%R<F%N=',@=F5S=&5D
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M(&]F('1H92!W87)R86YT(&%P<')O>&EM871E9"`D-C$L,#`P(&%N9"!W87,@
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M:61T:#H@-S4E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<B!S='EL93TS1"=B86-K9W)O
M=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^
M#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^17AE<F-I<V4@<')I
M8V4\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M
M<VEZ93H@,3!P=#LG(&-O;'-P86X],T0R/B0@)B,Q-C`[)B,Q-C`[)B,Q-C`[
M)B,Q-C`[,BXR,#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@
M<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!W:61T:#H@.#$E.R!F;VYT+7-I>F4Z(#$P<'0[)SY%>'!E8W1E9"!D:79I
M9&5N9',\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`R)3L@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!W:61T:#H@,24[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q
M-24[(&9O;G0M<VEZ93H@,3!P=#LG/C`\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="US:7IE.B`Q,'!T.R<^
M)3PO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z
M("-C8V9F8V,[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SY%>'!E
M8W1E9"!V;VQA=&EL:71Y/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M<VEZ93H@,3!P=#LG/C$P
M.#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US
M:7IE.B`Q,'!T.R<^)3PO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG
M<F]U;F0M8V]L;W(Z('=H:71E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q
M,'!T.R<^4FES:R!F<F5E(&EN=&5R97-T(')A=&4\+W1D/@T*/'1D('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US
M:7IE.B`Q,'!T.R<^,"XS-SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)3PO=&0^#0H\+W1R/@T*/'1R
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M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^,B!Y96%R<SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N
M9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[
M)SY%>'!E8W1E9"!F;W)F96ET=7)E<SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P
M<'0[)SXP/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXE/"]T9#X-"CPO='(^#0H\+W1A8FQE/@T*/'`@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X
M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^
M)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@
M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R<^3VX@1&5C96UB97(@,C`L(#(P,3$L('1H92!#;VUP
M86YY(&5N=&5R960@:6YT;R!A(&-O;G-U;'1I;F<@86=R965M96YT(&9O<B!F
M:6YA;F-I86P@861V:7-O<GD@<V5R=FEC97,L(&9O<B!A('!E<FEO9"!O9B!T
M=V5L=F4@;6]N=&AS+B!!<R!C;VUP96YS871I;VX@9F]R('-U8V@@<V5R=FEC
M97,L('1H92!C;VYS=6QT86YT(&ES('!A:60@82!M;VYT:&QY(&9E92!A;F0@
M;VX@1F5B<G5A<GD@,BP@,C`Q,BP@=V%S(&ES<W5E9"!A('=A<G)A;G0@97AE
M<F-I<V%B;&4@9F]R(#$P,"PP,#`@<VAA<F5S(&]F('1H92!#;VUP86YY)B,X
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M9B!T:&4@=V%R<F%N="!A<'!R;WAI;6%T960@)#(P,"PP,#`@86YD('=A<R!M
M96%S=7)E9"!U<VEN9R!T:&4@0FQA8VLM4V-H;VQE<R!V86QU871I;VX@;6]D
M96PN(%1H92!A<W-U;7!T:6]N<R!U<V5D(&)Y('1H92!#;VUP86YY(&%R92!S
M=6UM87)I>F5D(&EN('1H92!F;VQL;W=I;F<@=&%B;&4Z/"]P/@T*/'`@<W1Y
M;&4],T0G;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[)B,Q-C`[/"]P/@T*/'1A8FQE
M('-T>6QE/3-$)W=I9'1H.B`W-24[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P
M<V4[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE
M/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-C8V9F8V,[('9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SY%
M>&5R8VES92!P<FEC93PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<@8V]L<W!A;CTS1#(^)"8C,38P.R8C
M,38P.R8C,38P.R8C,38P.R`Q+C$T/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*
M/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('=I9'1H.B`X,24[(&9O;G0M<VEZ93H@,3!P=#LG/D5X
M<&5C=&5D(&1I=FED96YD<SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#(E
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@=VED=&@Z(#$U)3L@9F]N="US:7IE.B`Q,'!T.R<^,#PO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXE/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R
M;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<VEZ93H@
M,3!P=#LG/D5X<&5C=&5D('9O;&%T:6QI='D\+W1D/@T*/'1D('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE
M.B`Q,'!T.R<^,3<T/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXE/"]T9#X-"CPO='(^#0H\='(@<W1Y
M;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F
M;VYT+7-I>F4Z(#$P<'0[)SY2:7-K(&9R964@:6YT97)E<W0@<F%T93PO=&0^
M#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-
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M9F4@;V8@=V%R<F%N=#PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXU('EE
M87)S/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS
M1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93L@=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M<VEZ93H@,3!P=#LG/D5X<&5C=&5D(&9O<F9E:71U<F5S/"]T9#X-"CQT9"!S
M='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O
M;G0M<VEZ93H@,3!P=#LG/C`\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M<VEZ93H@,3!P=#LG/B4\+W1D/@T*/"]T<CX-"CPO
M=&%B;&4^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G
M:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O
M;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY/;B!!
M<')I;"`V+"`R,#$Q+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!#;VUM
M;VX@4W1O8VL@4'5R8VAA<V4@06=R965M96YT('=I=&@@86X@:6YS=&ET=71I
M;VYA;"!I;G9E<W1O<BX@07,@<&%R="!O9B!T:&ES(&%G<F5E;65N="P@=&AE
M($-O;7!A;GD@:7-S=65D(&$@=V%R<F%N="!T;R!P=7)C:&%S92`X-#0L,SDQ
M('-H87)E<R!O9B!C;VUM;VX@<W1O8VLN(%1H92!W87)R86YT<R!H879E(&%N
M(&5X97)C:7-E('!R:6-E(&]F("0Q+C`P(&%N9"!A(&QI9F4@;V8@9FEF=&5E
M;B!M;VYT:',N(%1H92!W87)R86YT<R!V97-T960@:6UM961I871E;'D@86YD
M(&5X<&ER92!!=6=U<W0@,3`L(#(P,3(N($%S(&]F($UA<F-H(#,Q+"`R,#$R
M+"`S-#0L,SDQ(&]F('1H97-E('=A<G)A;G1S(')E;6%I;F5D(&]U='-T86YD
M:6YG+CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA
M<F=I;CH@,'!T(#!P>#L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I
M;65S+"!S97)I9CLG/B8C,38P.SQB<B`@+SY/;B!*86YU87)Y(#(X+"`R,#$Q
M+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!#;VUM;VX@4W1O8VL@4'5R
M8VAA<V4@06=R965M96YT('=I=&@@=&AR964@:6YS=&ET=71I;VYA;"!I;G9E
M<W1O<G,N($%S('!A<G0@;V8@=&AI<R!A9W)E96UE;G0L('1H92!#;VUP86YY
M(&ES<W5E9"!W87)R86YT<R!T;R!P=7)C:&%S92`Q+#0R."PU-S(@<VAA<F5S
M(&]F(&-O;6UO;B!S=&]C:RX@5&AE('=A<G)A;G1S(&AA=F4@86X@97AE<F-I
M<V4@<')I8V4@;V8@)#$N-#`@86YD(&$@;&EF92!O9B!F:69T965N(&UO;G1H
M<RX@5&AE('=A<G)A;G1S('9E<W1E9"!I;6UE9&EA=&5L>2!A;F0@97AP:7)E
M($UA>2`Q+"`R,#$R+B!!<R!O9B!-87)C:"`S,2P@,C`Q,BP@-S0V+#0R.2!O
M9B!T:&5S92!W87)R86YT<R!R96UA:6YE9"!O=71S=&%N9&EN9RX\+W`^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P
M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y
M.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[)SY/;B!*=6QY(#(L(#(P,3`L('1H92!#;VUP86YY
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M;&EF92!O9B`U('EE87)S+B!4:&4@=V%R<F%N=',@=F5S=&5D(&]N($IA;G5A
M<GD@,2P@,C`Q,2!A;F0@97AP:7)E($1E8V5M8F5R(#,Q+"`R,#$U+B!3:6YC
M92!T:&5S92!W87)R86YT<R!W97)E(&=R86YT960@87,@<&%R="!O9B!A;B!E
M<75I='D@<F%I<V4L('1H92!#;VUP86YY(&AA<R!T<F5A=&5D('1H96T@87,@
M82!D:7)E8W0@;V9F97)I;F<@8V]S="X@5&AE(')E<W5L="!O9B!T:&4@=')A
M;G-A8W1I;VX@:&%S(&YO(&%F9F5C="!T;R!E<75I='DN($%S(&]F($UA<F-H
M(#,Q+"`R,#$R+"`Q."PQ.#(@;V8@=&AE<V4@=V%R<F%N=',@<F5M86EN960@
M;W5T<W1A;F1I;F<N/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S
M=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R<^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@
M<W1Y;&4],T0G;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[02!S=6UM87)Y(&]F('=A
M<G)A;G0@86-T:79I=&EE<R!A<R!O9B!-87)C:"`S,2P@,C`Q,BP@86YD(&9O
M<B!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,2P@:7,@87,@9F]L
M;&]W<SH\+W`^#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="`P<'@[(&9O;G0Z
M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\
M+W`^#0H\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#@P)3L@8F]R9&5R+6-O;&QA
M<'-E.B!C;VQL87!S93L@9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I
M;65S+"!S97)I9CLG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N
M.B!C96YT97([(&9O;G0M<VEZ93H@,3!P=#L@9F]N="UW96EG:'0Z(&)O;&0[
M)R!C;VQS<&%N/3-$,CY787)R86YT<SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7=E:6=H
M=#H@8F]L9#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#%P=#L@9F]N=#H@8F]L9"`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E
M<CL@9F]N=#H@8F]L9"`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
M<FEF.R<@8V]L<W!A;CTS1#(^5V5I9VAT960@/&)R("`O/D%V97)A9V4F(S$V
M,#M%>&5R8VES92!0<FEC93PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#%P=#L@9F]N=#H@8F]L9"`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4]
M,T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[
M('=I9'1H.B`V-"4[(&9O;G0M<VEZ93H@,3!P=#LG/D)A;&%N8V4@)B,X,C$Q
M.R!$96-E;6)E<B`S,2P@,C`Q,#PO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$E.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@=VED=&@Z(#$U)3L@9F]N="US:7IE.B`Q,'!T.R<^,2PQ,S$L,#<X
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@
M,24[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N
M="US:7IE.B`Q,'!T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[('=I9'1H.B`Q-24[(&9O;G0M<VEZ93H@,3!P=#LG/C,N-#D\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q
M)3L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@
M<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[('9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y.R!F;VYT+7-I>F4Z(#$P<'0[)SY'<F%N=&5D/"]T9#X-"CQT9"!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M
M<VEZ93H@,3!P=#LG/C(L,C<R+#DV,SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-
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M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^*#$U+#8Q-3PO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q
M,'!T.R<^*3PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ+C`S/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P
M<'0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O
M=6YD+6-O;&]R.B!W:&ET93L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('!A9&1I;F<M8F]T
M=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#LG/D5X<&ER960\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P
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M;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M
M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXR+C`X/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@
M,7!T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT
M<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M:G5S=&EF>3L@9F]N="US:7IE.B`Q,'!T.R<^0F%L86YC92`F(S@R,3$[($1E
M8V5M8F5R(#,Q+"`R,#$Q/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M<VEZ93H@,3!P=#LG/C,L
M,C4Y+#$X-CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F
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M=&EF>3L@9F]N="US:7IE.B`Q,'!T.R<^1W)A;G1E9#PO=&0^#0H\=&0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXS-3`L,#`P/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@9F]N="US:7IE.B`Q,'!T.R<^,2XY,#PO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T
M9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(V-C
M9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&9O;G0M<VEZ93H@,3!P=#LG/D5X97)C
M:7-E9#PO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT
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M;W1T;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T.R<^17AP:7)E9#PO=&0^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N
M="US:7IE.B`Q,'!T.R<^+3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,7!T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M
M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXM/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S
M='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA
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M;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M
M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXR+#0Q-"PY,C(\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T
M=&]M.B`R+C5P=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXR+C,V/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A
M8VMG<F]U;F0M8V]L;W(Z('=H:71E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R<^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N
M9"UC;VQO<CH@(V-C9F9C8SL@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('!A9&1I;F<M8F]T
M=&]M.B`R+C5P=#L@9F]N="US:7IE.B`Q,'!T.R<^0F%L86YC92`F(S@R,3$[
M($UA<F-H(#,Q+"`R,#$R("8C.#(Q,3L@97AE<F-I<V%B;&4\+W1D/@T*/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H
M=#L@9F]N="US:7IE.B`Q,'!T.R<^,BPR,30L.3(R/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[
M(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N
M-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T
M.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE.B`Q
M,'!T.R<^,BXS-SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF
M(S$V,#L\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=M87)G
M:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@
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M93TS1"=W:61T:#H@.#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F
M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<@8V5L
M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([
M(&9O;G0M<VEZ93H@,3!P=#LG(&-O;'-P86X],T0R/D5X97)C:7-E/&)R("`O
M/E!R:6-E/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T
M('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&9O;G0M<VEZ93H@,3!P=#LG
M(&-O;'-P86X],T0R/E=A<G)A;G1S/&)R("`O/D]U='-T86YD:6YG/"]T9#X-
M"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z
M(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT
M+6%L:6=N.B!C96YT97([(&9O;G0M<VEZ93H@,3!P=#LG(&-O;'-P86X],T0R
M/E=A<G)A;G1S/&)R("`O/D5X97)C:7-A8FQE/"]T9#X-"CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT
M97([(&9O;G0M<VEZ93H@,3!P=#LG(&-O;'-P86X],T0R/E=E:6=H=&5D)B,Q
M-C`[079E<F%G93QB<B`@+SY296UA:6YI;F<\8G(@("\^0V]N=')A8W1U86PF
M(S$V,#M,:69E/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,7!T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&9O;G0M<VEZ93H@,3!P
M=#LG(&-O;'-P86X],T0R/D%G9W)E9V%T93QB<B`@+SY);G1R:6YS:6,@5F%L
M=64\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE
M/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED
M=&@Z(#$E.R!F;VYT+7-I>F4Z(#$P<'0[)SXD/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z(#$V)3L@9F]N="US:7IE.B`Q
M,'!T.R<^,2XP,#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@=VED=&@Z(#$E.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W=I9'1H.B`R)3L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T
M:#H@,24[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[('=I9'1H.B`Q-B4[(&9O;G0M<VEZ
M93H@,3!P=#LG/C,V.2PS.3$\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
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M9VXZ(&QE9G0[('=I9'1H.B`Q)3L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@=VED=&@Z
M(#$X)3L@9F]N="US:7IE.B`Q,'!T.R<^,"XS-B!Y96%R<SPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@=VED=&@Z(#$E.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`R
M)3L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[(&9O;G0M<VEZ93H@,3!P
M=#LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W
M:61T:#H@,38E.R!F;VYT+7-I>F4Z(#$P<'0[)SXT-#,L,#`P/"]T9#X-"CQT
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M.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^,2XQ-#PO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[(&9O;G0M<VEZ93H@,3!P=#LG/C$P,"PP,#`\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ,#`L,#`P
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^
M-"XX-"!Y96%R<SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M<VEZ
M93H@,3!P=#LG/C$P-BPP,#`\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\+W1R
M/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R!V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M<VEZ93H@,3!P=#LG/C$N,S(\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXQ
M."PQ.#(\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P
M<'0[)SXQ."PQ.#(\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
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M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@9F]N="US:7IE.B`Q,'!T.R<^,38L,#`P/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\
M+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C
M8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)#PO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M<VEZ93H@
M,3!P=#LG/C$N-#`\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXW,C$L-#(Y/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@
M9F]N="US:7IE.B`Q,'!T.R<^-S(Q+#0R.3PO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<VEZ93H@
M,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&9O;G0M<VEZ93H@,3!P=#LG/C`N,#@@>65A<G,\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<VEZ93H@,3!P=#LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXU-S<L,#`P/"]T
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M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^,C4P+#`P,#PO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[(&9O;G0M<VEZ93H@,3!P=#LG/C4P+#`P,#PO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[
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M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[
M)SXM/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT
M+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS
M1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="US:7IE.B`Q,'!T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[(&9O;G0M<VEZ93H@,3!P=#LG/C(N,C(\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT
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M=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^-3$W+#(U
M-SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I
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M,T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
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M=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^-C$L,C`W
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^
M-C$L,C`W/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE.B`Q
M,'!T.R<^,RXS,"!Y96%R<SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
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M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^,RXW
M-3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US
M:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7-I
M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M<VEZ93H@,3!P=#LG
M/C4P+#`P,#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M<VEZ93H@
M,3!P=#LG/C4P+#`P,#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
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M#0H\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-
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M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ
M93H@,3!P=#LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R!P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z(#$P<'0[)SXV
M+C,V/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D
M:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ
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M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[
M('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO
M=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<^,S(W
M+#0U-CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D
M9&EN9RUB;W1T;VTZ(#%P=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7-I
M>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#%P="!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXP+C8Q('EE87)S/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T.R!F
M;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO
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M;F<M8F]T=&]M.B`Q<'0[(&9O;G0M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^
M#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-C8V9F
M8V,[('9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N="US:7IE
M.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[(&9O;G0M<VEZ93H@,3!P
M=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#(N-7!T.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N-7!T(&1O=6)L93L@=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B
M;&4[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4Z(#$P<'0[)SXR+#0Q
M-"PY,C(\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A
M9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[
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M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N="US:7IE.B`Q
M,'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M<VEZ93H@,3!P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,BXU<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H
M=#L@9F]N="US:7IE.B`Q,'!T.R<^,2XX,2!Y96%R<SPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T
M.R!F;VYT+7-I>F4Z(#$P<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<VEZ93H@,3!P
M=#LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#(N-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M<VEZ93H@
M,3!P=#LG/C$L,30R+#`P,#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!F;VYT+7-I>F4Z(#$P
M<'0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CPO=&%B;&4^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
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M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/E-T;V-K:&]L9&5R<R<@17%U:71Y/&)R/CPO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3(\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W1O8VMH;VQD
M97)S)R!%<75I='D@3F]T92!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K:&]L9&5R<R<@17%U:71Y
M($YO=&4@1&ES8VQO<W5R92!;5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQT86)L92!S='EL93TS1"=M87)G:6XM=&]P.B`P
M<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M(&UA<F=I;BUB;W1T;VTZ(#!P>#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D
M9&EN9STS1#`^#0H\='(@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@
M=F5R=&EC86PM86QI9VXZ('1O<#LG/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`P
M:6X[)SX\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I
M9'1H.B`P+C(U:6X[)SX\8CXX+CPO8CX\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&IU<W1I9GD[)SX\8CY3=&]C:VAO;&1E<G,F(S@R,3<[($5Q
M=6ET>3PO8CX\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=M
M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L
M:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM
M97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY$=7)I;F<@=&AE('1H<F5E
M(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q,BP@=&AE($-O;7!A;GD@:7-S
M=65D(#(X.2PS-#,@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:RP@:6X@8V]N;F5C
M=&EO;B!W:71H('1H92!E>&5R8VES92!O9B!S=&]C:R!O<'1I;VYS+"!F;W(@
M<')O8V5E9',@;V8@87!P<F]X:6UA=&5L>2`D-C@L,#`P+B!4:&4@0V]M<&%N
M>2!A;'-O(&ES<W5E9"`Q+#$Y-"PR-C0@<VAA<F5S(&]F(&-O;6UO;B!S=&]C
M:R!I;B!C;VYN96-T:6]N('=I=&@@=&AE(&5X97)C:7-E(&]F('=A<G)A;G1S
M+"!F;W(@<')O8V5E9',@;V8@87!P<F]X:6UA=&5L>2`D,2XU(&UI;&QI;VXN
M/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M-C@T,F-D,31?.#AC.%\T,F4S7V$Q,69?934R,S8W,#ED9F0Y#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8X-#)C9#$T7S@X8SA?-#)E,U]A,3%F
M7V4U,C,V-S`Y9&9D.2]7;W)K<VAE971S+U-H965T,30N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$5,13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=6)S97%U96YT($5V96YT
M<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R
M,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E-U8G-E<75E;G0@179E;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W5B<V5Q=65N="!%=F5N
M=',@6U1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\=&%B;&4@<W1Y;&4],T0G;6%R9VEN+71O<#H@,'!X.R!F;VYT.B`Q,'!T
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XM8F]T=&]M
M.B`V<'0[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('9E<G1I8V%L+6%L:6=N
M.B!T;W`[)SX-"CQT9"!S='EL93TS1"=W:61T:#H@,&EN.R<^/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,"XR-6EN.R<^
M/&(^.2X\+V(^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y.R<^/&(^4W5B<V5Q=65N="!%=F5N=#PO8CYS/"]T9#X-"CPO='(^#0H\
M+W1A8FQE/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R
M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R<^/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S
M=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R
M;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^3VX@36%Y(#$L
M(#(P,3(L('1H92!#;VUP86YY('=A<R!I;F9O<FUE9"!B>2!"97)M86X@)F%M
M<#L@0V]M<&%N>2P@4"Y!+B`H)B,X,C(P.T)E<FUA;B`F86UP.R!#;VUP86YY
M)B,X,C(Q.RDL('1H92!#;VUP86YY)B,X,C$W.W,@:6YD97!E;F1E;G0@<F5G
M:7-T97)E9"!A8V-O=6YT:6YG(&9I<FTL('1H870@9'5R:6YG(&$@<F5G=6QA
M<B!0=6)L:6,@0V]M<&%N>2!!8V-O=6YT:6YG($]V97)S:6=H="!";V%R9"`H
M)B,X,C(P.U!#04]")B,X,C(Q.RD@:6YS<&5C=&EO;B!O9B!"97)M86X@)F%M
M<#L@0V]M<&%N>2P@=&AE(%!#04]"(&ES<W5E9"!A(&-O;6UE;G0@=&AA="!T
M:&4@875D:70@;W!I;FEO;B!I;F-L=61E9"!I;B!T:&4@0V]M<&%N>28C.#(Q
M-SMS($%N;G5A;"!297!O<G0@;VX@1F]R;2`Q,"U+(&9O<B!T:&4@>65A<B!E
M;F1E9"!$96-E;6)E<B`S,2P@,C`Q,2!W87,@:7-S=65D(&)Y(&$@<&%R=&YE
M<B!A="!"97)M86X@)F%M<#L@0V]M<&%N>2!W:&\@=V%S(&YO="!A=71H;W)I
M>F5D('5N9&5R('1H92!00T%/0B!R=6QE<R!T;R!I<W-U92!T:&4@;W!I;FEO
M;B!O<B!A8W0@87,@;W5R(&YA;65D(&5N9V%G96UE;G0@<&%R=&YE<B!W:71H
M(')E<W!E8W0@=&\@=&AE($9O<FT@,3`M2R!A=61I="`H;W(@<')I;W(@,C`Q
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M:6]N<R!O9B!!8V-O=6YT86YT<RDN/"]P/@T*/'`@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]P/@T*/'`@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P<'0@,'!X
M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R<^
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M<75E<W0@=&\@=&AE(&5X=&5N="!I="!B96-O;65S(&YE8V5S<V%R>2X\+W`^
M#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P
M="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[)SXF(S$V,#LF(S$V,#LF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SY/;B!-87D@,3`L(#(P
M,3(L($IE9F9R97D@2BX@2W)A=W,@=V%S(&%P<&]I;G1E9"!A<R!T:&4@:6YD
M97!E;F1E;G0L(&YO;BUE>&5C=71I=F4@0VAA:7)M86X@;V8@=&AE($)O87)D
M+B!&;W(@:&ES('-E<G9I8V4@87,@:6YD97!E;F1E;G0L(&YO;BUE>&5C=71I
M=F4@0VAA:7)M86X@;V8@=&AE($)O87)D+"!-<BX@2W)A=W,@=VEL;"!R96-E
M:79E(&%N;G5A;"!C;VUP96YS871I;VX@;V8@)#$U,"PP,#`N($%D9&ET:6]N
M86QL>2P@37(N($MR87=S('=A<R!G<F%N=&5D(&]P=&EO;G,@=&\@<'5R8VAA
M<V4@,3`P+#`P,"!S:&%R97,@;V8@=&AE($-O;7!A;GDF(S@R,3<[<R!C;VUM
M;VX@<W1O8VL@=VET:"!A;B!E>&5R8VES92!P<FEC92!E<75A;"!T;R!O=7(@
M<&5R('-H87)E(&UA<FME="!P<FEC92!O;B!T:&4@9&%T92!O9B!I<W-U92X@
M5&AE<V4@;W!T:6]N<R!W:6QL('9E<W0@<')O(')A=&$L('%U87)T97)L>2!O
M=F5R(&$@='=O('EE87(@<&5R:6]D('=I=&@@=&AE(&9I<G-T('%U87)T97)L
M>2!I<W-U86YC92!O9B`Q,BPU,#`@;W!T:6]N<R!V97-T:6YG(&EM;65D:6%T
M96QY+B!4:&4@0V]M<&%N>2!M96%S=7)E9"!T:&4@9F%I<B!V86QU92!O9B!T
M:&4@<W1O8VL@;W!T:6]N<R!A="!A<'!R;WAI;6%T96QY("0Q-C8L,#`P('5S
M:6YG(&$@0FQA8VLM4V-H;VQE<R!V86QU871I;VX@;6]D96P[('1H97-E('=A
M<G)A;G1S('=E<F4@:6YD97AE9"!T;R!T:&4@0V]M<&%N>28C.#(Q-SMS(&]W
M;B!S=&]C:RX\+W`^#0H\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y
M.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=T97AT
M+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W`^#0H\
M<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P
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M.SPO<#X-"CQT86)L92!S='EL93TS1"=W:61T:#H@-#`E.R!B;W)D97(M8V]L
M;&%P<V4Z(&-O;&QA<'-E.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,#X-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C8V-F9F-C.R!V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G=VED=&@Z
M(#8X)3L@9F]N="US:7IE.B`Q,'!T.R<^17AE<F-I<V4@<')I8V4\+W1D/@T*
M/'1D('-T>6QE/3-$)W=I9'1H.B`R)3L@9F]N="US:7IE.B`Q,'!T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('=I
M9'1H.B`S,"4[(&9O;G0M<VEZ93H@,3!P=#LG/B0Q+C<P/"]T9#X-"CPO='(^
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M)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="US:7IE.B`Q,'!T.R<^,3<Q)3PO
M=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H
M:71E.R!V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE.B`Q,'!T.R<^4FES:R!F<F5E
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M=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M<VEZ93H@,3!P
M=#LG/C`E/"]T9#X-"CPO='(^#0H\+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C@T,F-D,31?.#AC.%\T,F4S7V$Q
M,69?934R,S8W,#ED9F0Y#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+S8X-#)C9#$T7S@X8SA?-#)E,U]A,3%F7V4U,C,V-S`Y9&9D.2]7;W)K<VAE
M971S+V9I;&5L:7-T+GAM;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C:&5M
M87,M;6EC<F]S;V9T+6-O;3IO9F9I8V4Z;V9F:6-E(CX-"B`\;SI-86EN1FEL
M92!(4F5F/3-$(BXN+U=O<FMB;V]K+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970P,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#(N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`S+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970P-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,#4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`V
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-RYH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,#@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#`Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q
M,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3$N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$R+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970Q,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,30N:'1M;"(O/@T*/"]X;6P^#0HM+2TM+2T]7TYE>'1087)T7S8X-#)C9#$T
@7S@X8SA?-#)E,U]A,3%F7V4U,C,V-S`Y9&9D.2TM#0H`
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
        <td class="text"><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>3.&#160;&#160;&#160;Summary of Significant Accounting Policies</b></p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Principles of Consolidation</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">All inter-company transactions and accounts have been eliminated in consolidation.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Use of Estimates</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S.A. requires management to make estimates and assumptions that affect the reported amounts reported in the consolidated financial statements and accompanying notes. Such estimates and assumptions impact, among others, the following: the amount allocated to goodwill, the estimated useful lives for property and equipment, fair value of warrants and stock options granted for services or compensation, respectively, estimates of the probability and potential magnitude of contingent liabilities, and the valuation allowance for deferred tax assets due to continuing and expected future operating losses.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events. Accordingly, actual results could differ from those estimates.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;<br  /><b><i>Accounts Receivable and Allowance for Doubtful Accounts</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Accounts receivable were reported at realizable value, net of allowances for doubtful accounts, which were estimated and recorded in the period the related revenue was recorded. The Company estimated and reviewed the collectability of its receivables based on a number of factors, including the period they were outstanding. Historical collection and payer reimbursement experience was an integral part of the estimation process related to allowances for doubtful accounts associated with Adeona Clinical Laboratory. In addition, the Company regularly assessed the state of its billing operations in order to identify issues, which impacted the collectability of these receivables or reserve estimates. Revisions to the allowances for doubtful accounts estimates were recorded as an adjustment to bad debt expense. Receivables deemed uncollectible were charged against the allowance for doubtful accounts. Recoveries of receivables previously written-off are recorded as credits to the allowance for doubtful accounts.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>&#160;</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Revenue Recognition</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company records revenue when all of the following have occurred: (1) persuasive evidence of an arrangement exists, (2) the service is completed without further obligation, (3) the sales price to the customer is fixed or determinable, and (4) collectability is reasonably assured.&#160;&#160;The Company recognizes milestone payments or upfront payments that have no contingencies as revenue when payment is received.&#160;&#160;For the three months ended March 31, 2012 and 2011, the Company&#8217;s only stream of revenue was laboratory revenue.&#160;Laboratory revenues are a component of discontinued operations for the three months ended March 31, 2012 and 2011. <i>See Note 4 &#8211; Discontinued Operations of Adeona Clinical Laboratory and Note Receivable.</i></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i>License Revenues</i></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company&#8217;s licensing agreements may contain multiple elements, such as non-refundable up-front fees, payments related to the achievement of particular milestones and royalties. Fees associated with substantive at risk performance-based milestones are recognized as revenue upon completion of the scientific or regulatory event specified in the agreement. When the Company has substantive continuing performance obligations under an arrangement, revenue is recognized over the performance period of the obligations using a time-based proportional performance approach. Under the time-based method, revenue is recognized over the arrangement&#8217;s estimated performance period based on the elapsed time compared to the total estimated performance period. Revenue recognized at any point in time is limited to the amount of non-contingent payments received or due. When the Company has no substantive continuing performance obligations under an arrangement, it recognizes revenue as the related fees become due.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Revenues from royalties on third-party sales of licensed technologies are generally recognized in accordance with the contract terms when the royalties can be reliably determined and collectibility is reasonably assured. To date, the Company has not received any royalty revenues.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On May 6, 2010, the Company entered into the Meda Agreement for the development and commercialization of Effirma (oral flupirtine) for fibromyalgia.&#160; As consideration for the sublicense, the Company received an up-front payment of $2.5 million upon execution of the Meda Agreement. This payment was recorded as license revenue in 2010. Pursuant to the Company&#8217;s license agreement with McLean Hospital, the Company paid 15% of the $2.5 million payment ($375,000), that was netted against the revenues received from Meda AB. The Company is also entitled to additional milestone payments of $5 million upon filing of an NDA with the U.S. FDA for oral flupirtine for fibromyalgia and $10 million upon marketing approval. The Meda Agreement also provides that the Company is entitled to receive net royalties of 7% of net sales of oral flupirtine approved for the treatment of fibromyalgia covered by issued patent claims in the U.S. and Japan.&#160;The Meda Agreement provides that Meda AB will assume all future development costs for the commercialization of oral flupirtine for fibromyalgia. Pursuant to the terms of the Company&#8217;s agreement with McLean Hospital, the Company is obligated to pay half of all future royalties the Company receives.&#160;&#160;Future milestone payments will be recorded as revenue when payment is received as there are no future deliverables, and it is non-refundable.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><i>Laboratory Revenues</i></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company primarily recognized revenue for services rendered upon completion of the testing process. Billing for services reimbursed by third-party payers, including Medicare and Medicaid, were recorded as revenues, net of allowances for differences between amounts billed and the estimated receipts from such payers.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company maintained a sales allowance to compensate for the difference in its billing practices and insurance company reimbursements. In determining this allowance, the Company looked at several factors, the most significant of which is the average difference between the amount charged and the amount reimbursed by insurance carriers over the prior 12 months, otherwise known as the yearly average adjustment amount. The allowance taken was the averaged yearly average adjustment amount for these prior periods and multiplied by the period&#8217;s actual gross sales to determine the actual sales allowance for each period.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company generated reimbursements from&#160;3 significant insurance providers in March 31, 2012 and 2011, as follows:</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">Customer</td>
<td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">2012</td>
<td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">2011</td>
<td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: center; width: 30%; font-size: 10pt;">A</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
<td style="width: 2%; font-size: 10pt;">&#160;</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: center; width: 30%; font-size: 10pt;">68%</td>
<td style="text-align: left; width: 1%; font-size: 10pt;"></td>
<td style="width: 2%; font-size: 10pt;">&#160;</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: center; width: 30%; font-size: 10pt;">69%</td>
<td style="text-align: left; width: 1%; font-size: 10pt;"></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;">B</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;">5%</td>
<td style="text-align: left; font-size: 10pt;"></td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;">18%</td>
<td style="text-align: left; font-size: 10pt;"></td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;">C</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;">9%</td>
<td style="text-align: left; font-size: 10pt;"></td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;">5%</td>
<td style="text-align: left; font-size: 10pt;"></td>
</tr>
</table>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Risks and Uncertainties</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company's operations could be subject to significant risks and uncertainties including financial, operational and regulatory risks and the potential risk of business failure. The global economic crisis has caused a general tightening in the credit markets, lower levels of liquidity, increases in the rates of default and bankruptcy, and extreme volatility in credit, equity and fixed income markets. These conditions may not only limit our access to capital, but also make it difficult for our customers, our vendors and us to accurately forecast and plan future business activities.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Cash and Cash Equivalents</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Cash and cash equivalents include cash and highly liquid short-term investments with original maturities of three months or less.&#160;&#160;At March 31, 2012 and 2011, respectively, the Company had no cash equivalents.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>&#160;</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Goodwill</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Goodwill was not amortized, and was tested for impairment at the reporting unit level annually and in interim periods if certain events occur indicating that the carrying value of goodwill was impaired. A reporting unit was an operating segment for which discrete financial information was available and was regularly reviewed by management. The Company had one reporting unit, Adeona Clinical Laboratory, to which goodwill was assigned.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">ASC No. 350 requires a two-step approach to test goodwill for impairment for each reporting unit. The first step tests for impairment by applying fair value-based tests to a reporting unit. The second step, if deemed necessary, measures the impairment by applying fair value-based tests to specific assets and liabilities within the reporting unit. Application of the goodwill impairment tests require judgment, including identification of reporting units, assignment of assets and liabilities to each reporting unit, assignment of goodwill to each reporting unit, and determination of the fair value of each reporting unit. The determination of fair value for a reporting unit could be materially affected by changes in these estimates and assumptions.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">At December 31, 2011, in connection with the Company classifying Adeona Clinical Laboratory as discontinued operations, previously recorded goodwill was considered impaired. <i>See Note 4 &#8211; Discontinued Operations of Adeona Clinical Laboratory and Note Receivable</i>.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Net Earnings (Loss) per Share</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Net earnings (loss) per share is computed by dividing net earnings (loss) less preferred dividends for the period by the weighted average number of common shares outstanding. Diluted earnings (loss) per share is computed by dividing net income (loss) less preferred dividends by the weighted average number of common shares outstanding including the effect of common share equivalents.&#160;Since the Company reported a net loss for the three months ended March 31, 2012 and 2011, all common equivalent shares would be anti-dilutive; as such there is no separate computation for diluted loss per share. The number of options and warrants for the purchase of common stock, that were excluded from the computations of net loss per common share for the three months ended March 31, 2012 were 3,843,465 and 2,414,922, respectively, and for the three months ended March 31, 2011 were 2,273,072 and 2,554,650, respectively.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Research and Development Costs</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company expenses research and development costs as incurred. Research and development expenses consist primarily of license fees, manufacturing costs, salaries, stock-based compensation and related personnel costs, fees paid to consultants and outside service providers for laboratory development, legal expenses resulting from intellectual property prosecution and other expenses relating to the design, development, testing and enhancement of the Company&#8217;s product candidates.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Stock-Based Payment Arrangements</i></b></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Generally, all forms of stock-based payments, including stock option grants, warrants, restricted stock grants and stock appreciation rights are measured at their fair value on the awards&#8217; grant date typically using a Black-Scholes pricing model, based on the estimated number of awards that are ultimately expected to vest. Stock-based compensation awards issued to non-employees for services rendered are recorded at either the fair value of the services rendered or the fair value of the stock-based payment, whichever is more readily determinable. The expense resulting from stock-based payments are recorded in research and development expense or general and administrative expense in the consolidated statement of operations, depending on the nature of the services provided.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Reclassifications</i></b></p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">To conform prior period amounts to current year classifications, the Company has reclassified assets, liabilities, revenues and expenses associated with the sale of Adeona Clinical Laboratory to discontinued operations. These reclassifications had no impact on the Company&#8217;s previously reported financial condition, results of operations or cash flows.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 22<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EPYAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
        <td class="nump">$ 6,802<span></span></td>
        <td class="nump">$ 6,678<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - net</a></td>
        <td class="nump">440<span></span></td>
        <td class="nump">405<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
        <td class="nump">83<span></span></td>
        <td class="nump">16<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Assets of discontinued operations</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">23<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
        <td class="nump">7,325<span></span></td>
        <td class="nump">7,122<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">303<span></span></td>
        <td class="nump">323<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetNoncurrent', window );">Long-term note receivable</a></td>
        <td class="nump">700<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_DepositsAndOtherAssetsNoncurrent', window );">Deposits and other assets</a></td>
        <td class="nump">21<span></span></td>
        <td class="nump">31<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
        <td class="nump">8,349<span></span></td>
        <td class="nump">7,476<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Stockholders' Equity</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">316<span></span></td>
        <td class="nump">388<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
        <td class="nump">127<span></span></td>
        <td class="nump">29<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
        <td class="nump">443<span></span></td>
        <td class="nump">417<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
        <td class="nump">443<span></span></td>
        <td class="nump">417<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 100,000,000 shares authorized, 32,857,609 issued and 32,776,127 outstanding and 31,374,002 issued and 31,292,520 outstanding</a></td>
        <td class="nump">33<span></span></td>
        <td class="nump">31<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
        <td class="nump">60,946<span></span></td>
        <td class="nump">58,901<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(53,073)<span></span></td>
        <td class="num">(51,873)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
        <td class="nump">7,906<span></span></td>
        <td class="nump">7,059<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
        <td class="nump">$ 8,349<span></span></td>
        <td class="nump">$ 7,476<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_DepositsAndOtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and also includes aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet due to materiality considerations. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_DepositsAndOtherAssetsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapitalCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br> -Section S99<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Publisher FASB<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Concepts (CON)<br><br><br><br> -Number 6<br><br><br><br> -Paragraph 25<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Section 45<br><br><br><br> -SubTopic 10<br><br><br><br> -Topic 210<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate value (measured at the lower of net carrying value or fair value less cost of disposal) for current assets (assets with expected useful life shorter than one year or one operating cycle, whichever is longer) of a disposal group, including a component of the entity (discontinued operation), to be sold or that has subsequently been disposed of through sale, as of the financial statement date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 144<br><br><br><br> -Paragraph 46<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e1107-107759<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrestricted cash available for day-to-day operating needs, for an entity that has cash equivalents, but does not aggregate cash equivalents with cash on the balance sheet.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7<br><br><br><br> -Footnote 1<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Cash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>An amount representing an agreement for an unconditional promise by the maker to pay the Entity (holder) a definite sum of money at a future date more than one year from the balance sheet date, net of any write-downs taken for collection uncertainty on the part of the holder. Such amount may include accrued interest receivable in accordance with the terms of the debt. The debt also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among a myriad of other features and characteristics. This amount does not include amounts related to receivables held-for-sale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NotesAndLoansReceivableNetNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 129<br><br><br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 5<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph b, c<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A3<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations [Text Block]</a></td>
        <td class="text"><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>1.&#160;&#160;&#160;Organization</b></p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Synthetic Biologics, Inc. (the &#8220;Company&#8221; or &#8220;Synthetic Biologics&#8221;), formerly Adeona Pharmaceuticals, Inc., is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. In the area of synthetic biology, the Company is initially developing a product candidate to treat pulmonary arterial hypertension (PAH). The Company also intends to expand new and existing collaborations in the synthetic biology area. In addition, Synthetic Biologics has several clinical-stage programs that are being funded, or partially funded, by grants, charitable organizations and corporate partners. In this area we are developing, or have partnered the development of, product candidates to treat relapsing-remitting multiple sclerosis (MS), cognitive dysfunction in MS, fibromyalgia and amyotrophic lateral sclerosis (ALS).</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="border-bottom: black 1pt solid; text-align: center; width: 24%; padding-right: 0.8pt; font-weight: bold;"><b>Medical Indication</b></td>
<td style="text-align: center; width: 2%; padding-right: 0.8pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; width: 24%; padding-right: 0.8pt; font-weight: bold;"><b>Product Candidate</b></td>
<td style="text-align: center; width: 2%; padding-right: 0.8pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; width: 48%; padding-right: 0.8pt; font-weight: bold;"><b>Status</b></td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: center; padding-right: 0.8pt;">PAH</td>
<td style="text-align: center; padding-right: 0.8pt;">&#160;</td>
<td style="text-align: center; padding-right: 0.8pt;">Synthetic DNA-based therapy</td>
<td style="text-align: center; padding-right: 0.8pt;">&#160;</td>
<td style="text-align: center; padding-right: 0.8pt;">Preclinical</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: center; padding-right: 0.8pt;">&#160;</td>
<td style="text-align: center; padding-right: 0.8pt;">&#160;</td>
<td style="text-align: center; padding-right: 0.8pt;">&#160;</td>
<td style="text-align: center; padding-right: 0.8pt;">&#160;</td>
<td style="text-align: center; padding-right: 0.8pt;">&#160;</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: center; padding-right: 0.8pt;">Relapsing-remitting MS</td>
<td style="text-align: center; padding-right: 0.8pt;">&#160;</td>
<td>
<p style="text-align: center; margin: 0pt 0.8pt 0pt 0px; font: 10pt times new roman, times, serif;">Trimesta</p>
<p style="text-align: center; margin: 0pt 0.8pt 0pt 0px; font: 10pt times new roman, times, serif;">(oral estriol)</p>
</td>
<td style="text-align: center; padding-right: 0.8pt;">&#160;</td>
<td style="text-align: center; padding-right: 0.8pt;">All patients enrolled in Phase II clinical trial;<br  />dosing and monitoring underway</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: center; padding-right: 0.8pt;">&#160;</td>
<td style="text-align: center; padding-right: 0.8pt;">&#160;</td>
<td style="text-align: center; padding-right: 0.8pt;">&#160;</td>
<td style="text-align: center; padding-right: 0.8pt;">&#160;</td>
<td style="text-align: center; padding-right: 0.8pt;">&#160;</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: center; padding-right: 0.8pt;">Cognitive dysfunction in<br  />MS</td>
<td style="text-align: center; padding-right: 0.8pt;">&#160;</td>
<td>
<p style="text-align: center; margin: 0pt 0.8pt 0pt 0px; font: 10pt times new roman, times, serif;">Trimesta</p>
<p style="text-align: center; margin: 0pt 0.8pt 0pt 0px; font: 10pt times new roman, times, serif;">(oral estriol)</p>
</td>
<td style="text-align: center; padding-right: 0.8pt;">&#160;</td>
<td style="text-align: center; padding-right: 0.8pt;">Patient enrollment underway in Phase II<br  />clinical trial</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: center; padding-right: 0.8pt;">&#160;</td>
<td style="text-align: center; padding-right: 0.8pt;">&#160;</td>
<td style="text-align: center; padding-right: 0.8pt;">&#160;</td>
<td style="text-align: center; padding-right: 0.8pt;">&#160;</td>
<td style="text-align: center; padding-right: 0.8pt;">&#160;</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: center; padding-right: 0.8pt;">Fibromyalgia</td>
<td style="text-align: center; padding-right: 0.8pt;">&#160;</td>
<td style="text-align: center; padding-right: 0.8pt;">Effirma</td>
<td style="text-align: center; padding-right: 0.8pt;">&#160;</td>
<td style="text-align: center; padding-right: 0.8pt;">Partnered with Meda AB</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: center; padding-right: 0.8pt;">&#160;</td>
<td style="text-align: center; padding-right: 0.8pt;">&#160;</td>
<td style="text-align: center; padding-right: 0.8pt;">(oral flupirtine)</td>
<td style="text-align: center; padding-right: 0.8pt;">&#160;</td>
<td style="text-align: center; padding-right: 0.8pt;">&#160;</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: center; padding-right: 0.8pt;">&#160;</td>
<td style="text-align: center; padding-right: 0.8pt;">&#160;</td>
<td style="text-align: center; padding-right: 0.8pt;">&#160;</td>
<td style="text-align: center; padding-right: 0.8pt;">&#160;</td>
<td style="text-align: center; padding-right: 0.8pt;">&#160;</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: center; padding-right: 0.8pt;">ALS</td>
<td style="text-align: center; padding-right: 0.8pt;">&#160;</td>
<td style="text-align: center; padding-right: 0.8pt;">AEN-100</td>
<td style="text-align: center; padding-right: 0.8pt;">&#160;</td>
<td style="text-align: center; padding-right: 0.8pt;">Phase II/III clinical trial preparation underway</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: center; padding-right: 0.8pt;">&#160;</td>
<td style="text-align: center; padding-right: 0.8pt;">&#160;</td>
<td style="text-align: center; padding-right: 0.8pt;">(gastroretentive zinc acetate)</td>
<td style="text-align: center; padding-right: 0.8pt;">&#160;</td>
<td style="text-align: center; padding-right: 0.8pt;">&#160;</td>
</tr>
</table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Name Statement of Position (SOP)<br><br> -Publisher AICPA<br><br> -Number 94-6<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6003-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NatureOfOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Basis of Presentation<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Business Description and Basis of Presentation [Text Block]</a></td>
        <td class="text"><p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b>2.&#160;&#160;&#160;Basis of Presentation</b></p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p>
<p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The accompanying unaudited consolidated interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules and regulations of the United States Securities and Exchange Commission for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X.</p>
<p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p>
<p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The financial information as of December 31, 2011, is derived from the audited financial statements presented in the Company&#8217;s Annual Report on Form 10-K/A for the year ended December 31, 2011. The unaudited consolidated interim financial statements should be read in conjunction with the Company&#8217;s Annual Report on Form 10-K/A, which contains the audited financial statements and notes thereto, together with the Management&#8217;s Discussion and Analysis, for the year ended December 31, 2011.</p>
<p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p>
<p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Certain information or footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been consolidated or omitted, pursuant to the rules and regulations of the Securities and Exchange Commission for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a comprehensive presentation of financial position, results of operations, or cash flows. It is management's opinion, however, that all material adjustments (consisting of normal recurring adjustments) have been made which are necessary for a fair financial statement presentation. The interim results for the period ended March 31, 2012, are not necessarily indicative of results for the full year.</p>
<p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; background-color: white; margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company has seven subsidiaries, Pipex Therapeutics, Inc. (&#8220;Pipex Therapeutics&#8221;), Effective Pharmaceuticals, Inc. (&#8220;EPI&#8221;), Solovax, Inc. (&#8220;Solovax&#8221;), CD4 Biosciences, Inc. (&#8220;CD4&#8221;), Epitope Pharmaceuticals, Inc. (&#8220;Epitope&#8221;), Healthmine, Inc. (&#8220;Healthmine&#8221;) and Putney Drug Corp. (&#8220;Putney&#8221;). As of March 31, 2012, EPI, Healthmine and Putney are wholly owned and Pipex Therapeutics, Solovax, CD4 and Epitope are majority-owned.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ECMAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets [Parenthetical] (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump">10,000,000<span></span></td>
        <td class="nump">10,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">100,000,000<span></span></td>
        <td class="nump">100,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">32,857,609<span></span></td>
        <td class="nump">31,374,002<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump">32,776,127<span></span></td>
        <td class="nump">31,292,520<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ESAAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>May 14, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">Synthetic Biologics, Inc.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0000894158<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Smaller Reporting Company<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
        <td class="text">syn<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">33,016,175<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Mar. 31,
         2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document as an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type is limited to the same value as the supporting SEC submission type, minus any "/A" suffix. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, 497, NCSR, N-CSR, N-CSRS, N-Q, 10-KT, 10-QT, 20-FT, POS AM and Other.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Trading symbol of an instrument as listed on an exchange.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_TradingSymbol</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EZSAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Operations (USD $)<br>In Thousands, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Costs and Expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump">$ 1,468<span></span></td>
        <td class="nump">$ 1,233<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">386<span></span></td>
        <td class="nump">231<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total Operating Costs and Expenses</a></td>
        <td class="nump">1,854<span></span></td>
        <td class="nump">1,464<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from Continuing Operations</a></td>
        <td class="num">(1,854)<span></span></td>
        <td class="num">(1,464)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income (Expense):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantExpenses', window );">Warrant expense</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(716)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ChangeInFairValueOfWarrantLiability', window );">Change in fair value of warrant liability</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(94)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on the sale of equipment</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(5)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income</a></td>
        <td class="nump">5<span></span></td>
        <td class="nump">56<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total Other Income (Expense), net</a></td>
        <td class="nump">5<span></span></td>
        <td class="num">(759)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net Loss from Continuing Operations</a></td>
        <td class="num">(1,849)<span></span></td>
        <td class="num">(2,223)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Net Income from Discontinued Operations</a></td>
        <td class="nump">649<span></span></td>
        <td class="nump">37<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
        <td class="num">$ (1,200)<span></span></td>
        <td class="num">$ (2,186)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net Income (Loss) Per Share - Basic and Dilutive:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Continuing operations (in dollars per share)</a></td>
        <td class="num">$ (0.06)<span></span></td>
        <td class="num">$ (0.09)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare', window );">Discontinued operations (in dollars per share)</a></td>
        <td class="nump">$ 0.02<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net Loss Per Share (in dollars per share)</a></td>
        <td class="num">$ (0.04)<span></span></td>
        <td class="num">$ (0.09)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive', window );">Weighted average number of shares outstanding during the period - Basic and Dilutive (in shares)</a></td>
        <td class="nump">32,003,164<span></span></td>
        <td class="nump">25,220,694<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ChangeInFairValueOfWarrantLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ChangeInFairValueOfWarrantLiability</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_WarrantExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expenses incurred for warrant during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_WarrantExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The average number of shares or units issued and outstanding that are used in calculating basic and diluted EPS.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_WeightedAverageNumberOfCommonSharesOutstandingDuringPeriodBasicAndDilutive</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDilutedAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the sale price or salvage price and the book value of a property, plant, and equipment asset that was sold or retired during the reporting period. This element refers to the gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnSaleOfPropertyPlantEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the income or loss from continuing operations attributable to the parent which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 18<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921628&amp;loc=SL4613673-111683<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph b(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 10<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the overall income (loss) from a disposal group apportioned to the parent that is classified as a component of the entity, net of income tax, reported as a separate component of income before extraordinary items after deduction or consideration of the amount which may be allocable to noncontrolling interests, if any. Includes the following (net of tax): income (loss) from operations during the phase-out period, gain (loss) on disposal, provision (or any reversals of earlier provisions) for loss on disposal, and adjustments of a prior period gain (loss) on disposal.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921628&amp;loc=SL4569616-111683<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph b(2)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of income (loss) derived from discontinued operations during the period, net of related tax effect, per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpenseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of other income amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Audit and Accounting Guide (AAG)<br><br> -Number AAG-BRD<br><br> -Chapter 4<br><br> -Paragraph 80<br><br> -Subparagraph Exhibit 4-4<br><br> -IssueDate 2006-05-01<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNonoperatingIncome</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph g<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 2<br><br> -Paragraph 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 86<br><br> -Paragraph 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock Purchase Warrants<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockPurchaseWarrantsAbstract', window );"><strong>Stock Purchase Warrants [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockPurchaseWarrantsTextBlock', window );">Stock Purchase Warrants [Text Block]</a></td>
        <td class="text"><table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0">
<tr style="text-align: justify; vertical-align: top;">
<td style="text-align: left; width: 0.25in;"><b>7.</b></td>
<td style="text-align: justify;"><b>Stock Purchase Warrants</b></td>
</tr>
<tr style="text-align: justify; vertical-align: top;">
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: justify;">&#160;</td>
</tr>
</table>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On March 15, 2012, the Company entered into a consulting agreement for a financial communications program, for a period of twelve months that began on February 20, 2012. As compensation for such program, the consultant is paid a monthly fee and will be issued a performance warrant exercisable for 250,000 shares of the Company&#8217;s common stock based on achievement of certain milestones. Upon initiation of the program, 50,000 of the performance warrants vested. The performance warrant is exercisable for a period of two years from the date the agreement was executed for an exercise price equal to the price of the Company&#8217;s common stock on the date of execution. The fair value of the warrant approximated $61,000 and was measured using the Black-Scholes valuation model. The assumptions used by the Company are summarized in the following table:</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 75%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="font-size: 10pt;">Exercise price</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;" colspan="2">$ &#160;&#160;&#160;&#160;2.20</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; width: 81%; font-size: 10pt;">Expected dividends</td>
<td style="width: 2%; font-size: 10pt;">&#160;</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: right; width: 15%; font-size: 10pt;">0</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">%</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; font-size: 10pt;">Expected volatility</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">108</td>
<td style="text-align: left; font-size: 10pt;">%</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; font-size: 10pt;">Risk free interest rate</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">0.37</td>
<td style="text-align: left; font-size: 10pt;">%</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; font-size: 10pt;">Expected life of warrant</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">2 years</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; font-size: 10pt;">Expected forfeitures</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">0</td>
<td style="text-align: left; font-size: 10pt;">%</td>
</tr>
</table>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On December 20, 2011, the Company entered into a consulting agreement for financial advisory services, for a period of twelve months. As compensation for such services, the consultant is paid a monthly fee and on February 2, 2012, was issued a warrant exercisable for 100,000 shares of the Company&#8217;s common stock. The warrant is exercisable upon issuance for a period of five years from the date of issue at an exercise price equal to the price of the Company&#8217;s common stock on the date of issue. The fair value of the warrant approximated $200,000 and was measured using the Black-Scholes valuation model. The assumptions used by the Company are summarized in the following table:</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;&#160;</p>
<table style="width: 75%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="font-size: 10pt;">Exercise price</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;" colspan="2">$&#160;&#160;&#160;&#160; 1.14</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; width: 81%; font-size: 10pt;">Expected dividends</td>
<td style="width: 2%; font-size: 10pt;">&#160;</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: right; width: 15%; font-size: 10pt;">0</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">%</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; font-size: 10pt;">Expected volatility</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">174</td>
<td style="text-align: left; font-size: 10pt;">%</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; font-size: 10pt;">Risk free interest rate</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">0.71</td>
<td style="text-align: left; font-size: 10pt;">%</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; font-size: 10pt;">Expected life of warrant</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">5 years</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; font-size: 10pt;">Expected forfeitures</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">0</td>
<td style="text-align: left; font-size: 10pt;">%</td>
</tr>
</table>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On April 6, 2011, the Company entered into a Common Stock Purchase Agreement with an institutional investor. As part of this agreement, the Company issued a warrant to purchase 844,391 shares of common stock. The warrants have an exercise price of $1.00 and a life of fifteen months. The warrants vested immediately and expire August 10, 2012. As of March 31, 2012, 344,391 of these warrants remained outstanding.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;<br  />On January 28, 2011, the Company entered into a Common Stock Purchase Agreement with three institutional investors. As part of this agreement, the Company issued warrants to purchase 1,428,572 shares of common stock. The warrants have an exercise price of $1.40 and a life of fifteen months. The warrants vested immediately and expire May 1, 2012. As of March 31, 2012, 746,429 of these warrants remained outstanding.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On July 2, 2010, the Company entered into a Common Stock Purchase Agreement with a single investor. As part of this agreement, the Company issued warrants to purchase 60,606 shares of common stock to the placement agent, or its permitted assigns. The warrants have an exercise price of $1.32 and a life of 5 years. The warrants vested on January 1, 2011 and expire December 31, 2015. Since these warrants were granted as part of an equity raise, the Company has treated them as a direct offering cost. The result of the transaction has no affect to equity. As of March 31, 2012, 18,182 of these warrants remained outstanding.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;A summary of warrant activities as of March 31, 2012, and for the year ended December 31, 2011, is as follows:</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">Warrants</td>
<td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1pt; font: bold 10pt times new roman, times, serif;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font: bold 10pt times new roman, times, serif;" colspan="2">Weighted <br  />Average&#160;Exercise Price</td>
<td style="padding-bottom: 1pt; font: bold 10pt times new roman, times, serif;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; width: 64%; font-size: 10pt;">Balance &#8211; December 31, 2010</td>
<td style="width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: right; width: 15%; font-size: 10pt;">1,131,078</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
<td style="width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">$</td>
<td style="text-align: right; width: 15%; font-size: 10pt;">3.49</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify; font-size: 10pt;">Granted</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">2,272,963</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">1.25</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; font-size: 10pt;">Exercised</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">(15,615</td>
<td style="text-align: left; font-size: 10pt;">)</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">1.03</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify; padding-bottom: 1pt; font-size: 10pt;">Expired</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">(129,240</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">)</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">2.08</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; font-size: 10pt;">Balance &#8211; December 31, 2011</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">3,259,186</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">1.95</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify; font-size: 10pt;">Granted</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">350,000</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">1.90</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; font-size: 10pt;">Exercised</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">(1,194,264</td>
<td style="text-align: left; font-size: 10pt;">)</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">1.24</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify; padding-bottom: 1pt; font-size: 10pt;">Expired</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">-</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">-</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; padding-bottom: 2.5pt; font-size: 10pt;">Balance &#8211; March 31, 2012 - outstanding</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">2,414,922</td>
<td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">2.36</td>
<td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; padding-bottom: 2.5pt; font-size: 10pt;">Balance &#8211; March 31, 2012 &#8211; exercisable</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">2,214,922</td>
<td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">2.37</td>
<td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
</tr>
</table>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The warrants outstanding as of March 31, 2012, are as follows:</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p>
<table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="2">Exercise<br  />Price</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="2">Warrants<br  />Outstanding</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="2">Warrants<br  />Exercisable</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="2">Weighted&#160;Average<br  />Remaining<br  />Contractual&#160;Life</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="2">Aggregate<br  />Intrinsic Value</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; width: 1%; font-size: 10pt;">$</td>
<td style="text-align: right; width: 16%; font-size: 10pt;">1.00</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
<td style="width: 2%; font-size: 10pt;">&#160;</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: right; width: 16%; font-size: 10pt;">369,391</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
<td style="width: 2%; font-size: 10pt;">&#160;</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: right; width: 16%; font-size: 10pt;">369,391</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
<td style="width: 2%; font-size: 10pt;">&#160;</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: right; width: 18%; font-size: 10pt;">0.36 years</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
<td style="width: 2%; font-size: 10pt;">&#160;</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">$</td>
<td style="text-align: right; width: 16%; font-size: 10pt;">443,000</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; font-size: 10pt;">$</td>
<td style="text-align: right; font-size: 10pt;">1.14</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">100,000</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">100,000</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">4.84 years</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">106,000</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; font-size: 10pt;">$</td>
<td style="text-align: right; font-size: 10pt;">1.32</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">18,182</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">18,182</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">3.75 years</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">16,000</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; font-size: 10pt;">$</td>
<td style="text-align: right; font-size: 10pt;">1.40</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">721,429</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">721,429</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">0.08 years</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">577,000</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; font-size: 10pt;">$</td>
<td style="text-align: right; font-size: 10pt;">2.20</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">250,000</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">50,000</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">1.96 years</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">-</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; font-size: 10pt;">$</td>
<td style="text-align: right; font-size: 10pt;">2.22</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">517,257</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">517,257</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">4.66 years</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">-</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; font-size: 10pt;">$</td>
<td style="text-align: right; font-size: 10pt;">3.30</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">61,207</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">61,207</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">3.30 years</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">-</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; font-size: 10pt;">$</td>
<td style="text-align: right; font-size: 10pt;">3.75</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">50,000</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">50,000</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">3.88 years</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">-</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">$</td>
<td style="text-align: right; padding-bottom: 1pt; font-size: 10pt;">6.36</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">327,456</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">327,456</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">0.61 years</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">-</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">2,414,922</td>
<td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">2,214,922</td>
<td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">1.81 years</td>
<td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">1,142,000</td>
<td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
</tr>
</table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockPurchaseWarrantsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockPurchaseWarrantsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockPurchaseWarrantsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for stock purchase warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockPurchaseWarrantsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</a></td>
        <td class="text"><table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0">
<tr style="text-align: justify; vertical-align: top;">
<td style="width: 0in;"></td>
<td style="text-align: left; width: 0.25in;"><b>6.</b></td>
<td style="text-align: justify;"><b>Stock-Based Compensation</b></td>
</tr>
</table>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">During 2001, Pipex Therapeutics&#8217; board of directors and stockholders adopted the 2001 Stock Incentive Plan (the &#8220;2001 Stock Plan&#8221;). This plan was assumed by Pipex in the October 2006 merger with Sheffield. As of the date of the merger, there were 1,489,353 options issued and outstanding under the 2001 plan. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2001 plan shall not exceed 250,000. All awards pursuant to the 2001 Stock Plan shall terminate upon the termination of the grantee&#8217;s employment for any reason. Awards include options, restricted shares, stock appreciation rights, performance shares and cash-based awards (the &#8220;Awards&#8221;). The 2001 Stock Plan contains certain anti-dilution provisions in the event of a stock split, stock dividend or other capital adjustment, as defined in the plan. The 2001 Stock Plan provides for a Committee of the Board to grant awards and to determine the exercise price, vesting term, expiration date and all other terms and conditions of the awards, including acceleration of the vesting of an award at any time. As of March 31, 2012, there were 1,066,007 options issued and outstanding under the 2001 Stock Plan.</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On March 20, 2007, the Company&#8217;s board of directors approved the Company&#8217;s 2007 Stock Incentive Plan (the &#8220;2007 Stock Plan&#8221;) for the issuance of up to 2,500,000 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. This plan was approved by stockholders on November 2, 2007. The exercise price of stock options under the 2007 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company&#8217;s common stock on the date the option is granted. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2001 plan shall not exceed 250,000. Options become exercisable over various periods from the date of grant, and generally expire ten years after the grant date. As of March 31, 2012, there are 1,031,394 options issued and outstanding under the 2007 Stock Plan.</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On November 2, 2010, the board of directors and stockholders adopted the 2010 Stock Incentive Plan (&#8220;2010 Stock Plan&#8221;) for the issuance of up to 3,000,000 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. The exercise price of stock options under the 2010 Stock Plan is determined by the compensation committee of the Board of Directors, and may be equal to or greater than the fair market value of the Company&#8217;s common stock on the date the option is granted. Options become exercisable over various periods from the date of grant, and generally expire seven to ten years after the grant date. As of March 31, 2012, there are 1,746,064 options issued and outstanding under the 2010 Stock Plan.</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">In the event of an employee&#8217;s termination, the Company will cease to recognize compensation expense for that employee. There is no deferred compensation recorded upon initial grant date, instead, the fair value of the stock-based payment is recognized ratably over the stated vesting period.</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company has applied fair value accounting for all stock-based payment awards since inception. The fair value of each option or warrant granted is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes assumptions used in the months ended March 31, 2012 and 2011 are as follows:</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;&#160;</p>
<table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="3">Three&#160;Months&#160;Ended&#160;March&#160;31,</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;">2012</td>
<td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;">2011</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: justify; font-size: 10pt;">Exercise price</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;">$1.14 &#8211; $2.47</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;">$1.21 &#8211; $2.22</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; width: 62%; font-size: 10pt;">Expected dividends</td>
<td style="width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: center; width: 18%; font-size: 10pt;">0%</td>
<td style="width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: center; width: 18%; font-size: 10pt;">0%</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify; font-size: 10pt;">Expected volatility</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;">108% &#8211; 174%</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;">185% &#8211; 188%</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; font-size: 10pt;">Risk free interest rates</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;">0.37% &#8211; 1.98%</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;">2.81% &#8211; 3.58%</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify; font-size: 10pt;">Expected life options</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;">10 years</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;">5 years &#8211; 7 years</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; font-size: 10pt;">Expected forfeitures</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;">0%</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;">0%</td>
</tr>
</table>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company records stock-based compensation based upon the stated vested provisions in the related agreements, with recognition of expense recorded on the straight line basis over the term of the related agreement. The vesting provisions for these agreements have various terms as follows:</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 3%; padding-right: 0.8pt;">&#160;</td>
<td style="width: 3%; padding-right: 0.8pt;">&#9679;</td>
<td style="text-align: justify; width: 94%; padding-right: 0.8pt;">immediate vesting,</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-right: 0.8pt;">&#160;</td>
<td style="padding-right: 0.8pt;">&#9679;</td>
<td style="text-align: justify; padding-right: 0.8pt;">one-half vesting immediately and the remainder over three years</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-right: 0.8pt;">&#160;</td>
<td style="padding-right: 0.8pt;">&#9679;</td>
<td style="text-align: justify; padding-right: 0.8pt;">monthly over three years,</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-right: 0.8pt;">&#160;</td>
<td style="padding-right: 0.8pt;">&#9679;</td>
<td style="text-align: justify; padding-right: 0.8pt;">quarterly over three years,</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-right: 0.8pt;">&#160;</td>
<td style="padding-right: 0.8pt;">&#9679;</td>
<td style="text-align: justify; padding-right: 0.8pt;">annually over three years,</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-right: 0.8pt;">&#160;</td>
<td style="padding-right: 0.8pt;">&#9679;</td>
<td style="text-align: justify; padding-right: 0.8pt;">one-third immediate vesting and remaining annually over two years,</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-right: 0.8pt;">&#160;</td>
<td style="padding-right: 0.8pt;">&#9679;&#160;</td>
<td style="text-align: justify; padding-right: 0.8pt;">one-eighth immediate vesting with remaining vesting over two years,</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-right: 0.8pt;">&#160;</td>
<td style="padding-right: 0.8pt;">&#9679;</td>
<td style="text-align: justify; padding-right: 0.8pt;">one-half immediate vesting with remaining vesting over nine months; and</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-right: 0.8pt;">&#160;</td>
<td style="padding-right: 0.8pt;">&#9679;</td>
<td style="text-align: justify; padding-right: 0.8pt;">one quarter immediate vesting with the remaining over three years.</td>
</tr>
</table>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">During the three months ended March 31, 2012, the Company granted 1,300,000 options to employees and consultants having a fair value of approximately $3 million based upon the Black-Scholes option pricing model.&#160; During the same period of 2011, the Company granted 324,502 options to employees having a fair value of approximately $433,000 based upon the Black-Scholes option pricing model.</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">A summary of stock option activities as of March 31, 2012, and for the year ended December 31, 2011, is as follows:</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">Options</td>
<td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1pt; font: bold 10pt times new roman, times, serif;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font: bold 10pt times new roman, times, serif;" colspan="2">Weighted <br  />Average <br  />&#160;Exercise <br  />Price</td>
<td style="padding-bottom: 1pt; font: bold 10pt times new roman, times, serif;">&#160;</td>
<td style="padding-bottom: 1pt; font: bold 10pt times new roman, times, serif;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font: bold 10pt times new roman, times, serif;" colspan="2">Weighted Average Remaining <br  />Contractual <br  />Life</td>
<td style="padding-bottom: 1pt; font: bold 10pt times new roman, times, serif;">&#160;</td>
<td style="padding-bottom: 1pt; font: bold 10pt times new roman, times, serif;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font: bold 10pt times new roman, times, serif;" colspan="2">Aggregate <br  />Intrinsic <br  />Value</td>
<td style="padding-bottom: 1pt; font: bold 10pt times new roman, times, serif;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; width: 48%; font-size: 10pt;">Balance &#8211; December 31, 2010</td>
<td style="width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: right; width: 10%; font-size: 10pt;">2,539,091</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
<td style="width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">$</td>
<td style="text-align: right; width: 10%; font-size: 10pt;">1.32</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
<td style="width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: right; width: 10%; font-size: 10pt;">&#160;</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
<td style="width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: right; width: 10%; font-size: 10pt;">&#160;</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify; font-size: 10pt;">Granted</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">557,002</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">1.26</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; font-size: 10pt;">Exercised</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">(23,333</td>
<td style="text-align: left; font-size: 10pt;">)</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">0.57</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify; padding-bottom: 1pt; font-size: 10pt;">Forfeited or expired</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">(93,750</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">)</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">0.59</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; font-size: 10pt;">Balance &#8211; December 31, 2011</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">2,979,010</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">1.34</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify; font-size: 10pt;">Granted</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">1,300,000</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">2.35</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; font-size: 10pt;">Exercised</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">(289,343</td>
<td style="text-align: left; font-size: 10pt;">)</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">0.23</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify; padding-bottom: 1pt; font-size: 10pt;">Forfeited or expired</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">(146,202</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">)</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">0.80</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="text-align: right; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; padding-bottom: 2.5pt; font-size: 10pt;">Balance &#8211; March 31, 2012 &#8211; outstanding</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">3,843,465</td>
<td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">1.79</td>
<td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">7.18 years</td>
<td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">2,230,000</td>
<td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; padding-bottom: 2.5pt; font-size: 10pt;">Balance &#8211; March 31, 2012 &#8211; exercisable</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">2,323,320</td>
<td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">1.62</td>
<td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">5.73 years</td>
<td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">1,814,000</td>
<td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
</tr>
</table>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;&#160;</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">The options outstanding and exercisable as of March 31, 2012, are as follows:</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="margin: 0px;">&#160;</p>
<table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="border-bottom: black 1pt solid; text-align: center; padding-bottom: 1pt; font-size: 10pt;" colspan="13"><b>Options&#160;Outstanding&#160;</b></td>
<td style="padding-bottom: 1pt; font-size: 10pt;"><b>&#160;</b></td>
<td style="border-bottom: black 1pt solid; text-align: center; padding-bottom: 1pt; font-size: 10pt;" colspan="9"><b>&#160;Options&#160;Exercisable</b></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center; font-size: 10pt;" colspan="2">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;" colspan="2">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;" colspan="2">Weighted</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;">Weighted&#160;Average</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;" colspan="2">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;" colspan="2">Weighted</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;">Weighted&#160;Average</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center; font-size: 10pt;" colspan="2">Range&#160;of</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;" colspan="2">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;" colspan="2">Average</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;">Remaining</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;" colspan="2">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;" colspan="2">Average</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;">Remaining</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="2">Exercise&#160;Price</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="2">Options</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="2">Exercise&#160;Price</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;">Contractual&#160;Life</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="2">Options</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="2">Exercise&#160;Price</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;">Contractual&#160;Life</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: center; width: 12%; font-size: 10pt;">$0.09 - $4.57</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
<td style="width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: right; width: 12%; font-size: 10pt;">3,753,466</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
<td style="width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">$</td>
<td style="text-align: right; width: 12%; font-size: 10pt;">1.69</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
<td style="width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: center; width: 13%; font-size: 10pt;">7.29 years</td>
<td style="width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: right; width: 11%; font-size: 10pt;">2,233,321</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
<td style="width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">$</td>
<td style="text-align: right; width: 11%; font-size: 10pt;">1.44</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
<td style="width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: center; width: 13%; font-size: 10pt;">5.86 years</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="text-align: center; padding-bottom: 1pt; font-size: 10pt;">$4.58 - $9.05</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">89,999</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">5.93</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; padding-bottom: 1pt; font-size: 10pt;">2.51 years</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">89,999</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">5.93</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; padding-bottom: 1pt; font-size: 10pt;">2.51 years</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="text-align: center; padding-bottom: 2.5pt; font-size: 10pt;">$0.09 - $9.05</td>
<td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">3,843,465</td>
<td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">1.79</td>
<td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: center; font-size: 10pt;">7.18 years</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">2,323,320</td>
<td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">1.62</td>
<td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: center; font-size: 10pt;">5.73 years</td>
</tr>
</table>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The options outstanding and exercisable as of March 31, 2011, are as follows:</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p>
<p style="margin: 0px;">&#160;</p>
<table style="width: 100%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="13"><b>&#160;Options&#160;Outstanding</b></td>
<td style="font-size: 10pt;"><b>&#160;</b></td>
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="9"><b>&#160;Options&#160;Exercisable</b></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center; font-size: 10pt;" colspan="2">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;" colspan="2">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;" colspan="2">Weighted</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;">Weighted&#160;Average</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;" colspan="2">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;" colspan="2">Weighted</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;">Weighted&#160;Average</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center; font-size: 10pt;" colspan="2">Range&#160;of</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;" colspan="2">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;" colspan="2">Average</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;">Remaining</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;" colspan="2">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;" colspan="2">Average</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;">Remaining</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="2">Exercise&#160;Price</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="2">Options</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="2">Exercise&#160;Price</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;">Contractual&#160;Life</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="2">Options</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;" colspan="2">Exercise&#160;Price</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt;">Contractual&#160;Life</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: center; width: 12%; font-size: 10pt;">$0.09 - $4.57</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
<td style="width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: right; width: 12%; font-size: 10pt;">2,721,921</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
<td style="width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">$</td>
<td style="text-align: right; width: 12%; font-size: 10pt;">1.22</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
<td style="width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: center; width: 13%; font-size: 10pt;">6.75 years</td>
<td style="width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: right; width: 11%; font-size: 10pt;">2,183,073</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
<td style="width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">$</td>
<td style="text-align: right; width: 11%; font-size: 10pt;">1.32</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
<td style="width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: center; width: 13%; font-size: 10pt;">6.27 years</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="text-align: center; padding-bottom: 1pt; font-size: 10pt;">$4.58 - $9.05</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">89,999</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">5.93</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; padding-bottom: 1pt; font-size: 10pt;">3.51 years</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">89,999</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">5.93</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; padding-bottom: 1pt; font-size: 10pt;">3.51 years</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="text-align: center; padding-bottom: 2.5pt; font-size: 10pt;">$0.09 - $9.05</td>
<td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">2,811,926</td>
<td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">1.37</td>
<td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: center; font-size: 10pt;">6.65 years</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">2,273,072</td>
<td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">1.50</td>
<td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: center; font-size: 10pt;">6.16 years</td>
</tr>
</table>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"><b><i>Options of Subsidiary</i></b></p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">During 2004 and 2007, CD4 granted 30,000 options. On August 5, 2009, 10,000 of these options expired. As of March 31, 2012, a total of 20,000 options were outstanding and exercisable with an exercise price of $0.20 and a remaining contractual life of 0.12 years.</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">As of March 31, 2012, Epitope has 50,000 options outstanding and 20,000 options exercisable with an exercise price of $0.001 and a remaining contractual life of 6.25 years.&#160;&#160;These options were granted during 2008, vest annually over 5 years, and have a fair value of $50, which was determined using the Black-Scholes model with the following assumptions: expected dividend yield of 0%; expected volatility of 200%, risk free interest rate of 2.47% and an expected life of 10 years.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 93-6<br><br> -Paragraph 53<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph 64, 65, A240<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
        <td class="text"><table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0">
<tr style="text-align: justify; vertical-align: top;">
<td style="width: 0in;"></td>
<td style="text-align: left; width: 0.25in;"><b>8.</b></td>
<td style="text-align: justify;"><b>Stockholders&#8217; Equity</b></td>
</tr>
</table>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">During the three months ended March 31, 2012, the Company issued 289,343 shares of common stock, in connection with the exercise of stock options, for proceeds of approximately $68,000. The Company also issued 1,194,264 shares of common stock in connection with the exercise of warrants, for proceeds of approximately $1.5 million.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable).  Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187143-122770<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 4<br><br> -Section 08<br><br> -Paragraph d<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 43<br><br> -Chapter 1<br><br> -Section B<br><br> -Paragraph 7, 11A<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 20: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 21: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 22: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 23: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
        <td class="text"><table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 6pt;" cellspacing="0" cellpadding="0">
<tr style="text-align: justify; vertical-align: top;">
<td style="width: 0in;"></td>
<td style="text-align: left; width: 0.25in;"><b>9.</b></td>
<td style="text-align: justify;"><b>Subsequent Event</b>s</td>
</tr>
</table>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On May 1, 2012, the Company was informed by Berman &amp; Company, P.A. (&#8220;Berman &amp; Company&#8221;), the Company&#8217;s independent registered accounting firm, that during a regular Public Company Accounting Oversight Board (&#8220;PCAOB&#8221;) inspection of Berman &amp; Company, the PCAOB issued a comment that the audit opinion included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2011 was issued by a partner at Berman &amp; Company who was not authorized under the PCAOB rules to issue the opinion or act as our named engagement partner with respect to the Form 10-K audit (or prior 2011 Form 10-Q interim reviews) after the original engagement partner rotated off the account under the Securities and Exchange Commission&#8217;s independence rules as it pertains to partner rotation (S-X Rule 2-01 - Qualifications of Accountants).</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Company received funds from the exercise of warrants but will not issue any shares under any of its outstanding registration statements on Form S-3 until such time as it receives guidance from the SEC whether the issue disclosed herein affects the Company&#8217;s ability to continue to issue securities thereunder. The Company intends to return all of the funds to the warrant holders. The Company has sought guidance from the SEC staff regarding this matter and intends to file a waiver request to the extent it becomes necessary.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;&#160;&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">On May 10, 2012, Jeffrey J. Kraws was appointed as the independent, non-executive Chairman of the Board. For his service as independent, non-executive Chairman of the Board, Mr. Kraws will receive annual compensation of $150,000. Additionally, Mr. Kraws was granted options to purchase 100,000 shares of the Company&#8217;s common stock with an exercise price equal to our per share market price on the date of issue. These options will vest pro rata, quarterly over a two year period with the first quarterly issuance of 12,500 options vesting immediately. The Company measured the fair value of the stock options at approximately $166,000 using a Black-Scholes valuation model; these warrants were indexed to the Company&#8217;s own stock.</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">The Black-Scholes assumptions used in calculating the fair value of the stock options are as follows:</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;&#160;</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 40%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="width: 68%; font-size: 10pt;">Exercise price</td>
<td style="width: 2%; font-size: 10pt;">&#160;</td>
<td style="text-align: center; width: 30%; font-size: 10pt;">$1.70</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; font-size: 10pt;">Expected dividends</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;">0%</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; font-size: 10pt;">Expected volatility</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;">171%</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; font-size: 10pt;">Risk free interest rate</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;">1.28%</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; font-size: 10pt;">Expected life of options</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;">7 years</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; font-size: 10pt;">Expected forfeitures</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;">0%</td>
</tr>
</table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EAXAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net loss</a></td>
        <td class="num">$ (1,849)<span></span></td>
        <td class="num">$ (2,223)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Net income from discontinued operations</a></td>
        <td class="nump">649<span></span></td>
        <td class="nump">37<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activites:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
        <td class="nump">508<span></span></td>
        <td class="nump">768<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedAsCompensation', window );">Stock issued as employee compensation</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">76<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedForConsultingFees', window );">Stock issued for consulting fees</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">58<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantExpenses', window );">Warrant expense</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">716<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ChangeInFairValueOfWarrantLiability', window );">Change in fair value of warrant liability</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">94<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
        <td class="nump">20<span></span></td>
        <td class="nump">80<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for uncollectible accounts receivable</a></td>
        <td class="nump">8<span></span></td>
        <td class="nump">21<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on sale of equipment</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">5<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfAccountsReceivable', window );">Gain on the settlement of accounts payable</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(63)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
        <td class="num">(43)<span></span></td>
        <td class="num">(111)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
        <td class="num">(67)<span></span></td>
        <td class="nump">268<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInNotesReceivableCurrent', window );">Note receivable</a></td>
        <td class="num">(700)<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_IncreaseDecreaseInDepositsAndOtherAssets', window );">Deposits and other assets</a></td>
        <td class="nump">10<span></span></td>
        <td class="nump">68<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Assets of discontinued operations</a></td>
        <td class="nump">23<span></span></td>
        <td class="nump">3<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
        <td class="num">(72)<span></span></td>
        <td class="nump">154<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
        <td class="nump">98<span></span></td>
        <td class="num">(192)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Liabilities of discontinued operations</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(40)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Used In Operating Activities</a></td>
        <td class="num">(1,415)<span></span></td>
        <td class="num">(281)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from the sale of equipment</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Provided By Investing Activities</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises', window );">Proceeds from issuance of common stock for stock option exercises</a></td>
        <td class="nump">68<span></span></td>
        <td class="nump">8<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises', window );">Proceeds from issuance of common stock for warrant exercises</a></td>
        <td class="nump">1,471<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises', window );">Proceeds from issuance of common stock</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">4,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecoveryOfDirectCosts', window );">Cash paid as direct offering costs</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(296)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided By Financing Activities</a></td>
        <td class="nump">1,539<span></span></td>
        <td class="nump">3,712<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashPeriodIncreaseDecrease', window );">Net increase in cash</a></td>
        <td class="nump">124<span></span></td>
        <td class="nump">3,432<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash at beginning of period</a></td>
        <td class="nump">6,678<span></span></td>
        <td class="nump">2,649<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash at end of period</a></td>
        <td class="nump">6,802<span></span></td>
        <td class="nump">6,080<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for taxes</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ChangeInFairValueOfWarrantLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ChangeInFairValueOfWarrantLiability</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in assets of discontinued operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_IncreaseDecreaseInAssetsOfDisposalGroupIncludingDiscontinuedOperation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_IncreaseDecreaseInDepositsAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate net change during the reporting period in moneys given as security, collateral, or margin deposits. Also includes, net change in other operating assets not otherwise defined in the taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_IncreaseDecreaseInDepositsAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in liabilities of discontinued operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_IncreaseDecreaseInLiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity excluding stock option and warrant exercised during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ProceedsFromIssuanceOfCommonStockExcludingStockOptionAndWarrantExercises</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity for stock option exercised.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ProceedsFromIssuanceOfCommonStockForStockOptionExercises</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity for warrant exercises.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_ProceedsFromIssuanceOfCommonStockForWarrantExercises</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedAsCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncash expense that accounts for the value of stock options distributed to employees as compensation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockIssuedAsCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedForConsultingFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The fair value of restricted stock or stock options granted to nonemployees as payment for consulting fees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_StockIssuedForConsultingFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_WarrantExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expenses incurred for warrant during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>syn_WarrantExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>syn_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrestricted cash available for day-to-day operating needs, for an entity that has cash equivalents, but does not aggregate cash equivalents with cash on the balance sheet.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7<br><br> -Footnote 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Cash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) in cash, excluding cash equivalents, for an entity that has cash equivalents, but does not aggregate cash equivalents with cash on the balance sheet. For example, an entity that aggregates cash equivalents with investments discloses the balance of cash excluding cash equivalents on the balance sheet and the change in cash excluding cash equivalents on the statement of cash flows. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 5<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Depreciation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Reflects the net positive or negative amount derived from subtracting from net proceeds of sale, the carrying amounts, net of allocated reserves, of accounts receivable transferred to a third party in a transaction that qualifies for sales treatment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Statement of Position (SOP)<br><br> -Number 01-6<br><br> -Paragraph 13<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 860<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6942082&amp;loc=d3e107425-111719<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnSaleOfAccountsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the sale price or salvage price and the book value of a property, plant, and equipment asset that was sold or retired during the reporting period. This element refers to the gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GainLossOnSaleOfPropertyPlantEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the income or loss from continuing operations attributable to the parent which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 18<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921628&amp;loc=SL4613673-111683<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph b(1)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the overall income (loss) from a disposal group apportioned to the parent that is classified as a component of the entity, net of income tax, reported as a separate component of income before extraordinary items after deduction or consideration of the amount which may be allocable to noncontrolling interests, if any. Includes the following (net of tax): income (loss) from operations during the phase-out period, gain (loss) on disposal, provision (or any reversals of earlier provisions) for loss on disposal, and adjustments of a prior period gain (loss) on disposal.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6921628&amp;loc=SL4569616-111683<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph b(2)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 27<br><br> -Subparagraph f<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxesPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInNotesReceivableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period of amounts due within one year (or one business cycle) from note holders for outstanding loans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInNotesReceivableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other current operating assets not separately disclosed in the statement of cash flows.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherCurrentAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 29<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from financing activity for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from investing activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 16<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the current period expense charged against operations, the offset which is generally to the allowance for doubtful accounts for the purpose of reducing receivables, including notes receivable, to an amount that approximates their net realizable value (the amount expected to be collected).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.5)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProvisionForDoubtfulAccounts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecoveryOfDirectCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Return of or reimbursements received in relation to direct costs and expenses previously paid or incurred.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RecoveryOfDirectCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalCashFlowInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Selected Balance Sheet Information<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Supplemental Balance Sheet Disclosures [Text Block]</a></td>
        <td class="text"><table style="margin-top: 0px; font: 10pt times new roman, times, serif; margin-bottom: 0px;" cellspacing="0" cellpadding="0">
<tr style="text-align: justify; vertical-align: top;">
<td style="text-align: left; width: 0.25in;"><b>5.</b></td>
<td style="text-align: justify;"><b>Selected Balance Sheet Information</b></td>
</tr>
</table>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;"></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Accounts receivable consisted of the following at March 31, 2012 and December 31, 2011 <i>(in thousands):</i></p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">March 31, 2012</td>
<td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">December 31, 2011</td>
<td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; width: 62%; font-size: 10pt;">Accounts receivable</td>
<td style="width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">$</td>
<td style="text-align: right; width: 15%; font-size: 10pt;">736</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
<td style="width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">$</td>
<td style="text-align: right; width: 17%; font-size: 10pt;">692</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">Bad debt allowance - customer</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">(296</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">)</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">(287</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">)</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; padding-bottom: 2.5pt; font-size: 10pt;">Accounts receivable, net</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">440</td>
<td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">405</td>
<td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
</tr>
</table>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;&#160;&#160;</p>
<p style="text-align: justify; margin: 0pt 0px; font: 10pt times new roman, times, serif;">Property and Equipment consisted of the following at March 31, 2012, and December 31, 2011 <i>(in thousands)</i>:</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<table style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">March&#160;31,&#160;2012</td>
<td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-size: 10pt; font-weight: bold;" colspan="2">December&#160;31, 2011</td>
<td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; width: 62%; font-size: 10pt;">Manufacturing equipment</td>
<td style="width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">$</td>
<td style="text-align: right; width: 15%; font-size: 10pt;">400</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
<td style="width: 1%; font-size: 10pt;">&#160;</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">$</td>
<td style="text-align: right; width: 17%; font-size: 10pt;">400</td>
<td style="text-align: left; width: 1%; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify; font-size: 10pt;">Computer and office equipment</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">159</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">159</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: justify; padding-bottom: 1pt; font-size: 10pt;">Laboratory equipment</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">136</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">136</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;Total</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">695</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">695</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="background-color: #ccffcc; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">Less accumulated depreciation</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">(392</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">)</td>
<td style="padding-bottom: 1pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: left; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 1pt solid; text-align: right; font-size: 10pt;">(372</td>
<td style="text-align: left; padding-bottom: 1pt; font-size: 10pt;">)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify; padding-bottom: 2.5pt; font-size: 10pt;">Property and equipment, net</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">303</td>
<td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
<td style="border-bottom: black 2.5pt double; text-align: left; font-size: 10pt;">$</td>
<td style="border-bottom: black 2.5pt double; text-align: right; font-size: 10pt;">323</td>
<td style="text-align: left; padding-bottom: 2.5pt; font-size: 10pt;">&#160;</td>
</tr>
</table>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">&#160;</p>
<p style="margin: 0pt 0px; font: 10pt times new roman, times, serif;">Depreciation expense for the three months ended March 31, 2012 and 2011 was $20,000 and $80,000, respectively.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.4.0.6</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>7</ContextCount>
  <ElementCount>88</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/StatementOfFinancialPositionClassified</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Balance Sheets [Parenthetical]</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/Balancesheetparenthetical</Role>
      <ShortName>Consolidated Balance Sheets [Parenthetical]</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/StatementOfIncomeAlternative</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/StatementOfCashFlowsIndirect</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>006 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>007 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/BasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>009 - Disclosure - Discontinued Operations of Adeona Clinical Laboratory and Note Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/DiscontinuedOperationsOfAdeonaClinicalLaboratoryAndNoteReceivable</Role>
      <ShortName>Discontinued Operations of Adeona Clinical Laboratory and Note Receivable</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>010 - Disclosure - Selected Balance Sheet Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/PropertyAndEquipment</Role>
      <ShortName>Selected Balance Sheet Information</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>011 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>012 - Disclosure - Stock Purchase Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/StockPurchaseWarrants</Role>
      <ShortName>Stock Purchase Warrants</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>013 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>014 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adeonapharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare had a mix of decimals attribute values: 0 2.</Log>
    <Log type="Info">Process Flow-Through: 002 - Statement - Consolidated Balance Sheets</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Mar. 31, 2011'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2010'</Log>
    <Log type="Info">Process Flow-Through: 003 - Statement - Consolidated Balance Sheets [Parenthetical]</Log>
    <Log type="Info">Process Flow-Through: 004 - Statement - Consolidated Statements of Operations</Log>
    <Log type="Info">Process Flow-Through: 005 - Statement - Consolidated Statements of Cash Flows</Log>
  </Logs>
  <InputFiles>
    <File>syn-20120331.xml</File>
    <File>syn-20120331.xsd</File>
    <File>syn-20120331_cal.xml</File>
    <File>syn-20120331_def.xml</File>
    <File>syn-20120331_lab.xml</File>
    <File>syn-20120331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
